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ABSTRACT 
 
Drug design is a task as challenging as important in today’s science. New and more 
effective drugs lead to a general improvement in health but also contribute to the 
advance of science. The development of new drugs is a very complex and demanding 
interdisciplinary process, where several areas must cooperate. Significant efforts are 
constantly made to decrease the time of the typical drug discovery cycle, wich would 
also reduce the huge amount of money involved. Computer-aided drug design (CADD) 
has a major role in the shortening of the research cycle and reducing the expenses of 
the all process. The main goal of this thesis is to test and develop methods to predict 
binding and solvation free energies. Free energy calculations are useful in a wide 
variety of applications like phase and reaction equilibria, solvation, binding affinity, 
stability, kinetics, among others. It is also one of the most difficult quantities to 
compute. Free energy calculations almost always involve computation of free energy 
differences, measured between two systems, that can be computed in many ways. 
Finding a methodology that can address this with good compromise between 
computational cost and accuracy is a constant demand. 
The work presented in this thesis comprises the studies made to determine several 
free energy differences, namely solvation and binding free energies. In addition, the 
experimental values dispersed in the literature were clustered in a database, in an 
effort to collect disperse information and to serve as a base to other approaches. 
Chapter 1 presents an introduction to drug design and the importance of free energies. 
In chapter 2 the basic principles associated to the techniques used in theoretical and 
computational chemistry are presented. Chapter 3 describes the several studies 
performed, together with the results obtained, and the individual conclusions drawn. It 
is also presented the database with all the tables elaborated and the tests for additivity. 
Finally, chapter 4 outlines the general conclusions from this work. 
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RESUMO 
O drug design é, hoje em dia, uma tarefa tão importante como desafiante para a 
ciência. O avanço da ciência ocorre também com os novos e mais eficientes fármacos 
que ajudam geralmente a melhorar a saúde. O desenvolvimento de novos fármacos é 
um processo interdisciplinar complexo e exigente que exige a cooperação de várias 
áreas. São contantemente feitos esforço significativos para diminuir o tempo 
despendido tipicamente para descobrir um novo medicamento, diminuído assim 
também o gasto finanveiro inerente. Computer-aided drug design (CADD) – design de 
novos fármacos ajudado por computador – tem um enorme papel em reduzir o tempo 
e as despesas de todo o processo. O principal objectivo desta tese é testar e 
desenvolver métodos para prever energias livres de ligação e de solvatação. Os 
cálculos de energia livre têm várias aplicações como equilíbrios de fase e de reacção, 
solvatação, afinidade de ligação, estabilização, cinética, entre outras. A energia livre é 
uma das quantidades mais difícil de calcular computacionalmente. Os cálculos de 
energias livres quase sempre envolvem variação de energias livres, medidas entre 
dois sistemas, que pode ser calculada de várias maneiras. Descobrir a metodologia 
que trate esta questão com um bom compromisso entre precisão e custo 
computational é uma procura constante. 
O trabalho apresentado nesta tese inclui o estudo de varias variações de energias 
livres, nomeadamente de solvatação e de ligação. Adicionalmente, os valores 
experimentais disperses na literature foram agregados numa base de dados, num 
esforço para juntar informação e servir de base para os cálculos computacionais. No 
capítulo 1 está presente uma introdução ao Drug design e à importância das energias 
livres. No capítulo 2 são apresentados os princípios das técnicas utilizadas. O capítulo 
3 descreve o diversos estudos executados, juntamente com os resultados obtidos e as 
principais conclusões. É também apresentada a base de dados, com as tabelas 
elaboradas e testes de aditividade. Finalmente, no capítulo 4 estão as conclusões 
gerais desta tese de doutoramento. 
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1. INTRODUCTION 
1.1. DRUG DESIGN 
1.1.1. INTRODUCTION 
Computer aided design can be presented as the use of the computer systems to aid in 
the creation, modification, analysis or optimization of a design.1 Probably one of the 
most time consuming and cost-intensive design process is the Drug Design, especially 
if we account for the all process (design, development and commercialization). 
Drug Design consists in finding new/improved drugs based on biological targets that 
can be shown to be related to a certain disease. The drug, usually a small organic 
molecule, has to bring benefits to the human health, and commonly interacts with its 
biomolecular target, activating or inhibiting its functions. We can consider seven steps 
in the pipeline of drug discovery: disease selection, target selection, lead compound 
identification, lead optimization, preclinical trial testing, clinical trial testing and 
pharmacogenomic optimization.2  
 
FIGURE 1: Drug discovery and development pipeline 
Disease selection entails the collection of all available biological and clinical data. It is 
driven by the need to treat human diseases, to improve the quality of life, but also by 
economic aspects. The second step is pivotal in drug discovery. The identification and 
validation of molecular targets and the search of the corresponding gene and protein 
are the coordinates that will establish the next steps. It can point to 4 different 
scenarios: 
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No target structure 
No known ligands 
 Target structure 
No known ligands 
 
No target structure 
Ligands 
 
Target structure 
Ligands 
 
TABLE 1: Different scenarios to consider before drug optimization 
 
Lead compound identification and optimization strategies depend on the information 
available and it will be furthered discussed. The entire process can take from 12 to 14 
years, being the last stages ruled by unsurpassable time-consuming, costly and strict 
requirements: 
- Preclinical studies (pharmacokinetics, pharmacodynamics) 
- Phase I clinical trials (healthy human subjects) 
- Phase II clinical trials (100 to 500 patients) 
- Phase III clinical trials (more than 1000 patients) 
- Phase IV clinical trials (long term trials) 
- Review and Approval 
The drug approval process comprises various stages and every country has its own 
regulatory authority. So, in order to reduce this long pipeline, the focus should be in 
increasing the efficiency of the early stages, the discovery and optimization. 
A favorable outcome of drug administration is to nullify or at least relieve the disease. 
The new drugs for testing may have natural origin (plants, animals, microorganisms) 
and/or result from chemical synthesis. These compounds can be rejected because of 
many reasons like absence or low activity, toxicity or carcinogenity, complexity of 
synthesis, insufficient efficiency, high production costs, etc.3 Therefore, we can define 
safety, efficacy and economy as the three criteria which should be considered during 
the search of a new drug. 
All biological processes in the human body are connected in a tight and not well 
understood web. When the behavior of select receptors or enzymes are modified they 
may stimulate negative effects in other systems. As we all are aware, side effects are 
thus expected as we take nearly any drug.  
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The scope of drug discovery is complex, challenging and multidisciplinary. The aim of 
finding new/improved drug candidates with superior pharmacological properties 
requires a total and inclusive choice of the available tools. Empirical trial-and-error 
methods have been replaced by targeted therapy (drugs that can act on specific 
targets) during the past few decades. 
 
1.1.2. COMPUTER AIDED DRUG DESIGN (CADD) 
Theoretical Chemistry penetrates several fields as it addresses chemical and physical 
observations. It had its boost in the 1920s and 30s and laid the foundations for the birth 
of computational chemistry, fed by the rapid growth in software and hardware in the 
80s and 90s. The importance of computational results was recognized by the Nobel 
Prize of Chemistry awarded in 1998 to John Pople (development of computational 
methods in quantum chemistry) and Walter Kohn (for his development of the Density-
Functional Theory).4 
The use of computational chemistry to discover, enhance, or study drugs and related 
biologically active molecules is called computer aided drug design (CADD). CADD 
facilitates the design and discovery of new therapeutic solutions, playing a pivotal role 
in drug discovery and development. It is an unavoidable tool in the pharmaceutical 
industry. The drug discovery and development process experienced a profitable boost 
with the use of computational chemistry strategies and also by significant concurrent 
advances in structural biology, especially protein crystallography (protein structures 
upon which could be the base to computational drug design studies). Among the many 
benefits that CADD provides we can highlight the valuable insights into experimental 
findings and mechanism of action, new suggestions for molecular structures to 
synthesize, and the ability to make cost-effective decisions before expensive synthesis 
is started.5 
Three clusters must be considered and its information integrated for a good outcome in 
drug design: the drug, the target and the drug–target complex. The availability of data 
has been growing for all this 3 domains. Many databases of small molecules are 
currently available. These present collections of structures, or provide additional data 
(bio-activity of the compounds and their protein targets), or attempt to link molecule 
information with their biological targets. As example we can mention some of the 
better-known small-molecule databases relevant for drug discovery: ZINC6 PubChem7, 
ChEMBLdb8, ChemSpider9, etc. It is important to integrate the available information 
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and knowledge about the systems that we want to study. As an enormous amount of 
biological macromolecule and small molecule information became accessible, the 
applicability of computational drug discovery reached almost every stage in the drug 
discovery pipeline (target identification and validation, lead discovery and optimization 
and preclinical tests).10 The available physicochemical information points towards the 
strategy that could, probably, lead to more successful results. Regarding that, the 
choice will fall in direct or indirect methods. Direct methods are based on the 
knowledge of properties and features of the spatial structure of the target 
(enzyme/receptor), and is also called structure-based drug design. Indirect methods  
are based on comparative analysis of known active and inactive compounds in order to 
discover common basic properties of these and correlate them with the biological 
activity - ligand-based drug design. 
 
1.1.2.1. STRUCTURE-BASED DRUG DESIGN (SBDD) 
Where structural data of the target protein exist, structure-based drug design (SBDD) is 
the most applied strategy. The structure of biomolecules conditions their functions and 
interactions. This strategy uses the information contained in the three-dimensional 
structure of a macromolecular target and of the related ligand-target complexes to 
design novel drugs. The three-dimensional structure can determined by X-ray 
crystallography, NMR spectroscopy or protein homology modelling, and allows the 
understanding of the nature of the binding site and detailed interactions with the ligand. 
This leads to the design of more effective and target specific compounds. SBDD relies 
in the central assumption that good ligands must have complementarity to their target 
receptor, at structural and chemical level. These drugs bear as principal advantage the 
high specificity to target site, thus inducing fewer side effects. Designing new drugs 
based on the structure is better than the time consuming and less logical conventional 
methods. SBDD made important contributions in the field of cancer chemotherapy, 
drug resistant infections and neurological diseases.11 
Approved drug resulting from the application of structure-based drug design: 
The carbonic anhydrase inhibitor dorzolamide is the first accepted example of the 
application of structure-based drug design and it was approved in 1995.12 The anti-HIV 
therapy as well as the increasing use of antibiotics generated the need to fight drug 
resistance. SBDD has here a fruitful and extremely important field to work in, as it can 
identify the molecular basis of these drug resistances and provide new/better solutions. 
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Other examples of application can be found in anticancer drugs, anti-inflammatory 
agents and in drugs for neurological diseases.11 
 
1.1.2.2. LIGAND-BASED DRUG DESIGN (LBDD) 
In the absence of the spatial structure of the target molecule, ligand-based drug design 
is the strategy to follow. It is based on the Similarity Property Principle, first stated by 
Johnson and Maggiora13, that says that structurally similar molecules are expected to 
have similar properties. Hence, is performed an analysis of sets of structures of ligands 
with known biological activity in order to correlate ligand activity to structural 
information. There are, clearly, exceptions to take into account, because in some cases 
a small change in the structure can lead to a big change in a property14. Indeed, ligand-
based procedures are extremely dependent on the quantity and quality of experimental 
data. However, the principle provides a rule of thumb widely applicable with many 
successful outcomes as in the anti-malaria compounds and others15,16. 
LBDD can be used for lead compounds discovery but also for the optimization of 
known ligands. 
 
1.1.2.3. PROS AND CONS 
Nowadays, drug-design projects often start with hundreds of thousands or even 
millions of compounds. We can point two important targets for computational 
chemistry: to obtain knowledge of physical details not easily accessible to experiment 
and to raise hypothesis that aid and lead experiment.17 Several methods can be 
considered, however, each method has its limitations. 
Computer aided techniques in drug design5: 
- Docking 
- Structure-based virtual screening (SBVS) 
- Ligand-based virtual screening (LBVS) 
- Pharmacophore modeling 
- Homology modeling 
- Quantitative Structure-Activity relationship (QSARs) 
- Thermodynamic Integration (TI) 
- Computational Alanine Scanning Mutagenesis (ASM) 
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Docking is used when the structure of the target is known. It helps predicting the most 
favorable spatial position of a set of ligands to the target macromolecule, in order to 
form a stable complex. With the use of scoring functions, the strength of association or 
binding affinity between the two molecules is predicted and the results are ranked. This 
technique allows to examine lots of compounds and variants but it still has issues of 
flexibility and scoring to solve. The high or low activity of the selected compounds 
needs experimental verification. There are several programs like DOCK, AUTODOCK, 
GOLD, GLIDE, etc., but the best choice is to make some tests in the specific 
environment in question before deciding. 
Facing the enormous amount of information available, one of the most important tools 
is virtual screening (VS). It consists in a set of computer methods that allow the screen 
of large databases or collections of chemical structures in order to identify those which 
are most probable to bind to the target. This computational search can be applied to 
libraries with physically existing compounds or in libraries with not yet synthesized 
compounds, and it is, to say the least, a good way to start. It can be divided into SBVS 
(3D structure of a target) and LBVS (3D structure of known ligands) according with the 
information obtainable at the beginning of the screening. These two approaches can be 
combined. VS can be both an alternative as a complement to high-troughput screening 
(quickly experimental chemical, genetic or pharmacological tests)18. 
Pharmacophore modeling and Homology modeling are used in the absence of 
structure information. In the first case, the base concept is the similarity between 
ligands. Common chemical features from 3D structures of a set of known ligands which 
represent a set of interactions of interest of the receptor in study are chosen. Usually, 
there are chosen hydrogen-bond acceptors, hydrogen-bond donors, hydrophobic 
regions and positively or negatively charged groups. Homology modeling is used in the 
lack of x-ray crystallography or NMR structure but when the sequence of amino acids is 
available. Using the 3D structure of one or more similar proteins as templates, based 
on the concept that similar sequences lead to similar structures. 
In QSARs techniques the aim is to correlate structural or property physicochemical 
descriptors (hydrophobicity, topology, electronic properties, and steric effects) of 
compounds with their activities. By a multiple regression analysis its revealed the 
relationship between descriptors and biological activity, allowing the prediction of the 
activity of new similar compounds3. This technique can be performed in 2D or 3D-
QSAR to also account for the importance of 3D spatial arrangement of the 
physiochemical properties19. Developed on the 19th century20, QSARs are widely used 
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to rationalize experimental binding data or inhibitory activity of chemical compounds, in 
drug design. 
The binding of two molecules into a complex depends on the standard free energy 
change associated to that process. Thermodynamic integration is used to compute the 
difference in free energy of a system between two given states, as during the binding 
process between a ligand and its target receptor. With Monte Carlo or Molecular 
Dynamics simulations, thermodynamic parameters are changed slowly along the path 
from initial to final state, in equilibrium. Being able to predict molecule binding affinities 
leads to a reduction of the time and resources in drug design or lead optimization 
applications. The identification of compounds that binds best and the evaluation of the 
binding selectivity across different targets are possible by the use of thermodynamic 
cycles, a feature that will be explained ahead (section 2.4). Other techniques routinely 
estimate binding affinities but are less reliable21, whereas TI is more rigorous and 
accurate. 
Alanine Scanning Mutagenesis (ASM) is used to evaluate the contributions of individual 
amino acid side-chains to the activity and binding affinities of proteins. Mutation of an 
amino acid to alanine, small and chemically inert, allows to determine how important is 
that residue to the stability or function of the protein. Its use in the analysis of protein–
protein interactions, which are important for various diseases, makes it a very useful 
tool for research and drug discovery. Because experimental ASM is slow and with high 
costs both in terms of time and methodology, computational methodologies like MM-
PBSA (Molecular Mechanics-Poisson–Boltzmann Surface Area) and the MM-GBSA 
(Molecular Mechanics-Generalized Born Surface Area) have gained considerable 
importance. A good example is an alanine-scanning mutagenesis protocol developed 
in this group that helps to predict the location important residues at interfaces, 
calculating the relative free energy change (ΔΔG) between the wild-type and mutant 
complex on mutation of an individual residue to alanine22. 
 
All the world’s major pharmaceutical and biotechnology companies use computational 
design tools. A computational chemist wishing to succeed in drug discovery must be 
familiar with the full variety of computational approaches available23. Despite all the 
technological development in recent decades, the financial impact of drug discovery 
and development (an average of 12 to 14 years to be approved for marketing) is still 
tremendous. It is estimated that the cost of bringing a new drug to the end of Phase III 
FCUP 
NEW COMPUTATIONAL METHODS TO CALCULATE  
DRUG-RECEPTOR BINDING FREE ENERGIES 
32 
 
clinical testing is market is more than one billion euros. New technologies tends to 
reduce research and development costs in approximately one-third, according to the 
Dimasi study.24 
 
1.1.3. FUTURE 
We can naturally say that there is an unending need for better and safer drugs in the 
clinic. There is also a constant pursuit to improve the productivity of drug discovery and 
development. Although the drugs designed via molecular approaches attack usually 
single targets, the off target interactions can cause side effects and usually are not 
accounted for. These are only noticed during large clinical trials or during use in 
market.  
 
1.1.3.1. PHARMACOGENETICS 
As said by Professor E. J. Begg, one drug or one dose does not fit all.25 The 
differences in response to drugs due to genetic variation were noticed since the 50’s 
and also the use of the term Pharmacogenetics26. The latter studies the influences of 
drug metabolisms and drug responses, induced by hereditary factors. Genes control 
proteins and their function. Abnormal proteins, as a result of genes mutation, will cause 
unusual or absent interactions with the drug. Despite of the completion of the Human 
Genome Project27 , the variation of the approximately 3 billion base pairs sequence 
from one person to another that affects the individual responses to drugs is huge. The 
variability in therapeutic and adverse effects are more and more important to drugs 
efficacy and safety characteristics. Variations (for example, single nucleotide 
polymorphisms (SNPs), base insertions or deletions, copy-number variations,etc.) may 
explain why different patients, presenting the same plasma concentration of  a drug, 
can have different responses to it in clinical treatments. The patient profile – age, 
weight, sex, ethnicity, smoking, alcohol, concurrent diseases, current drug therapy, etc. 
– and the drug profile - pharmacokinetics, indications, interactions, adverse effects, 
dosing regimen, etc. – must be combined in order to choose the right drug, at the right 
dose, for the right patient.  
Human genomics provided “a seedbed” to pharmacogenetics, allowing the discovery of 
new genetic variations that potentially underlie variability in drug response. A new area, 
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pharmacogenomics, results from this and by DNA analyses and gene expression maps 
studies  how an individual’s genetic inheritance affects the body’s response to drugs28. 
There are some publications giving notice of these studies in important therapeutic 
areas like infectious diseases, cardiology and hematology, oncology, etc.26. For drug 
companies, the easier slogan one dose for everyone is becoming not applicable and 
dose individualization can sometimes be more important than whether one approach is 
better than another. Tailoring drug therapy based on an individual’s genetic makeup is 
undoubtedly the way forward.  
 
1.1.3.2. GENE THERAPY 
The need for effective treatments to human genetic diseases requested a different 
approach. The origin of a rising number of those diseases was traced to the molecular 
level, providing tools for a treatment through an attack directly on mutant genes – gene 
therapy. It consists in introducing genetic material into cells for a therapeutic purpose. 
In other words, detecting a genetic defect associated with a disease and correcting that 
defect. The delivery of the functional copies of the gene can be done using viruses, 
non-viral methods or hybrid methods (combine two or more techniques). This therapy 
can be addressed in four ways: 
- add a normal copy of a defective gene to restore the synthesis of a missing protein, 
such as an enzyme; 
- add of a gene to code for a protein that is not necessarily missing but that may be of 
therapeutic benefit and difficult to administer exogenously; 
- induce of transducing non-physiological sequences which have antiviral activity, such 
as antisense oligonucleotides or sequences; 
- add suicide genes that can be transduced into undesirable cells (cancer cells or 
infected cells) to sensitize them to specific substances which will  trigger selective 
destruction of the targeted cells. 
It is common to divide gene therapy in two categories — somatic gene therapy and 
germ line gene therapy. The first is the one approved in humans by current legislation 
and consists in the insertion of genetic material in target cells but the modification does 
not pass along to the next generation. It guarantees the integrity of the genome 
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avoiding the risk of propagating an artificial transgene within a species. That is what 
happens when the change is made in germ line cell therapy. 
Although the term gene therapy appeared in the 70s29, it was only in 1990 that the first 
clinical trial with humans was made, for a severe immune system deficiency called 
ADA - Adenosine Deaminase Deficiency30. The good results seemed promising but 
soon side effects obscured the therapeutic successes. Systemic inflammatory 
responses31, immune rejection of genetically corrected cells32 and insertional 
oncogenesis33, with severe and sometimes fatal consequences. Despite the 
throwbacks, gene therapy has grown over the years into a steady and consistent 
progress. In order to understand the unique pathophysiology of each genetic diseases 
it is imperative to fully understand the disease mechanism. The study of adverse 
events causes gave rise to the design of new vectors and the development of tools and 
models to predict their safety and efficacy.  
A recent report stated that over 1800 gene therapy clinical trials have been completed, 
are ongoing or have been approved worldwide34, the majority of them in the context of 
cancer. Gene therapy has an enormous therapeutic potential and is a promising field 
for drug design techniques. 
 
1.1.3.3. POLYPHARMACOLOGY 
Complex diseases present a strong resistance against perturbations and are always 
controlled by more than one biochemical cause. That leads often to the ineffectiveness 
of drugs that sometimes don’t even reach the market. These multi-factorial diseases 
(ex.: diabetes, high blood pressure, cancer, schizophrenia, or bi-polar disorder), have a 
number of genetic and non-genetic influences that determine whether someone will get 
the disease or not. That makes it hard to achieve the best results using single target 
drugs. Polypharmacology and modern approaches that aim multi-targeted drugs thus 
acquire a rising significance. Hence, a new paradigm emerges. A recent study 
advocates the protocol of making drugs that hit collections of drug targets 
simultaneously. This uses automated drug design by computer that takes advantage of 
large databases of drug-target interactions.35 Because undesired interactions 
frequently cause toxicity and adverse effects, drug designers attempt to reduce it 
increasing the selectivity of a drug for one target over others. This new strategy can 
oppose that multi-target drugs, when rationally designed, can have a wider therapeutic 
window and thus prove to be safer drugs.36 
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A recent study for the automated design of ligands against profiles of multiple drug 
targets showed the pivotal importance of computational chemistry. This protocol 
contributed to a successful outcome (75 percent of the 800 drug-target predictions 
were confirmed in test-tube (in vitro) experiments,).35 Multi-Targeted Drug Discovery 
(MTDD) appears as the next road to travel. In clinical practice, combination therapy is 
commonly used. Simple drugs do not cure complex diseases36. 
 
The future of drug design will undoubtedly involve basic science disciplines that have 
always been at the heart of drug discovery. Information about the target 
biomacromolecules (structural biology), design and synthesize the drug candidates 
(chemistry) and determination of the effects of the interaction between drug and target 
(pharmacology) is always the path to follow. New or improved methods, based in 
bioinformatics, pharmacogenomics, and nanotechnology, for instance, will help writing 
the next chapters in drug design. 
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1.2. SOLVATION FREE ENERGY ΔGSOLV  
1.2.1. INTRODUCTION 
According to IUPAC, solvation is any stabilizing interaction of a solute (or solute 
moiety) and the solvent or a similar interaction of solvent with groups of an insoluble 
material.37 Solvation effects are an essential part in the analysis of reactions that 
occurs in liquid phase, the water being the solvent par excellence. Water is the most 
abundant component of our planet (75%) and of biological organisms (78%). Moreover, 
the majority of biological processes take place in solution, where water is in 
innumerous cases more than an inactive participant. It influences the processes from 
start to finish. Solvation free energy (ΔGsolv)  is the amount of energy necessary to 
transfer a molecule from gas to an solvated environment. When that transfer is to water 
it can be referred also as hydration free energy. Protein-ligand binding and the 
transport of drugs across membranes are closely connected to the solvation energy as 
it is an important component of binding free energy. The exposure or protection of 
chemical groups from solvent influences the binding process and this involves 
desolvation of the ligand in the thermodynamic process. Therefore, the determination 
of ΔGsolv is a valorous objective pursued since the beginnings of computer-aided drug 
design38. 
Experimental solvation free energies can be precisely measured and are available for a 
few hundreds of small organic compounds. These values can be obtained from a 
variety of experimental sources ( Henry’s law constants, saturated vapor pressures of 
the solute over the pure liquid phase combined with aqueous solubilities, and activity 
coefficients at infinite dilution for the solutes in water)39 and are usually related to a 
convenient standard state: transferring 1 mol/L of ideal-gas into 1 mol/L of ideal 
solution of a solute molecule in a solvent. Nevertheless, experimental data are sparse 
and limited to mostly monofunctional molecules, with the aggravating that some older 
values require confirmation.40 The molecules with importance to chemical, biological, 
and pharmaceutical sciences are usually polyfuntional (ex. drug molecules) and 
computational methods that can provide reliable solvation free energies gain major 
weight in the study of chemical/biochemical processes. Some of the reasons that made 
free energy calculations not a first choice38, like the complexity of the set up and the 
computational cost, were override by the fast growing of computational resources. FEP 
and TI brought also work strategies more feasible and with positive outcomes.41 The 
need to validate methodologies in diverse and important systems still persists.. The 
need for more simulations still persists. 
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1.2.2. SOLVENT 
The solubility of a compound in and between various media is a pivotal 
physicochemical parameter, directly correlated with biological activity. The 
development of a variety of models and computational techniques to address solvation 
faces an important question: How to treat the solvent (water, in this case)? On the 
theoretical perspective, the solvent can be classified taking into account the solvent 
molecules. If all solvent molecules are explicitly represented, taking into account the 
molecular details of each individual molecule, the method considered is with explicit 
solvent. If the solvent is represented as a continuum uniform polarizable medium of 
fixed dielectric constant with the solute placed in a suitably shaped cavity, the model is 
called implicit solvent. Both approaches are widely used, with successes and failures 
drawing on the advantages and disadvantages of each. The use of implicit solvent has 
in its favor a less time-consuming calculations, because of the reduction in the 
system’s number of degrees of freedom, and the hability to use quantum mechanical 
calculations for the dissolved solute. Explicit solvation models are more rigorous and 
usually considered more accurate. The explicit consideration of solvent molecules 
represents best the molecular environment. However, this detailed insight requires 
extensive computer resources. The many particles involved in the calculations results 
in a greater computational cost and increases the complexity of the simulation. 
As examples of implicit solvation methods we can refer SMx42 (Solvation Model x, with 
x being a version number; currently x=8), by Cramer, Truhlar et al; COSMO43 
(conductor screening model) by Klamt et al, PCM44 (dielectric polarized continuum 
model, IEF-PCM45 (integral equation formalism PCM), C-PCM46,47 (conductor PCM) by 
Tomasi et al, SVPE48 (surface and volume polarization for electrostatics), SS(V)PE49 
(surface and simulation of volume polarization for electrostatics) by Chipman et al, 
PBSA50 (Poisson-Boltzmann solvent accessible surface area), GBSA51 (Generalized 
Born model augmented with the hydrophobic solvent accessible surface area SA term). 
From the many explicit solvent models used to represent solvent effects in small and 
macromolecular systems, the TIP3P52 water model reproduces experimental structural 
properties accurately (Jorgensen, 1983) with an affordable computer time for 
calculations. Another models may be considered like TIP4P, TIP5P, SPC, etc53. FEP 
and TI are techniques that use explicit solvent models. TI the one focused in my 
research. The choice of a distinct model for the solvation process depends on the 
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compromise between computational cost and accuracy for the property we want to 
study. 
 
1.2.3. RECENT APPROACHES 
Presently, an important objective is the determination of accurate and reliable values 
for the solvation free energies with affordable computational costs. Free energy 
calculations benefits with the computational power available nowadays but sampling 
and simulations of large and complex biomolecular systems are still a challenge. The 
prediction of solvation free energy for small molecules is a good choice that provides 
valuable results. It is a surrogate in the desolvation of the ligand as the protein-ligand 
process is concerned and allows a more easy balance between accuracy and speed of 
the methodology. Due to the relatively sparse and sometimes repetitive amount of 
experimental data, the validation of computational results presents difficulties. The 
difference between computational and experimental values may result from sampling, 
force field or methodological problems40. Hence, several studies like blind challenges to 
computational solvation energies, has been performed in order to, among other 
purposes, test methods and force fields40,54-58. Optimization of atomic radii and surface 
tension coefficients for continuum solvent models59, or explicit solvent molecular free 
energy perturbation simulations using OPLS 2.060are example of some of the recent 
strategies. In spite of the low mean unsigned error (difference between experimental 
and theoretical values) provided by these fresh approaches (<1kcal/mol) the excessive 
parameterization can damage the transferability of the methodology and diminish the 
ability to foresee in new and/or diverse problems. There is also a pressing call for more 
good experimental data for larger and more diverse groups of compounds, especially 
for drug-like molecules. Predicting free energies of solvation plays an pivotal role in 
rational drug design and its importance is widely recognized5,61,62. 
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1.3. PROTEIN-PROTEIN RECOGNITION 
The possibility of studying an experimental property separated into partial contributions 
not accessible by experiment was always a strong motor for performing computer 
simulations. One of the more challenging properties in medicinal chemistry is the 
computation of the free energy of ligand binding (ΔGbind) between biological molecules. 
Association and dissociation of cellular proteins are dynamic processes regulated by 
different cellular mechanisms, composing a complex network of interactions. The 
ensemble of molecular physical interactions in an organism (proteins, nucleic acids and 
small organic compounds) is called interactome63 and it helps substantially to the 
regulation and accomplishment of most biological processes. Building this protein-
protein interaction (PPI) maps requests an interdisciplinary approach, joining 
techniques from the mathematical, computational, physical and engineering sciences. 
It was estimated that the Human interactome encloses 130000 PPIs although only a 
very small part of these are identified64. 
Proteins are involved in the key processes such as metabolism, signal transduction, 
immune response, transport and cell cycle. Protein-protein interactions are largely 
responsible for these biological functions where a single molecule can influence many 
other cell components. PPIs are usually non covalent and can occur between identical 
or non-identical chains. They can be classified as obligate or non-obligate, taking into 
account if the complexes formed may or may not exist independently65. According to 
the complex lifetime, PPIs can be categorized in two different types: when the 
interaction between proteins is strong and irreversible, it is called permanent; if the 
protein-protein interaction can easily associate and dissociates in vivo, it is called 
transient. The latter can be sub-divided in strong (require a molecular trigger to shift the 
oligomeric equilibrium) and weak (the interaction is formed and broken continuously) 
complexes. Ligand binding is often a transient strong interaction. Permanent interaction 
sites are more conserved than transient interfaces and present more hydrophobic 
residues. Transient interfaces tend to have more polar residues66. Although this 
categorization can be of some help, the different categories are not rigid.  All 
interactions and complexes depend on the concentration of the components and on the 
free energy change involved in the formation of the complex67. 
The type of interactions conditions the nature and function of PPIs. The study of PPIs it 
is yet in its beginnings, especially if we consider that, in Protein Data Bank (PDB), there 
are only about 300 structures available out of the thousands PPIs enrolled in public 
databases68. Databases differ by the amount and the quality of data, species involved 
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and type of interactions69. Integrating different data sources can provide an enhanced 
performance of the PPI studies.  
For many years, PPIs druggability70 was not considered because of the large size of 
the interfaces (1000-2000 Å2) between two proteins, the lack of pockets and grooves, 
its hydrophobicity and the disperse distribution among the polymer chain of the 
involved amino acids. Despite these, there are some examples of PPIs inhibition with 
low-molecular-weight ligands71,72 and myths about protein-protein interfaces have been 
broken: the existence of small subsets of residues with higher contribution to the free 
energy of binding or the awareness that interaction interfaces are dynamic and can 
present differences in its structure when in solution than they appear in co-crystal 
structures.  
A number of experimental methods were developed to gather information related with 
PPIs73, like yeast two hybrid (Y2H), protein microarrays or mutation based experiments 
(alanine-scanning). In the latter, the residues of interest are sequentially mutated to 
alanine and the mutants are probed in binding assays. From the analysis of the free 
energy upon binding it is possible to determine the domains involved in the interaction. 
If the difference between the binding free energy in the wild-type complex (without 
mutations) and the binding free energy of the mutated complex is high, then the wild 
type residue is important to the interaction. It means that the mutation lead to an higher 
energy and thus contributing to a less stable complex.  The residues, according to their 
contribution to the binding free energy, can be classified as hot-spots (> 4.0 kcal/mol), 
warm spots (between 2.0 and 4.0 kcal/mol), null-spots (between0.0 and 2.0 kcal/mol) 
and cold spots (< 0.0 kcal/mol). Hot spots have specific properties in comparison with 
the rest of residues, like its localization (tend to be grouped in dense clusters), its 
conservation or even the preponderance of certain amino acids: tryptophan, tyrosine, 
and arginine. They constitute less than half of the contact surface and usually can be 
found in the center of the interface. The correct detection of these residues is a key 
issue with huge practical application such as rational drug design and protein 
engineering. Alanine scanning mutagenesis (ASM) has been widely applied but it is a 
costly and time consuming experimental method.  
The discrepancies found when comparing the experimental results drove to the 
development of computational methods that could address PPIs also. Several 
computational methods to determine information related with protein-protein 
interactions, with different levels of detail, have been used73. In computational alanine-
scanning mutagenesis, different types of amino acids are mutated by alanine in the 
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protein-protein interface. Then, the thermodynamic effect is studied in the complex 
structure by the theoretical calculation of the binding free energy. Computational 
methodologies are usually faster and cheaper than experimental techniques. The 
objectives can be divided in two purposes: to predict a protein complex or interaction, 
and to explain some experimental results, reducing the time and complexity of 
additional experiments. 
From the analysis of protein-protein networks several important information has been 
unveiled: proteins functions and pathways, physiological processes, the molecular 
basis of some diseases, etc.. Drug Design thus has a special interest in PPIs and 
benefits with increase knowledge of these networks. 
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2. COMPUTATIONAL METHODS 
2.1. SCOPE 
The fundamentals processes of life are the result of a complex combination of 
individual chemicals and chemical reactions. In order to understand the function of 
biological molecules and specially the relationship between structure and function, 
many studies have been made. Computational chemistry has a fundamental and 
important role, whether as an independent research area or as a valorous partner in 
experimental studies. 
Theoretical and computational chemistry can address each problem using several 
methodologies that have been developed, with the aim to interpret and study them from 
different point of views. This chapter intends to present the theoretical foundations 
associated with the techniques used in the studies presented in section Results and 
Discussion. 
Section 2.2 provides an overview of Molecular Mechanics, with especially attention to 
force fields and, more particular, to the ones presented in Amber. 
Molecular dynamics is discussed in section 2.3, where the choices for simulations are 
presented. The limitations that this entails are not left aside. 
Section 2.3 outlines the key concepts free energy calculations, reviewing particularly 
Themodynamic Integration and MMPBSA methodologies. 
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2.2. MOLECULAR MECHANICS 
2.2.1. INTRODUCTION 
Molecular Mechanics (MM) is used to study chemical and biological systems and is 
traditionally based in classical mechanics. Classical mechanics is often referred to as 
Newtonian mechanics because it employs Newton’s laws to describe the 
movement/interactions of particles. MM is used for the prediction of physical properties 
like molecular structure or energy, among others. The structure and energy of 
molecules is calculated based on the properties of the atoms not dealing explicitly with 
the electrons and nuclei. Since electrons have much lower mass than the nuclei and 
move at much greater velocity, they instantaneously adjust to the nuclei movements 
(Born–Oppenheimer approximation). As both electrons and the quantum aspects of the 
nuclear motion are neglected, the properties of the atoms is treated by the force field 
(FF) equations and parameterization. FF will be addressed later. Therefore, atoms are 
the smallest unit of the system, represented by the combination of nuclear properties 
and the average distribution of electrons. A “ball and spring” model is normally 
employed, where atoms are represented by point spheres whose mass is defined by 
their relative atomic masses, joined by mechanical springs, corresponding to the 
covalent bonds in the structure. 
This approximation allows the study of large systems, composed by thousands of 
atoms, with an affordable computational cost. Apart from the advantages, like any other 
choice in life, MM have also limitations: 
- these methods cannot be applied to chemical problems that depend on the 
electronic distribution in a molecule. Bond formation, bond breaking or 
molecular properties depending on subtle electronic details are not 
reproducible.  
- each FF is parameterized for a determinate class of molecules (proteins, 
nucleic acids, lipids, specific classes of organic molecules), where the best 
results can be obtained. Out of that scope, the quality of the results is 
compromised.  
 
2.2.2. FORCE FIELDS 
MM methods calculate the energy of the system on the basis of the nuclei coordinates, 
producing potential energy surfaces. Therefore, the total potential energy of the system 
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is given by the sum of all the energies (attractive and repulsive) between the atoms in 
the structure. An individual expression, parameterized for a given set of standard 
atoms types, is used to describe the covalent (bonding, angles and torsional) and 
noncovalent (van der Waals and electrostatic) contributions. The need to evaluate 
energy functions a large number of times during a simulation causes the need of 
simple functions aided by adjustable empirical parameters. The parameters are 
obtained by experimental or higher level computational data. The energy function 
together with the set of empirical parameters is known as a Force Field. 
There are many different molecular mechanics force fields available, and most of them 
share 3 components: a set of equations defining the potential energy; a series of atom 
types that depends on the hybridization, charge and the types of the atoms to which an 
atom is bonded; a parameter set that defines force constants to relate atomic 
characteristics to energy components and structural data. 
FF also has a typical equation for the potential energy (𝐸𝑀𝑀) that can be presented in 
this general form: 
𝐸𝑀𝑀  =  𝐸𝑠𝑡𝑟𝑒𝑡𝑐ℎ𝑖𝑛𝑔 + 𝐸𝑏𝑒𝑛𝑑𝑖𝑛𝑔  +  𝐸𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑎𝑙 + 𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐  +  𝐸𝑣𝑑𝑤  
The terms on this equation concern the most fundamental contributions to the energy 
of the system: 
- 𝐸𝑠𝑡𝑟𝑒𝑡𝑐ℎ𝑖𝑛𝑔  - bond stretching - deformation of the bond length between two 
atoms, 
- 𝐸𝑏𝑒𝑛𝑑𝑖𝑛𝑔  - angle bending - variation in bond angles between atoms, 
- 𝐸𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑎𝑙  - torsional - torsion for the dihedral angles, 
- 𝐸𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐  - coulombic - interactions resulting from the presence of atomic 
charges,  
- 𝐸𝑣𝑑𝑤  - van der Waals - dispersive attractions and Pauli repulsions. 
 
The first 3 terms relate to covalent bonds between atoms whereas the last 2 terms 
relate to non-covalent interactions. Some force fields may include other terms in order 
to improve the results obtained, like, for example, cross terms, improper torsions and 
out-of-plane bending terms. However, the relation between the gain in accuracy and 
the increase in the computational cost must be considered. 
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2.2.2.1. BOND STRETCHING 
This term regards the elongation and shortening of bond lengths within molecules. The 
harmonic description of the bond can be done applying the Hooke’s law: 
 
𝑉𝑙  =  
1
2
𝑘𝑙(𝑙 − 𝑙0)
2 
 
The term 𝑘𝑙 is the force constant of the correspondent bond, 𝑙 is the distance between 
the two bonded atoms and 𝑙0 the equilibrium value. 
The most common force fields use the harmonic potential to describe the bond 
between two atoms provided that the system is close to the equilibrium. Even though 
the application of different potentials such as the Morse potential can be more 
accurate, they are more difficult to compute efficiently, thus typically avoided in 
biomolecular force fields.  
 
2.2.2.2. ANGLE BENDING 
The variation of the bond angles can also be described by a harmonic potential: 
𝑉𝜃  =  
1
2
𝑘𝜃(𝜃 − 𝜃0)
2 
In this equation, θ is the angle between atoms (θ0is the equilibrium angle value) and kθ 
is the force constant associated to the bending mode. The accuracy of this term can 
also be improved by the addition of higher order terms. 
 
2.2.2.3. TORSIONAL ENERGY 
The torsional energy concerns the energy variation associated to the rotation around a 
BC bond in a set of four atoms ABCD linked together. The dihedral angle is defined as 
the angle formed by the planes containing the atoms ABC and BCD. It may vary over a 
range of [0º,360º] or [-180º,+180º]. This energy function has to be periodic, which 
means that is if the connection rotate 360º, the energy must return to the same value. 
The function can be written as: 
 
𝑉𝜔 =  ∑
1
2
𝑉𝑖  [1 + cos(𝑛𝜔 −  𝛾)]
𝑖
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In this equation ω is the dihedral angle, 𝑛  is the correspondent multiplicity, i.e. a 
quantity that gives the number of minimum points in the function as the bond is rotated 
by 360º. Vi is the correspondent torsional force constant, 𝛾 determines the angle (s) 
where the torsion potential passes through a minimum value, and 𝑖  indicates the 
number of dihedral angles in the system. (This equation is used in Amber Force 
Fields). 
As rotation around the bond has usually a low energy cost, large deviations from the 
minimum energy at room temperature can occur. Also, some force fields add an 
additional term for the "improper torsional" to enforce the planarity of aromatic rings 
and other conjugated systems. 
 
2.2.2.4. ELECTROSTATIC INTERACTIONS 
The electrostatic energy term describes the non-bonding interactions resulting from 
atomic charges or permanent dipoles of the molecules. Positively and negatively 
charged regions result from the electronegativity of the atoms that constitutes de 
molecule. Electrostatic interactions can be calculated from the sum of the interactions 
between pairs of atoms, according with the atomic charges assigned to each individual 
atom, by the equation: 
𝑉𝑒𝑙(𝑖, 𝑗) =
1
4𝜋𝜀
 
𝑞𝑖𝑞𝑗
𝑟𝑖,𝑗
 
The 𝑞𝑖𝑞𝑗  are the atomic charges, 𝑟𝑖,𝑗  is the interatomic distance, and the dielectric 
constant (ε) accounts for the effect of the surrounding environment, not explicitly 
included in the modeled system and the force field. 
The way the atomic charges are calculated, which can be done by quantum 
mechanically or semi-empirically, influences the calculation of the electrostatic energy. 
The most used methods for the calculation of point charges involves the analysis of 
Mulliken populations or fitting  the quantum electrostatic potential to the one generated 
by the point charges. 
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2.2.2.5. VAN DER WAALS INTERACTIONS 
The van der Waals interactions are the sum of the attractive and repulsive forces 
between atoms which are not directly linked. It is not generated by the average 
electronic density distribution and therefore does not depend on the atomic charges. 
These interactions are attractive at small distances, but when the distance increases it 
tends to zero. However, at small small distances, due to Pauli exclusion principle, 
these interactions are repulsive. The van der Waals energy term is normally 
approximated by a Lennard-Jones potential, which can be represented as: 
𝑉𝑣𝑑𝑤(𝑖, 𝑗) = 4𝜀𝑖𝑗 [(
𝜎𝑖𝑗
𝑟𝑖𝑗
)
12
− (
𝜎𝑖𝑗
𝑟𝑖𝑗
)
6
] 
In this equation 𝑟𝑖𝑗 is the distance between the interacting atoms, 𝜎𝑖𝑗 is determines the 
distance at which the energy is minimal (which corresponds to δ21/2) of the atoms i and 
j, and  𝜀𝑖𝑗 is the Lennard-Jones potential energy depth. The first term of the subtraction 
accounts for repulsion, whereas the second term describes the attraction. 
Although there are other ways to obtain more rigorous results, once again the 
computational cost has to be considered. So, the very efficient Lennard-Jones potential 
is used in many force-fields, especially for proteins. 
 
The selection of the Force Field to use depends, first of all, on the system you want to 
study. There are FF which provide parameters for all types of atoms and others, more 
specific, parameterized for a particular kind of molecules (e.g. proteins, carbohydrates, 
or nucleotides), that allow higher quality in the results obtained for such molecules. 
Since they are parameterized in conceptually different ways, the comparison between 
force fields has to rely on the ability to reproduce observable data. Individual 
parameters are not transferable. It is possible to highlight, among the available FF 
families, the following: 
 AMBER (Assisted Model Building and Energy Refinement); 
 CHARMM (Chemistry at HARvard Macromolecular Mechanics) 
 OPLS-AA (Optimized Potential for Liquid Simulations) 
 MM (Molecular Mechanics) 
 CFF (Consistent Force Field) 
 UFF (Universal Force Field) 
 GROMACS (Groningen Machine for Chemical Simulations) 
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 MM 2-4 
 MM FF 
The first 3 ones are commonly used when addressing biological systems, being 
AMBER the one used in this work. 
 
2.2.3. AMBER 
2.2.3.1. INTRODUCTION 
This force field was originally developed by Peter Kollman's group at the University of 
California, San Francisco. It was initially parameterized for calculations with proteins 
and nucleic acids, where several studies testified its good results. Nowadays, AMBER 
stands for a family of force fields and is also the name for the molecular dynamics 
software package that simulates them. It is considered "all-atom" because it provides 
parameters for all atoms of the system, including hydrogens. The AMBER force fields 
are efficient dealing with peptides, proteins, and nucleic acids (ff94, ff96, ff98, ff99, 
ff99EP, ff02, ff02EP, ff03, ff12SB), small organic molecules (GAFF – Generalized 
AMBER force field), carbohydrates (GLYCAM force fields) and a modular lipid force 
field (Lipid11). The AMBER energy function may be written as: 
𝐸 = ∑ 𝐾𝑟(𝑟 − 𝑟𝑒𝑞)
𝑟
2
+ ∑ 𝐾𝜃(𝜃 − 𝜃𝑒𝑞)
2
+ ∑
𝐾𝜔
𝑡
[1 + 𝑐𝑜𝑠(𝑛𝜔 − 𝛾)] + ∑ (
𝐴𝑖𝑗
𝑟𝑖𝑗
12 −
𝐵𝑖𝑗
𝑟𝑖𝑗
6 ) + ∑
𝑞𝑖𝑞𝑗
𝜀𝑟𝑖𝑗
𝑖>𝑗𝑖>𝑗𝜔𝜃
 
 
In this work, we have used the Duan et al. force field, called ff03 and also the GAFF 
force field. 
 
2.2.3.2. FORCE FIELD FF03 
Since the publication of the first Amber force field, the most commonly used for 
biomolecular simulation was the ‘‘Cornell et al.’’ force field - ff94.As some limitations in 
this force field were reported, such as over-stabilization of α-helices, the need to 
improve led to a variety of new ‘‘Amber’’ force fields, each one with advantages and 
disadvantages also. Duan et al. introduced an extensive modification to Amber force 
field, called ff03, that used a fundamentally different concept for the derivation of partial 
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atomic charges. A low-dielectric continuum model corresponding to an organic solvent 
environment (with a dielectric constant of 4) was included directly in the QM calculation 
of the dihedral parameters and the electrostatic potentials. 
 
2.2.3.3. GAFF 
GAFF was designed to be compatible with the available Amber force fields for proteins 
and nucleic acids. It was developed in order to work well both for the biological and 
organic molecule. GAFF has parameters for a great number of molecules 
(pharmaceutical ones included) that are composed of H, C, N, O, S, P, and halogens. It 
applies a simple harmonic function form and incorporates both empirical and heuristic 
models to estimate force constants and partial atomic charges. The current 
implementation of the GAFF force field consists of 33 basic atom types and 22 special 
atom types. The charge methods used can be HF/6-31G* RESP or AM1-BCC. 
GAFF is an important molecular mechanical tool for drug design, especially in binding 
free energy calculations and molecular docking studies. 
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2.3. MOLECULAR DYNAMICS 
2.3.1. INTRODUCTION 
The need to understand how the dynamic properties of molecules affects its functional 
behaviour lead to the development of a computer simulation technique that allows us to 
predict the time evolution of a system of interacting particles (atoms, molecules, etc.) – 
Molecular Dynamics (MD). It was in the 50s, with the development of computational 
power, that MD methodology was introduced, but was only in 1977 that the first protein 
simulations appeared, with the simulation of the bovine pancreatic trypsin inhibitor 
(BPTI).74  
By allowing the access to dynamic properties of a system, MD simulations became a 
valuable tool in the study of transport coefficients, protein stability, ligand binding, 
protein folding, among others. Molecular dynamics simulation techniques are also used 
in procedures such as X-ray crystallography and NMR structure determination. 
With molecular dynamics it is possible to describe how positions, velocities, and 
orientations of molecules change over time by solving Newton's equations of motion. 
The evaluation of the individual particle motion as a function of time enables the 
complex and dynamic processes that take place in biological systems to be analyzed. 
By the equation of motion, present next, where F is the force exerted on the particle, m 
is its mass and a is its acceleration, it is possible to determine the acceleration of each 
atom in the system: 
𝑭 = 𝑚𝐚 
MD generates a trajectory that describes the positions, velocities and accelerations of 
the particles as they vary with time by integrating Newton’s laws of motion. For 
example, in an system of N particles, the force acting on particle I in the 𝑥 direction is 
given by: 
𝑑2𝑥𝑖
𝑑𝑡2
= −
𝐹𝑥𝑖
𝑚𝑖
 
The particle has a mass (𝑚𝑖) and describes a trajectory along one coordinate (𝑥𝑖). 𝐹𝑥𝑖 
represents the force acting on that particle in that direction. This calculation is repeated 
for every particle in the three directions. The calculation of the force acting on each 
atom and the integration of the equations of motion in order to know their positions with 
respect to time generates an ensemble were the average values of properties can be 
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determined. Once the positions and velocities of each atom are known, the state of the 
system can be predicted at any time. This is, therefore, a deterministic methodology.  
Due to the complicated nature of this potential energy calculation, there is no analytical 
solution to the equations of motion for systems with more than two interacting particles 
and they must be solved numerically. Numerous algorithms have been developed for 
integrating the Newton’s equations of motion. One of these is the Verlet algorithm. It 
does not use explicit velocities and calculates the particles new position (t+Δt) using 
positions and accelerations at time t and the positions from time t-Δt. Important 
features of the Verlet algorithm are that its time reversible; that fact that it requires just 
one force evaluation per step; the fact that it is low order in time, hence permitting 
longer timesteps; and finally that it has modest storage requirements. However, this 
algorithm has only moderate accuracy. 
Another algorithm of choice is the leap-frog algorithm. In this algorithm, the velocities 
are explicitly calculated. The velocities for a time t+1/2Δt are calculated first, and then 
these velocities are used to calculate the positions r at the time t+Δt. Therefore, the 
velocities leap over the positions and then the positions leap over the velocities, 
successively. The Leap-frog algorithm is more precise but has also some 
disadvantages: velocities are not calculated at the same time as the positions, and it is 
computationally time consuming. 
Other popular integration algorithms include the velocity Verlet algorithm75, and the 
Beeman’s algorithm76. When selecting which one to use, it is important to guarantee 
that it will be able to conserve energy and momentum, permit an integration time step 
as large as possible and, of course, it should be computationally efficient.  
 
2.3.2. SIMULATION LENGTH AND TIME STEP 
MD is an extensively used research tool in disciplines which include physics, chemistry, 
materials science, biology, and geology, among others. With respect to biological 
phenomena there is a wide range of time scales over which specific processes occur. 
Local motions (e.g. atomic fluctuations) can take just some femtoseconds (fs) or 
picoseconds (ps), but global motions (e.g. folding/unfolding) may take hours. So, how 
long should a simulation run depend on the system and the physical properties of 
interest. The typical number of steps that are feasible with modern resources can range 
from 106 – 108, and the time step is usually of  ~10-15s (1fs). 
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The time step needs to be small enough to minimize integration errors and also large 
enough for the designed computation time to be feasible. When calculating the position 
of the atom at a certain instant, it is considered that the force acting on it is kept 
constant during the time interval Δt. Δt has to be small because the lower the value of 
Δt, the most accurate are the results. The choice of the time step must result of a 
balance between economy and accuracy. A small time step implies that much more 
computational time will be needed to simulate a given MD run, limiting its use in large 
systems (the CPU cost is between N2 and N, depending on the use of cutoff conditions 
or particle mesh Ewald techniques, with N being the number of atoms). Too large time 
steps, on the other hand, tend to promote instability in the integration algorithm and 
could lead the simulation to abort due to lack of energy conservation. 
A fairly common rule when simulating flexible molecules is the choice of an integration 
step which is at least an order of magnitude smaller than the time scale associated with 
faster movement which occurs in the system. This will typically be the bond stretching 
(vibration period of ca. 10 fs), so in practice, time step is normally 1 fs. A way to 
increase of the integration step without compromising the numerical stability of the 
simulation is to freeze the higher-frequency vibrations (e.g. involving hydrogen atoms) 
by constraining the correspondent bonds to their equilibrium values, without affecting 
the remaining degrees of freedom. For this, it is important that only the properties that 
are independent of these degrees of freedom should be evaluated. This approximation 
allows to considerer the highest frequency vibrations to be the ones between heavy 
atoms (around 2 to 5 times slower than vibrations of the bonds containing hydrogen 
atoms), enabling the use of a time step of 2fs. 
The method employed is the use of the SHAKE algorithm. This algorithm, in a 
simplistic way, assumes that the length of the X-H bond can be considered constant. 
SHAKE is an iterative procedure that involves solving the unconstrained equations of 
motion and retrospectively determining the constraint forces that need to be applied at 
the beginning of the time step to ensure that the bond lengths are maintained at 
constant length. This algorithm can be applied also to all bond-stretching motions in the 
system, allowing for time steps as large as 3 fs.  
 
2.3.3. ENSEMBLES 
A molecular dynamics simulation generates a sequence of points in phase space as a 
function of time, which are characterized by fixed values of thermodynamic variables. 
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This collection of all possible systems which have different microscopic states but have 
an identical macroscopic or thermodynamic state is called ensemble. Ensembles are, 
thus, characterized by fixed values of thermodynamic variables like energy, 
temperature, pressure, volume and number of particles, among others. To correspond 
to a well established macroscopic state, it must have α+2 state functions or 
thermodynamic variables defined, where α is the number of components present in the 
system. 
In the beginning, it was accepted that MD simulations could only be performed in a 
Microcanonical ensemble (NVE), characterized by a fixed number of atoms, N, a fixed 
volume, V, and a fixed energy, E. This corresponds to an isolated system and 
experiments are most often conducted on samples in thermal and/or mechanical 
contact with their surroundings. Nowadays, this simulation is usually performed as a 
benchmark to ensure the numerical integrator is implemented correctly and that the 
time step is small enough. 
Temperature control is also an aspect of particular importance for performing a 
molecular dynamics simulation. Temperature is related to the total kinetic energy of the 
system (if it is at equilibrium) that should vary symmetrically to the variation of potential 
energy in an isolated system. The latter is dependent on the position of all particles 
constituting the system. To maintain the average temperature of the system constant 
one can use the Canonical Ensemble (NVT - fixed number of atoms, N, a fixed volume, 
V, and a fixed temperature, T) or the Isobaric-Isothermal Ensemble (NPT - fixed 
number of atoms, N, a fixed pressure, P, and a fixed temperature, T). To maintain the 
constant temperature, the simulated system is embedded in an infinite heat bath by the 
application of a thermostat. The most commonly used are the Nosé-Hoover, 
Berendsen and Langevin. 
The simulations of this work presented were made in the NPT ensemble, controlling 
the pressure and temperature through isotropic pressure scaling and a Langevin 
thermostat. 
Initially, previous to the data collection, the NVT ensemble was used in order to allow 
the system to relax, achiving equilibrium within a fixed volume. In the Langevin 
thermostat, at each time step, every particle is subject to a random (stochastic) force 
and to a friction (dissipative) force. The equation of motion for the particle i is: 
𝑚𝑎𝑖 = 𝐹𝑖 − 𝑚𝛾𝑣𝑖 + 𝑊𝑖(𝑡) 
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Here 𝛾 is a friction coefficient with units of s-1 and W is a random force that is 
uncorrelated in time and between particles. 
Most MD simulations have an equilibration period, during which time the system is 
allowed to achieve a realistic configuration. After that the production part of the 
simulation begins, and property averages are accumulated. The temperature coupling 
is often used during the equilibration period so that the temperature begins low and 
then rises to the desired system temperature for the production phase. 
 
2.3.4. CUT-OFF AND BOUNDARY CONDITIONS 
The behavior of finite systems is very different from that of infinite ones. The size of the 
systems simulated by molecular dynamics is usually limited by the available computing 
power. As a spherical system increases in size, its volume grows as the cube of the 
radius while its surface grows as the square. Atoms near the boundaries have fewer 
neighbors than atoms located inside. Surface effects may thus play a little role in the 
chemistry of macroscopic systems. However, MD simulations tend to constrain the size 
of the system to be so small that surface effects cannot be neglected, because of 
computational resources. 
The typical solution to overcome both the problem of the ”finite” size of the system and 
to minimize the surface effects is to use periodic boundary conditions (PBC). PBC 
assumes that the box containing the atoms in the simulation is surrounded by identical 
copies of itself in all directions. All the “image” particles move solidary with their 
”original” particle from the simulated box and only one of them is effectively simulated. 
This is an artificial method of increasing the size of the system under study. When a 
particle enters or leaves the simulation region, an image particle leaves or enters that 
same unit cell from an opposite point on the surface of the unit cell. Hence, the number 
of particles from the simulation region is always conserved. 
The dimension of the unit cell is an important practical question because each particle 
in the simulation box should interact only with the other particles in the box, and not 
also with their images. This would make the number of interacting pairs to increase 
enormously. There are several ways to address this, like the minimum image 
convention and a force cut-off distance. Both are based on the truncation method of 
interactions from a certain interatomic distance.The minimum image convention defines 
that each particle interacts only once with a given particle. So, among all images of a 
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particle, consider only the closest and neglect the rest. The force cutoff also defines 
that, beyond that distance, particle pairs simply do not see each other. Thus, all cell 
dimensions must be at least as large as the largest cut-off length employed in the 
simulation and the cutoff distance must be less than half of the simulation cell 
dimension, to avoid that a particle would interact with its own image. When the MD is 
performed to a typical biomolecular system (e.g. biomolecule in a solvent) the 
dimensions of the unit cell should encompass the dimensions of the molecule plus at 
least twice the largest cut-off distance. 
Special attention must be paid to the case when considering properties influenced by 
long-range correlations, like for charged and dipolar systems. 
 
2.3.5. LIMITATIONS OF MOLECULAR DYNAMICS  
Simulations act as a bridge between theory and experiment. MD methodology can be 
useful testing a theory, comparing a model with experimental results or even carrying 
out simulations on the computer that are difficult or impossible in the laboratory. 
However, is not without limitations.  
 
2.3.5.1. USE OF CLASSICAL FIELDS 
The classical description of interatomic interaction and atomic motion cannot be used 
to model some phenomena like, for e.g., changes in chemical bonding or the presence 
of important noncovalent intermediates. Also the nuclear quantum effects are important 
for lighter atoms (e.g. H, He, Li) or when the temperature of the system is low, where 
the classical approximation led to poor results. 
The realistic results of simulations arise if the potential energy function mimics the 
forces experienced by the ‘real’ atoms. Availability of good potential functions is one of 
the main conditions for expansion of the area of applicability of the MD simulations to 
understand and predict the properties and behavior of physical systems. Quantum (or 
ab initio) MD simulations for all valence electrons are still impractical for large systems. 
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2.3.5.2. TIME AND LENGTH SCALE LIMITATIONS 
Although computers are always improving, will they be ever be big enough and fast 
enough? Nowadays, MD simulations can be performed on systems containing 
hundreds of thousands of atoms. Simulation times range from a few nanoseconds to 
more than one microsecond. However, the limitations on the size (number of atoms) 
and time of the simulation constrain the MD simulations yet. The number of atoms that 
can be included in the simulation (104 – 107) conditions the computational cell size. The 
structural features of interest and spatial correlation lengths in the simulation should be 
smaller than the size of the computational cell. Thus, to address this it is necessary to 
treat different length scales at different levels of theory, as in the case of enzymatic 
reactions, for example. 
To have reliable simulations, the simulation time must be longer than the relaxation 
time of the quantities of interest. But, different properties have different relaxation times 
and biologically important processes extend over many orders of magnitude of time. In 
the same system, there can be phenomena that take picoseconds while others may 
take minutes. For that, the time limitation is the most severe problem in MD simulations 
nowadays. 
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2.4. FREE ENERGY CALCULATIONS 
2.4.1. INTRODUCTION 
Free energy is considered the principal quantity in thermodynamics and allows to 
understand how chemical species recognize each other, associate or react. 
Phenomena like conformational equilibria and molecular association, enzyme reaction 
mechanism, partitioning between immiscible liquids, ion transport, electron transfer, 
receptor-drug interaction, protein-protein and protein-DNA association, and protein 
stability require the knowledge of the underlying free energy. 
The free energy is usually expressed as a function of Helmholtz, F (for system with 
NVT constant), or Gibbs function, G (NPT ensemble). The latter ensemble represents 
typical laboratory conditions and since living cells also operate at such conditions, it is 
correct to say that Gibbs free energy dictates the direction of biochemical processes.77  
The definition of the Helmholtz free energy and the Gibbs free energy can be explained 
considering the equations set out by the first and second laws of thermodynamics: 
∆𝑈 = 𝑄 + 𝑊 ≅ ∆𝑈 = 𝛿𝑄 − 𝑝𝑑𝑉 
𝑑𝑆 =
𝛿𝑄
𝑇
 
Where 𝑈 is the internal energy, 𝑄 is the heat exchanged between the system and its 
surroundings (𝛿𝑄 corresponds to the infinitesimal increment of heat supplied to the 
system from its surroundings, 𝑊 is the work done on the system, which corresponds to 
the product, 𝑝𝑑𝑉  (p of pressure and dV of volume change), 𝑑𝑆  is the infinitesimal 
increment in the entropy and T is the temperature. These equations refer to reversible 
processes. 
Hence, for the Helmholtz free energy (A): 
𝐴 = 𝑈 − 𝑇𝑆 
𝑑𝐴 = 𝑑𝑈 − 𝑇𝑑𝑆 − 𝑆𝑑𝑇 
𝑑𝐴 = 𝑇𝑑𝑆 − 𝑝𝑑𝑉 − 𝑇𝑑𝑆 − 𝑆𝑑𝑇 
𝑑𝐴 = −𝑝𝑑𝑉 − 𝑆𝑑𝑇 
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For Gibbs free energy (G), with H being the enthalpy: 
𝐺 = 𝐻 − 𝑇𝑆 
𝐺 = 𝑈 + 𝑝𝑉 − 𝑇𝑆 
𝑑𝐺 = 𝑑𝑈 + 𝑉𝑑𝑝 + 𝑝𝑑𝑉 − 𝑇𝑑𝑆 − 𝑆𝑑𝑇 
𝑑𝐺 = 𝑇𝑑𝑆 − 𝑝𝑑𝑉 + 𝑉𝑑𝑝 + 𝑝𝑑𝑉 − 𝑇𝑑𝑆 − 𝑆𝑑𝑇 
𝑑𝐺 = 𝑉𝑑𝑝 − 𝑆𝑑𝑇 
In terms of differentials, the symbol “d” means that ̄ are inexact differentials, i.e. that 
they depend on the path and not only on the initial and final states.  
In a free energy simulation, if the total number of particles remains constant, it is 
possible to assume that ΔPV is zero, in which case the Gibbs and Helmholtz free 
energy changes are identical.78 The Gibbs free energy can be defined as the energy 
that can be converted into work at a uniform temperature and pressure throughout a 
system. Here it will be referred only as Gibbs free energy. 
Free energy is a state function, so it is independent on the path of the reaction. The 
total free energy can be calculated as the sum of the free energies between similar 
intermediates, regardless the manner in which a particular equilibrium state is reached 
or prepared. Also, the energy function can be modified and manipulated with enormous 
flexibility in computer simulations, which allows that a known system can be 
transformed into a wide range of other systems of interest with relative ease. 
Hence, the calculation of free energy differences is one of the most interesting 
applications of biomolecular simulations. To obtain a good estimate of the absolute free 
energy of a system it would require to sample all possible configurations of a system, 
which is not viable. The absolute free energy can only be calculated directly in a limited 
number of cases, like small simple systems governed by a very simple Hamiltonian. 
So, in chemistry, the main interest is in the changes over the course of a chemical 
process, rather than in absolute values of its thermodynamic functions. 
Computationally, the calculation of the difference in free energy between two related 
states, A and B, of a system is usually the aim. These states (or possibly the series of 
pairs of states A and B) can correspond to the binding of two compounds to the same 
receptor or different conformations of the same molecular system, for example. The 
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free energy difference is related with to the relative probability of finding a system in a 
given state as opposed to another. 
The roots of these theoretical calculations of free energy are in the fifties with the work 
of Zwanzig79, but only with the increase in computational power and the emergence of 
a wide variety of methods that both the efficiency and the accuracy of free energy 
calculations improved. It was only until the 80s that the first macromolecular free 
energy calculations were published. The initial studies showed an excellent agreement 
between theory and experiment and encouraged the application of these calculations 
to increasingly complex molecular assemblies. But, issues related to sufficient 
sampling and to the adequacy of the force field emerged. Calculated free energy 
differences showed a tendency to deviate from the experimental target value as more 
sampling was made, leading to the belief that first results reflected good fortune rather 
than actual accuracy of computer simulations.80 Efforts were made to address these 
issues and now it is possible to obtain predictions with quality that is truly as good as 
suggested in the beginning. 
Albeit free energy simulations provide a direct link between the microscopic structure 
and fluctuations of a system, this important equilibrium thermodynamic property is 
difficult to determine. Hence, several efforts have been made to develop fast but also 
accurate methodologies that could embrace a wide range of research areas. 
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2.4.2. FREE ENERGY CALCULATIONS FOR DRUG DISCOVERY 
Computational techniques are increasingly used in pharmaceutical drug discovery. 
Among them, free energy calculations have high importance in computer-aided drug 
design. With precise and accurate estimates of the free energy differences of a system 
obtained directly from numerical simulations, the need to measure thermodynamic 
properties of a system by experiment can be greatly reduced. Processes like protein–
ligand binding and drug partitioning across the cell membrane cannot be predicted 
reliably without the knowledge of the associated free energy changes. However, time is 
one of the major issues. If the calculations takes longer to perform than a candidate 
drug molecule can be synthesized and tested, there is little benefit from attempting the 
calculation. There are, thus, continuous searches for new and improved 
methodologies, for better use of the permanent growth of computational power or just 
for a different approach of the problem, that can guide drug discovery. 
For Drug Design, the rational design of ligands binding to macromolecules with high 
affinity and specificity is one of the major goals. Computing the affinity of a molecule for 
a receptor (ΔGbind) is pivotal in the study of the driving forces for any biochemical 
process that involves molecular recognition. Calculating the binding energy, with 
quantitative accuracy, in protein complexes, or comparing complexes (ΔΔGbind) is a key 
component for identification, characterization and structure-optimization for novel or 
improved drugs. Computational studies that can accurately predict small molecule 
binding affinities or the binding selectivity across different targets are very usefull, 
reducing the time and resources required. Direct calculations of the free energies of 
binding of pharmacologic compounds and targets is particularly difficult when the 
significant structural changes involved. 
The study of drug transport to the site of action (pharmacokinetics) and drug 
interactions at the site of activity and the consequent effect (pharmacodynamics) is of 
major importance for new drugs discovery. To be transported in the blood, a favorable 
interaction of the drug with water is pivotal, but the determination of the solvation free 
energy (ΔGsolv) is an arduous task. Chemical properties and processes are often 
different in solution from the gas phase, so the solvent effect cannot be neglected. 
Therefore, computational studies, usually done in small molecules (where solvent 
molecules equilibrate more easily) are extremely useful. The ability to predict 
computationally solvation free energies for a series of small molecules entails important 
information for the discovery of new and/or improved drugs, especially in the lead 
optimization stages. Solvation free energy can help predicting proton affinities of small 
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molecules, partition properties of novel molecules before their syntheses and binding 
affinities to biomolecular drug targets in water.81 
Computational approaches can be used to reproduce qualitatively an experimental 
measurement and interpret it in terms of microscopic interactions. In this case, if the 
systems of interest are very similar, limited conformational sampling and short 
simulations will be needed, leading to an easier task. But MD free energy calculations 
can be arduous if we want to predict accurately and precisely an unknown free energy 
difference or a transformation that involves large conformational changes. Then, longer 
simulations will be needed as well as comparisons between different force fields to 
assess the accuracy. 
The development of drugs is thus a very complex and demanding interdisciplinary 
process and there is not a magic solution to a drug design problem. The characteristics 
of the system itself and the information available lead the experimental techniques or 
theoretical and computational tools to apply.  
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2.4.3. THERMODYNAMIC CYCLES 
The efficiency of free energy calculations depends greatly on the pathway that is 
chosen and the nature of the changes imposed on the system. The changes due to 
physical phenomena between two molecular systems (e.g.: ligand and receptor or 
proteins differing in one or a few amino acids) can be large and complicated. The use 
of thermodynamic cycles allows the selection of more efficient paths that cancel out 
these problematic changes by exploiting nonphysical pathways.  
Also the calculation of the absolute free energies of solvation can be tricky and subject 
to large errors. A direct calculation of solvation of a compound in water requires 
simulating the transfer from the gas phase (vacuum) to an aqueous phase, with the 
subsequent solvent reorganization. The introduction of a solute into an equilibrated 
water box can cause unphysical high energies. With the use of thermodynamic cycles, 
it is possible to calculate solvation free energies differences, where one compound is 
transformed into another using an alchemical approach. Because free energy is a state 
function, the difference in the transmutation free energies in the gas phase and in 
aqueous solution must be equal to the difference in the absolute solvation free 
energies.78 In the work presented in this thesis, two types of free energy differences 
were calculated: ΔΔGsolv of small molecules (after the addition of specific functional 
groups) and ΔΔGbind between protein pairs. 
Consider the two thermodynamic cycles, representative of the processes studied in this 
work: ∆∆𝐺(𝑔)
𝐴→𝐵 
I. Solvation 
 
 
 
SCHEME 1. Schematic representation of the thermodynamic cycle involved in the calculation of the ΔΔGsolv free 
energies associated to the transformations in the gas-phase (∆𝑮(𝒈)
𝑨→𝑩) and in solution ((∆𝑮(𝒂𝒒)
𝑨→𝑩). 
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From this, it is possible to say that: 
∆∆𝐺𝑠𝑜𝑙𝑣  = (∆𝐺(𝑎𝑞)
𝐴→𝐵) − (∆𝐺(𝑔)
𝐴→𝐵)   = ∆𝐺𝑠𝑜𝑙𝑣
𝐵  −  ∆𝐺𝑠𝑜𝑙𝑣 
𝐴   
Considering the solvation thermodynamic cycle, vertical legs correspond to processes 
that can usually be studied experimentally and horizontal legs correspond to a 
chemical transmutation that cannot be performed experimentally. The difference 
between the two vertical quantities must be equal to the difference between the two 
horizontal quantities. While the former difference is easier to measure, the latter is 
easier to compute. 
 
II. Binding  
 
 
  
SCHEME 2. Thermodynamic cycle for calculating the binding free energy difference between the wild type 
protein:protein complex and the mutant protein:protein complex. Consider  ∆𝐆𝐀+𝐁→𝐀𝐁 and ∆𝐆𝐀+𝐁′→𝐀𝐁′ are binding free 
energies for the wild type and the mutant respectively, both in the complex form. 
In the binding thermodynamic cycle, the difference in chemical transmutation is on the 
vertical legs and the experimental results reflect the horizontal leg processes. Since the 
free energy is a state function, the horizontal and vertical legs both provide routes to 
the difference in binding free energies.82 When we use the TI approach, the vertical 
process is the one simulated in the calculations and can be presented as: 
∆∆𝐺𝑏𝑖𝑛𝑑  = ∆𝐺𝑃𝑟𝑜𝑡𝐴𝑤𝑡→𝑃𝑟𝑜𝑡𝐴𝑚𝑢𝑡(𝑎𝑞)  −  ∆𝐺𝐶𝑜𝑚𝑝𝑙𝑒𝑥𝑤𝑡→𝐶𝑜𝑚𝑝𝑙𝑒𝑥𝑚𝑢𝑡(𝑎𝑞)  
As Thermodynamic Integration allows to calculate a free energy difference for which no 
experimental verification is available, the use of a thermodynamic cycle helps to 
connect the result from a series of TI calculations to physical observables. 
When we calculate the difference in binding free energy trough MMPBSA methodology, 
the process represented by the horizontal legs of the cycle is considered. Hence, the 
difference in binding free energies can be written as: 
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∆∆𝐺𝑏𝑖𝑛𝑑  = ∆𝐺𝑏𝑖𝑛𝑑
𝑚𝑢𝑡  − ∆𝐺𝑏𝑖𝑛𝑑
𝑤𝑡   
For the MMPBSA approach, free energy calculation is based in three individual energy 
calculations: one with the ligand, one with the protein and one with the protein-ligand 
complex. So, the binding free energy is calculated by the subtraction of the energies of 
the individual molecules from the protein-ligand complex, as represented next: 
∆𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔−𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒  = 𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥  − (𝐺𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 + 𝐺𝑙𝑖𝑔𝑎𝑛𝑑) 
The accuracy of a free-energy calculation can be enhanced by a clever choice of the 
systems states, pathways, and cycles. Free energy cycles can be used to simplify 
simulations covering a wide variety of processes. The methods more widely used at 
MM level to calculate free energy are: Thermodynamic Integration (TI), Free Energy 
Perturbation (FEP), Potentials of Mean Force (PMF), Umbrella Sampling (US), Steered 
Molecular Dynamics, Molecular Mechanics-Poisson Boltzmann-Surface Area 
(MMPBSA) and Molecular Mechanics-Generalized Born-Surface Area (MMGBSA). In 
this work, the methods that were used were TI and MMPBSA. 
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2.4.4. THEMODYNAMIC INTEGRATION 
2.4.4.1. INTRODUCTION 
The choice of the method employed to estimate the changes in free energy is of major 
importance since it may affect the efficiency of the calculation and the amount of 
sampling necessary to reach proper convergence. Alchemical methods based on 
Molecular Dynamics (MD) or Monte Carlo (MC) sampling allows accurate calculations. 
The name “alchemical” free energy calculations is justified if the transitions between 
the states exploit nonphysical pathways. In an alchemical transformation, a chemical 
species is transformed into another via a pathway of nonphysical (alchemical) states. 
The alchemical processes are often more tractable to computational simulation than 
the physical process itself, especially when considering biochemical systems. MD-
based computational methods for free energy calculations can be divided into 
equilibrium and non-equilibrium approaches. 
Thermodynamic integration (TI) is an equilibrium method that allows the estimation of 
the free energy difference between two discrete states. The two states are coupled by 
a control variable λ, where for λ=0 the system is represented by a Hamiltonian 
corresponding to the initial state and for λ=1 by a Hamiltonian corresponding to the 
final state. Intermediate (nonphysical) states are defined by intermediate values of λ. It 
is is one of the most rigorous methods for free energy calculations83,84. It does not 
require additional empirical parameters other than those implicit in the force field, but it 
is a computationally expensive approach. The aim is to calculate the free energy as a 
difference between two-states, A and B, for that using the Zwanzig’s formula: 
∆𝐺𝐴→𝐵 = 𝐺𝐵 −  𝐺𝐴 = −𝑘𝑇 𝑙𝑛 〈𝑒𝑥𝑝 (−
∆𝑉
𝑘𝑇
)〉𝐴 
In this equation k is the Boltzmann constant, V is the potential energy of the system, 
and T is the temperature in Kelvin. A denotes an ensemble average (generated from 
molecular dynamics or Monte Carlos simulations). 
This equation implies that the difference between VA and VB must be very small, 
because the configurations sampled on the potential VA should have a considerable 
probability to occur in potential VB (ΔV has to be small). Usually, an approximation in 
several steps is adopted to implement the above equation. This multi-step approach, 
which defines a path between the states A and B, introduces a set of intermediate 
potential energy functions typically constructed as a linear combination of initial states 
A and end B. The coupling parameter λ may take on values from 0 to 1 is used, giving 
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rise to a number of points where each point is represented by a potential energy 
function corresponding to a certain value of λ. Since, as it was already mentioned, free 
energy is a state function, any reversible path linking A and B can be used to 
computationally measure the energy difference between the two states of interest. 
Considering that the λ-steps should be small and with λ →0, the difference in Gibbs 
energy between two states A and B is expressed as an integral over λ: 
∆𝐺 = ∫ 〈
𝜕𝑉(𝜆)
𝜕𝜆
〉𝜆 𝑑𝜆
1
0
 
This ensemble average of the derivative of the potential energy with respect to λ is the 
equation used in Thermodynamic Integration free energy calculations. 
To obtain a credible estimation of the free energy difference, the system must be in 
equilibrium at all times and must be sampled at each point with a set of representative 
configurations also in balance. 
One of the main requirements of thermodynamic integration is that the path should be 
reversible, and consequentely free from any hysteresis. When simulations are run in 
the forward direction (0→1) and in the reverse direction (1→0), the amount of 
hysteresis between them is a measure of the non-reversibility in the integration. The 
choice of reference state with its structure and energy as close as possible to the final 
state of interest can minimize the hysteresis. For this, one of the most usual strategy is 
to make the transformation splitting the path in intermediates. Hence, although the 
initial and final structure and energy may be meaningly different, in the intermediate 
states the differences are smaller. 
 
Free energy is probably the most important quantity in thermodynamics and one of the 
central topics in biophysics. Efficient and accurate calculation of this property is still a 
big challenge in computational chemistry, for many relevant systems with local 
minimum energy configurations separated by energy barriers. Thermodynamic 
integration is one of the choices to perform accurate and rigorous calculations81. 
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2.4.4.2. DUAL TOPOLOGY 
The free energy difference between two molecular systems may be calculated from 
molecular dynamics simulations using a single or dual-topology representation of the 
system. This choice of simulation methodology determines the correct treatment of 
changes in bond and bond angle parameters, as well as the interpretation of results. 
In single-topology approaches, the properties in a portion of the system are smoothly 
transformed from the first molecule to the second as a function of λ. Every atom in the 
initial state has a counterpart in the final state, and so the number of atoms does not 
change in the transformation. To accomplish this, dummy atoms are introduced. The 
dummy atoms have no non-bonded energy terms (van der Waals or electrostatic 
terms) associated with them, but they are connected to the rest of the system through 
bonded terms.  
The effect of differences between a system with dummy atoms and the real system it 
represents must be investigated and may require corrections. 
In dual-topology approaches, there are distinct initial and final molecules 
simultaneously present, but no force-field interactions between the two are calculated. 
One topology corresponds to the λ = 0 endpoint, and the other corresponds to the λ = 1 
endpoint. The parts of the system that change interact with the rest of the system, but 
not with each other at intermediate values of λ. The number of atoms in this approach 
is the sum of the number of atoms that change between the initial and final state, plus 
the number of atoms that remain the same. 
In practice, there is not an approach with entirely satisfactory results. At extreme values 
of λ, dual-topology present some difficulties85, but to calculate a free energy difference 
for systems where the topology of a closed ring changes, the most rigorous way to 
define the system is to use dual topologies83. 
TI is appreciably more efficient with the dual topology system, but the two approaches 
appear to be of comparable efficiency for longer simulation times. 
 
2.4.4.3. SOFT-CORE POTENTIALS 
In theory, since free energy is a state function, simulations of any transformation 
connecting two end-points of interests would lead to a correct free energy difference. 
However, some numerical instability called 'end-point catastrophes' tends to occur 
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when λ becomes close to 0 or 1. This is associated with vanishing or appearing atoms 
where other particles are already present. The classical description of the nonbonded 
interactions in the molecular mechanics force fields (Lennard-Jones potential for the 
Pauli repulsion and long-range dispersion and the Coulomb potential for electrostatic 
interactions) justify it. Hence, the potential energy as well as the forces between two 
particles go to infinity when the distance between the particles approaches zero and it 
can cause two problems. First, related with the infinite repulsive (1/r12) Lennard-Jones 
term for r =0, because when an atom has no interactions, other atoms can lie on top of 
it. This will cause the energy of that state in which this atom becomes suddenly present 
with its full interaction tends to infinite, as well as its derivative, as the interatomic 
distance tends towards 0. Second, related with a deficient configurational sampling 
introduced by appearing/disappearing atoms. The repulsive Lennard-Jones potential of 
a very small atom is still infinite for r = 0, which means that that sampling of the 
positions occupied by vanishing atoms cannot be accomplished until these atoms have 
completely disappeared. In confined geometries, like protein binding site, the space 
occupied by vanishing atoms cannot be properly filled until the very last end-point 
simulation. The MD dynamics can become unstable near the end-points of vanishing 
atoms because, for very small atoms, the associated forces change too rapidly with the 
distance, requiring successively smaller steps.86  
This problem can be addressed with "soft-core" potential functions which keep pairwise 
interaction energies finite for all configurations and provide smooth free energy curves. 
The soft-core potential is an alternate functional form of the Lennard-Jones potential 
that shifts the pair-wise separation of the transforming atoms, increasing their distance 
extreme λ values. In this work, the soft core potential employed was the implemented 
into the AMBER program in which non-bonded vdW interactions are represented by a 
λ-dependent modified LJ equation: 
𝑉"softcore"𝑣𝑑𝑊 = 4𝜀 (1 − 𝜆 [
1
[𝛼𝜆 + (𝑟 𝜎⁄ )6]2
−
1
𝛼𝜆 + (𝑟 𝜎⁄ )6
]) 
ε and σ are the common LJ parameters, r is the atomic distance, and α is an adjustable 
constant. 
This modified LJ-equation thus prevents the origin singularity type of free energy 
divergence from happening. 
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2.4.4.4. CAPABILITIES AND LIMITATIONS 
TI is one of the favorite methods for free energy calculations. Nevertheless, it is not a 
perfect methodology and so it has strengths and weaknesses. 
The first problem that arises is the need of adequate sampling of phase space, a 
fundamental problem in any molecular simulation. The length of the simulations as well 
as the choice of the correct region of the conformational space are important to this 
issue. In spite of the computational cost that may sum, TI has the advantage that more 
and longer simulations could be added at different lambda points. It is possible to add 
as many additional data points as needed to refine the results without having to redo 
the initial calculations.  
Another important step for reliable free-energy changes TI simulations is the choice 
and implementation of the Force Field. This is pivotal to minimize the error due 
inaccuracies in the potential energy function, long-range electrostatic interactions, 
molecular polarization, etc., even though no absolutely perfect force field exists. Within 
the force field and model resolution employed, there are TI calculations that present 
high accuracy for small compounds.87,88 The practical use of TI approaches in the 
context of macromolecular processes can present some limitations because of the 
ruggedness of energy surfaces. But the fact that during the TI processes only the 
interactions of the relatively small mutated parts of the molecules within the system are 
directly considered can help to override this.89  
Molecular simulations imparts great flexibility and versatility and TI methodology has in 
the possibility of employing non-physical paths one of the strong points. However, both 
states of the system should not be too different so they will occupy similar regions of 
conformation space, and therefore reduce the statistical noise in the free energy 
estimates.  
The integration error implicit in the TI method is considered as disadvantage of this 
approach. The fact of the continuous integral is approximated by a discrete sum, using 
a numerical integration scheme, should not be critical if  the integrand varies smoothly 
and is evaluated at a sufficiently large number of ”λ” points. 
As a result of the multiple studies developed in this area, two different methodological 
problems arouse: overfitting and lack of pharmaceutical representativity. The first one 
result of the use small and sometimes static amount of known data that lead to good 
performance only within the classes of compounds considered. In order to achive good 
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results within a determinated group, the risk is to specify too much and therefore 
reducing the success when applying on different classes. The latter problem concerns 
the specificity of drug-like compounds. Drug-like compounds are sparsely distributed 
through chemistry space. Drug-like is defined as those compounds that have 
sufficiently acceptable ADME properties (absorption, distribution, metabolism, and 
excretion) and acceptable toxicity properties to survive through the completion of 
human Phase I clinical trials.90 Regardless of the important simple additive parameters 
resultant of small monofunctional molecules studies, many times the poli-functionality 
of drug-like compounds do not present the desired sensitivity. 
In spite of this all, the TI methodology is applied regularly for calculating the free energy 
(binding, solvation and other properties). Various versions are programmed in the 
commonly used molecular mechanics/ molecular dynamics software packages. 
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2.4.5. MMPBSA - MOLECULAR MECHANICS/POISSON-BOLTZMANN 
SURFACE AREA 
2.4.5.1. INTRODUCTION 
The MM-PBSA methodology (Molecular mechanics/Poisson-Boltzmann Surface Area) 
is a method that combines molecular mechanics and continuum solvent calculations. It 
allows the evaluation of solvation and binding free energies and can be been applied to 
a wide variety of macromolecules and complexes of macromolecules with ligands or 
each other. The free energy difference can be calculated between any two states, even 
when the two states are quite dissimilar from each other. This approach has its roots in 
the mid 90’s with the first successful implementation being attributed to Srinivasan.91,92. 
The MM-PBSA methodology has as major advantage its low computational cost with 
results with good agreement with experiment ones.93,94 This method is based on an 
analysis of molecular dynamics trajectories using a continuum solvation approach. The 
binding free energy can be decomposed in three components: 
 internal energy of the system (𝐸𝑀𝑀); 
 free energy of solvation (ΔGsolvation); 
 solute entropy effects (TΔS). 
To estimate the free energy of a complex system, a molecular dynamics simulation of 
the complex (protein-ligand) in a periodic box with water and counterions is carried out, 
with a correct representation of long-range electrostatic effects (e.g. PME), saving a set 
of representative structures. An ensemble of different conformations is extracted from 
MD trajectories and for each snapshot the solvent molecules are removed and the free 
energy is calculated according to the following equation: 
𝐺 =  𝐸𝑀𝑀 +  𝐺𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛 − 𝑇𝑆 
EMM is the average molecular mechanical energy, calculated with the same force field 
used in MD and including bond, angle, torsion, van der Waals, and electrostatic terms. 
No cut-offs are included, in order to incorporate all of the nonbonded interactions. 
ΔGsolvation is the solvation free energy, with the nonpolar part of solvation free energy 
being estimated by empirical methods based on solvent accessible surface and the 
electrostatic contribution to solvation being calculated by solving the Poisson-
Boltzmann (PB) equation: 
𝐺𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛 = 𝐺𝑃𝐵 + 𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟  
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TΔS is the solute entropy, estimated using normal mode or quasi harmonic analysis. 
This final term is likely to be equal for the two molecules, being many times ignored 
when ligands all roughly the same size. This avoids time intensive calculation for very 
little added information. 
The Poisson-Boltzmann equation is computed using the Delphi program: 
∇𝜀(𝑟)∇∅(𝑟) − 𝑘′∅(𝑟) = −4𝜋𝜌(𝑟) 
In this equation ϕ(r) is the electrostatic potential, ε(r) is the dielectric function, ρ(r) is the 
charge density, and k’ is related to the Debye-Huckel inverse length. The derivatives of 
the Poisson-Boltzmann equation are determined with a finite difference formula and 
iteratively solved until convergence is reached. In general terms, the electrostatic 
component of the solvation free energy can be regarded as the change of electrostatic 
energy resulting from transferring the solute from a low dielectric medium (vacuum) to 
a high-dielectric medium (solution), while keeping the same dielectric value for the 
solute. 
∆𝐺𝑃𝐵 =
1
2
∑ 𝑞𝑖(∅𝑖
80 − ∅𝑖
1)
𝑖
 
The nonpolar solvation term is approximated according with the equation: 
∆𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 = 𝛾(𝑆𝐴𝑆𝐴) + 𝛽 
where SASA is the solvent accessible area estimated with the molsurf program 
developed by Mike Connolly95, and γ = 0.00542 kcal/Å2 and β = 0.92 kcal/mol. 
The MM/PBSA model, like other implicit models is based on the assumption that 
electrostatic and nonpolar contributions to the free energy can be treated separately in 
a simple additive way.96 
The binding free energy between a ligand and a receptor (ΔGbinding) is determined from 
the following equation: 
∆𝛥𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔 = ∆𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − ∆𝐺𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 − ∆𝐺𝑙𝑖𝑔𝑎𝑛𝑑 
From the initial MD trajectory, the terms ΔGreceptor and ΔGligand are estimaded by 
removing the remaining partner. By assuming that the structure of the receptor and 
ligand are maintained upon binding, the snapshots for all three species can be 
obtained from a single trajectory for a complex. 
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2.4.5.2. CAPABILITIES AND LIMITATIONS 
The ability to accurately calculate the average free energy for a given macromolecular 
system in various different conformations or structures and to determine the free 
energy of binding of a protein-ligand complex, adds a very important asset to in silico 
computation. In the accuracy/speed ratio, MM-PBSA achieves a good compromise, 
being so a computationally efficient methods comparing with very accurate and reliable 
methods such as TI. 
Two appealing features that have established MM-PBSA in the past few years are 
solvent treatment and sampling. By using a continuum model, all the solvent 
coordinates are implicitly integrated and easily tunable, simplifying the dimension of the 
problem and allowing faster equilibration times, and, depending on the model, shorter 
computation times. Nevertheless, if there are water molecules that establish important 
interactions in the process, the use of them explicitly could lead to a better agreement 
with experiment. 
The more efficient sampling is due to free energy calculations being done only between 
the two “end points” instead of calculating along a mapping coordinate. By not 
sampling intermediates, this allows a reduction in computation costs. This will, 
however, introduce larger errors than others with more thorough (rigorous) sampling 
but despite these larger uncertainties, the ΔG results present a accountable agreement 
with experiment97,98. 
This methodology, of course, is not without problems. One of those is the calculation of 
the entropic contribution. Commonly, it is assumed that the entropic contributions are 
negligible if the ligands are of related size because they cancel each other. Although 
this approximation can be appealing and true, different ligands present a different 
number and type of degrees of freedom according with the complex association that 
should be considered. Also, the change of conformation of the ligands when free in 
solution and receptor-bound can influence the proper binding energetics. In this case, 
single conformation of the protein-ligand receptor may seem insufficient and 
reductionist. 
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3. RESULTS AND DISCUSSION 
This chapter gives an account of the studies performed during this PhD, distributed by 
3 articles (2 published and 1 submitted), a database and additivity studies. 
The study of ΔGsolv and ΔΔGsolv free energies is presented in sections 3.1 and 3.2. In 
section 3.1, the strengths and weaknesses of 5 theoretical methods used to calculate 
solvation free energies were tested for 53 typical alcohol and alkane small molecules. 
Also, the determination of solvation free energies changes for 28 common alkane-
alcohol transformations (by the substitution of an hydrogen atom for a hydroxyl 
substituent) were performed. The work presented in section 3.2 the solvation free 
energy change (ΔΔGsolv) for a total of 92 transformations (substitution group: CH3, F, 
Cl, Br, I, NH2, CONH2 and NO2) in small molecules was predicted using 
Thermodynamic Integration (TI) and compared with the experimental values. The aim 
was to asses if TI is a suitable choice in CADD when no experimental data is available. 
In section 3.3 the study of protein−protein binding free energy differences upon alanine 
mutation of interfacial residues (ΔΔGbind) is presented. In four protein−protein 
complexes, two protocols were tested: ASM, based on the Molecular 
Mechanics/Poisson−Boltzmann Surface Area (MM-PBSA) approach and 
Thermodynamic Integration (TI). Comparison of the values obtained with these two 
methodologies against the experimental ones aimed to disclosure which should be the 
path to calculate efficiently this kind of crucial property (ΔΔGbind) in drug design and 
protein engineering. 
The database present in section 3.4 results from the collection of experimental and 
calculated values for ΔGsolv and ΔΔGsolv free energies. Two tables were elaborated with 
experimental ΔGsolv and ΔΔGsolv free energy values, for 241 and 204 compounds each. 
Calculated ΔΔGsolv free energy values, with Thermodynamic Integration, are also 
presented for 286 transformations. The different contributions to free energies of 
solvation of 10 functional groups, is also calculated based in the experimental values.  
Using the information available in the database, the different contributions to free 
energies of solvation of 10 functional groups were used to make some additivity 
studies, presented in section 3.5. Twenty five compounds were decomposed into 
fragments and each contribution of these added to a scaffold molecule. The variability 
of the compounds is related to the availability of experimental values in the literature. 
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3.1. COMPARATIVE ASSESSMENT OF COMPUTATIONAL METHODS FOR THE 
DETERMINATION OF SOLVATION FREE ENERGIES IN ALCOHOL-BASED 
MOLECULES 
 
PREFACE 
 
Free energy plays an important role in thermodynamics. An important challenge in 
computational drug optimization is to determine differences in free energies between 
related drug molecules, where solvation is an essential factor. Solvation Gibbs energy 
is considered the real measure of the average free energy of interaction of solute with 
its surroundings. 99 
In this study, we have evaluated the performance of five commonly used polarized 
continuum model (PCM) methodologies in the determination of solvation free energies 
for 53 typical alcohol and alkane small molecules. We also determined solvation free 
energies changes for 28 common alkane-alcohol transformations using these PCM 
methods, a thermodynamic integration (TI) protocol and of the Poisson–Boltzmann 
(PB) and generalized Born (GB) methodologies. 
It was our goals to accuratly calculate solvation free energies with different methologies 
and asses its performance as well to address the effect of a specific addition (HO) that 
occupies a prominent place in drug optimization efforts. 
The results show that the solvation model D (SMD) performs better among the PCM-
based approaches in estimating solvation free energies for alcohol molecules, and 
solvation free energy changes for alkane-alcohol transformations, with an average 
error below 1 kcal/mol for both quantities. For HO addition to aromatic rings, TI yield 
better results which indicate this methodology as good choice in the calculation of 
ΔΔGsolv in drug-like molecules. 
 
Regarding the contributions to the paper, Sílvia Alexandra Pinto Martins did all the 
practical work and wrote the first draft of the manuscript. 
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Comparative Assessment of Computational Methods for
the Determination of Solvation Free Energies in
Alcohol-Based Molecules
Silvia A. Martinsy and Sergio F. Sousa*,y
The determination of differences in solvation free energies
between related drug molecules remains an important challenge
in computational drug optimization, when fast and accurate
calculation of differences in binding free energy are required. In
this study, we have evaluated the performance of five commonly
used polarized continuum model (PCM) methodologies in the
determination of solvation free energies for 53 typical alcohol and
alkane small molecules. In addition, the performance of these PCM
methods, of a thermodynamic integration (TI) protocol and of the
Poisson–Boltzmann (PB) and generalized Born (GB) methods, were
tested in the determination of solvation free energies changes for
28 common alkane-alcohol transformations, by the substitution of
an hydrogen atom for a hydroxyl substituent. The results show
that the solvation model D (SMD) performs better among the
PCM-based approaches in estimating solvation free energies for
alcohol molecules, and solvation free energy changes for alkane-
alcohol transformations, with an average error below 1 kcal/mol
for both quantities. However, for the determination of solvation
free energy changes on alkane-alcohol transformation, PB and TI
yielded better results. TI was particularly accurate in the treatment
of hydroxyl groups additions to aromatic rings (0.53 kcal/mol), a
common transformation when optimizing drug-binding in
computer-aided drug design.VC 2013 Wiley Periodicals, Inc.
DOI: 10.1002/jcc.23264
Introduction
The environment plays an essential role in the large plethora
of biochemical phenomena, and its effect is often critical for a
correct atomistic description of molecular biological systems
and for an accurate determination of many of the properties
associated. In particular, water, the biological solvent of choice
and the most profuse constituent of living organisms, plays a
particularly important role in biological processes. The inclu-
sion of the effect of the solvent in computational models is
particularly challenging, although several methods able to rep-
resent molecules in solution, at different levels of sophistica-
tion, have been developed.[1–5] The level of detail used to
describe the chemical system, the physical rules underlying
the process of interest, and the mathematical formulas used in
describing these rules are among the various features that dis-
tinguish between the different alternatives available.[2]
Although gas-phase predictions can render faster and very
accurate results for some chemical processes and molecular
properties, there is a whole range of phenomena and molecu-
lar features that cannot be accurately addressed by such
means. In these cases, the influence of the solvent has to be
accounted for.[6]
Two general types of strategies are normally used to
account for the influence of the solvent in computational
chemical calculations: the inclusion of explicit solvent mole-
cules, and the use of a continuum solvent model. The first
strategy is in principle more accurate and allows a better rep-
resentation of a larger variety of processes, particularly when
the solvent is directly involved. However, explicitly treating the
large number of solvent molecules required to model a bulk
solution is extremely demanding from the computational point
of view, normally limiting the application of such strategies to
the molecular mechanical level, through the use of classical
force fields. The use of a continuum solvent model is signifi-
cantly less expensive and allows the solvent to be modeled
implicitly, that is, treated as an environment. Hence, this strat-
egy has found application into a wide range of conventional
methods, including quantum mechanical and molecular me-
chanical approaches.
In spite of the very important developments that have char-
acterized the last decades, computer-aided drug design
(CADD) still faces a number of very challenging problems.
Notable examples include the accurate prediction of the bind-
ing pose[7–12] and the correct modeling of the water mole-
cules.[13–15] Another important difficulty in CADD is the accu-
rate prediction of drug-receptor binding free energies
(DGbinding). As biochemical-relevant drug–receptor interactions
take place in an aqueous environment, being able to account
for the effect of the solvent is essential to model such
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processes computationally.[8,12,16] Hence, when calculating
drug-receptor DGbinding, one of the most difficult challenges
comes often from the determination of the solvation free
energy (DGsolvation) associated, with the presently available
methodologies having still limitations, both in terms of accu-
racy and computational time associated. The accurate calcula-
tion of solvation free energies has long been a challenging
problem, particularly within MM force fields[17–20], although
over the past years some improved computational approaches
have been developed to overcome this problem.[21–27] How-
ever, there are still substantial challenges for computational
chemists in tackling these problems, issues that force the
adoption of some compromises (in terms of accuracy, preci-
sion, and reliability) to obtain timely results.
The addition of hydroxyl groups (HO) occupies a prominent
place in drug optimization efforts, being typically one of the
first changes to be performed when trying to improve the af-
finity between a given drug and its receptor.[28] In fact, this
small hydrophilic substituent presents a number of features
that contribute to a rich and diverse chemistry, including the
presence of partial negative charge at the oxygen atom and
the ability to establish hydrogen bonds, both as donor and as
acceptor with functional groups on the receptor and with
water. It imparts to molecules some of the reactive and inter-
active properties of the AOH of water, and it increases water
solubility. These reasons make it a particularly challenging
group, albeit crucial, in the determination of solvation free
energies for CADD.
Here, we describe the application of five commonly used
polarized continuum model (PCM) methodologies in the deter-
mination of DGsolvation free energies for alcohol molecules and
for some related alkanes. In addition, the performance of the
same five PCM methods, of a simplified thermodynamic inte-
gration (TI) protocol, and of the Poisson–Boltzmann (PB) and a
generalized Born (GB) methods (with the AMBER force field),
were tested in the determination of solvation free energies
changes (DDGsolvation) on HO addition for common alkane-
alcohol transformations. In particular, the performance of these
methods was tested in the formation of primary alcohols, sec-
ondary alcohols, tertiary alcohols, cyclic alcohols, and aromatic
alcohols from the corresponding alkane-based molecules, rep-
resenting typical HO additions in standard drug-like molecules,
as those frequently encountered in CADD.
Computational Methods
PCM-based methodologies
General Protocol. The performance of five commonly used
PCM-based methodologies was evaluated in the determination
of DGsolvation free energies for typical alkane and alcohol small
molecules and in the estimating DDGsolvation free energies for
common alkane-alcohol transformations, by the substitution of
a hydrogen atom by a hydroxyl substituent.
The PCM methods tested were the polarizable conductor
continuum model,[29,30] the integral-equation-formalism polar-
izable continuum model (IEF-PCM),[31–34] the static isodensity
polarizable continuum model (IPCM),[35] the self-consistent iso-
density polarizable continuum model (SCI-PCM),[35] and the
more recent SMD model.[36] Calculations were carried out
using the Gaussian 09 suite of programs,[37] using for all the
PCM methods the default parameters as implemented in this
software package.
Following a gas-phase optimization at the MP2/6-31G(d,p)
level of theory, the solvation free energy for 29 alcohol and 24
alkane molecules was estimated from the free energy differ-
ence between a gas-phase single-point calculation and a PCM
single-point calculation with water as solvent (e ¼ 78.39), as
represented in the following equation:
DGsolvation ¼ GwaterPCM  GGas phase
This process was repeated for each of the five PCM
approaches outlined above and in the gas-phase, with single-
point energies calculated with four different levels of theory:
HF/6-31G(d), B3LYP/6-31G(d), M06-2X/6-31G(d), and M06-2X/cc-
PVTZ. Results were compared against experimental reference
data.[38–47] Care was taken to include combinations of theoreti-
cal level /basis set that could be effectively used in future
studies using realistic-sized drug-like molecules. This particular
choice of theoretical level/basis set was made taking into spe-
cial consideration the ones used in the parameterization of the
IEF-PCM[31–34] or SMD methods.[36]
These DGsolvation free energies were used to determine
DDGsolvation free energies for a total of 28 alkane-alcohol trans-
formations and compared also against experimental reference
data taken from the literature.[38–47]
Effect of Using Different Conformations. The specific molecular
conformation chosen for the PCM calculations is expected to
affect to some degree final DDGsolvation free energies as the
protocol here used considers a single structure per molecule.
This approximation and the specific geometry chosen per mol-
ecule should have a more dramatic impact for transformations
involving molecules with a high number of rotatable bonds
than in the case of smaller molecules.
To evaluate the impact of this approximation on the
DDGsolvation free energies calculated, we have performed addi-
tional calculations on a specific set of six representative and
diverse alkane-alcohol transformations: (i) the formation of two
primary alcohols (Propane/1-Propanol and Hexane/1-Hexanol);
(ii) the formation of two secondary alcohols (Propane/2-Propa-
nol and Hexane/2-Hexanol); and (iii) the formation of two
aromatic alcohols (benzene/Phenol and m-xylene/3,5-dimethyl-
phenol). These tests were performed for CPCM and SMD for
the B3LYP/6-31G(d) level of theory.
For each of the molecules involved, 10 ns of molecular
dynamic simulation were performed using AMBER 10[48] in
both implicit and gas-phase, using a time-step of 1 fs, together
with an infinite cut-off for the nonbonded interactions and
general AMBER force field parameters with restrained electro-
static potential (RESP) charges at the HF/6-31G(d) level of
theory. The modified GB implicit solvent model developed by
Onufriev et al. was used for the implicit MD simulations.
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An ensemble of 10 random structures was selected from
each trajectory (the final structure at each ns of simulation).
Each structure was optimized with the corresponding PCM
method or in the gas-phase, and the energy of each of the
optimized structures was calculated with the corresponding
method. Hence, new DDGsolvation free energies were calculated
from the corresponding ensemble averages. Values were com-
pared to those obtained from a single-static structure, as cal-
culated with the general protocol described previously.
Thermodynamic integration
TI is a powerful computational technique to determine free
energy differences between different states. Even though it is
classical in formulation (with accuracy ultimately depending on
that of the force field), TI can be a very competitive computa-
tional technique. TI takes particular advantage of the fact the
free energy is a state function, and that as such the free
energy change between two states depends only on the initial
and final state of the transformation and not on the particular
path involved between the two states. Hence, paths involved
in TI can be real chemical processes or alchemical processes,
such as the alchemical transformation of a hydrogen atom
into a hydroxyl group.
In this study, TI was used to calculate the solvation free
energies changes (DDGsolvation) on HO addition for a total of
28 alkane-alcohol transformations, by the substitution of a
hydrogen atom by a hydroxyl substituent the thermodynamic
cycle represented in Scheme 1 was used.
The test set used in this process included in particular the
formation of eight primary alcohols, five secondary alcohols,
three tertiary alcohols, two cyclic alcohols, and 10 aromatic
alcohols from the corresponding alkanes.
Using a coupling parameter (k), it is possible to compute
the free energy difference between two states A and B, with
the equation:
DGAlk!Alc ¼
Z1
0
@VðkÞ
@k
 
k
dk
A corresponds to the initial state (Alkane), with k ¼ 0, and B
corresponds to the final state (Alcohol), with k ¼ 1. In particu-
lar, and according to Scheme 1, this process was repeated in
solution and in the gas-phase. TI calculations were performed
using AMBER 10[48] with soft-core potentials and using the
general Amber force field.[49] Alkanes and alcohols were para-
meterized using the antechamber[50] module of AMBER with
charges derived at the HF/6-31G(d) level of theory, a typical
procedure when handling drug-like molecules through molec-
ular dynamics simulations.
Each TI transformation was performed in three steps. In the
first step, the atomic partial charge on the selected hydrogen
was turned off. In the second one, the van der Waals-transfor-
mation is performed, with the disappearance of the selected
hydrogen and the simultaneous appearance of the hydroxyl
group. Finally, in the third step, the atomic partial charge of
the hydroxyl group is switched on.
In each step, nine k values were used (k ¼ 0.1, 0.2, 0.3, 0.4,
0.5, 0.6, 0.7, 0.8, and 0.9), a common choice when using TI to
calculate free energy differences.[51–55] At each lambda value,
the starting structure was minimized for 500 steps, using the
steepest descent minimization algorithm in step 2, and steep-
est descent followed by conjugate gradient algorithm in the
other two steps. Next, the resultant structure was equilibrated
during 50 ps, at constant pressure. Production simulations of 1
ns for each k in the Isothermal-isobaric (NPT) ensemble were
performed, using the Langevin thermostat[56] with a collision
frequency of 1.0 ps1 at 300 K, a time step of 1 fs, and a cut-
off of 9 A˚ for the nonbonded interactions. Final values were
integrated numerically using the trapezoidal rule. TI calcula-
tions in water were performed with explicit solvent (TIP3P,
minimum 12 A˚ to the box side) and under periodic boundary
conditions with PME.[57] This protocol was carefully validated
against experimental data for an initial dataset of five com-
pounds (one from each class) in direct and reverse directions,
and for several simulation lengths ranging from 200 ps to 5
ns. Further increase in the simulation time beyond 1 ns yielded
only marginal improvements in the calculated DDGsolvation free
energies (less than 5%). Under these conditions, an average
hysteresis of 0.14 kcal/mol was obtained, justifying the choices
made.
PB and GB models of solvation
For each molecule, a 10 ns molecular dynamics simulation in
implicit solvent was performed with AMBER 10[48] using the
modified GB implicit solvent model developed by Onufriev
et al.[58] Onufriev-Bashford-Case (OBC), implemented as IGB ¼
5 in AMBER 10). The same force field parameters used with TI
were used in these simulations. A time-step of 1 fs was used
together with an infinite cut-off for the nonbonded
interactions.
Thousand structures were taken from each trajectory (one
at each 10 ps) and used for the PB and GB calculations of the
solvation free energy.
PB calculations were performed with a grid-based finite dif-
ference solution to the PB equation with zero salt concentra-
tion and modified Bondi radii (corresponding to mbondi2 in
AMBER) for small molecules.[58] A grid spacing of 0.1 A˚ was
Scheme 1. Schematic representation of the thermodynamic cycle involved
in the calculation of the DDGsolvation free energies associated to alkane-
alcohol transformations in the gas-phase (DGAlk!AlcðgÞ ) and in solution
DGAlk!AlcðaqÞ , using thermodynamic integration.
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used for generating the grids. Thousand iterations were per-
formed per calculation. Interior and exterior dielectric con-
stants of 1 and 80, respectively were used. The same 1000
structures per trajectory were considered in the GB calcula-
tions. These were performed with the OBC implicit model
described above for the molecular dynamics simulations,[58]
with the same interior and exterior dielectric constants as
used in the PB calculations.
The DGnonpolar contribution to the total solvation free energy
was estimated using a term proportional to the total solvent
accessible surface area of the molecule calculated with Mol-
Surf,[59] with proportionality constant derived from experimen-
tal solvation energies of small nonpolar molecules (0.0072).
Results and Discussion
Determination of DGsolvation free energies
Table 1 presents the average mean signed errors (MSE) in the
calculation of DGsolvation free energies for 53 typical alcohol
and alkane molecules with the different combinations of
method/basis set used in this study. The results show distinct
behavioral patterns for alcohol and alkane molecules.
DGsolvation free energies for alcohol molecules are systemati-
cally overestimated with the PCM-based approaches tested,
whereas those for alkane molecules are underestimated.
IPCM gave the best average MSE values for alcohols, but
also the less accurate average MSE values for alkane molecules
[e.g., 10.78 kcal/mol with HF/6-31G(d)]. CPCM and IEF-PCM
methods resulted in very similar average MSE values for both
alcohol and alkane molecules for all the theoretical levels
tested, with a maximum average difference between both
methods of 0.04 kcal/mol. SMD showed a good behavior with
all the theoretical levels tested for alcohol molecules, but gave
only reasonable MSE values with B3LYP/6-31G(d).
In terms of the theoretical level used in the calculations,
B3LYP/6-31G(d) exhibits the highest average MSE values for
most PCM-based methods in the treatment of alcohol mole-
cules, with average MSE values in the range of 0.49 kcal/mol (for
IPCM) and 2.03 kcal/mol (for IEF-PCM). For alkanes, however, all
the other theoretical levels did not perform as well, with average
MSE values in the range 3.72 to 10.78 kcal/mol. In this case,
B3LYP/6-31G(d) average MSE values vary between 1.69 kcal/
mol (for IPCM) and 0.45 kcal/mol (for SMD).
Table 2 presents the average mean unsigned errors (MUE) in
the calculation of DGsolvation free energies for typical alcohol
and alkane molecules with the different combinations of
method/basis set used in this study. The MUE values obtained
were typically smaller for alcohols than for alkanes. The lowest
average MUEs for alcohols and alkanes were obtained with
B3LYP/6-31G(d) for all the PCM-based methods tested. For
alcohols, the best performance was obtained with SMD (1.11
kcal/mol), followed by IPCM (1.28 kcal/mol), and SCI-PCM (1.72
kcal/mol). CPCM and IEF-PCM resulted in similar average MUE
values of, respectively, 2.00 and 2.03 kcal/mol. For alkane
molecules, a very similar pattern was observed with SMD giv-
ing the best result (average MUE of 0.45 kcal/mol), followed
by SCI-PCM, CPCM, and IEF-PCM (1.76 kcal/mol) and IPCM
(1.83 kcal/mol). All the other theoretical levels gave much
higher average MUE values (above 3.92 kcal/mol).
From the results presented in Tables 1 and 2 and the resulting
discussions, B3LYP/6-31G(d) was chosen as the best combination.
Detailed results are presented for the 29 alcohol molecules
tested with the different PCM-based methods in Table 3.
Table 3 illustrates the MUEs in the calculation of DGsolvation
free energies for typical alcohol molecules at the B3LYP/6-
31G(d) level of theory with different PCM-based approaches.
IPCM and SMD exhibited the best performance in terms
MUE for most molecules, with a MUE below 1.00 kcal/mol for,
respectively, 75 and 71% of all the alcohol molecules tested.
IPCM in particular, was able to estimate the DGsolvation free
energies with a MUE below 0.5 kcal/mol for 50% of all mole-
cules tested, albeit with a significantly higher computational
cost. However, although for SMD the MUE was higher than 2.0
kcal/mol for only three molecules (3-hexanol, 2,4-dimehtylphe-
nol, and 2-hydroxynaphalene), with IPCM several MUE above
3.0 kcal/mol were obtained (e.g., 2-hydroxynaphalene, penta-
nol, 1-hydroxynaphalene, and octanol). An interesting tend-
ency was also that SMD gave lowest MUE than CPCM and IEF-
PCM for all the 29 alcohol molecules tested, although the
cases were SMD was less accurate corresponded also to those
when CPCM and IEF-PCM typically gave higher MUEs.
These results demonstrate that SMD and B3LYP/6-31G(d) are
a competitive alternative to calculate DGsolvation free energies
for typical alcohol molecules, within a PCM-based approach.
This level of performance was well-maintained across the
Table 1. Average mean signed errors (MSE) in the calculation of
DGsolvation free energies for typical alcohol and alkane molecules with the
different combinations of method /basis set used in this study.
MSE CPCM IEF-PCM SMD SCI-PCM IPCM
Alcohols HF/6-31G(d) 1.06 1.09 0.08 0.65 0.93
B3LYP/6-31G(d) 2.00 2.03 1.09 1.72 0.49
M06-2X/6-31G(d) 1.48 1.52 0.68 1.10 0.17
M06-2X/CC-PVTZ 1.60 1.63 0.90 1.76 0.49
Alkanes HF/6-31G(d) 4.30 4.27 5.04 4.53 10.78
B3LYP/6-31G(d) 1.39 1.38 0.45 1.29 1.69
M06-2X/6-31G(d) 3.81 3.78 4.20 4.17 10.10
M06-2X/CC-PVTZ 3.72 3.69 4.05 3.77 5.71
Values expressed in kcal/mol.
Table 2. Average mean unsigned error (MUE) in the calculation of
DGsolvation free energies for typical alcohol and alkane molecules with the
different combinations of method /basis set used in this study.
MUE CPCM IEF-PCM SMD SCI-PCM IPCM
Alcohols HF/6-31G(d) 2.38 2.38 3.24 2.54 3.06
B3LYP/6-31G(d) 2.00 2.03 1.11 1.72 1.28
M06-2X/6-31G(d) 2.34 2.34 3.07 2.47 2.68
M06-2X/CC-PVTZ 2.30 2.31 2.95 2.41 2.40
Alkanes HF/6-31G(d) 4.50 4.47 5.79 4.71 10.87
B3LYP/6-31G(d) 1.76 1.76 0.51 1.76 1.83
M06-2X/6-31G(d) 4.04 4.01 5.02 4.38 10.20
M06-2X/CC-PVTZ 3.94 3.92 4.79 4.00 5.79
Values expressed in kcal/mol.
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different classes of alcohol molecules evaluated in this study.
This superior performance of SMD in the calculation of solva-
tion free energies is not surprising, taking into consideration
that this method was parameterized in particular to give reli-
able values of solvation free energy.[36] It is currently the rec-
ommended choice within Gaussian 09 to calculate solvation
free energies.[37] The reader should, however, be aware that
for other properties, the other PCM methods can often give
better results.
Determination of DDGsolvation free energies
PCM-based approaches, such as the ones used to calculate
DGsolvation free energies in the previous section, consider that
the molecules evaluated exist in solution and in the gas-phase
in a single-stable conformation. This is an obvious approxima-
tion, as most molecules (particularly those of greater length)
circle between an ensemble of different relevant conforma-
tions. It is also important to take into consideration that the
approach presented to calculate DGsolvation free energies fur-
ther assumes that the molecules adopt the very same geome-
try in solution and in the gas-phase. Hence, the approach here
described represents a lower-end estimate to the difference in
the solvation free energy that can be obtained with a
PCM-based method. Furthermore, it is an approach that can
be performed within a very reasonable time-frame, an aspect
of particular importance to enable a future generalization of
this protocol for the estimation of solvation free energies in re-
alistic drug-like molecules.
To go beyond these two approximations and to test a com-
petitive alternative to determine differences in solvation free
energies as those arising from the addition of an hydroxyl
group to an initial scaffold molecule (e.g., an alkane), a com-
mon challenge in computational drug development efforts, we
have tested a TI protocol to estimate DDGsolvation free energies
on HO addition. Additionally, the much faster PB and GB meth-
ods were also used to estimate DDGsolvation free energies on
HO addition. A total of 28 alkane-alcohol transformations were
tested. Results were compared with experimental reference
data and with values estimated from PCM-based approaches
and are presented in Table 4.
The performance of the different methods was tested for
different types of substitutions, namely those involving the for-
mation of eight primary alcohols, five secondary alcohols,
three tertiary alcohols, two cyclic alcohols, and 10 aromatic
alcohols from the corresponding alkanes.
The results presented in Table 4 and summarized in Figure 1
show that all PCM-based methodologies tend to overestimate
the DDGsolvation free energies on HO addition, particularly
CPCM and IEF-PCM with average MSE values of 3.68 and 3.71
kcal/mol, respectively. The best result among the PCM meth-
ods was obtained with SMD with an average MSE of 0.78 kcal/
mol, the only PCM method with an average MSEs and MUEs
values below 1 kcal/mol.
For CPCM and IEF-PCM, the error in the determination of
DDGsolvation free energies on HO addition is systematically
around 4.0 kcal/mol for all the transformations tested involving
linear molecules, with a maximum error deviations from this
average value in the case of 2-propanol (3.83 kcal/mol) and 3-
pentanol (4.32 kcal/mol). This result can justify the application
of an empirical correction factor of 4.0 kcal/mol in future cal-
culations involving these methods in the estimation of
DDGsolvation free energies on HO addition for linear molecules
(average MSE of all the transformations involving linear mole-
cules for CPCM and IEF-PCM). For cyclic and aromatic com-
pounds, a more diverse variation was encountered. A similar
scenario was also found for SCI-PCM, particularly for the for-
mation of primary alcohols, even though in this case there is a
smaller systematic difference (around 3.6 kcal/mol).
One way to improve the performance of the different PCM
methods tested would be to increase the number of structures
used for each molecule. Table 5 presents a comparison of the
results obtained with CPCM and SMD using the general proto-
col, which considers one structure per molecule, against the
results obtained with an improved protocol that uses 10 struc-
tures per molecule, extracted from 10 ns MD trajectories, for a
selection of structurally diverse HO additions. As expected, the
use of a single structure per molecule has a less significant
impact in the accuracy for the transformations involving mole-
cules with a low number of rotatable bonds than in the case
of the larger and more flexible molecules. Hence, for the for-
mation of 1-Propanol and 2-Propanol improvements of less
than 0.2 kcal/mol in the MUE were observed for CPCM and
SMD when using an ensemble of 10 structures. In the case of
Table 3. Mean unsigned error (MUE) in the calculation of DGsolvation
free energies for typical alcohol molecules at the B3LYP/6-31G(d) level of
theory in kcal/mol.
Alcohol CPCM IEF-PCM SMD SCI-PCM IPCM
1-Hydroxynaphthalene 3.22 3.26 1.90 2.92 3.43
2-Hydroxynaphthalene 3.49 3.53 2.03 3.18 5.13
2-Methylphenol 2.09 2.13 0.92 2.02 1.12
2-Methylbutane-2-ol 1.73 1.76 1.11 1.59 0.21
2-Methylpentane-2-ol 1.21 1.24 0.85 0.99 0.74
2-Methylpropane-2-ol 1.60 1.63 0.74 1.43 0.83
2,3-Dimethylphenol 2.46 2.50 1.73 2.22 2.43
2,4-Dimethylphenol 2.83 2.86 2.14 2.50 2.05
2,5-Dimethylphenol 2.22 2.25 1.41 2.17 1.54
2,6-Dimethylphenol 1.75 1.79 0.94 1.83 2.01
3,4-Dimethylphenol 0.50 0.53 0.34 0.11 0.35
3,5-Dimethylphenol 2.33 2.36 1.69 1.97 1.00
3-Hexanol 3.87 3.90 3.36 3.74 2.71
3-Pentanol 1.80 1.82 1.06 1.61 0.42
4-Methylphenol 2.19 2.22 1.16 1.74 0.98
Butanol 1.72 1.74 0.79 1.34 0.83
Cyclohexanol 2.30 2.33 0.58 2.03 0.63
Cyclopentanol 2.52 2.55 1.03 2.19 0.44
Ethanol 1.99 2.01 0.73 1.61 0.45
Fenol 2.61 2.64 1.17 2.15 0.03
Heptanol 1.20 1.23 0.89 0.78 0.31
Hexanol 1.33 1.36 0.83 0.94 0.08
Methanol 1.93 1.95 0.75 1.42 0.07
Octanol 0.91 0.94 0.70 0.45 3.71
Pentanol 1.46 1.49 0.71 1.07 4.01
Propanol 1.87 1.89 0.74 1.48 0.40
2-Butanol 1.74 1.76 0.75 1.48 0.21
2-Pentanol 1.50 1.53 0.74 1.28 0.18
2-Propanol 1.76 1.78 0.47 1.49 0.78
Average 2.00 2.03 1.11 1.72 1.28
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larger molecules, with an increased number of rotatable
bonds, such as in the formation of 1-Hexanol and 3-Hexanol,
the improvements observed were more significant, in the
range of 0.50–0.60 kcal/mol. In the formation of aromatic alco-
hols, both procedures resulted in MUE values differing less
than 0.15 kcal/mol. Hence, the use of a more sophisticated
protocol, involving an ensemble of structures for each mole-
cule, can improve the accuracy of the results, but the magni-
tude of this effect is in general small, not affecting significantly
the conclusions on the relative performance of the different
PCM methods for HO addition.
The TI protocol here described yields an average MSE of
0.60 kcal/mol, and an average MUE of 0.98 kcal/mol and
proved to be a very accurate alternative. This method underes-
timated the DDGsolvation free energies on HO addition for all
the nonaromatic molecules evaluated (total 18) and overesti-
mated this same quantity for most aromatic molecules
evaluated. Although for the formation of primary alcohol mol-
ecules, it gave an average error almost twice as large as that
obtained with SMD, its relative performance in the determina-
tion of DDGsolvation free energies improved for secondary and
tertiary alcohols for which the difference in the average MUE
errors between both methodologies fell to 0.18 and 0.05 kcal/
mol.
For the cyclic molecules evaluated SMD gave significantly
better results than TI, but for the aromatic molecules consid-
ered TI gave the best results, with an average MUE of only
0.54 kcal/mol and with 70% of the DDGsolvation free energies
predicted with an error of less than 0.30 kcal/mol. The three
exceptions were for related to the formation of phenol, 4-
methylphenol, and 3,5-dimethylphenol. As aromatic rings are
very common in drug-like molecules, the good performance of
the TI protocol here outlined, together with the rather general
approach used in treating these molecules (in particular the
use of GAFF) opens good perspectives in the use of this TI
protocol for estimating DDGsolvation free energies for drug-like
molecules in CADD.
Interesting also, was the performance of the PB and GB
methods. For some of the types of substitutions tested (e.g.,
the formation of primary alcohols and of cyclic alcohols), GB
Figure 1. Average MSE in the determination of DDGsolvation free energies on HO addition for the formation of different types of alcohol molecules from
the corresponding alkanes.
Table 5. Performance of the CPCM and SMD using a single structure or an ensemble of 10 structures taken from an MD simulation in the
determination of DDGsolvation free energies on HO addition in comparison with the experimental results.
[31–40]
Error (kcal/mol)
CPCM SMD
Alkane Alcohol
Exp. value
(kcal/mol)
Single
structure Ensemble[a] Difference
Single
structure Ensemble[a] Difference
Primary Propane 1-Propanol 6.813 3.93 3.86 0.07 0.79 0.61 0.18
Hexane 1-Hexanol 6.913 4.02 3.52 0.50 0.86 0.22 0.62
Secondary Propane 2-Propanol 6.738 3.83 3.88 þ0.05 0.52 0.63 þ0.09
Hexane 3-Hexanol 6.597 4.20 3.70 0.50 1.02 0.47 0.55
Aromatic Benzene Phenol 5.720 3.36 3.35 0.01 1.09 0.95 0.14
m-Xylene 3,5-Dimethylphenol 5.443 3.11 3.02 0.09 0.77 0.63 0.14
Average 3.74 3.56 0.19 0.84 0.59 0.26
[a] Ensemble average taken from the PCM values calculated for 10 random structures taken from a 10 ns MD simulation of each molecule.
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gave results with a comparable level of accuracy of TI. Its per-
formance was, however, significantly worse in the formation of
secondary, tertiary, and aromatic alcohols. In general, however,
the performance of GB was better than that of the several
PCM methods tested, with the exception of SMD. PB gave
results consistently better than GB and, with the exception of
the formation of aromatic alcohols, at the same level of accu-
racy or better than TI itself. In the formation of aromatic alco-
hols on HO addition, TI still gave the best result for 80% of
the transformations evaluated.
Figure 2 presents the correlation plots of the calculated and
experimental DDGsolvation free energy values for the several
computational approaches evaluated in this study, comple-
menting the analysis of the MSE and MUE presented previ-
ously. The correlation coefficients presented show that SMD,
CPCM, and IEF-PCM exhibit the higher correlation between ex-
perimental and calculated DDGsolvation values in the formation
of alcohol molecules, despite the fact that both CPCM and
IEF-PCM systematically overestimate the corresponding
DDGsolvation values. The correlation coefficients obtained with
the other PCM methods were, however, much smaller. As
expected, the correlation of the values obtained with TI is sig-
nificantly better than those obtained with the much faster PB
and GB methods, despite the fact that the latter often yield
competitive average MUE values.
Conclusions
The accurate prediction of drug-receptor binding free energies
is a particularly important difficulty for CADD, with the estima-
tion of DGsolvation being one of the most challenging steps of
the process. When optimizing drug binding in CADD, this prob-
lem can be simplified to that of the estimation of the change in
the DGsolvation (i.e., the calculation of DDGsolvation) resulting from
the chemical substitution in the drug-like candidate.
In this study, we have evaluated the performance of five
commonly used PCM methodologies in the determination of
solvation free energies for 53 typical alcohol and alkane small
molecules. In addition, the performance of these PCM meth-
ods, of a TI scheme, and of the PB and GB methods were also
tested in the determination of solvation free energies changes
for alkane-alcohol transformations.
The results obtained point out SMD as the most accurate
PCM-based approach (among the alternatives tested, and
using the standard default options) in estimating solvation
free energies for alcohol molecules, and solvation free energy
changes for alkane-alcohol transformations, with an average
error below 1 kcal/mol for both quantities.
The TI protocol, here optimized, provided DDGsolvation values
for alkane-alcohol transformation, at the same level of SMD for
some of the transformation types. The PB method also proved
Figure 2. Correlation plots of the calculated and experimental DDGsolvation free energy values for the several computational approaches evaluated in this
study with the corresponding correlation values.
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to be quite a reasonable alternative, giving competitive results
in the determination of DDGsolvation free energy values, even in
comparison with TI, and at a fraction of the computational
cost of the latter. However, for HO addition to aromatic rings,
a common substitution in drug design efforts, when optimiz-
ing drug binding, the performance of TI in comparison with all
the other methods is significantly better. This conclusion sup-
ports the application of this TI protocol in future computa-
tional studies addressing the calculation of DDGsolvation in
drug-like molecules.
Keywords: hydration free energies  alchemical  polarizable
continuum models  thermodynamic integration  binding free
energies  Poisson–Boltzmann  generalized Born  AMBER
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3.2. PREDICTION OF SOLVATION FREE ENERGIES WITH THERMODYNAMIC 
INTEGRATION USING THE GENERAL AMBER FORCE FIELD  
 
PREFACE 
 
The study of free energies in transformations of a system from one thermodynamic 
state to another are used to determine quantities such as binding affinities, solubilities 
and allow predicting equilibrium constants. In hit-to-lead efforts, increased activity and 
selectivity and/or reduced dose levels and side effects can be accomplished with small 
but specific changes. 
It was our aim in this work to compare experimental and calculated solvation free 
energies for typical additions considered in hit-to.lead, analyzing trends and optimizing 
the TI protocol tested previously. Hence, solvation free energy changes (ΔΔGsolv) for a 
total of 92 transformations, divided in 5 groups according to the substitution group: 
CH3, F, Cl, Br, I, NH2, CONH2 and NO2, in small molecules was predicted using 
Thermodynamic Integration (TI). 
The results showed a good agreement between experimental and predicted values, 
within ± 1 kcal/mol for almost all functional group additions. NO2 addition showed a 
larger and systematic underestimation of the predicted ΔΔGsolv. 
The good compromise between time and accuracy for small molecules makes TI 
methodology a promising choice in this CADD approaches. 
 
Regarding the contributions to the paper, Sílvia Alexandra Pinto Martins did all the 
practical work and wrote the first draft of the manuscript.  
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ABSTRACT: Computer-aided drug design (CADD) techniques can be very
eﬀective in reducing costs and speeding up drug discovery. The determination
of binding and solvation free energies is pivotal for this process and is,
therefore, the subject of many studies. In this work, the solvation free energy
change (ΔΔGsolv) for a total of 92 transformations in small molecules was
predicted using Thermodynamic Integration (TI). It was our aim to compare
experimental and calculated solvation free energies for typical and prime
additions considered in drug optimizations, analyzing trends, and optimizing a
TI protocol. The results showed a good agreement between experimental and
predicted values, with an overestimation of the predicted values for CH3,
halogens, and NH2, as well as an underestimation for CONH2, but all fall within ±1 kcal/mol. NO2 addition showed a larger and
systematic underestimation of the predicted ΔΔGsolv, indicating the need for special attention in these cases. For small molecules,
if no experimental data is available, using TI as a theoretical strategy thus appears to be a suitable choice in CADD. It provides a
good compromise between time and accuracy.
■ INTRODUCTION
Life results from a complex combination of individual chemicals
and chemical reactions and one of the primary goals in
computer-aided drug design (CADD) is the determination of
the binding free energy and of the solvation free energy that
play a role in those reactions.1
In drug optimization eﬀorts, two goals are expected for the
new/improved drug: increased activity and reduced dose levels
and/or increased selectivity and reduced side eﬀects. While
trying to improve the aﬃnity between a given drug and its
receptor, one of the most common strategies in silico
approaches is to make small changes by adding suitable
substituents. With computational studies, it is possible to
simulate a wide variety of substitutions and predict their eﬀect
in the protein-aﬃnity of the compound.
Binding and solvation free energies are intricately connected,
being the latter frequently required for an accurate determi-
nation of the ﬁrst. The properties of the molecules present in
any chemical or biological system are dependent on
interactions with the environment, and therefore, special
attention needs to be given to the solvation eﬀects. When we
consider biochemical reactions, water is the solvent par
excellence and it often plays a critical role on them as water
can act both as an hydrogen-bond donor and acceptor. The free
energy of solvation has a major importance in the
determination of solubilities, partition coeﬁcients, association
and disassociation, binding constants, phase equilibria, and
reaction rates.2 Free energy is one of the most important
quantities in thermodynamics, but it is also a challenging task to
calculate it eﬃciently and accurately. The solvation free energy
of small molecules can help to understand desolvation of the
ligand in the thermodynamic process of protein−ligand
binding,3−5 playing an important role in the process.
In this study, we have compared experimental and calculated
solvation free energies diﬀerences (ΔΔGsolv) for a set of 92
transformations in small molecules, divided in 5 groups
according to the substitution group considered: methyl,
halogen (F, Cl, Br, and I), amino, amide, and nitro. The
experimental values were gathered from diﬀerent source
documents and the computational calculations were performed
with Thermodynamic Integration (TI), using explicit solvent.
TI is considered a suitable and accurate method to determine
free energies. The substitutions evaluated in this study are taken
as typical and in the group of the ﬁrst considered in drug
optimizations, with eﬀects in the lipophilicity/hydrophilicity,
steric/electronic properties, among others. Since absolute
solvation free energies have been experimentally determined
for a considerable amount of small molecules, the study allows
for a direct comparison between the experimental and
calculated values. So, we also intended to test an optimized
TI protocol applied previously to HO additions6 in order to
address properly the changes in ΔΔGsolv brought by these
transformations. It is our aim to present trends and provide a
theoretical strategy when there are no experimental data
available.
Received: April 22, 2014
Published: July 23, 2014
Article
pubs.acs.org/JCTC
© 2014 American Chemical Society 3570 dx.doi.org/10.1021/ct500346y | J. Chem. Theory Comput. 2014, 10, 3570−3577
■ METHODOLOGY
Thermodynamic Integration was originally proposed by
Kirkwood7 and is widely used to calculate solvation free
energies, with good results even though computationally
expensive. It is an equilibrium method that allows the
estimation of the free energy diﬀerences between two discrete
states, an initial reference state (state A), and a ﬁnal target state
(state B). In equilibrium methods, a hybrid system is used to
transform system A into B, where an average of values obtained
from intermediates are used to calculate the free energy
diﬀerence. In the thermodynamic integration approach, a path
between the states is deﬁned, and by using a thermodynamic
cycle, it is possible to computationally measure the energy
diﬀerence, provided that the path is reversible. Free energy is a
state function, and therefore, the transformation process can be
chemical or alchemical. The free energy diﬀerence between two
molecules (A and B) can be obtained using the following
thermodynamic cycle, shown in Scheme 1.
In this study, we performed alchemical transformations of a
hydrogen atom into another functional group. TI was used here
to calculate the solvation free energies changes (ΔΔGsolv) of a
total of 92 of those transformations. Five sets of functional
group additions were considered: methyl, halogens, amino,
amide, and nitro. In each transformation, a hydrogen atom was
substituted by a functional group, transforming molecule A into
molecule B as represented by the thermodynamic cycle (in
Scheme 1). Using a coupling parameter (λ), it is possible to
compute the free energy diﬀerence between two states A and B,
with the equation:
∫ λλ λΔ =
∂
∂ λ
G
V( )
d
0
1
The coupling parameter varies from 0 to 1 corresponding
respectively to the initial A and ﬁnal B states. Basically, the free
energy diﬀerence, ΔGA→B, is the integral from 0 to 1 of the
expectation value of ∂V(λ)/∂λ, where V is the potential energy.
The integral may be evaluated numerically using a number of
discrete λ points.8−10
The process was repeated in solution and in the gas-phase.
TI calculations were performed using AMBER 1011 with soft-
core potentials and using the general Amber force ﬁeld
(GAFF).12 All molecules were parametrized using the
antechamber13 module of AMBER with charges derived at
the HF/6-31G(d) level of theory. These options represent
typical choices for standard organic molecules composed of H,
C, N, O, S, P, and halogens, and therefore, these choices are
usual when handling drug-like molecules through molecular
dynamics simulations, particularly in protein complexes.
For reasons of simulation stability, the transformations have
been divided into three substeps each: ﬁrst, the atomic partial
charge on the selected hydrogen was removed (ΔG1); second,
the disappearance of the selected hydrogen takes place with the
simultaneous appearance of the functional group (the van der
Waals (vdW) interactions and radii were transformed from one
to the other, −ΔG2); and ﬁnally, the atomic partial charge(s)
of the substituent group were switched on (ΔG3). We have
used soft-core potentials in substep 2, which are modiﬁed
Lennard-Jones potentials that prevent simulation instabilities
due to the truncation of the potential to small energy values for
short, very repulsive distances.
In each step, nine λ values were considered (λ = 0.1, 0.2, 0.3,
0.4, 0.5, 0.6, 0.7, 0.8, and 0.9), which is a typical option when
using TI to calculate free energy diﬀerences.14−16 For each λ
value, the starting structure was minimized for 500 steps. In the
substeps 1 and 3 (described above), this was performed using
steepest descent followed by conjugate gradient algorithms. In
substep 2, only the steepest descent minimization algorithm
was used.
Next, the resultant structure was equilibrated for 50 ps, at
constant pressure. Production simulations of 1 ns for each λ in
the isothermal−isobaric (NPT) ensemble were performed,
using the Langevin thermostat17 with a collision frequency of
1.0 ps−1 at 300 K, a time step of 1 fs, and a cutoﬀ of 9 Å for the
nonbonded interactions. Final values were integrated numeri-
cally using the trapezoidal rule. TI calculations in water were
performed with explicit solvent (TIP3P, minimum 12 Å to the
box side) and under periodic boundary conditions with PME.
This protocol has been previously tested in the determination
of ΔΔGsolv upon OH addition6 against other computational
methods, including the Poisson−Boltzmann (PB) and
Generalized Born18 (GB) methods, the Polarizable Conductor
Continuum model (C-PCM),19,20 the Integral-Equation-For-
malism Polarizable Continuum Model (IEF-PCM),21−23 the
Static Isodensity Polarizable Continuum Model (IPCM),24 the
Self-Consistent Isodensity Polarizable Continuum Model (SCI-
PCM),24 and the SMD model.25
Several studies focused in solvation free energies predic-
tion,26−29 creating a large amount of available experimental
data. Experimental values were obtained from the liter-
ature.25,30−38 The ΔΔGsolv experimental values result from
the diﬀerence between the molecule with the added functional
group (CH3, F, Cl, Br, I, NH2, CONH2, and NO2) and the
original one (e.g., ΔGsolvchloroethane − ΔGsolvethane, for the addition of a
chloride atom to a primary aliphatic carbon atom).
■ RESULTS AND DISCUSSION
Data Set. In this study, we have assessed the performance of
a thermodynamic integration protocol in the determination of
the solvation free energy change (ΔΔGsolv) for a total of 92
transformations, starting from typical linear, branched, cyclic,
aromatic, and heterocyclic alkane molecules by replacing a
hydrogen atom by a diﬀerent substituent.
One transformation typically takes 20 h in an 8 processors
Xeon 3.0 GHz machine, with this TI protocol.
These substitutions can be grouped into 5 categories based
on the nature of the substituent group: (1) methyl substitution
(40 transformations); (2) halogen substitution (29 trans-
formations, including 1 case for ﬂuorine, 13 cases for the
chlorine, 9 cases for bromine and 6 for iodine); (3) amino
substitution (8 cases); (4) amide substitution (3 cases); (5)
nitro substitution (12 transformations). It was our intention to
Scheme 1. Schematic Representation of the Thermodynamic
Cycle Involved in the Calculation of the ΔΔGsolv Associated
to the Considered Transformations in the Gas-Phase and in
Solution, Using TI
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ﬁnd out if each functional group presents a deﬁnite trend or at
least a well-deﬁned range of values for the ΔΔGsolv
contribution. The data were also grouped, for each substitution,
according to the speciﬁc position of the substitution and the
type of chain, to identify characteristic subtrends.
The distribution, together with its subdivisions is presented
in detail in Figure 1. This relative number of cases per category
reﬂects the availability of experimental solvation free energy
data in the literature.
Distribution of Experimental and Computational
Values. Figure 2 presents the experimental and computational
values for ΔΔGsolv free energies obtained for the diﬀerent
substitution types. Comparing the ranges of experimental and
computational values for ΔΔGsolv free energies obtained from
the addition of diﬀerent groups to the diﬀerent compound
classes, it is possible to evaluate trends. For the nitro group
addition, a displacement (shift) of the computational values to
the left was observed, when comparing with the corresponding
experimental data. This suggests a systematic underestimation
of the predicted ΔΔGsolv energies upon NO2 addition. For the
other substitutions, however, the most noticeable feature is
considerable larger amplitude in the range of computationally
predicted values, when compared with the experimental ones.
However, most of the individual values (indicated through
vertical bars in both categories) fall in relatively narrow and
similar ranges.
In fact, in the addition of a methyl group, it is possible to see
that almost all computational values are distributed in a similar
range as the experimental values, except for one case. This
corresponds to the pentane → hexane transformation that
presents a predicted value of −2.92 kcal/mol when its
experimental value is of 0.17 kcal/mol. With two other cases,
halogens and amino group additions, the range of values for
predicted ΔΔGsolv energies is within the range of the
experimental values, and if we analyze the vertical bars, there
is also a common distribution of them. There is an
experimental value for the toluene → p-chlorotoluene trans-
formation that expands the experimental bar to the right, and if
we did not consider this value, the computational values would
present only a slight shift to the right comparing to the
experimental values. In amide group addition, the availability of
only 3 cases precludes a substantive deﬁnition of a trend.
In general, however, it can be concluded that both
alternatives yield characteristic and comparable values for
each substitution type, although the computational approach
can lead to some outliers.
Comparison of the Mean Averages. Table 1 presents an
overview of the mean averages for the experimental and
computational values of ΔΔGsolv free energies, resulting from
the addition of diﬀerent groups (CH3, F, Cl, Br, I, NH2,
CONH2, and NO2). It presents also the corresponding
standard deviation, and minimum and maximal values. Figure
3 presents a comparison of the mean average and standard
deviation of the experimental and computational values for
ΔΔGsolv free energies, obtained for the diﬀerent trans-
formations. It complements the observations made concerning
Figure 2. In particular, it conﬁrms the relatively good agreement
in the average values for the diﬀerent transformations, with a
higher standard deviation for the computational values.
In CH3, NH2, and NO2 additions the experimental average is
above the computational average, whereas with halogens and
CONH2 addition the experimental average is below the
computational one.
In methyl group addition, the experimental values for this
transformation are smaller than 0.5 kcal/mol, therefore leading
to a small mean, 0.07 kcal/mol, with an also small variation,
0.21 kcal/mol. We can point out as a reason for that, the
negligible eﬀect of this group addition. The predicted values,
although presenting a slight higher mean and deviation values
(0.11 and 0.55 kcal/mol), also remain in acceptable proximity
to the 0.5 kcal/mol.
When considering the halogen group addition, the diﬀerence
between experimental and computational averages is a little
over 0.5 kcal/mol, with a similar standard deviation for both:
1.17 and 1.10 kcal/mol, respectively. Nevertheless, this does
not occur with all four diﬀerent additions within this group.
Considering bromide addition, the diﬀerence of computational
and experimental averages reaches almost 1 kcal/mol, with both
standard deviations over 0.5 kcal/mol. With the iodide
addition, the diﬀerences are larger, nearly 1.5 kcal/mol, with
a smaller variation on the experimental values than on the
computational ones.
Figure 1. Number of substitutions considered in this study distributed
by class.
Figure 2. Ranges of experimental and computational values for
ΔΔGsolv free energies obtained from the addition of diﬀerent groups to
diﬀerent compound classes. Values expressed in kcal/mol. Lines in
bold indicate the individual experimental and computational values.
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The addition of an amino group (−NH2) presents very
similar experimental and calculated averages, −7.42 and −7.57
kcal/mol respectively, with a higher standard deviation in the
experimental values. The transformation benzene → aniline
exhibits the greater discrepancy between experimental and
computational values −4.52 and −7.65 kcal/mol, respectively.
The addition of a nitro substituent (−NO2) originates the
greater diﬀerence between averages (average diﬀerence of 2.5
kcal/mol). Comparing the values, in 9 of the 12 cases
considered, the calculated values are underestimated in more
than 2 kcal. The phenol → 2-nitrophenol transformation
presents the higher diﬀerence found in this study for
experimental and predicted values: almost 5 kcal/mol. For a
nitro addition in a primary position, the experimental values are
around −5.4 kcal/mol, but if the addition is in an aromatic ring,
the magnitude of the values rises to around −3 kcal/mol. The
predicted values in a primary position have an average of −7.78
kcal/mol, and an average of −5.03 kcal/mol when the addition
is made in an aromatic ring. These results can justify the
application of an empirical correction factor of −2.0/2.5 kcal/
mol in future calculations, when predicting the ΔΔGsolv free
energies for NO2 addition. Another option could be to
redetermine the molecular mechanical parameters associated
with this group in order to better reproduce the solvation free
energies, if NO2 solvation assumes a leading role in the
calculations that we want to perform.
Table 1. Experimental and Computational Values of ΔΔGsolv Free Energies Resulting from the Addition of Diﬀerent Groups
(CH3, F, Cl, Br, I, NH2, CONH2, and NO2) to Diﬀerent Compound Classes
a
ΔΔGsolv exp ΔΔGsolv calc
addition to mean avg. min max mean avg. min max
CH3 0.07 ± 0.21 −0.45 0.48 0.11 ± 0.55 −2.92 0.87
primary carbon 0.15 ± 0.12 −0.14 0.25 −0.13 ± 1.10 −2.92 0.87
secondary carbon 0.28 ± 0.09 0.18 0.43 0.02 ± 0.25 −0.49 0.30
tertiary carbon 0.25 ± 0.07 0.19 0.36 0.00 ± 0.04 −0.03 0.05
cyclic carbon 0.44 ± 0.04 0.40 0.48 0.22 ± 0.01 0.21 0.23
aromatic ring −0.04 ± 0.11 −0.31 0.04 0.34 ± 0.20 −0.07 0.59
heterocyclics −0.12 ± 0.15 −0.45 0.07 0.19 ± 0.20 −0.17 0.48
halogens −1.65 ± 1.17 −0.99 ± 1.10
F 0.08 0.80
aromatic ring 0.08 0.80
Cl −1.40 ± 1.42 −2.46 2.75 −1.24 ± 1.16 −2.20 0.53
primary carbon −2.35 ± 0.09 −2.46 −2.24 −2.09 ± 0.11 −2.20 −1.92
secondary carbon −2.19 ± 0.10 −2.27 −2.03 −1.95 ± 0.12 −2.08 −1.75
tertiary carbon −1.22 −1.88
aromatic ring 0.28 ± 1.46 −1.09 2.75 0.49 ± 0.07 0.36 0.53
Br −1.84 ± 0.79 −2.54 −0.56 −0.91 ± 1.08 −1.78 0.75
primary carbon −2.50 ± 0.05 −2.54 −2.42 −1.71 ± 0.07 −1.78 −1.59
secondary carbon −2.45 −1.68
tertiary carbon −1.47 −1.52
aromatic ring −0.89 ± 0.46 −1.54 −0.56 0.61 ± 0.10 0.51 0.75
I −2.20 ± 0.08 −2.56 −0.86 −0.86 ± 0.72 −1.33 0.73
primary carbon −2.47 ± 0.08 −2.56 −2.35 −1.19 ± 0.11 −1.33 −1.07
secondary carbon −2.43 −1.13
aromatic ring −0.86 0.73
NH2 −7.42 ± 1.21 −8.35 −4.52 −7.57 ± 0.38 −8.05 −6.67
primary carbon −7.84 ± 0.55 −8.35 −6.54 −7.56 ± 0.41 −8.05 −6.67
aromatic ring −4.52 −7.65
CONH2 −11.00 ± 0.65 −11.53 −10.10 −10.51 ± 1.56 −12.11 −8.40
primary carbon −11.46 ± 0.07 −11.53 −11.38 −11.56 ± 0.55 −12.11 −11.01
aromatic ring −10.10 −8.40
NO2 −3.83 ± 2.09 −5.97 2.01 −6.37 ± 1.68 −8.44 −2.79
primary carbon −5.43 ± 0.30 −5.97 −5.15 −7.78 ± 0.75 −8.44 −6.30
secondary carbon −5.11 −7.36
aromatic ring −2.29 ± 1.98 −4.06 2.01 −5.03 ± 1.24 −6.99 −2.79
aMean average values for each group are presented in bold. Values expressed in kcal/mol.
Figure 3. Comparison of averages and deviations of experimental and
computational values for ΔΔGsolv free energies obtained from the
addition of diﬀerent groups to diﬀerent compound classes. Values
expressed in kcal/mol.
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In the 3 cases of amide group addition, both averages diﬀer
by 0.5 kcal/mol, but the variation is more evident in the
calculated values, because the minimum and maximum are
more apart. More cases would be necessary for a more
grounded analysis.
It is important to notice that in aromatic scaﬀold addition, in
some cases (CH3, Br and I), the experimental and calculated
values albeit similar present diﬀerent signs, that is, while the
experimental value indicates unfavorable to desolvate (neg-
ative), the calculated appear as favorable to desolvate (positive).
This should be taken into account in the MSE and MUE
analysis.
Figure 4 presents the averages of mean signed error (MSE)
and mean unsigned error (MUE) in the calculation of ΔΔGsolv
free energies for the 5 additions tested in this study. Table 2
further decomposes these values taking into consideration the
carbon atom that is subjected to the addition. The results of
MSE show that the calculated values are overestimated for
methyl, halogen and amide additions and underestimated for
amino and nitro additions.
There is a small underestimation for methyl addition to
primary, secondary and cyclic carbons and a small over-
estimation for tertiary, aromatic, and heterocyclic carbons.
For the addition of halogens, an MSE of 0.66 kcal/mol was
obtained. However, for the four diﬀerent additions within this
group, the MSE varies signiﬁcantly as present in Table 2. Since
in the ﬂuorine addition there is only one case considered,
limiting the representativeness of the result, it is possible to say
that as we descend along the halogen group in the periodic
table, the MSE increases. That is, the predicted values are
successively more overestimated.
The MSE average for amino addition is small and negative
(−0.15 kcal/mol) but it is greatly inﬂuenced by the MSE value
for the benzene → aniline transformation. This is the only case
of amino addition to an aromatic carbon and the predicted
value is underestimated by 3 kcal/mol. Considering the
remaining cases analyzed, corresponding to additions to a
primary carbon, the MSE value is positive and lower than 0.5
kcal/mol, which indicates a small overestimation of the
calculated values.
In the amide addition, the analysis of just three cases leads to
an MSE of 0.5 kcal/mol although for the aromatic carbon
amino addition the predicted value is overestimated by almost 2
kcal/mol.
The MSE value for the nitro addition is the higher for all the
transformations in this study, −2.54 kcal/mol, indicating also
the larger underestimation of the calculated values. Even if we
analyze the MSE for the 3 diﬀerent compound classes, it is
always over 2 kcal/mol. This uniformity suggests the existence
of a systematic error for this class of compounds, which could
be the result of a limitation of the force ﬁeld employed.
Figure 4. Average MUE and MSE in the determination of ΔΔGsolv
free energies from the addition of diﬀerent groups to diﬀerent
compound classes. Values expressed in kcal/mol.
Table 2. Mean Unsigned Error (MUE) and Mean Signed
Error (MSE) in the Calculation of ΔΔGsolv Free for the
Addition of CH3, F, Cl, Br, I, NH2, CONH2, and NO2 to
Diﬀerent Compound Classesa
addition to no. cases avg. MSE avg. MUE
CH3 40 0.04 0.38
primary carbon 8 −0.27 0.63
secondary carbon 7 −0.27 0.29
tertiary carbon 3 −0.26 0.26
cyclic carbon 2 −0.22 0.22
aromatic ring 8 0.38 0.40
heterocyclics 12 0.31 0.31
halogens 29 0.66 0.87
F 1 0.72 0.72
aromatic ring 1 0.72 0.72
Cl 13 0.16 0.62
primary carbon 4 0.25 0.25
secondary carbon 4 0.25 0.27
tertiary carbon 1 −0.66 0.66
aromatic ring 4 0.20 1.31
Br 9 0.93 0.94
primary carbon 4 0.79 0.79
secondary carbon 1 0.77 0.77
tertiary carbon 1 −0.04 0.04
aromatic ring 3 1.50 1.50
I 6 1.34 1.34
primary carbon 4 1.28 1.28
secondary carbon 1 1.30 1.30
aromatic ring 1 1.59 1.59
NH2 8 −0.15 0.70
primary carbon 7 0.28 0.36
aromatic ring 1 −3.13 3.13
CONH2 3 0.50 0.88
primary carbon 2 −0.10 0.47
aromatic ring 1 1.70 1.70
NO2 12 −2.54 2.54
primary carbon 5 −2.35 2.35
secondary carbon 1 −2.25 2.25
aromatic ring 6 −2.74 2.74
aValues expressed in kcal/mol.
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The results of MUE in the calculation of ΔΔGsolv free
energies, presented also in Figure 4, show that for 4 of the 5
additions tested in this study, the predicted values diﬀer for less
than 1 kcal/mol. Only in the nitro group addition, the
calculated and experimental values are apart for about 2.5 kcal/
mol as suggested from the previous analysis.
General Trends. Figure 5 presents a correlation plot of the
calculated and experimental ΔΔGsolv free energy values for the
diﬀerent classes of transformations tested. The solid line
represents the ideal 1:1 correlation and the dashed lines
represent acceptable deviations of ±1 kcal/mol (i.e., over-
estimation or underestimation by the computational method up
to 1 kcal/mol). The outliers identiﬁed in Figure 2 were not
included in the preparation of Figure 5.
We can see that all the methyl addition cases are
concentrated in the same area and within the acceptable
region. It is possible to point out the pentane → hexane as an
outlier as it can be easily seen. For the halogens group addition,
two sets can be distinguished. One, however, is more populated
and close to the ideal line although almost all cases are located
in the upper acceptable region (i.e., overestimated). An outlier
is once more noticeable, the p-toluene → p-chlorotoluene. The
value for this transformation, places it well below the acceptable
region (underestimated), thus contradicting the general trend
for this group.
The amino group addition set presents a correlated
distribution, with all the values being within acceptable region
and close to the ideal line. Once again an outlier is present,
benzene → aniline, more than 5 kcal away from the perfect
correlation. Although the 3 cases for the amide addition, as
already noticed, diminish the ability to a consistent analysis,
these transformations are placed near the 1:1 correlation.
The nitro group addition gives the worst results, with all the
points placed below the acceptable region line. Although the
phenol→ nitrophenol transformation is also of the same trend,
it is distant from the other points, being therefore an outlier. In
spite of the diﬀerences between the 5 group additions, it is
possible to deﬁne for each an area that will help in future
predictions.
■ CONCLUSIONS
The estimation of solvation free energies represents an
important piece of the complex puzzle when studying drug-
receptor aﬃnity. A compromise between computational cost
and accuracy for a reliable prediction of ΔΔGsolv energies can
lead to a consequent boost in binding free energies calculations,
so necessary in drug design.
In this study, we have calculated the solvation free energy
change (ΔΔGsolv) for a total of 92 transformations in small
molecules, using Thermodynamic Integration. Based on the
functional group considered for the additions (CH3, F, Cl, Br, I,
NH2, CONH2, and NO2), the position of the substitution and
the type of chain, we searched for trends and evaluated the
standard TI protocol.
The distribution of experimental and computational values
reveals larger amplitudes in the range of computationally
predicted values, when compared with the experimental ones.
Nevertheless, the analysis of the individual values indicates the
presence of some outliers.
A good agreement between the average values for the
diﬀerent transformations is present, with a higher standard
deviation for the computational values. In 3 categories (CH3,
halogens, and NH2 additions), the calculated values are
overestimated, whereas with the other two (CONH2 an NO2
addition) there is an underestimation. According to an ideal 1:1
correlation, it is evident that 4 of the 5 additions tested are
within the acceptable deviation. The results of Table 1 help the
reader to be aware of the possible errors that might be expected
in his/her calculations. The solvation free energy value
obtained computationally can be corrected using the diﬀerences
between MD and experiment presented.
The nitro group addition values suggest a systematic
underestimation of the predicted ΔΔGsolv, more than 1 kcal/
mol. The mean average evaluation indicates the need of a
correction factor (such as 2.5 kcal/mol) or perhaps a diﬀerent
parametrization for the force ﬁeld, in those cases.
The position of the substitution and the type of chain that
serves as scaﬀold has a medium but not negligible eﬀect,
present both in experimental as computational values and it
must be taken into account too.
The TI methodology can be computationally very intensive,
especially for large systems and/or large number of structural
changes. However, due to the accurate and precise results,
which it ensures, is a valuable help for this kind of studies,
helping deﬁning trends to future predictions.
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3.3. COMPUTATIONAL ALANINE SCANNING MUTAGENESIS: MM-PBSA VS TI 
 
PREFACE 
 
Predicting the binding free energy of proteic ligands to macromolecules can have great 
practical values in identifying novel or improved molecules that can bind to target 
receptors and act as therapeutic drugs. The studies of interfaces protein-protein are 
pivotal to the understanding of molecular recognition and the physical basis of affinity. 
Protein association is responsive to mutational events, especially in particular residues 
(hot-spots) responsible for the majority of the interaction energy. 
In this study, we have calculated the protein−protein binding free energy differences 
upon alanine mutation of interfacial residues (ΔΔGbind) both with a computational ASM 
protocol (MMPBSA) and TI, for 22 mutations. It was our aim to compare the efficiency 
and the accuracy of the two methodologies against accurate experimental data was 
available.  
The results demonstrate that the much faster ASM protocol gives results at the same 
level of accuracy as the TI method but at a small fraction of the computational time 
required to run TI.  
Regarding the contributions to the paper, Sílvia Alexandra Pinto Martins did the TI 
calculations and wrote the first draft of the manuscript. 
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ABSTRACT: Understanding protein−protein association and being
able to determine the crucial residues responsible for their association
(hot-spots) is a key issue with huge practical applications such as rational
drug design and protein engineering. A variety of computational
methods exist to detect hot-spots residues, but the development of a
fast and accurate quantitative alanine scanning mutagenesis (ASM)
continues to be crucial. Using four protein−protein complexes, we have
compared a variation of the standard computational ASM protocol
developed at our group, based on the Molecular Mechanics/Poisson−Boltzmann Surface Area (MM-PBSA) approach, against
Thermodynamic Integration (TI), a well-known and accurate but computationally expensive method. To compare the eﬃciency
and the accuracy of the two methods, we have calculated the protein−protein binding free energy diﬀerences upon alanine
mutation of interfacial residues (ΔΔGbind). In relation to the experimental ΔΔGbind values, the average error obtained with TI
was 1.53 kcal/mol, while the ASM protocol resulted in an average error of 1.18 kcal/mol. The results demonstrate that the much
faster ASM protocol gives results at the same level of accuracy as the TI method but at a fraction of the computational time
required to run TI. This ASM protocol is therefore a strong and eﬃcient alternative to the systematic evaluation of protein−
protein interfaces, involving hundreds of amino acid residues in search of hot-spots.
I. INTRODUCTION
Proteins participate in almost every level of cell function.
However, often they do not accomplish their function on their
own, they need to associate with other molecules, namely other
proteins, in order to fulﬁll their biological functions.1
Understanding protein−protein association and being able to
determine the crucial residues responsible for their association
has been a subject of intense research in the last decades. Bogan
and Thorn demonstrated that only a few residues in a protein−
protein interface are responsible for the binding: the hot-spots.2
These are deﬁned as residues that upon alanine mutation
generate a binding free energy diﬀerence (ΔΔGbind) higher
than 2.0 kcal/mol.2 The correct detection of these residues is a
key issue with huge practical application such as rational drug
design and protein engineering.3 Alanine scanning mutagenesis
(ASM) has been widely applied to the characterization of these
interfaces. However, experimental ASM is a costly and time-
consuming task, which urged the need for fast and accurate
theoretical methods. A huge amount of algorithms of increasing
complexity have been employed to address the binding energy
between biological molecules. They can be divided essentially
into three types: empirical functions or simple physical
methods that use knowledge-based simpliﬁed models to
evaluate complex association; fully atomistic methods that
estimate the binding free energy as a result of mutating the
residues of the interacting molecules; or, more recently, feature-
based approaches.4 The feature-based approaches tend to be
more qualitative than quantitative.5−12 Therefore, an atomistic
and accurate quantitative ASM method is still crucial to detect
hot-spots.
Free energy is probably the most important quantity in
thermodynamics and one of the central topics in biophysics.
Nevertheless, for many relevant systems with local minimum
energy conﬁgurations separated by energy barriers, eﬃcient and
accurate calculation of this property is still a big challenge in
computational chemistry. Thermodynamic integration (TI) is
the key choice to perform accurate calculations of the binding
strength of protein complexes. This rigorous method yields
accurate free energy diﬀerences relying on equilibrium sampling
of an entire transformation path, from an initial to a ﬁnal state.
It is implemented numerically and utilizes a thermodynamic
cycle and the fact that the free energy is a state function.
However, as suﬃcient statistical sampling must be carried out,
the use of TI turns out to be computationally very intensive and
it is therefore limited in the screening of a large number of
structural perturbations. Another methodological approach,
which has become more attractive in the past few years for
estimating binding free energies of protein−protein complexes,
is the MM-PBSA (Molecular Mechanics/Poisson−Boltzmann
Surface Area) method.13−15 This method is a fully atomistic
approach that combines molecular mechanics and continuum
solvent. A few years ago, we developed a simple computational
protocol that relies on the MM-PBSA approach but combines
the use of diﬀerent dielectric constants when diﬀerent residues
are mutated to alanine. The conformational sampling, the
relaxation, and reorganization due to the mutation for an
alanine are not explicitly included in the MM-PBSA formalism.
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Therefore, the scaling of the macroscopic parameter (internal
dielectric constant) to larger values when larger reorganizations
are expected mimics these eﬀects. Using a set of three internal
dielectric constants exclusively characteristic of the mutated
amino acid (2 for the nonpolar amino acids, 3 for the polar
residues, and 4 for the charged amino acids plus histidine), it
was possible to increase the agreement with the experimental
results for the ΔΔGbind values. To test our ASM protocol
against such an accurate method as TI, we chose to apply them
both to four distinct proteic complexes: (i) Vascular
Endothel ia l Growth Factor and FLT-1 Receptor
(PDBID:1FLT);16 (ii) Barnase and Barnstar (PBDID:1BRS);17
(iii) Bacterial cell division ZipA and Ftsz (PDBID:1F47[2]);18
and (iv) Igg1 Kappa D1.3 FV and Hen Egg white lysozyme
(PDBID:1VFB[4]).19 These systems were selected based on
the existence of experimental binding free energy (ΔΔGbind)
values for the interfacial residues upon alanine mutations and
their dissimilar properties in terms of size, chemical and
physical character. Their biological importance and typical
interfaces makes them a perfect data set.
II. METHODOLOGY
A. System Setup. In our four reference systems,
protonation states of the diﬀerent residues were determined
using the PDB2PQR server at http://kryptonite.nbcr.net/
pdb2pqr/20 with the PROPKA methodology.21−23
B. Alanine Scanning Mutagenesis. a. Molecular Dy-
namics Simulations. The MD simulations were performed
using the AMBER9 package24 with the Duan et al. force ﬁeld.25
Two diﬀerent simulations were performed: one in an implicit
solvent using the Generalized Born (GB) solvent26 and another
using TIP3P explicit water molecules. Each complex was
solvated by explicit waters that extended 10 Å from any edge of
the box to the protein atoms. Counter ions were added to the
boxes to neutralize the system. In each of the simulations, the
system was initially minimized to remove bad contacts using
the steepest descent algorithm followed by conjugated gradient.
The systems were then subjected to 2 ns of heating (in NVT
ensemble) in which the temperature was gradually raised to 300
K, followed by 6 ns runs in the NPT ensemble. The
Langevin27,28 thermostat was used, and the electrostatics
interactions were calculated using the particle mesh Ewald
(PME) method.29 Both lengths involving hydrogen atoms were
constrained using the SHAKE algorithm.30 The equations of
motion were integrated with a 2 fs time-step and the
nonbonded interactions were truncated with a 16 Å and a 10
Å cutoﬀ, in the GB and in explicit solvent simulations,
respectively. The ﬁnal structures resulting not only from both
minimizations (in explicit and implicit solvent) but also from
the MD simulations trajectories were subsequently subjected to
alanine mutation.
b. Alanine Scanning Mutagenesis Protocol. The MM-
PBSA (Molecular Mechanics Poisson−Boltzmann Surface
Area) script15 integrated into the AMBER9 package24 was
used to calculate the binding free energy diﬀerence (ΔΔGbind)
upon alanine mutation. It combines a continuum approach to
model solvent interactions with an MM-based approach to
atomistically model protein−protein interactions. The protein
structures used to calculate the binding free energy may come
either from a MD simulation or just from energy minimization
of the X-ray structures. This provides speed and accuracy and
has been quite used in the last years.4,13,15,31−39 The MM-PBSA
approach ﬁrst developed by Massova et al.15 was adapted by
Moreira et al.4 to implement an accurate ASM protocol. In the
case of geometry-optimized structures, the mutant complexes
are generated by a single truncation of the mutated side chain,
replacing Cα with a hydrogen atom and setting the Cα-H
direction to that of the former Cα-Cβ. In the case of the
structures generated by MD simulations, a total of 320
snapshots of the complexes were extracted in the last 1 ns of
the run. The ΔΔGbind is written as the diﬀerence between the
mutant and wild type complexes deﬁned as
ΔΔ = Δ − ΔG G Gbind bindmut bindwt (1)
Typical contributions to the free energy include the internal
energy (bond, dihedral, and angle), the electrostatic and the van
der Waals interactions, the free energy of polar solvation, the
free energy of nonpolar solvation, and the entropic
contribution:
= + + +
+ −
G E E E G
G TS
molecule int ernal electrostatic vdW polar solvation
nonpolar solvation (2)
For the calculations of relative free energies between closely
related complexes, it is assumed that the entropic contributions
are negligible as it essentially cancel each other in eq 2.13 The
ﬁrst three terms of eq 2 were calculated with no cutoﬀ. The
Gpolar solvation term was calculated by solving the Poisson−
Boltzmann equation with the software DELPHI.40,41 In this
continuum method, the protein is modeled as a dielectric
continuum of low polarizability embedded in a dielectric
medium of high polarizability. We have used a set of values for
the DELPHI parameters that in a previous study have
constituted a good compromise between accuracy and
computational speed.42 Therefore, we used a value of 2.5
grids/Å for scale (the reciprocal of the grid spacing); a value of
0.001 kT/c for the convergence criterion; a 90% for the ﬁll of
the grid box; and the Coulombic method to set the potentials at
the boundaries of the ﬁnite-diﬀerence grid. The dielectric
boundary was taken as the molecular surface deﬁned by a 1.4 Å
probe sphere and by spheres centered on each atom with radii
taken from the Parse43 vdW radii parameter set. The key aspect
of our ASM protocol is the use of three dielectric constants
(with the value 2 for nonpolar residues, 3 for polar residues,
and 4 for charged residues plus histidine) to mimic the
expected rearrangement upon alanine mutation. It is important
to highlight that we have used only one trajectory for the
computational energy analysis, as it has been shown to give the
best results.4 Side-chain reorientation was implicitly included in
the formalism by raising the internal dielectric constant. The
nonpolar contribution to the solvation free energy due to van
der Waals interactions between the solute and the solvent was
modeled as a term dependent on the solvent accessible surface
area (SASA) of the molecule. It was estimated to be 0.00542 X
SASA+0.92 using the molsurf program developed by Mike
Connolly.44 As a systematic mutation of residues on protein−
protein interfaces (PPI) is a fastidious and time-consuming
methodological approach, we have recently developed a
VMD45 plugin (http://compbiochem.org/Software/
compasm/Home.html).46 This plugin has a friendly graphical
interface and was used in this work.
C. Thermodynamic Integration. The thermodynamic
integration (TI) method allows for the calculation of the
diﬀerence in free energy between two given states. Equation 3
can be derived directly from the conﬁguration integral. From
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this equation the free energy between two states of a given
system can be obtained using the coupling parameter (λ)
approach. The coupling parameter varies from 0 to 1
corresponding respectively to the initial A and ﬁnal B states.
Basically, the free energy diﬀerence, ΔGA→B, is the integral from
0 to 1 of the expectation value of ∂V(λ)/∂λ, where V is the
potential energy. The integral in eq 3 may be evaluated
numerically using a number of discrete λ points.
∫ λλ λΔ =
∂
∂ λ
→
⎛
⎝⎜
⎞
⎠⎟G
V( )
dA B
0
1
(3)
The TI method was used to calculate the diﬀerence in the
free energy of binding, upon mutation of an interface residue to
an alanine (ΔΔGbind) in order to test the eﬀectiveness of the
ASM protocol. The ΔΔGbind was evaluated using the
thermodynamic cycle shown in Scheme 1.
From the thermodynamic cycle, we get eqs 5 and 6:
ΔΔ = Δ − ΔG G Gbind bindmut bindwt (5)
ΔΔ = Δ − Δ→ →G G Gbind complex complex ligand ligandtwt mut w mut
(6)
Two diﬀerent transformations need to be simulated, wild
type to mutant in the ligand, ΔGligandwt→ligandmut and wild type to
mutant in the complex ΔGcomplexwt→complexmut. For reasons of
simulation stability, these two transformations have been
divided into three substeps each: ﬁrst, the atomic partial
charges on the side chain atoms were removed (ΔG1); second,
the van der Waals (vdW) potentials and radii were transformed
from the wt values into the alanine residues (ΔG2); and ﬁnally,
the side chain had its atomic partial charges switched on to
their alanine values (ΔG3). This was done because having a
nonzero charge on an atom while the vdW interactions with its
surroundings are getting weaker can lead to well-known
simulation instabilities. Also, for reasons of simulation stability,
we have used softcore potentials in substep 2, which are
modiﬁed Lennard-Jones potentials that prevent simulation
instabilities due to the truncation of the potential to small
energy values for small or zero radius. We note that it is
impossible to directly assign a Coulombic or vdW partitioning
to the total free energy as these are both path dependent.
We can now express ΔGligandwt→ligandmut, ΔGcomplexwt→complexmut,
and ΔΔGbind as a function of ΔG1, ΔG2, and ΔG3, and we get
eqs 7, 8, and 9:
Δ = Δ + Δ + Δ→G G G Gligand ligand ligand1 ligand2 ligand3wt mut (7)
Δ = Δ + Δ + Δ→G G G Gcomplex complex complex1 complex2 complex3wt mut
(8)
ΔΔ = Δ + Δ + Δ
− Δ + Δ + Δ
G G G G
G G G
( )
( )
bind complex
1
complex
2
complex
3
ligand
1
ligand
2
ligand
3
(9)
We have computed the free energy of each substep of each
transformation with the AMBER10 software.47 Each substep
was performed in explicit solvent and under periodic boundary
conditions with nine λ values (0.10, 0.20, 0.30, 0.40, 0.50, 0.60,
0.70, 0.80, 0.90). For each λ value running in each substep, we
have carried out 500 steps of steepest descent minimization, a
50 ps density equilibration run, and a 200 ps NPT production
run. The total simulation time to mutate just one wild type
residue into an alanine was 13 500 ps. Free energy derivatives
(∂V/∂λ) were collected independently for each λ from the
production run. A time step of 1 fs is used together with the
SHAKE algorithm. Ewald sums with a 9 Å cutoﬀ in the real
part, isotropic pressure scaling, and a Langevin type thermostat
to maintain the temperature at 300 K were also used. Each
system was centered in a cubic box of water with a minimum
distance of 12 Å between any protein atom and the box side.
The standard amino acid residues were accounted for by the
use of the Duan et al. AMBER force ﬁeld.25 The TIP3P water
model was used.
It is important to notice here that the conditions used in the
ASM and TI studies diﬀer in some particular aspects (e.g., the
time step used and the size of the water buﬀer). For a perfect
comparison, it would be, in principle, preferable to keep the
same conditions in both studies. However, our objectives here
were more ambitious. We wanted to show that our computa-
tional ASM protocol could compete in terms of accuracy with
Thermodynamic Integration even when a more rigorous TI
protocol was employed. For this reason, we have used a smaller,
more rigorous time step in TI together with a larger water
buﬀer in TI.
III. RESULTS AND DISCUSSION
Experimental ASM is long, laborious, and costly. An important
advantage of computer simulations over experiments is not only
to provide faster estimates of the binding free energy diﬀerence
but also to enhance our understanding of the nature of complex
formation in terms of the biophysical features of the process,
because they add molecular insight into the macroscopic
properties measured therein. Computational ASM is a tool that,
if well used, can assist experimental ASM by making it more
capable and more proﬁtable. A reliable computational ASM
protocol would allow minimizing the number of experimental
Scheme 1. Thermodynamic Cycle for Calculating the Binding Free Energy Diﬀerence between the Wild Type Residues and the
Mutant Residues in the Four Complexes Considereda
aΔGbindingwt and ΔGbindingmut are binding free energies for the wild type and the mutant respectively.
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assays carried out, because it would identify the residues that
are most probably hot-spots and the residues that will almost
surely be null-spots. Therefore, it is important to ﬁnd an
atomistic and accurate quantitative ASM protocol capable of
reproducing the experimental mutagenesis values.
To test our already established ASM protocol against such an
accurate method as TI, we have calculated the ΔΔGbind with
both methodological alternatives for the four systems.
Experimental ΔΔGbind values were used as reference
values.18,48−52 We have also analyzed advantages and
disadvantages for both methods as well as their range of
applicability and limitations, their expected performance, and
their precision and accuracy.
A. Data Set. Our data set comprises four complexes with
various chemical and physical characteristics. The complex
VEGF:FLT-1 (Figure 1) has a high biological importance and a
relatively small interfacial area. To decrease the computational
time involved in the calculations with both methods, we have
used the VEGF dimer and only one FLT-1 monomer. The
complex Barnase−Barnstar is a well know complex with a very
charged interface; the complex between the bacterial cell
division ZipA and Fts has a small, hydrophobic interface, and
the complex between the Igg1 Kappa D1.3 FV and the Hen
Egg white lysozyme has the largest of the interfaces under
study. The data set of 22 residues has 45% of hot-spots and
55% of null-spots, and within these groups, the ΔΔGbind has a
large range: 2.29−6.00 and 0.00−1.80 kcal/mol, respectively.
To better understand the chemical composition of the data set,
we can divided it in three groups: charged (Asp and Glu, His,
Lys and Arg), polar (Ser, Thr, Asn, Gln, Tyr), and nonpolar
(Val, Ile, Leu, Met, Phe, Trp). The percentages within our data
set are 36%, 32%, and 32%, respectively. So, it represents a
perfect data set test for the comparison and the development of
computational methods.
B. ASM Protocol. The ﬁnal structures from both the
minimizations (in explicit and implicit solvent) as well as the
trajectories from the MD simulations (in explicit and implicit
solvent) were subjected to mutation and subsequent calculation
of ΔΔGbind. In Supporting Information, it can be seen that in
both cases (implicit and explicit) the 320 snapshots were
extracted from the last nanosecond of the fully equilibrated part
of the MD simulations.
The ΔΔGbind between the wild-type residues and the alanine
mutant variants obtained with the ASM protocol are presented
in Table 1. The uncertainties of the calculated values (standard
deviations) and the comparisons with the experimental values
are also presented in Table 1.
Diﬀerent variations of the ASM protocol are shown in Table
1: (1) implicit solvent molecular dynamics (320 structures);
(2) implicit solvent with molecular mechanics minimization
only (1 structure); (3) explicit solvent with molecular dynamics
(320 structures); (4) explicit solvent with molecular mechanics
minimization only (1 structure).
The results from the protocols involving only molecular
mechanics (MM) show the worst agreement with the
experimental values, particularly those from the MM in implicit
solvent, with an average deviation from the experimental value
of 2.51 kcal/mol and a maximum diﬀerence of 7.25 kcal/mol.
The standard deviation of the mean, deﬁned as σ/√n, where n
is the number of snapshots and σ is the standard deviation
between snapshots, is not presented for the MM results because
such results are based on one single structure, the MM
optimized structure. As expected, an extremely fast minimiza-
tion with a single structure subjected to the ASM protocol is
not suﬃcient to obtain accurate results.
From both MD, implicit and explicit solvent, it is worth
noting that there are diﬀerences in the precision (related with
standard deviation, the ability of the measurement to be
consistently reproduced), accuracy (how close a result comes to
the experimental value, average error), and reliability (related
with maximum error, the ability to generate the same result).
There are signiﬁcant diﬀerences in the individual results, with
the standard deviation ranging from 0.21 to 1.20 kcal/mol in
implicit solvent and from 0.2 to 1.47 kcal/mol in explicit
solvent. The results from the implicit solvent are, hence, more
precise. The largest diﬀerences from the experimental values are
obtained in explicit solvent, with a mean error of 1.77 kcal/mol
and a maximum error of 5.89 kcal/mol while the mean and
maximum errors from the MD in implicit solvent are
signiﬁcantly lower, 1.18 and 4.69 kcal/mol, respectively. The
results from implicit solvent are therefore also in this case more
accurate.
The use of the implicit solvent to calculate ΔΔGbind leads to
a better agreement with the experimental data. The preference
for the implicit solvent over the explicit solvent can be justiﬁed
by several reasons, namely the smaller simulation time
necessary compared to that of the explicit solvent method,
the more complete exploration of the conformational space due
to the lack of the viscous damping forces of the water, the
reduced lengthy equilibration of water compared to that of the
explicit water simulation, and the easier interpretation of the
results since the water degrees of freedom are absent.
Additionally, the ASM protocol was optimized for the use of
an MD trajectory of the wild-type system in implicit solvent.
Moreover, the MD in implicit solvent for the complex
VEGF:FLT-1 used as reference is 4.2 times faster than the
MD in explicit solvent in our cluster. The ASM protocol in
implicit solvent has been used with success in the study of
several biological systems, including the IgG1 streptococcal
protein G (C2 fragment) complex,32 the FTase complex,53 and
the antibody HyHEL-1034 with the antibody FVD1.3,36 and the
Figure 1. Representation of the interface between the VEGF dimer
and the FLT-1 monomer highlighting Tyr21 and Leu66 in red (hot-
spots), Lys16 and Ile46 in orange, and His186 in yellow
(PDBID:1FLT). VEGF monomer1 is represented in black tube,
VEGF monomer2 in gray tube, the FLT-1 receptor in surface.
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MDM2-P53 complex.37 Furthermore, in previous benchmark-
ing studies against experimental data, it has been shown to have
an overall success of 82% in identifying hot spots and to yield a
mean unsigned error of around 0.8 kcal/mol.4,33 The following
section analyses the accuracy of the more computationally
demanding thermodynamic integration method.
C. Thermodynamic Integration Method. In Table 2, we
present the binding free energy diﬀerences as calculated by TI
and the respective RMS, the correspondent uncertainty, and
the comparison of the ΔΔGbind with the experimental values.
To improve the results, more simulations could be added at
diﬀerent λ points (this is indeed one of the strong points of TI,
you can add as many additional data points as you want to
reﬁne your result without having to redo the initial
calculations), more production time could be used (for better
convergence and more complete conformational sampling), or
even more sophisticated numerical integration schemes could
be used (we have used the trapezoidal rule to integrate
numerically). The used protocol takes more than 15 days in an
eight processor machine of our computer cluster for just one
mutation, and the mentioned improvements would lead to a
further increase of the simulation time. Relative to the
experimental value, the largest diﬀerences obtained are for
Tyr3 and Phe9, both for 1F47 with deviations of 5.09 and 3.18
kcal/mol, respectively. The ΔΔGbind of the other residues
tested are even closer to the experimental value with deviations
of 0.02 kcal/mol, 0.09 and 0.17 kcal/mol, for Asp2 (1F47),
His86, and Leu66 (1FLT), respectively.
D. MM-PBSA vs TI. TI is one of the most accurate methods
to compute free energies. (Free Energy Perturbation is equally
eﬃcient and the diﬀerence mainly pertains to the formula used
for evaluating the free energy). In the past decade, the
computational ASM method has been shown to yield
particularly accurate, precise, and reliable results. The main
question that we try to answer in this study is “How
competitive, in terms of accuracy and computational time, is
the computational ASM protocol, in relation to TI, in
calculating the change in the free energy of binding, upon
mutation of an interfacial residue to an alanine?”
For that purpose, we compared the results of both methods
in Table 3.
From Table 3, we can conclude that both methods are
capable of predicting the experimental mutagenesis results. As
far as the diﬀerences between calculated and experimental
values are concerned, |ΔΔGcalc − ΔΔGexp| ranges from 0.06 to
4.69 with the ASM protocol and from 0.02 to 5.09 kcal/mol
with TI. The average of |ΔΔGcalc − ΔΔGexp| for the 22 residues
tested is 1.18 kcal/mol with the ASM protocol and a little
higher (1.53 kcal/mol) with TI. ASM method is an atomistic
quantitative computational method, capable of reproducing the
experimental mutagenesis values.
There are several points from the methodological point of
view that diﬀer between both methods as far as alanine
mutagenesis is concerned. TI is a computationally demanding
methodology that produces reliable, although huge amount of
data to be analyzed. On the other side, the ASM protocol
produces much less data, using MM-PBSA a much faster
methodology and a considerably easier technique. These
limitations are particularly relevant when the interfaces are
large, because the computational time with TI grows linearly
with the number of mutations. For ASM, the most computa-
tionally demanding part of the calculation is the initial
Table 2. Diﬀerences in Binding Free Energies between the Wild-Type Residues and the Alanine Mutant Variants Obtained with
Thermodynamic Integrationa
mutation ΔΔGexpb kcal/mol ΔΔGTI kcal/mol SD |ΔΔGTI − ΔΔGexp|
1FLT Lys16Ala 0.35 1.28 0.74 0.93
Tyr21Ala 2.85 2.55 0.48 0.30
Leu66Ala 2.28 2.45 0.45 0.17
Ile46Ala 0.82 −0.23 0.45 1.05
His86Ala 0.00 0.09 0.51 0.09
1BRS Arg59Ala 5.2 4.87 0.71 0.33
Arg87Ala 5.5 8.23 0.76 2.70
His102Ala 6.0 3.40 0.48 2.60
Tyr29Ala 3.4 5.13 0.52 1.73
Thr42Ala 1.8 2.96 0.41 1.16
1F47 Phe9Ala 2.44 5.62 0.44 3.18
Leu10Ala 2.29 5.18 0.43 2.89
Asp2Ala 0.69 0.67 0.64 0.02
Tyr3Ala 0.86 5.95 0.50 5.09
Leu4Ala 0.92 −1.82 0.46 2.74
Asp5Ala 1.73 2.15 0.64 0.42
1VFB Trp92Ala 1.71 0.93 0.55 0.78
Tyr101Ala >4.0 −1.01 0.56 >1.01
Val120Ala 0.9 −0.95 0.46 1.85
Gln121Ala 2.9 4.90 0.50 2.00
Ser93Ala 0.11 −0.11 0.38 0.22
Arg125Ala 1.8 3.66 0.73 1.86
mean ⟨0.54⟩ 1.53
max ⟨0.76⟩ 5.09
aAlso shown are the uncertainties of the free energy diﬀerences and the comparisons with the experimental values. All values are given in kcal/mol.
bΔΔGexp is the ΔΔGbind experimental; ΔΔGTI is the ΔΔGbind obtained with TI; SD is the standard deviation error; |ΔΔGTI − ΔΔGexp| is the
absolute diﬀerence between the theoretical and experimental values.
Journal of Chemical Theory and Computation Article
dx.doi.org/10.1021/ct4000372 | J. Chem. Theory Comput. 2013, 9, 1311−13191316
molecular dynamics simulation, which is performed for the
wild-type system. This typically takes about 80−90% of the
total time required to evaluate by computational ASM a
typically sized protein−protein interface. Only the remaining
10−20% of the computational time grows linearly with the
number of mutations evaluated. Hence, considering 10 or 100
mutations in ASM does not signiﬁcantly increase the CPU time
associated, whereas in TI would imply a 10-fold increase.
With this ASM protocol, we can easily and quickly calculate
the diﬀerence in free energy of binding, upon mutation of
several interfacial amino acid residues from a fast dynamics in
implicit solvent and using the VMD plugin within the same
time frame that is required in TI to evaluate a single mutation.
IV. CONCLUSIONS
In this study, we have calculated the protein−protein binding
free energy diﬀerences upon alanine mutation of interfacial
residues (ΔΔGbind) both with the computational ASM protocol
and TI, for 22 critical mutations for which accurate
experimental data was available.
Even though the present test set can be regarded as relatively
small, it involves quite diverse mutations, representative in
terms of type and range of energy value associated to those
typically encountered when studying protein−protein interfaces
by experimental ASM. Hence, we feel conﬁdent about the
conclusion derived from this comparison.
Globally, the results show that this faster and easier
computational ASM protocol is capable of reproducing
experimental mutagenesis results with good accuracy, at the
same level of accuracy of TI, and its use is very appealing in the
systematic study of protein−protein interfaces. Naturally, TI
has a wider range of applications in the sense that it can be
applied in the study of other mutations (not only alanine
scanning mutagenesis) and in more general applications, with a
high computational cost associated.
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Table 3. TI vs ASM in the Study of VEGF: FLT-1 Interface Residuesa
MM-PBSA
implicit solvent
TI MD
mutation ΔΔGexp ΔΔGbind SD |ΔΔGcalc − ΔΔGexp| ΔΔGbind SD |ΔΔGcalc − ΔΔGexp| |ΔΔGASM − ΔΔGTI|
1FLT-1 Lys16Ala 0.35 1.28 0.74 0.93 0.03 0.74 0.32 1.25
Tyr21Ala 2.85 2.55 0.48 0.30 2.14 1.02 0.71 0.41
Leu66Ala 2.28 2.45 0.45 0.17 1.37 1.15 0.91 1.08
Ile46Ala 0.82 −0.23 0.45 1.05 0.02 1.20 0.80 0.25
His86Ala 0.00 0.09 0.51 0.09 0.06 0.82 0.06 0.03
1BRS Arg59Ala 5.2 4.87 0.71 0.33 6.68 0.57 1.48 1.81
Arg87Ala 5.5 8.23 0.76 2.70 10.19 0.89 4.69 1.96
His102Ala 6.0 3.40 0.48 2.60 5.71 0.58 0.29 3.40
Tyr29Ala 3.4 5.13 0.52 1.73 5.68 0.60 2.28 0.55
Thr42Ala 1.8 2.96 0.41 1.16 1.86 0.36 0.06 1.10
1F47 Phe9Ala 2.44 5.62 0.44 3.18 3.42 0.48 0.98 2.20
Leu10Ala 2.29 5.18 0.43 2.89 2.95 0.47 0.66 2.23
Asp2Ala 0.69 0.67 0.64 0.02 −1.55 0.51 2.24 2.22
Tyr3Ala 0.86 5.95 0.50 5.09 3.20 0.42 2.34 2.74
Leu4Ala 0.92 −1.82 0.46 2.74 2.18 0.48 1.26 4.00
Asp5Ala 1.73 2.15 0.64 0.42 −0.61 0.51 2.34 2.76
1VFB Trp92Ala 1.71 0.93 0.55 0.78 2.17 0.31 0.46 1.24
Tyr101Ala >4.0 2.99 0.56 >1.01 3.80 0.87 >0.2 0.81
Val120Ala 0.9 −0.95 0.46 1.85 1.33 0.34 0.43 2.28
Gln121Ala 2.9 4.90 0.50 2.00 3.85 0.21 0.95 1.05
Ser93Ala 0.11 −0.11 0.38 0.22 0.22 0.42 0.11 0.33
Arg125Ala 1.8 3.66 0.73 1.86 3.11 0.75 1.31 0.55
mean 0.54 1.53 0.62 1.18 1.56
max. 0.76 5.09 1.20 4.69 4.00
aΔΔGbind is the diﬀerence in the free energy of binding; ΔΔGexp is the ΔΔGbind experimental; ΔΔGcalc is the ΔΔGbindwt→mut obtained with ASM
protocol; SD is the standard deviation error; |ΔΔGcalc − ΔΔGexp| is the absolute diﬀerence between the calculated and experimental values.
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Wong, K. F.; Paesani, F.; Vanicek, J.; Wu, X.; Brozell, S. R.;
Steinbrecher, T.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak,
V. Cui, G. Mathews, D. H.; Seetin, M. G.; Sagui, C.; Babin, V.;
Kollman, P. A. AMBER 10; University of California: San Francisco,
2008.
(48) Hawkins, R. E.; Russell, S. J.; Baier, M.; Winter, G. The
contribution of contact and noncontact residues of antibody in the
affinity of binding to antigenThe interaction of mutant D1.3
antibodies with lysozyme. J. Mol. Biol. 1993, 234, 958−964.
(49) DallAcqua, W.; Goldman, E. R.; Eisenstein, E.; Mariuzza, R. A. A
mutational analysis of the binding of two different proteins to the same
antibody. Biochemistry 1996, 35, 9667−9676.
(50) Schreiber, G.; Fersht, A. R. Interaction of Barnase with its
polypeptide inhibitor Barstar studied by protein engineering.
Biochemistry 1993, 32, 5145−5150.
(51) Keyt, B. A.; Nguyen, H. V.; Berleau, L. T.; Duarte, C. M.; Park,
J.; Chen, H.; Ferrara, N. Identification of vascular endothelial growth
factor determinants for binding KDR and FLT-1 receptors
Generation of receptor-selective VEGF variants by site-directed
mutagenesis. J. Biol. Chem. 1996, 271, 5638−5646.
(52) Schreiber, G.; Fersht, A. R. Energetics of protein−protein
interactionsAnalysis of the Barnase−Barstar interface by single
mutations and double mutant cycles. J. Mol. Biol. 1995, 248, 478−486.
(53) Perez, M. A.; Sousa, S. F.; Oliveira, E. F.; Fernandes, P. A.;
Ramos, M. J. Detection of farnesyltransferase interface hot spots
through computational alanine scanning mutagenesis. J. Phys. Chem. B
2011, 115, 15339−15354.
Journal of Chemical Theory and Computation Article
dx.doi.org/10.1021/ct4000372 | J. Chem. Theory Comput. 2013, 9, 1311−13191319
FCUP 
NEW COMPUTATIONAL METHODS TO CALCULATE  
DRUG-RECEPTOR BINDING FREE ENERGIES 
118 
 
 
 
  
FCUP 
NEW COMPUTATIONAL METHODS TO CALCULATE  
DRUG-RECEPTOR BINDING FREE ENERGIES 
119 
 
 
3.4. DATABASE OF SOLVATION FREE ENERGIES 
It was a major goal of this PhD to build a database with (mostly) experimental values, 
from the literature, for the free energy of solvation of varied compounds. The collected 
experimental data set encompass a broad range of common functional groups present 
in biological and drugable small molecules.100 These values were used to check the 
consistency of the calculated values and also to assess their predictability. 
Since experimental free energies of hydration are not available for proteins, most 
drugs, or protein:drug complexes, a reasonable alternative is to verify if theoretical  
calculation methods and parameters yield good results for these small organic 
molecules, for which experimental data are available. 
Scanning the literature, 10 papers stood out for the amount and/or variety of data 
available. Those were the base of our database. It became notorious, however, the 
overlapping data present in the literature as well the lack of recently measured values. 
 
3.4.1. EXPERIMENTAL VALUES OF ΔGSOLV FREE ENERGIES AVAILABLE IN 
THE LITERATURE 
Using the available data distributed in the literature, a table was filled successively, with 
the final value to the ΔGsolv free energy of the compound being the average of the 
values found. This is presented in TABLE 2. 
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Table 2.  Experimental solvation free energies of neutral compounds, as there are available in the literature. Values expressed in kcal/mol. 
Molecule Type 
Experimental ΔGsolv (kcal/mol) 
Average 
Cabani, S. 
et al 1981 
Wolfenden, R. 
et al 1981 
Viswanadhan, V. N. 
et al 1999 
Wang, J. 
et al 2001 
Gallicchio, E. 
et al 2002 
Jorgensen, W. L. 
et al 2004 
Rizzo, R. C. 
et al 2006 
Marenich, A. V. 
et al 2009 
Purisima, E. O. 
et al 2010 
Lee, S. 
et al 2010 
              
methane Alkane 2.00 1.94 1.98 1.98 1.91 
 
1.99 
  
1.98 1.97 ±0.03 
ethane Alkane 1.83 
 
1.81 1.83 1.83 
 
1.83 
 
1.83 1.83 1.83 ±0.01 
propane Alkane 1.96 1.99 2.02 1.96 1.96 1.96 1.96 
 
1.96 1.96 1.97 ±0.02 
butane Alkane 2.08 2.15 2.18 2.08 2.08 2.07 2.07 
 
2.07 2.08 2.10 ±0.04 
pentane Alkane 2.33 
 
2.36 2.33 2.33 
 
2.32 
 
2.32 2.33 2.33 ±0.01 
hexane Alkane 2.49 
 
2.58 2.49 2.49 2.48 2.48 
  
2.49 2.50 ±0.03 
heptane Alkane 2.62 
 
2.65 2.62 2.62 
 
2.67 
 
2.67 2.62 2.64 ±0.02 
octane Alkane 2.89 
 
2.93 2.89 2.89 2.88 2.88 
 
2.88 2.89 2.89 ±0.01 
2-methylpropane Alkane 2.32 2.28 2.32 2.32 2.32 
 
2.32 
 
2.32 2.32 2.31 ±0.01 
2-methylbutane Alkane 2.38 
   
2.38 
 
2.38 
 
2.38 
 
2.38 ±0.00 
2-methylpentane Alkane 2.52 
 
2.56 2.52 2.52 
 
2.51 
 
2.51 2.52 2.52 ±0.01 
3-methylpentane Alkane 2.51 
 
2.54 2.51 2.51 
 
2.51 
 
2.51 2.51 2.51 ±0.01 
2-methylhexane Alkane 
      
2.93 
 
2.93 
 
2.93 ±0.00 
3-methylhexane Alkane 
      
2.71 
 
2.71 
 
2.71 ±0.00 
3-methylheptane Alkane 
      
2.97 
 
2.97 
 
2.97 ±0.00 
cyclopentane Alkane 1.20 
 
1.22 1.2 1.2 
 
1.2 
 
1.2 1.2 1.20 ±0.01 
cyclohexane Alkane 1.23 
 
1.24 1.23 1.23 1.23 1.23 
 
1.23 1.23 1.23 ±0.00 
cycloheptane Alkane 0.80 
         
0.80 ±0.00 
cyclooctane Alkane 0.86 
         
0.86 ±0.00 
nonane Alkane 
      
3.13 
 
3.13 
 
3.13 ±0.00 
2,2-dimethylpropane Alkane 2.50 
 
2.69 2.5 2.5 
 
2.51 
 
2.51 2.5 2.53 ±0.06 
2,2-dimethylbutane Alkane 2.59 
 
2.63 2.59 
  
2.51 
 
2.51 2.59 2.57 ±0.04 
2,2-dimethylpentane Alkane 
      
2.88 
 
2.88 
 
2.88 ±0.00 
3,3-dimethylpentane Alkane 
      
2.56 
 
2.56 
 
2.56 ±0.00 
methylcyclopentane Alkane 1.60 
 
1.62 1.6 1.6 
 
1.59 
 
1.59 1.6 1.60 ±0.01 
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methylcyclohexane Alkane 1.71 
 
1.73 1.71 1.71 
 
1.7 1.71 1.7 1.71 1.71 ±0.01 
benzene Arenes -0.87 
 
-0.9 -0.89 -0.87 -0.86 -0.86 
 
-0.86 -0.89 -0.87 ±0.01 
toluene Arenes -0.89 -0.76 -0.77 -0.76 -0.89 -0.89 -0.89 
 
-0.89 -0.76 -0.83 ±0.06 
o-xylene Arenes -0.90 
 
-0.91 -0.9 -0.9 -0.9 -0.9 
 
-0.9 -0.9 -0.90 ±0.00 
m-xylene Arenes -0.84 
 
-0.82 -0.8 -0.84 
 
-0.83 
 
-0.83 -0.8 -0.82 ±0.01 
p-xylene Arenes -0.81 
 
-0.82 -0.8 -0.81 
 
-0.8 
 
-0.8 -0.8 -0.81 ±0.01 
naphtalene Arenes -2.39 
 
-2.45 -2.41 -2.39 -2.4 -2.4 
 
-2.4 -2.41 -2.41 ±0.02 
anthracene Arenes -4.23 
 
-4.34 -4.23 -4.23 
 
-3.95 
 
-3.95 -4.23 -4.17 ±0.13 
phenanthrene Arenes -3.95 
 
-4.12 -4.06 -3.95 
 
-3.88 
 
-3.88 -4.06 -3.99 ±0.08 
1,2,3-trimethylbenzene Arenes 
      
-1.21 
 
-1.21 
 
-1.21 ±0.00 
1,2,4-trimethylbenzene Arenes -0.86 
 
-0.87 -0.86 -0.86 
 
-0.86 
 
-0.86 -0.86 -0.86 ±0.00 
1,3,5-trimethylbenzene Arenes 
      
-0.9 
   
-0.90 ±0.00 
1-methylnapthalene Arenes -2.37 
   
-2.37 
 
-2.44 
 
-2.44 
 
-2.40 ±0.03 
1,3-dimethylnapthalene Arenes -2.47 
         
-2.47 ±0.00 
1,4-dimethylnapthalene Arenes -2.82 
       
-2.82 
 
-2.82 ±0.00 
2,3-dimethylnapthalene Arenes -2.78 
       
-2.78 
 
-2.78 ±0.00 
2,6-dimethylnapthalene Arenes -2.63 
       
-2.63 
 
-2.63 ±0.00 
2,7-dimethylnapthalene Arenes 
    
-2.63 
     
-2.63 ±0.00 
pyridine Heterocyclics -4.70 
  
-4.69 -4.7 
   
-4.69 
 
-4.69 ±0.00 
pyrrole Heterocyclics 
      
-4.78 
 
-4.78 
 
-4.78 ±0.00 
thiophene Heterocyclics 
      
-1.42 
 
-1.42 
 
-1.42 ±0.00 
imidazole Heterocyclics 
      
-9.63 
 
-9.63 
 
-9.63 ±0.00 
2-methylpyridine Heterocyclics -4.63 
  
-4.62 -4.63 
  
-4.63 -4.63 
 
-4.63 ±0.00 
3-methylpyridine Heterocyclics -4.77 
  
-4.77 -4.77 
  
-4.77 -4.77 
 
-4.77 ±0.00 
4-methylpyridine Heterocyclics -4.94 
  
-4.92 -4.83 
  
-4.94 -4.93 
 
-4.91 ±0.04 
2,3-dimethylpyridine Heterocyclics -4.83 
  
-4.81 
    
-4.82 
 
-4.82 ±0.01 
2,4-dimethylpyridine Heterocyclics -4.86 
  
-4.85 
    
-4.86 
 
-4.86 ±0.01 
2,5-dimethylpyridine Heterocyclics -4.72 
  
-4.7 
    
-4.72 
 
-4.71 ±0.01 
2,6-dimethylpyridine Heterocyclics -4.60 
  
-4.6 -4.6 
   
-4.59 
 
-4.60 ±0.00 
3,4-dimethylpyridine Heterocyclics -5.22 
  
-5.21 
   
-5.22 -5.22 
 
-5.22 ±0.00 
3,5-dimethylpyridine Heterocyclics -4.84 
  
-4.84 -4.84 
  
-4.84 -4.84 
 
-4.84 ±0.00 
2-methylindole Heterocyclics 
   
-5.91 
    
-5.88 
 
-5.90 ±0.01 
3-methylindole Heterocyclics 
 
-5.88 
        
-5.88 ±0.00 
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2-methylthiophene Heterocyclics 
        
-1.38 
 
-1.38 ±0.00 
2-methylimidazole Heterocyclics 
   
-10.25 
      
-10.25 ±0.00 
4-methylimidazole Heterocyclics 
 
-10.27 
      
-10.27 
 
-10.27 ±0.00 
aziridine Heterocyclics 
    
-5.42 -5.41 
    
-5.42 ±0.00 
azetidine Heterocyclics 
    
-5.56 
 
-5.56 
  
-5.56 -5.56 ±0.00 
morpholine Heterocyclics 
    
-7.17 -7.18 -7.17 
  
-7.17 -7.17 ±0.00 
N-methylmorpholine Heterocyclics 
    
-6.34 
 
-6.32 
  
-6.34 -6.33 ±0.01 
chloroethane haloalkanes -0.63 
 
-0.63 
  
-0.63 -0.63 -0.63 -0.63 -0.63 -0.63 ±0.00 
bromoethane haloalkanes -0.70 
 
-0.7 
  
-0.74 -0.7 -0.74 -0.7 -0.71 -0.71 ±0.02 
iodoethane haloalkanes -0.72 
 
-0.72 
  
-0.74 
 
-0.74 -0.72 -0.73 -0.73 ±0.01 
1-chloropropane haloalkanes -0.27 
 
-0.35 
  
-0.33 -0.27 -0.33 -0.35 -0.32 -0.32 ±0.03 
bromopropane haloalkanes -0.56 
 
-0.56 
  
-0.56 -0.56 -0.56 -0.56 -0.56 -0.56 ±0.00 
1-iodopropane haloalkanes -0.59 
 
-0.58 
 
-0.53 -0.53 
 
-0.53 -0.58 -0.56 -0.56 ±0.02 
1-chlorobutane haloalkanes -0.14 
 
-0.14 
  
-0.16 
 
-0.16 -0.14 -0.15 -0.15 ±0.01 
1-bromobutane haloalkanes -0.41 
 
-0.41 
  
-0.4 -0.41 -0.4 -0.41 -0.41 -0.41 ±0.00 
1-iodobutane haloalkanes -0.26 
 
-0.26 
  
-0.25 
 
-0.25 -0.26 -0.26 -0.26 ±0.00 
1-chloropentane haloalkanes -0.07 
 
-0.07 
  
-0.07 
 
-0.07 -0.07 -0.07 -0.07 ±0.00 
2-chloropropane haloalkanes -0.25 
 
-0.24 
   
-0.25 -0.25 -0.24 -0.25 -0.25 ±0.00 
2-bromopropane haloalkanes -0.48 
 
-0.48 
   
-0.48 -0.48 -0.48 -0.48 -0.48 ±0.00 
2-iodopropane haloalkanes -0.46 
 
-0.46 
  
-0.46 
 
-0.46 -0.46 -0.46 -0.46 ±0.00 
2-chlorobutane haloalkanes 
  
0.07 
   
0.07 
 
0.07 0.07 0.07 ±0.00 
2-chloropentane haloalkanes 0.07 
 
0.07 
   
0.07 
 
0.07 0.07 0.07 ±0.00 
3-chloropentane haloalkanes 0.04 
 
0.07 
     
0.07 0.06 0.06 ±0.01 
2-chloro-2-methylpropane haloalkanes 
       
1.09 
 
1.09 1.09 ±0.00 
2-bromo-2-methylpropane haloalkanes 
       
0.84 
 
0.84 0.84 ±0.00 
1,1-difluoroethane haloalkanes 
  
-0.11 
  
-0.11 -0.11 -0.11 -0.11 -0.11 -0.11 ±0.00 
1,1 dichloroethane haloalkanes 
  
-0.85 
  
-0.84 
 
-0.84 -0.85 -0.85 -0.85 ±0.00 
1,2 dichloroethane haloalkanes 
    
-1.79 -1.79 
 
-1.79 
 
-1.79 -1.79 ±0.00 
1,1,1 trichloroethane haloalkanes 
  
-0.25 
  
-0.19 -0.25 -0.19 -0.25 -0.23 -0.23 ±0.02 
1,1,2 trichloroethane haloalkanes 
  
-1.95 
  
-1.99 -1.95 -1.99 -1.95 -1.97 -1.97 ±0.02 
1,1,1,2 tetrachloroethane haloalkanes 
  
-1.15 
  
-1.28 -1.15 -1.28 -1.15 -1.20 -1.20 ±0.05 
1,1,2,2 tetrachloroethane haloalkanes 
  
-2.36 
  
-2.47 
 
-2.47 -2.36 -2.42 -2.42 ±0.04 
1,2-dibromoethane haloalkanes 
  
-2.1 
  
-2.33 
 
-2.33 -2.1 -2.22 -2.22 ±0.09 
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1,2 dichloropropane haloalkanes 
  
-1.25 
  
-1.27 
 
-1.27 -1.25 -1.26 -1.26 ±0.01 
1,3 dichloropropane haloalkanes 
  
-1.9 
  
-1.89 
 
-1.89 -1.9 -1.90 -1.90 ±0.00 
1,2-dibromopropane haloalkanes 
  
-1.94 
     
-1.94 -1.94 -1.94 ±0.00 
1,3-dibromopropane haloalkanes 
 
-1.99 -1.96 
     
-1.96 -1.97 -1.97 ±0.01 
1,1-dichlorobutane haloalkanes 
  
-0.7 
     
-0.7 -0.70 -0.70 ±0.00 
1,4-dichlorobutane haloalkanes 
     
-2.32 
   
-2.32 -2.32 ±0.00 
Fluorobenzene haloaromatic 
  
-0.78 
 
-0.81 -0.8 -0.78 -0.8 -0.78 -0.79 -0.79 ±0.01 
chlorobenzene haloaromatic -1.12 
 
-1.01 
 
-1.12 -1.12 -1.12 -1.12 -1.01 -1.09 -1.09 ±0.04 
bromobenzene haloaromatic -1.46 
 
-1.46 
 
-1.45 -1.46 -1.46 -1.46 -1.46 -1.46 -1.46 ±0.00 
iodobenzene haloaromatic 
  
-1.73 
 
-1.75 -1.74 
 
-1.74 -1.73 -1.74 -1.74 ±0.01 
2-chlorotoluene haloaromatic 
  
-1.15 
  
-1.14 -1.15 -1.14 -1.15 -1.15 -1.15 ±0.00 
2-bromotoluene haloaromatic 
      
-2.37 
  
-2.37 -2.37 ±0.00 
m-chlorotoluene haloaromatic 
        
-1.92 -1.92 -1.92 ±0.00 
p-chlorotoluene haloaromatic 
  
1.92 
      
1.92 1.92 ±0.00 
p-bromotoluene haloaromatic 
  
-1.39 
   
-1.39 -1.39 -1.39 -1.39 -1.39 ±0.00 
1,2-dichlorobenzene haloaromatic 
  
-1.36 
  
-1.36 -1.36 -1.36 -1.36 -1.36 -1.36 ±0.00 
1,3-dichlorobenzene haloaromatic 
  
-0.98 
  
-0.98 
 
-0.98 -0.98 -0.98 -0.98 ±0.00 
1,4-dichlorobenzene haloaromatic 
 
-1.02 -1.01 
  
-1.01 -1.01 
 
-1.01 -1.01 -1.01 ±0.00 
1,4-dibromobenzene haloaromatic 
  
-2.3 
  
-2.3 -2.3 -2.3 -2.3 -2.30 -2.30 ±0.00 
1,2,3-trichlorobenzene haloaromatic 
     
-1.24 
 
-1.24 
 
-1.24 -1.24 ±0.00 
1,2,4-trichlorobenzene haloaromatic 
     
-1.12 
 
-1.12 
 
-1.12 -1.12 ±0.00 
1,3,5-trichlorobenzene haloaromatic 
     
-0.78 
   
-0.78 -0.78 ±0.00 
1,2,3,4-tetrachlorobenzene haloaromatic 
     
-1.34 
 
-1.34 
 
-1.34 -1.34 ±0.00 
1,2,3,5-tetrachlorobenzene haloaromatic 
     
-1.62 
 
-1.62 
 
-1.62 -1.62 ±0.00 
1,2,4,5-tetrachlorobenzene haloaromatic 
     
-1.34 
 
-1.34 
 
-1.34 -1.34 ±0.00 
methanol Alcohols and Phenols -5.11 -5.06 -5.14 -5.07 -5.11 -5.1 -5.1 
 
-5.1 -5.07 -5.10 ±0.02 
ethanol Alcohols and Phenols -5.01 -4.88 -4.96 -4.9 -5.01 -5.01 -5 
 
-5 -4.9 -4.96 ±0.05 
1-propanol Alcohols and Phenols -4.83 
 
-4.92 -4.85 -4.83 
 
-4.85 
 
-4.85 -4.85 -4.85 ±0.03 
1-butanol Alcohols and Phenols -4.72 
 
-4.78 -4.72 -4.72 -4.72 -4.72 
 
-4.72 -4.72 -4.73 ±0.02 
1-pentanol Alcohols and Phenols -4.47 
 
-4.55 -4.49 -4.47 
 
-4.57 
 
-4.57 -4.49 -4.52 ±0.04 
1-hexanol Alcohols and Phenols -4.36 
 
-4.42 -4.36 -4.36 -4.41 -4.4 
 
-4.4 -4.36 -4.38 ±0.02 
1-heptanol Alcohols and Phenols -4.24 
 
-4.31 -4.25 
  
-4.21 
 
-4.21 -4.25 -4.25 ±0.03 
1-octanol Alcohols and Phenols -4.09 
 
-4.16 -4.1 
  
-4.09 
 
-4.09 -4.1 -4.11 ±0.02 
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2-propanol Alcohols and Phenols -4.76 
 
-4.81 -4.75 -4.76 -4.75 -4.74 
 
-4.74 -4.75 -4.76 ±0.02 
2-butanol Alcohols and Phenols -4.58 
 
-4.67 -4.61 -4.58 
 
-4.62 
 
-4.62 -4.61 -4.61 ±0.03 
2-pentanol Alcohols and Phenols -4.39 
 
-4.45 -4.39 -4.39 
 
-4.39 
 
-4.39 -4.39 -4.40 ±0.02 
3-pentanol Alcohols and Phenols -4.35 
  
-4.35 -4.35 
 
-4.35 
 
-4.35 -4.35 -4.35 ±0.00 
3-hexanol Alcohols and Phenols -4.08 
 
-3.73 -3.68 -4.08 
 
-4.06 
 
-4.06 -3.68 -3.91 ±0.17 
4-heptanol Alcohols and Phenols -4.01 
  
-4.01 
     
-4.01 -4.01 ±0.00 
2-methylpropane-2-ol Alcohols and Phenols -4.51 
   
-4.51 -4.48 -4.47 
 
-4.47 
 
-4.49 ±0.02 
2-methylbutane-2-ol Alcohols and Phenols -4.43 
  
-4.43 -4.43 
 
-4.43 
  
-4.43 -4.43 ±0.00 
2-methylpentane-2-ol Alcohols and Phenols -3.93 
 
-3.98 -3.93 -3.93 
 
-3.92 
 
-3.92 -3.93 -3.93 ±0.02 
cyclopentanol Alcohols and Phenols -5.49 
  
-5.49 -5.49 
 
-5.49 
 
-5.49 -5.49 -5.49 ±0.00 
cyclohexanol Alcohols and Phenols -5.48 
 
-5.02 -4.95 -5.48 -5.47 -5.46 
 
-5.46 -4.95 -5.28 ±0.23 
cycloheptanol Alcohols and Phenols -5.49 
  
-5.49 
  
-5.48 
 
-5.48 -5.49 -5.49 ±0.00 
phenol Alcohols and Phenols -6.62 
 
-6.62 -6.53 -6.62 -6.62 -6.61 
 
-6.61 -6.53 -6.59 ±0.04 
2-methylphenol Alcohols and Phenols -5.87 
  
-5.86 -5.87 
     
-5.87 ±0.01 
3-methylphenol Alcohols and Phenols 
   
-5.49 
      
-5.49 ±0.00 
4-methylphenol Alcohols and Phenols -6.14 
  
-6.12 -6.14 
     
-6.13 ±0.01 
2,3-dimethylphenol Alcohols and Phenols 
      
-6.16 
   
-6.16 ±0.00 
3,4-dimethylphenol Alcohols and Phenols 
      
-6.5 
   
-6.50 ±0.00 
2,6-dimethylphenol Alcohols and Phenols 
      
-5.26 
   
-5.26 ±0.00 
2,4-dimethylphenol Alcohols and Phenols 
      
-6.01 
   
-6.01 ±0.00 
3,5-dimethylphenol Alcohols and Phenols 
      
-6.27 
   
-6.27 ±0.00 
2,5-dimethylphenol Alcohols and Phenols 
      
-5.91 
   
-5.91 ±0.00 
1-hydroxynapthalene Alcohols and Phenols 
     
-7.68 -7.67 
 
-7.67 
 
-7.67 ±0.00 
2-hydroxynapthalene Alcohols and Phenols 
      
-8.11 
 
-8.11 
 
-8.11 ±0.00 
methoxymethane ethers 
      
-1.91 
 
-1.91 -1.92 -1.91 ±0.00 
methyl-ethyl-ether ethers 
      
-2.1 
 
-2.1 
 
-2.10 ±0.00 
methyl propyl ether ethers 
      
-1.66 
 
-1.66 -1.66 -1.66 ±0.00 
methyl isopropyl ether ethers 
      
-2.01 
 
-2.01 -2 -2.01 ±0.00 
t-butyl methyl ether ethers 
      
-2.21 
 
-2.21 -2.21 -2.21 ±0.00 
2-methoxyethanol ethers 
      
-6.76 
 
-6.76 -6.77 -6.76 ±0.00 
2-methoxyethanamine ethers 
      
-6.55 
 
-6.55 -6.55 -6.55 ±0.00 
2-methoxyphenol ethers 
      
-5.57 
 
-5.57 
 
-5.57 ±0.00 
3-methoxyphenol ethers 
      
-7.66 
 
-7.66 
 
-7.66 ±0.00 
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2-methoxyaniline ethers 
      
-6.12 
 
-6.12 
 
-6.12 ±0.00 
3-methoxyaniline ethers 
      
-7.29 
 
-7.29 
 
-7.29 ±0.00 
4-methoxyaniline ethers 
      
-7.48 
 
-7.48 
 
-7.48 ±0.00 
acetaldehyde Aldehydes 
      
-3.5 
  
-3.5 -3.50 ±0.00 
propionaldehyde Aldehydes 
      
-3.43 
 
-3.43 -3.44 -3.43 ±0.00 
butyraldehyde Aldehydes 
      
-3.18 
 
-3.18 -3.18 -3.18 ±0.00 
pentanal Aldehydes 
      
-3.03 
 
-3.03 -3.03 -3.03 ±0.00 
hexanal Aldehydes 
      
-2.81 
 
-2.81 -2.81 -2.81 ±0.00 
heptanal Aldehydes 
      
-2.67 
 
-2.67 -2.67 -2.67 ±0.00 
octanal Aldehydes 
      
-2.29 
 
-2.29 -2.29 -2.29 ±0.00 
nonanal Aldehydes 
      
-2.07 
 
-2.07 -2.07 -2.07 ±0.00 
isobutaldehyde Aldehydes 
      
-2.86 
 
-2.86 
 
-2.86 ±0.00 
benzaldehyde Aldehydes 
         
-4.02 -4.02 ±0.00 
m-hydroxybenzaldehyde Aldehydes 
         
-9.51 -9.51 ±0.00 
p-hydroxybenzaldehyde Aldehydes 
         
-10.48 -10.48 ±0.00 
formaldehyde Aldehydes 
      
-2.75 
 
-2.75 
 
-2.75 ±0.00 
ethanoic acid carboxylic acids 
      
-6.69 
 
-6.69 -6.7 -6.69 ±0.00 
propanoic acid carboxylic acids 
      
-6.46 
 
-6.46 -6.46 -6.46 ±0.00 
butanoic acid carboxylic acids 
      
-6.35 
 
-6.35 -6.35 -6.35 ±0.00 
pentanoic acid carboxylic acids 
      
-6.16 
 
-6.16 -6.16 -6.16 ±0.00 
hexanoic acid carboxylic acids 
      
-6.21 
 
-6.21 -6.21 -6.21 ±0.00 
N-methyl formamide Amides 
    
-10 
    
-10.00 -10.00 ±0.00 
acetamide Amides -9.71 -9.68 
 
-9.72 -9.71 -9.71 
 
-9.71 
  
-9.71 ±0.01 
propionamide Amides 
   
-9.42 -9.41 
     
-9.42 ±0.00 
benzamide Amides 
     
-11.01 
 
-10.9 -11 
 
-10.97 ±0.04 
N-methylacetamide Amides 
    
-10.08 -10.08 -10 
  
-10.00 -10.04 ±0.04 
N,N-dimethylformamide Amides 
     
-7.8 -7.81 
   
-7.81 ±0.00 
N,N-dimethyl-acetamide Amides 
    
-8.5 -8.55 
    
-8.53 ±0.02 
n-butylacetamide Amides 
      
-9.31 
   
-9.31 ±0.00 
methyl amine Amines -4.56 
  
-4.6 -4.56 
 
-4.55 -4.56 -4.55 -4.60 -4.57 ±0.02 
ethyl amine Amines -4.50 
 
-4.67 -4.61 -4.5 
 
-4.5 -4.5 -4.05 -4.61 -4.49 ±0.17 
n-propyl amine Amines -4.39 
 
-4.56 -4.5 -4.39 
 
-4.39 -4.39 -4.39 -4.50 -4.44 ±0.06 
n-butyl amine Amines -4.29 
 
-4.43 -4.38 -4.29 
 
-4.24 -4.29 -4.24 -4.38 -4.32 ±0.06 
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n-pentyl amine Amines -4.10 
 
-4.14 -4.09 -4.1 
 
-4.09 
 
-4.09 -4.09 -4.10 ±0.02 
n-hexyl amine Amines -4.03 
 
-4.09 -4.04 -4.03 
 
-3.95 
 
-3.95 -4.04 -4.02 ±0.04 
n-heptylamine Amines 
        
-3.79 
 
-3.79 ±0.00 
n-octylamine Amines 
      
-3.65 
 
-3.65 
 
-3.65 ±0.00 
ethylenediamine Amines 
  
-9.88 
      
-9.75 -9.82 ±0.05 
cyclohexylamine Amines 
      
-4.59 
   
-4.59 ±0.00 
aniline Amines 
   
-5.49 -4.9 -5.49 -5.49 
 
-5.49 -5.49 -5.39 ±0.20 
dimethyl amine Amines 
  
-4.34 
 
-4.29 -4.3 -4.29 
  
-4.28 -4.30 ±0.02 
diethyl amine Amines 
  
-4.12 
 
-4.07 
 
-4.07 
  
-4.06 -4.08 ±0.02 
di-n-propylamine Amines 
  
-3.7 
 
-3.66 
 
-3.65 
  
-3.65 -3.67 ±0.02 
di-n-butyl amine Amines 
  
-3.38 
 
-3.33 
 
-3.24 
  
-3.31 -3.32 ±0.04 
trimethyl amine Amines 
  
-3.27 
 
-3.24 -3.22 -3.2 
  
-3.23 -3.23 ±0.02 
pyrrolidine Amines 
  
-5.54 
 
-5.48 
 
-5.48 
  
-5.47 -5.49 ±0.02 
piperidine Amines 
  
-5.17 
 
-5.11 
 
-5.11 
  
-5.10 -5.12 ±0.02 
N-methylpyrrolidine Amines 
  
-4.02 
 
-3.98 
    
-3.97 -3.99 ±0.02 
N-methylpiperidine Amines 
  
-3.94 
 
-3.89 -3.78 -3.88 
  
-3.89 -3.88 ±0.05 
piperazine Amines 
     
-7.37 -7.4 
  
-7.40 -7.39 ±0.01 
N-methylpiperazine Amines 
      
-7.77 
  
-7.77 -7.77 ±0.00 
diisopropylamine Amines 
      
-3.22 
   
-3.22 ±0.00 
triethyl amine Amines 
  
-3.07 
 
-3.02 
 
-3.22 
  
-3.03 -3.09 ±0.07 
ammonia Amines 
    
-4.31 
 
-4.29 
  
-4.29 -4.30 ±0.01 
N,N-dimethyl aniline Amines 
         
-2.90 -2.90 ±0.00 
N,N-dimethylpiperazine Amines 
         
-7.58 -7.58 ±0.00 
1-amino-2-methoxy-ethane Amines 
    
-6.6 
     
-6.60 ±0.00 
acetonitrile nitriles 
  
-3.94 -3.89 -3.89 -3.85 
 
-3.89 -3.88 -3.89 -3.89 ±0.02 
propanenitrile nitriles 
  
-3.9 -3.85 -3.85 
 
-3.84 -3.85 -3.84 -3.85 -3.85 ±0.02 
butanenitrile nitriles 
  
-3.69 -3.64 -3.64 
 
-3.64 -3.64 -3.64 -3.64 -3.65 ±0.02 
pentanenitrile nitriles 
      
-3.52 
 
-3.52 
 
-3.52 ±0.00 
benzonitrile nitriles 
   
-4.1 
 
-4.22 -4.21 -4.1 -4.21 -4.1 -4.16 ±0.05 
3-cyanophenol nitriles 
    
-9.67 
 
-9.65 
 
-9.65 
 
-9.66 ±0.01 
4-cyanophenol nitriles 
    
-10.17 -10.18 -10.17 
 
-10.17 
 
-10.17 ±0.00 
3-cyanopyridine nitriles 
      
-6.75 
   
-6.75 ±0.00 
4-cyanopyridine nitriles 
      
-6.02 
 
-6.02 
 
-6.02 ±0.00 
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nitromethane Nitro compounds 
      
-4.02 -3.95 -4.02 
 
-4.00 ±0.03 
nitroethane Nitro compounds -3.71 
 
-3.76 -3.71 -3.71 -3.71 -3.71 -3.71 -3.71 -3.71 -3.72 ±0.01 
1-nitropropane Nitro compounds -3.34 
  
-3.34 -3.34 
 
-3.34 -3.34 -3.34 -3.34 -3.34 ±0.00 
1-nitrobutane Nitro compounds 
   
-3.08 
  
-3.09 -3.08 -3.09 -3.08 -3.08 ±0.00 
1-nitropentane Nitro compounds 
      
-2.82 
 
-2.82 
 
-2.82 ±0.00 
2-nitropropane Nitro compounds -3.14 
 
-3.18 -3.14 -3.14 
 
-3.13 -3.14 -3.13 -3.14 -3.14 ±0.01 
nitrobenzene Nitro compounds -4.12 
 
-4.17 -4.12 -4.12 -4.12 -4.12 -4.12 -4.12 -4.12 -4.13 ±0.01 
2-nitrophenol Nitro compounds 
      
-4.58 
 
-4.58 
 
-4.58 ±0.00 
3-nitrophenol Nitro compounds 
    
-9.63 
 
-9.62 
   
-9.63 ±0.00 
p-nitrophenol Nitro compounds 
  
-10.74 
 
-10.65 -10.65 -10.64 
 
-10.64 -10.6 -10.65 ±0.04 
2-nitrotoluene Nitro compounds 
  
-3.63 -3.59 
  
-3.58 
 
-3.58 -3.59 -3.59 ±0.02 
3-nitrotoluene Nitro compounds 
  
-3.5 -3.45 
  
-3.45 
 
-3.45 -3.45 -3.46 ±0.02 
m-nitroaniline Nitro compounds 
     
-8.86 
    
-8.86 ±0.00 
methanethiol thiols 
      
-1.24 
 
-1.24 -1.24 -1.24 ±0.00 
ethanethiol thiols 
      
-1.14 
 
-1.14 -1.3 -1.19 ±0.07 
1-propanethiol thiols 
      
-1.06 
 
-1.06 -1.05 -1.06 ±0.00 
n-butanethiol thiols 
      
-0.99 
 
-0.99 
 
-0.99 ±0.00 
thiophenol thiols 
      
-2.55 
 
-2.55 
 
-2.55 ±0.00 
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For each compound, Open Babel101 was used to generate mol2 structures and the 
Molecular Operating Environment (MOE)102 was applied to generate physical and 
structural properties for each one. The properties calculated for each molecule included 
the molecular weight, van der Walls volume and area, number of rings, number of 
atoms, volume and accessible surface areas, among others. 
Those were added to the database, in order to make it more thorough and some of 
them are represented in TABLE 3. 
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Table 3. Different properties for each compound in the database, generated by the Molecular Operating Environment (MOE). Experimental ΔGsolv average is also presented. 
Molecule Type 
Average 
ΔGsolv 
(kcal/mol) 
Acessible Surface Area (Å
2
) No. arom aa No. aa No. heavy aa No. rings vdW área (Å
2
) 
vdW 
Vol (Å
3
) 
Weight 
           
methane Alkane 1.97 146.6 0 5 1 0 45.9 38.3 16.0 
ethane Alkane 1.83 181.8 0 8 2 0 63.1 62.8 30.1 
propane Alkane 1.97 215.2 0 11 3 0 80.3 87.2 44.1 
butane Alkane 2.10 246.1 0 14 4 0 97.6 111.6 58.1 
pentane Alkane 2.33 273.9 0 17 5 0 114.8 136.0 72.2 
hexane Alkane 2.50 309.7 0 20 6 0 132.0 160.5 86.2 
heptane Alkane 2.64 339.8 0 23 7 0 149.2 184.9 100.2 
octane Alkane 2.89 359.1 0 26 8 0 166.5 209.3 114.2 
2-methylpropane Alkane 2.31 238.4 0 14 4 0 98.9 111.6 58.1 
2-methylbutane Alkane 2.38 266.3 0 17 5 0 116.1 136.0 72.2 
2-methylpentane Alkane 2.52 298.6 0 20 6 0 133.4 160.5 86.2 
3-methylpentane Alkane 2.51 295.2 0 20 6 0 133.4 160.5 86.2 
2-methylhexane Alkane 2.93 330.9 0 23 7 0 150.6 184.9 100.2 
3-methylhexane Alkane 2.71 320.8 0 23 7 0 150.6 184.9 100.2 
3-methylheptane Alkane 2.97 353.8 0 26 8 0 167.8 209.3 114.2 
cyclopentane Alkane 1.20 246.1 0 15 5 1 86.2 122.1 70.1 
cyclohexane Alkane 1.23 265.7 0 18 6 1 103.4 146.6 84.2 
cycloheptane Alkane 0.80 290.2 0 21 7 1 120.6 171.0 98.2 
cyclooctane Alkane 0.86 304.8 0 24 8 1 137.9 195.4 112.2 
nonane Alkane 3.13 369.3 0 29 9 0 183.7 233.8 128.3 
2,2-dimethylpropane Alkane 2.53 259.9 0 17 5 0 126.2 136.0 72.2 
2,2-dimethylbutane Alkane 2.57 284.9 0 20 6 0 143.4 160.5 86.2 
2,2-dimethylpentane Alkane 2.88 314.6 0 23 7 0 160.6 184.9 100.2 
3,3-dimethylpentane Alkane 2.56 304.5 0 23 7 0 160.6 184.9 100.2 
methylcyclopentane Alkane 1.60 272.6 0 18 6 1 104.7 146.6 84.2 
methylcyclohexane Alkane 1.71 291.2 0 21 7 1 122.0 171.0 98.2 
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benzene Arenes -0.87 247.3 6 12 6 1 99.1 128.9 78.1 
toluene Arenes -0.83 279.6 6 15 7 1 116.4 153.3 92.1 
o-xylene Arenes -0.90 299.7 6 18 8 1 133.6 177.7 106.2 
m-xylene Arenes -0.82 276.2 6 15 7 1 116.4 153.3 92.1 
p-xylene Arenes -0.81 309.6 6 18 8 1 133.6 177.7 106.2 
naphtalene Arenes -2.41 318.6 10 18 10 2 136.6 200.9 128.2 
anthracene Arenes -4.17 390.4 14 24 14 3 174.0 272.9 178.2 
phenanthrene Arenes -3.99 377.6 14 24 14 3 174.0 272.9 178.2 
1,2,3-trimethylbenzene Arenes -1.21 323.2 6 21 9 1 150.8 202.2 120.2 
1,2,4-trimethylbenzene Arenes -0.86 327.6 6 21 9 1 150.8 202.2 120.2 
1,3,5-trimethylbenzene Arenes -0.90 335.1 6 21 9 1 150.8 202.2 120.2 
1-methylnapthalene Arenes -2.40 335.0 10 21 11 2 153.8 225.3 142.2 
1,3-dimethylnapthalene Arenes -2.47 365.3 10 24 12 2 171.0 249.7 156.2 
1,4-dimethylnapthalene Arenes -2.82 358.6 10 24 12 2 171.0 249.7 156.2 
2,3-dimethylnapthalene Arenes -2.78 363.4 10 24 12 2 171.0 249.7 156.2 
2,6-dimethylnapthalene Arenes -2.63 380.4 10 24 12 2 171.0 249.7 156.2 
2,7-dimethylnapthalene Arenes -2.63 372.5 10 24 12 2 171.0 249.7 156.2 
pyridine Heterocyclics -4.69 237.6 6 11 6 1 97.3 119.8 79.1 
pyrrole Heterocyclics -4.78 221.3 5 10 5 1 83.8 102.2 67.1 
thiophene Heterocyclics -1.42 230.6 5 9 5 1 89.8 108.3 84.1 
imidazole Heterocyclics -9.63 217.0 5 9 5 1 82.0 93.1 68.1 
2-methylpyridine Heterocyclics -4.63 271.3 6 14 7 1 114.5 144.2 93.1 
3-methylpyridine Heterocyclics -4.77 266.9 6 14 7 1 114.5 144.2 93.1 
4-methylpyridine Heterocyclics -4.91 269.1 6 14 7 1 114.5 144.2 93.1 
2,3-dimethylpyridine Heterocyclics -4.82 291.2 6 17 8 1 131.7 168.7 107.2 
2,4-dimethylpyridine Heterocyclics -4.86 302.8 6 17 8 1 131.7 168.7 107.2 
2,5-dimethylpyridine Heterocyclics -4.71 302.4 6 17 8 1 131.7 168.7 107.2 
2,6-dimethylpyridine Heterocyclics -4.60 303.7 6 17 8 1 131.7 168.7 107.2 
3,4-dimethylpyridine Heterocyclics -5.22 292.7 6 17 8 1 131.7 168.7 107.2 
3,5-dimethylpyridine Heterocyclics -4.84 298.6 6 17 8 1 131.7 168.7 107.2 
2-methylindole Heterocyclics -5.90 328.7 0 20 10 2 139.2 201.6 132.2 
3-methylindole Heterocyclics -5.88 322.2 0 20 10 2 140.6 201.6 132.2 
2-methylthiophene Heterocyclics -1.38 262.0 5 12 6 1 107.0 132.7 98.2 
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2-methylimidazole Heterocyclics -10.25 252.3 5 12 6 1 99.2 117.6 82.1 
4-methylimidazole Heterocyclics -10.27 253.6 5 12 6 1 99.2 117.6 82.1 
aziridine Heterocyclics -5.42 194.5 0 9 3 1 60.7 69.0 44.1 
azetidine Heterocyclics -5.56 221.7 0 12 4 1 77.9 93.5 58.1 
morpholine Heterocyclics -7.17 251.5 0 16 6 1 110.2 128.5 88.1 
N-methylmorpholine Heterocyclics -6.33 277.3 0 19 7 1 137.6 154.6 102.2 
chloroethane haloalkanes -0.63 210.8 0 8 3 0 80.7 78.7 64.5 
bromoethane haloalkanes -0.71 224.7 0 8 3 0 92.4 91.7 109.0 
iodoethane haloalkanes -0.73 232.9 0 8 3 0 96.6 95.3 156.0 
1-chloropropane haloalkanes -0.32 242.1 0 11 4 0 97.9 103.1 78.5 
bromopropane haloalkanes -0.56 257.5 0 11 4 0 109.7 116.2 123.0 
1-iodopropane haloalkanes -0.56 264.1 0 11 4 0 113.8 119.7 170.0 
1-chlorobutane haloalkanes -0.15 272.6 0 14 5 0 115.1 127.6 92.6 
1-bromobutane haloalkanes -0.41 285.4 0 14 5 0 126.9 140.6 137.0 
1-iodobutane haloalkanes -0.26 293.8 0 14 5 0 131.1 144.2 184.0 
1-chloropentane haloalkanes -0.07 300.4 0 17 6 0 132.4 152.0 106.6 
2-chloropropane haloalkanes -0.25 236.3 0 11 4 0 97.9 103.1 78.5 
2-bromopropane haloalkanes -0.48 248.8 0 11 4 0 111.0 116.2 123.0 
2-iodopropane haloalkanes -0.46 256.2 0 11 4 0 114.3 119.7 170.0 
2-chlorobutane haloalkanes 0.07 262.0 0 14 5 0 115.1 127.6 92.6 
2-chloropentane haloalkanes 0.07 297.3 0 17 6 0 132.4 152.0 106.6 
3-chloropentane haloalkanes 0.06 292.6 0 17 6 0 132.4 152.0 106.6 
2-chloro-2-methylpropane haloalkanes 1.09 259.5 0 14 5 0 124.2 127.6 92.6 
2-bromo-2-methylpropane haloalkanes 0.84 268.0 0 14 5 0 138.3 140.6 137.0 
1,1-difluoroethane haloalkanes -0.11 196.2 0 8 4 0 71.9 69.0 66.0 
1,1 dichloroethane haloalkanes -0.85 234.1 0 8 4 0 98.3 94.7 99.0 
1,2 dichloroethane haloalkanes -1.79 236.5 0 8 4 0 98.3 94.7 99.0 
1,1,1 trichloroethane haloalkanes -0.23 254.4 0 8 5 0 120.3 110.6 133.4 
1,1,2 trichloroethane haloalkanes -1.97 258.7 0 8 5 0 115.8 110.6 133.4 
1,1,1,2 tetrachloroethane haloalkanes -1.20 275.5 0 8 6 0 137.9 126.6 167.8 
1,1,2,2 tetrachloroethane haloalkanes -2.42 280.3 0 8 6 0 133.4 126.6 167.8 
1,2-dibromoethane haloalkanes -2.22 268.3 0 8 4 0 121.8 120.7 187.9 
1,2 dichloropropane haloalkanes -1.26 263.5 0 11 5 0 115.5 119.1 113.0 
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1,3 dichloropropane haloalkanes -1.90 261.8 0 11 5 0 115.5 119.1 113.0 
1,2-dibromopropane haloalkanes -1.94 286.3 0 11 5 0 140.3 145.2 201.9 
1,3-dibromopropane haloalkanes -1.97 292.8 0 11 5 0 139.0 145.2 201.9 
1,1-dichlorobutane haloalkanes -0.70 288.6 0 14 6 0 132.7 143.5 127.0 
1,4-dichlorobutane haloalkanes -2.32 293.1 0 14 6 0 132.7 143.5 127.0 
Fluorobenzene haloaromatic -0.79 253.1 6 12 7 1 103.5 132.0 96.1 
chlorobenzene haloaromatic -1.09 273.4 6 12 7 1 116.7 144.8 112.6 
bromobenzene haloaromatic -1.46 287.5 6 12 7 1 128.5 157.9 157.0 
iodobenzene haloaromatic -1.74 293.2 6 12 7 1 132.6 161.4 204.0 
2-chlorotoluene haloaromatic -1.15 296.0 6 15 8 1 133.9 169.3 126.6 
2-bromotoluene haloaromatic -2.37 310.6 6 15 8 1 145.7 182.3 171.0 
m-chlorotoluene haloaromatic -1.92 301.8 6 15 8 1 133.9 169.3 126.6 
p-chlorotoluene haloaromatic 1.92 305.6 6 15 8 1 133.9 169.3 126.6 
p-bromotoluene haloaromatic -1.39 316.2 6 15 8 1 145.7 182.3 171.0 
1,2-dichlorobenzene haloaromatic -1.36 291.4 6 12 8 1 134.3 160.8 147.0 
1,3-dichlorobenzene haloaromatic -0.98 295.5 6 12 8 1 134.3 160.8 147.0 
1,4-dichlorobenzene haloaromatic -1.01 299.3 6 12 8 1 134.3 160.8 147.0 
1,4-dibromobenzene haloaromatic -2.30 331.4 6 12 8 1 157.8 186.8 235.9 
1,2,3-trichlorobenzene haloaromatic -1.24 314.3 6 12 9 1 151.9 176.7 181.4 
1,2,4-trichlorobenzene haloaromatic -1.12 315.1 6 12 9 1 151.9 176.7 181.4 
1,3,5-trichlorobenzene haloaromatic -0.78 319.3 6 12 9 1 151.9 176.7 181.4 
1,2,3,4-tetrachlorobenzene haloaromatic -1.34 335.8 6 12 10 1 169.4 192.7 215.9 
1,2,3,5-tetrachlorobenzene haloaromatic -1.62 337.5 6 12 10 1 169.4 192.7 215.9 
1,2,4,5-tetrachlorobenzene haloaromatic -1.34 338.1 6 12 10 1 169.4 192.7 215.9 
methanol Alcohols and Phenols -5.10 162.3 0 6 2 0 55.9 46.8 32.0 
ethanol Alcohols and Phenols -4.96 197.9 0 9 3 0 73.1 71.3 46.1 
1-propanol Alcohols and Phenols -4.85 230.3 0 12 4 0 90.3 95.7 60.1 
1-butanol Alcohols and Phenols -4.73 257.9 0 15 5 0 107.6 120.1 74.1 
1-pentanol Alcohols and Phenols -4.52 289.1 0 18 6 0 124.8 144.6 88.2 
1-hexanol Alcohols and Phenols -4.38 321.9 0 21 7 0 142.0 169.0 102.2 
1-heptanol Alcohols and Phenols -4.25 342.9 0 24 8 0 159.3 193.4 116.2 
1-octanol Alcohols and Phenols -4.11 371.7 0 27 9 0 176.5 217.9 130.2 
2-propanol Alcohols and Phenols -4.76 223.3 0 12 4 0 90.3 95.7 60.1 
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2-butanol Alcohols and Phenols -4.61 250.4 0 15 5 0 107.6 120.1 74.1 
2-pentanol Alcohols and Phenols -4.40 282.8 0 18 6 0 124.8 144.6 88.2 
3-pentanol Alcohols and Phenols -4.35 285.0 0 18 6 0 124.8 144.6 88.2 
3-hexanol Alcohols and Phenols -3.91 315.0 0 21 7 0 142.0 169.0 102.2 
4-heptanol Alcohols and Phenols -4.01 344.0 0 24 8 0 159.3 193.4 116.2 
2-methylpropane-2-ol Alcohols and Phenols -4.49 248.1 0 15 5 0 112.7 120.1 74.1 
2-methylbutane-2-ol Alcohols and Phenols -4.43 271.3 0 18 6 0 130.0 144.6 88.2 
2-methylpentane-2-ol Alcohols and Phenols -3.93 305.2 0 21 7 0 147.2 169.0 102.2 
cyclopentanol Alcohols and Phenols -5.49 255.4 0 16 6 1 96.2 130.7 86.1 
cyclohexanol Alcohols and Phenols -5.28 274.0 0 19 7 1 113.4 155.1 100.2 
cycloheptanol Alcohols and Phenols -5.49 296.8 0 22 8 1 130.7 179.5 114.2 
phenol Alcohols and Phenols -6.59 256.9 6 13 7 1 109.2 137.4 94.1 
2-methylphenol Alcohols and Phenols -5.87 282.8 6 16 8 1 126.4 161.8 108.1 
3-methylphenol Alcohols and Phenols -5.49 288.3 6 16 8 1 126.4 161.8 108.1 
4-methylphenol Alcohols and Phenols -6.13 286.9 6 16 8 1 126.4 161.8 108.1 
2,3-dimethylphenol Alcohols and Phenols -6.16 306.8 6 19 9 1 143.6 186.3 122.2 
3,4-dimethylphenol Alcohols and Phenols -6.50 310.3 6 19 9 1 143.6 186.3 122.2 
2,6-dimethylphenol Alcohols and Phenols -5.26 310.0 6 19 9 1 143.6 186.3 122.2 
2,4-dimethylphenol Alcohols and Phenols -6.01 313.8 6 19 9 1 143.6 186.3 122.2 
3,5-dimethylphenol Alcohols and Phenols -6.27 317.7 6 19 9 1 143.6 186.3 122.2 
2,5-dimethylphenol Alcohols and Phenols -5.91 320.0 6 19 9 1 143.6 186.3 122.2 
1-hydroxynapthalene Alcohols and Phenols -7.67 328.4 10 19 11 2 146.6 209.4 144.2 
2-hydroxynapthalene Alcohols and Phenols -8.11 331.8 10 19 11 2 146.6 209.4 144.2 
methoxymethane ethers -1.91 198.7 0 9 3 0 78.1 73.4 46.1 
methyl-ethyl-ether ethers -2.10 231.3 0 12 4 0 95.3 97.8 60.1 
methyl propyl ether ethers -1.66 266.2 0 15 5 0 112.6 122.3 74.1 
methyl isopropyl ether ethers -2.01 255.0 0 15 5 0 112.6 122.3 74.1 
t-butyl methyl ether ethers -2.21 277.6 0 18 6 0 134.9 146.7 88.2 
2-methoxyethanol ethers -6.76 244.9 0 13 5 0 105.4 106.4 76.1 
2-methoxyethanamine ethers -6.55 258.0 0 15 5 0 112.5 116.4 76.1 
2-methoxyphenol ethers -5.57 299.7 6 17 9 1 141.4 172.5 124.1 
3-methoxyphenol ethers -7.66 305.3 6 17 9 1 141.4 172.5 124.1 
2-methoxyaniline ethers -6.12 309.9 6 18 9 1 145.4 178.6 123.2 
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3-methoxyaniline ethers -7.29 311.1 6 18 9 1 145.4 178.6 123.2 
4-methoxyaniline ethers -7.48 308.8 6 18 9 1 145.4 178.6 123.2 
acetaldehyde Aldehydes -3.50 183.3 0 7 3 0 67.9 63.9 44.1 
propionaldehyde Aldehydes -3.43 215.2 0 10 4 0 85.1 88.4 58.1 
butyraldehyde Aldehydes -3.18 246.6 0 13 5 0 102.3 112.8 72.1 
pentanal Aldehydes -3.03 278.6 0 16 6 0 119.6 137.2 86.1 
hexanal Aldehydes -2.81 308.0 0 19 7 0 136.8 161.6 100.2 
heptanal Aldehydes -2.67 335.8 0 22 8 0 154.0 186.1 114.2 
octanal Aldehydes -2.29 373.3 0 25 9 0 171.3 210.5 128.2 
nonanal Aldehydes -2.07 405.2 0 28 10 0 188.5 234.9 142.2 
isobutaldehyde Aldehydes -2.86 242.7 0 13 5 0 103.7 112.8 72.1 
benzaldehyde Aldehydes -4.02 276.7 6 14 8 1 121.1 154.5 106.1 
m-hydroxybenzaldehyde Aldehydes -9.51 291.9 6 15 9 1 131.2 163.0 122.1 
p-hydroxybenzaldehyde Aldehydes -10.48 292.5 6 15 9 1 131.2 163.0 122.1 
formaldehyde Aldehydes -2.75 148.8 0 4 2 0 50.6 39.5 30.0 
ethanoic acid carboxylic acids -6.69 191.2 0 7 4 0 73.4 68.1 59.0 
propanoic acid carboxylic acids -6.46 223.4 0 10 5 0 90.6 92.5 73.1 
butanoic acid carboxylic acids -6.35 254.2 0 13 6 0 107.9 116.9 87.1 
pentanoic acid carboxylic acids -6.16 280.9 0 16 7 0 125.1 141.4 101.1 
hexanoic acid carboxylic acids -6.21 309.5 0 19 8 0 142.3 165.8 115.2 
N-methyl formamide Amides -10.00 212.5 0 9 4 0 87.1 80.7 59.1 
acetamide Amides -9.71 207.5 0 9 4 0 83.4 79.1 59.1 
propionamide Amides -9.42 237.9 0 12 5 0 100.6 103.5 73.1 
benzamide Amides -10.97 295.2 6 16 9 1 136.7 169.7 121.1 
N-methylacetamide Amides -10.04 235.3 0 12 5 0 102.9 104.6 73.1 
N,N-dimethylformamide Amides -7.81 234.4 0 12 5 0 112.9 106.3 73.1 
N,N-dimethyl-acetamide Amides -8.53 264.5 0 15 6 0 130.1 130.7 87.1 
n-butylacetamide Amides -9.31 332.0 0 21 8 0 154.5 177.9 115.2 
methyl amine Amines -4.57 179.4 0 8 2 0 63.0 56.9 32.1 
ethyl amine Amines -4.49 209.4 0 11 3 0 80.2 81.3 46.1 
n-propyl amine Amines -4.44 240.7 0 14 4 0 97.5 105.7 60.1 
n-butyl amine Amines -4.32 273.1 0 17 5 0 114.7 130.2 74.1 
n-pentyl amine Amines -4.10 305.9 0 20 6 0 131.9 154.6 88.2 
FCUP 
NEW COMPUTATIONAL METHODS TO CALCULATE  
DRUG-RECEPTOR BINDING FREE ENERGIES 
135 
 
n-hexyl amine Amines -4.02 336.8 0 23 7 0 149.2 179.0 102.2 
n-heptylamine Amines -3.79 354.1 0 26 8 0 166.4 203.5 116.2 
n-octylamine Amines -3.65 386.5 0 29 9 0 183.6 227.9 130.3 
ethylenediamine Amines -9.82 237.9 0 14 4 0 97.4 99.9 62.1 
cyclohexylamine Amines -4.59 283.6 0 21 7 1 120.5 165.1 100.2 
aniline Amines -5.39 267.4 6 14 7 1 113.2 143.5 93.1 
dimethyl amine Amines -4.30 211.9 0 11 3 0 89.3 82.9 46.1 
diethyl amine Amines -4.08 271.9 0 17 5 0 123.8 131.8 74.1 
di-n-propylamine Amines -3.67 333.6 0 23 7 0 158.2 180.6 102.2 
di-n-butyl amine Amines -3.32 380.3 0 29 9 0 192.7 229.5 130.3 
trimethyl amine Amines -3.23 237.4 0 14 4 0 116.7 109.0 60.1 
pyrrolidine Amines -5.49 244.5 0 15 5 1 95.1 117.9 72.1 
piperidine Amines -5.12 264.8 0 18 6 1 112.4 142.3 86.2 
N-methylpyrrolidine Amines -3.99 271.0 0 18 6 1 122.6 143.9 86.2 
N-methylpiperidine Amines -3.88 287.6 0 21 7 1 139.8 168.4 100.2 
piperazine Amines -7.39 263.2 0 18 6 1 121.4 138.1 88.2 
N-methylpiperazine Amines -7.77 286.8 0 21 7 1 148.8 164.1 102.2 
diisopropylamine Amines -3.22 319.5 0 23 7 0 158.2 180.6 102.2 
triethyl amine Amines -3.09 308.6 0 23 7 0 168.4 182.3 102.2 
ammonia Amines -4.30 140.7 0 5 1 0 42.1 30.8 18.0 
N,N-dimethyl aniline Amines -2.90 315.5 6 20 9 1 161.4 195.6 121.2 
N,N-dimethylpiperazine Amines -7.58 306.3 0 24 8 1 176.2 190.1 116.2 
1-amino-2-methoxy-ethane Amines -6.60 256.5 0 15 5 0 112.5 116.4 76.1 
acetonitrile nitriles -3.89 184.8 0 6 3 0 69.6 63.8 41.1 
propanenitrile nitriles -3.85 218.1 0 9 4 0 86.8 88.2 55.1 
butanenitrile nitriles -3.65 250.8 0 12 5 0 104.1 112.6 69.1 
pentanenitrile nitriles -3.52 281.7 0 15 6 0 121.3 137.0 83.1 
benzonitrile nitriles -4.16 277.8 6 13 8 1 122.9 154.3 103.1 
3-cyanophenol nitriles -9.66 292.2 6 14 9 1 132.9 162.8 119.1 
4-cyanophenol nitriles -10.17 292.7 6 14 9 1 132.9 162.8 119.1 
3-cyanopyridine nitriles -6.75 272.2 6 12 8 1 121.0 145.2 104.1 
4-cyanopyridine nitriles -6.02 271.4 6 12 8 1 121.0 145.2 104.1 
nitromethane Nitro compounds -4.00 189.1 0 7 4 0 74.0 62.2 61.0 
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nitroethane Nitro compounds -3.72 223.4 0 10 5 0 91.2 86.7 75.1 
1-nitropropane Nitro compounds -3.34 253.5 0 13 6 0 108.5 111.1 89.1 
1-nitrobutane Nitro compounds -3.08 283.9 0 16 7 0 125.7 135.5 103.1 
1-nitropentane Nitro compounds -2.82 309.7 0 19 8 0 142.9 159.9 117.1 
2-nitropropane Nitro compounds -3.14 247.6 0 13 6 0 108.5 111.1 89.1 
nitrobenzene Nitro compounds -4.13 278.5 6 14 9 1 127.3 152.8 123.1 
2-nitrophenol Nitro compounds -4.58 293.4 6 15 10 1 137.3 161.3 139.1 
3-nitrophenol Nitro compounds -9.63 296.3 6 15 10 1 137.3 161.3 139.1 
p-nitrophenol Nitro compounds -10.65 290.6 6 15 10 1 137.3 161.3 139.1 
2-nitrotoluene Nitro compounds -3.59 306.3 6 17 10 1 144.5 177.2 137.1 
3-nitrotoluene Nitro compounds -3.46 309.2 6 17 10 1 144.5 177.2 137.1 
m-nitroaniline Nitro compounds -8.86 302.8 6 16 10 1 141.3 167.4 138.1 
methanethiol thiols -1.24 184.1 0 6 2 0 67.7 59.6 48.1 
ethanethiol thiols -1.19 216.4 0 9 3 0 84.9 84.1 62.1 
1-propanethiol thiols -1.06 246.8 0 12 4 0 102.1 108.5 76.2 
n-butanethiol thiols -0.99 278.4 0 15 5 0 119.4 132.9 90.2 
thiophenol thiols -2.55 280.0 6 13 7 1 120.9 150.2 110.2 
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3.4.2. EXPERIMENTAL VALUES OF ΔΔGSOLV FREE ENERGIES RESULTING 
FROM THE ADDITION OF DIFFERENT GROUPS TO DIFFERENT COMPOUND 
CLASSES 
The experimental values were also used to help defining a typical contribution to the 
ΔGsolv free energy of a single chemical group added to a lead compound. The ΔΔGsolv 
experimental values result from the difference between the molecule with the added 
functional group (HO, CH3, F, Cl, Br, I, NH2, CONH2, NO2, COH, COOH, OCH3, SH and 
CN) and the molecule used as scaffold. Those values presented in Table 4, for a 
general perspective, and more individualized, with the corresponding contributions of 
each group, in section 3.4.3. 
TABLE 4. Experimental values of ΔΔGsolv free energies resulting from the addition of different groups (HO, CH3, F, Cl, 
Br, I, NH2, CONH2, NO2, COH, COOH, OCH3, SH and CN) to different compound classes. Values expressed in 
kcal/mol. 
Molecule A Molecule B group addition position ΔΔGsolv 
Methane Methanol HO Primary Carbon -7.06 
Ethane Ethanol HO Primary Carbon -6.79 
Propane 1-Propanol HO Primary Carbon -6.82 
Butane 1-Butanol HO Primary Carbon -6.82 
Pentane 1-Pentanol HO Primary Carbon -6.85 
Hexane 1-Hexanol HO Primary Carbon -6.88 
Heptane 1-Heptanol HO Primary Carbon -6.88 
Octane 1-Octanol HO Primary Carbon -7.00 
Propane 2-Propanol HO Secondary Carbon -6.73 
Butane 2-Butanol HO Secondary Carbon -6.71 
Pentane 2-Pentanol HO Secondary Carbon -6.73 
Pentane 3-Pentanol HO Secondary Carbon -6.68 
Pentane 3-Hexanol HO Secondary Carbon -6.41 
Pentane 4-Heptanol HO Secondary Carbon -6.65 
2-methylpropane 2-methylpropane-2-ol HO Tertiary Carbon -6.80 
2-methylbutane 2-methylbutane-2-ol HO Tertiary Carbon -6.81 
2-methylpentane 2-methylpentane-2-ol HO Tertiary Carbon -6.46 
cyclopentane cyclopentanol HO Cyclic Carbon -6.69 
cyclohexane cyclohexanol HO Cyclic Carbon -6.51 
cycloheptane cycloheptanol HO Cyclic Carbon -6.28 
Benzene Phenol HO Aromatic Ring -5.72 
Toluene 2-methylphenol HO Aromatic Ring -5.04 
Toluene 3-methylphenol HO Aromatic Ring -4.66 
Toluene 4-methylphenol HO Aromatic Ring -5.30 
o-xylene 2,3-dimethylphenol HO Aromatic Ring -5.26 
o-xylene 3,4-dimethylphenol HO Aromatic Ring -5.60 
m-xylene 2,6-dimethylphenol HO Aromatic Ring -4.44 
m-xylene 2,4-dimethylphenol HO Aromatic Ring -5.19 
m-xylene 3,5-dimethylphenol HO Aromatic Ring -5.45 
p-xylene 2,5-dimethylphenol HO Aromatic Ring -5.10 
naphtalene 1-hydroxynapthalene HO Aromatic Ring -5.27 
naphtalene 2-hydroxynapthalene HO Aromatic Ring -5.70 
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Methane Ethane CH3 Primary Carbon -0.14 
Ethane Propane CH3 Primary Carbon 0.14 
Propane Butane CH3 Primary Carbon 0.13 
Butane Pentane CH3 Primary Carbon 0.24 
Pentane Hexane CH3 Primary Carbon 0.17 
Hexane Heptane CH3 Primary Carbon 0.14 
Heptane Octane CH3 Primary Carbon 0.25 
Octane Nonane CH3 Primary Carbon 0.24 
Propane 2-methylpropane CH3 Secondary Carbon 0.35 
Butane 2-methylbutane CH3 Secondary Carbon 0.29 
Pentane 2-methylpentane CH3 Secondary Carbon 0.19 
Pentane 3-methylpentane CH3 Secondary Carbon 0.18 
Hexane 2-methylhexane CH3 Secondary Carbon 0.43 
Hexane 3-methylhexane CH3 Secondary Carbon 0.21 
Hexane 3-methylheptane CH3 Secondary Carbon 0.33 
2-methylpropane 2,2-dimethylpropane CH3 Tertiary Carbon 0.22 
2-methylbutane 2,2-dimethylbutane CH3 Tertiary Carbon 0.19 
2-methylpentane 2,2-dimethylpentane CH3 Tertiary Carbon 0.36 
3-methylpentane 3,3-dimethylpentane CH3 Tertiary Carbon 0.05 
cylopentane Methylcyclopentane CH3 Cyclic Carbon 0.40 
cyclohexane Methylcyclohexane CH3 Cyclic Carbon 0.48 
Benzene Toluene CH3 Aromatic Ring 0.04 
Toluene 1,2-dimethylbenzene (o-Xylene) CH3 Aromatic Ring -0.07 
Toluene 1,3-dimethylbenzene (m-Xylene) CH3 Aromatic Ring 0.01 
Toluene 1,4-dimethylbenzene (p-Xylene) CH3 Aromatic Ring 0.03 
o-xylene 1,2,3-trimethylbenzene CH3 Aromatic Ring -0.31 
o-xylene 1,2,4-trimethylbenzene CH3 Aromatic Ring 0.04 
m-xylene 1,3,5-trimethylbenzene CH3 Aromatic Ring -0.08 
naphtalene 1-Methylnapthalene CH3 Aromatic Ring 0.00 
naphtalene 1,3-Methylnapthalene CH3 Aromatic Ring -0.07 
naphtalene 1,4-Methylnapthalene CH3 Aromatic Ring -0.41 
naphtalene 2,3-Methylnapthalene CH3 Aromatic Ring -0.37 
naphtalene 2,6-Methylnapthalene CH3 Aromatic Ring -0.22 
naphtalene 2,7-Methylnapthalene CH3 Aromatic Ring -0.22 
Pyridine 2-methylpyridine CH3 Heterocyclic Carbon 0.07 
Pyridine 3-methylpyridine CH3 Heterocyclic Carbon -0.08 
Pyridine 4-methylpyridine CH3 Heterocyclic Carbon -0.22 
2-methylpyridine 2,3-dimethylpyridine CH3 Heterocyclic Carbon -0.19 
2-methylpyridine 2,4-dimethylpyridine CH3 Heterocyclic Carbon -0.23 
2-methylpyridine 2,5-dimethylpyridine CH3 Heterocyclic Carbon -0.08 
2-methylpyridine 2,6-dimethylpyridine CH3 Heterocyclic Carbon 0.03 
3-methylpyridine 3,4-dimethylpyridine CH3 Heterocyclic Carbon -0.45 
3-methylpyridine 3,5-dimethylpyridine CH3 Heterocyclic Carbon -0.07 
3-methylpyridine 2,3-dimethylpyridine CH3 Heterocyclic Carbon -0.04 
4-methylpyridine 2,4-dimethylpyridine CH3 Heterocyclic Carbon 0.06 
4-methylpyridine 3,4-dimethylpyridine CH3 Heterocyclic Carbon -0.30 
thiophene 2-Methylthiophene CH3 Heterocyclic Carbon 0.04 
Imidazole 2-Methylimidazole CH3 Heterocyclic Carbon -0.62 
Imidazole 4-Methylimidazole CH3 Heterocyclic Carbon -0.64 
     
Ethane Chloroethane Cl Primary Carbon -2.46 
Ethane Bromoethane Br Primary Carbon -2.54 
Ethane Iodoethane I Primary Carbon -2.56 
Propane 1-chloropropane Cl Primary Carbon -2.29 
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Propane Bromopropane Br Primary Carbon -2.53 
Propane 1-Iodopropane I Primary Carbon -2.53 
Butane 1-Chlorobutane Cl Primary Carbon -2.24 
Butane 1-Bromobutane Br Primary Carbon -2.50 
Butane 1-Iodobutane I Primary Carbon -2.35 
Pentane 1-Chloropentane Cl Primary Carbon -2.40 
Pentane 1-Bromopentane Br Primary Carbon -2.42 
Pentane 1-Iodopentane I Primary Carbon -2.46 
Propane 2-chloropropane Cl Secondary Carbon -2.21 
Propane 2-Bromopropane Br Secondary Carbon -2.45 
Propane 2-Iodopropane I Secondary Carbon -2.43 
Butane 2-Chlorobutane Cl Secondary Carbon -2.03 
Pentane 2-Chloropentane Cl Secondary Carbon -2.26 
Pentane 3-Chloropentane Cl Secondary Carbon -2.27 
2-methylpropane 2-chloro-2-methylpropane Cl Tertiary Carbon -1.22 
2-methylpropane 2-bromo-2-methylpropane Br Tertiary Carbon -1.47 
Benzene Fluorobenzene Fluor Aromatic Ring 0.08 
Benzene Chlorobenzene Cl Aromatic Ring -0.21 
Benzene Bromobenzene Br Aromatic Ring -0.58 
Benzene Iodobenzene I Aromatic Ring -0.86 
Toluene 2-Chlorotoluene Cl Aromatic Ring -0.31 
Toluene 2-Bromotoluene Br Aromatic Ring -1.54 
Toluene m-chlorotoluene Cl Aromatic Ring -1.09 
Toluene p-chlorotoluene Cl Aromatic Ring 2.75 
Toluene p-bromotoluene Br Aromatic Ring -0.56 
Chloroethane 1,1 dichloroethane Cl Primary Carbon -0.22 
Chloroethane 1,2 dichloroethane Cl Primary Carbon -1.16 
1,1 dichloroethane 1,1,1 trichloroethane Cl Primary Carbon 0.62 
1,1 dichloroethane 1,1,2 trichloroethane Cl Primary Carbon -1.12 
1,1,1 trichloroethane 1,1,1,2 tretrachloroethane Cl Primary Carbon -0.98 
1,1,2 trichloroethane 1,1,2,2 tretrachloroethane Cl Primary Carbon -0.45 
Bromoethane 1,2-dibromoethane Br Primary Carbon -1.50 
1-chloropropane 1,2 dichloropropane Cl Secondary Carbon -0.94 
1-chloropropane 1,3 dichloropropane Cl Secondary Carbon -1.58 
Bromopropane 1,2-dibromopropane Br Secondary Carbon -1.38 
Bromopropane 1,3-dibromopropane Br Secondary Carbon -1.41 
1-Chlorobutane 1,1-dichlorobutane Cl Primary Carbon -0.55 
1-Chlorobutane 1,4-dichlorobutane Cl Primary Carbon -2.17 
Chlorobenzene 1,2-dichlorobenzene Cl Aromatic Ring -0.27 
Chlorobenzene 1,3-dichlorobenzene Cl Aromatic Ring 0.11 
Chlorobenzene 1,4-dichlorobenzene Cl Aromatic Ring 0.08 
Bromobenzene 1,4-dibromobenzene Br Aromatic Ring -0.84 
1,2-dichlorobenzene 1,2,3-trichlorobenzene Cl Aromatic Ring 0.12 
1,2-dichlorobenzene 1,2,4-trichlorobenzene Cl Aromatic Ring 0.24 
1,3-dichlorobenzene 1,3,5-trichlorobenzene Cl Aromatic Ring 0.20 
1,2,3-trichlorobenzene 1,2,3,4-tetrachlorobenzene Cl Aromatic Ring -0.10 
1,2,3-trichlorobenzene 1,2,3,5-tetrachlorobenzene Cl Aromatic Ring -0.38 
1,2,4-trichlorobenzene 1,2,4,5-tetrachlorobenzene Cl Aromatic Ring -0.22 
     
Methane Methyl amine NH2 Primary Carbon -8.35 
Ethane Ethyl amine NH2 Primary Carbon -7.91 
Propane n-propyl amine NH2 Primary Carbon -7.96 
Butane n-butyl amine NH2 Primary Carbon -7.93 
Pentane n-pentyl amine NH2 Primary Carbon -8.06 
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Hexane n-hexyl amine NH2 Primary Carbon -8.12 
Heptane n-heptylamine NH2 Primary Carbon -6.43 
Octane n-octylamine NH2 Primary Carbon -6.54 
n-propyl amine Ethylenediamine NH2 Primary Carbon -3.83 
cyclohexane cyclohexylamine NH2 Cyclic Carbon -5.82 
Benzene Aniline NH2 Aromatic Ring -4.52 
     
Methane N-Methyl formamide CONH2 Primary Carbon -11.97 
Ethane Acetamide CONH2 Primary Carbon -11.53 
Propane Propionamide CONH2 Primary Carbon -11.38 
Benzene benzamide CONH2 Aromatic Ring -10.10 
     
Methane nitrometane NO2 Primary Carbon -5.97 
Ethane nitroethane NO2 Primary Carbon -5.54 
Propane 1-nitropropane NO2 Primary Carbon -5.31 
Butane 1-nitrobutane NO2 Primary Carbon -5.18 
Pentane 1-nitropentane NO2 Primary Carbon -5.15 
Propane 2-nitropropane NO2 Secondary Carbon -5.11 
Benzene nitrobenzene NO2 Aromatic Ring -3.25 
Phenol 2-nitrophenol NO2 Aromatic Ring 2.01 
Phenol 3-nitrophenol NO2 Aromatic Ring -3.03 
Phenol p-nitrophenol NO2 Aromatic Ring -4.06 
Toluene 2-nitrotoluene NO2 Aromatic Ring -2.76 
Toluene 3-nitrotoluene NO2 Aromatic Ring -2.63 
Aniline m-nitroaniline NO2 Aromatic Ring -3.47 
     
Methane acetaldehyde COH Primary Carbon -5.47 
Ethane propionaldehyde COH Primary Carbon -5.26 
Propane butyraldehyde COH Primary Carbon -5.15 
Butane Pentanal COH Primary Carbon -5.13 
Pentane Hexanal COH Primary Carbon -5.14 
Hexane Heptanal COH Primary Carbon -5.17 
Heptane Octanal COH Primary Carbon -4.93 
Octane Nonanal COH Primary Carbon -4.96 
Propane isobutaldehyde COH 
 
-4.83 
Benzene Benzaldehyde COH Aromatic Ring -3.15 
Phenol m-Hydroxybenzaldehyde COH Aromatic Ring -2.92 
Phenol p-Hydroxybenzaldehyde COH Aromatic Ring -3.89 
     
Methane Ethanoic acid COOH Primary Carbon -8.66 
Ethane Propanoic acid COOH Primary Carbon -8.29 
Propane Butanoic acid COOH Primary Carbon -8.32 
Butane Pentanoic acid COOH Primary Carbon -8.26 
Pentane Hexanoic acid COOH Primary Carbon -8.54 
     
Methane methoxymethane OCH3 Primary Carbon -3.88 
Ethane methyl ethyl ether OCH3 Primary Carbon -3.93 
Propane Methyl propyl ether OCH3 Primary Carbon -3.63 
Propane Methyl isopropyl ether OCH3 Primary Carbon -3.98 
Butane t-Butyl methyl ether OCH3  
-4.31 
Ethanol 2-Methoxyethanol OCH3 Primary Carbon -1.80 
Ethyl amine 2-methoxyethanamine OCH3 Primary Carbon -0.46 
Phenol 2-methoxyphenol OCH3 Aromatic Ring 1.02 
Phenol 3-methoxyphenol OCH3 Aromatic Ring -1.07 
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Aniline 2-methoxyaniline OCH3 Aromatic Ring -0.73 
Aniline 3-methoxyaniline OCH3 Aromatic Ring -1.90 
Aniline 4-methoxyaniline OCH3 Aromatic Ring -2.09 
     
Methane Methanethiol SH Primary Carbon -3.21 
Ethane Ethanethiol SH Primary Carbon -3.02 
Propane 1-Propanethiol SH Primary Carbon -3.03 
Butane n-butanethiol SH Primary Carbon -3.09 
Benzene Thiophenol SH Aromatic Ring -1.68 
     
Methane acetonitrile CN Primary Carbon -5.86 
Ethane propanenitrile CN Primary Carbon -5.68 
Propane butanenitrile CN Primary Carbon -5.62 
Butane pentanenitrile CN Primary Carbon -5.62 
Benzene benzonitrile CN Aromatic Ring -3.28 
Phenol 3-cyanophenol CN Aromatic Ring -3.06 
Phenol 4-cyanophenol CN Aromatic Ring -3.58 
Pyridine 3-cyanopyridine CN Heterocyclic Carbon -2.06 
Pyridine 4-cyanopyridine CN Heterocyclic Carbon -1.33 
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3.4.3. AVERAGE CONTRIBUTION TO ΔΔGSOLV FOR THE ADDITION OF 
DIFFERENT GROUPS TO DIFFERENT COMPOUND CLASSES 
 
3.4.3.1. HO ADDITION  
A group of 33 molecular transformations considering the addition of an hydroxyl 
group were analyzed to allow for a solid definition of their typical contributions to the 
free energy of solvation of the molecule ΔΔGsolv (∆𝐺𝑠𝑜𝑙𝑣
𝑎𝑙𝑐𝑜ℎ𝑜𝑙 − ∆𝐺𝑠𝑜𝑙𝑣
𝑠𝑐𝑎𝑓𝑜𝑙𝑑 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒), in 
Table 5. When we consider the addition of an hydroxyl group to a primary carbon, a 
typical contribution of -6.9 kcal/mol to the free energy was found. In the 8 cases 
considered the values ranged from a minimum of -7.06 to a maximum of -6.79 
kcal/mol, thus differing not more than 0.3 kcal/mol in the data set considered. If the 
addition is to a secondary carbon, the negative contribution decreases a little, to -
6.7 kcal/mol. The range of the 6 cases considered varies between -6.73 and -6.41 
kcal/mol. The addition of an hydroxyl group to a tertiary carbon has a not very 
different contribution, -6.7 kcal/mol, although we could only find data for 3 
transformations. That was also the case for the addition to a cyclic carbon, where 
an average contribution of -6.5 kcal/mol was found. When we consider the addition 
to an aromatic ring, the typical contribution is of -5.2 kcal/mol. In the range of the 12 
transformations considered, the larger group analyzed, has a maximum of -4.44 
kcal/mol and a minimum of -5.72 kcal/mol. In this case the larger difference to the 
typical contribution still does not reach 1 kcal/mol. There was only available in the 
literature information for one case for the addition of an hydroxyl group to an 
heterocyclic carbon. The contribution in that case was of -5.2 kcal/mol, although it 
cannot be considered representative for the heterocyclics. 
The addition of an hydroxyl group has a stronger impact to the free energy of 
solvation in primary carbons. The values for secondary and tertiary carbons are 
slightly less negative but the contributions in these three groups do not differ much 
(±0.24 kcal/mol). When we consider the addition to an aromatic ring the values 
show less impact. The contribution of HO to the free energy of solvation decreases 
along the table which can be explained by the effect of the transmission of charge 
through a chain of atoms in a molecule (inductive effect) and also the electron 
withdrawing or releasing properties of this substituent, as it happens with others, 
based on relevant ressonance structures (mesomeric effect). 
Considering the 33 transformations involving HO addition, the mean contribution to 
ΔΔGsolv is of -6.1 kcal/mol, which presents a maximum difference to the maximum 
and minimum ΔΔGsolv of 15%. The cases that presented the lowest values of 
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ΔΔGsolv were Methane -> Methanol (-7.06 kcal/mol) and Octane -> 1-Octanol (-7.00 
kcal/mol). The highest values occur in the transformations m-Xylene -> 2,6-
dimethylphenol (-4.44 kcal/mol) and Toluene -> 3-methylphenol (-4.66 kcal/mol). 
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TABLE 5. Average Contribution to ΔΔGsolv free energies in the addition of HO group to different compound classes. 
Values expressed in kcal/mol. 
HO addition to: Transformation 
ΔΔGsolv  
(kcal/mol) 
Contribution 
 (kcal/mol) 
      
Primary Carbon Methane Methanol -7.06 
-6.9 ± 0.1 
 
Ethane Ethanol -6.79 
 
Propane 1-Propanol -6.82 
 
Butane 1-Butanol -6.82 
 
Pentane 1-Pentanol -6.85 
 
Hexane 1-Hexanol -6.88 
 
Heptane 1-Heptanol -6.88 
 
Octane 1-Octanol -7.00 
      
Secondary Carbon Propane 2-Propanol -6.73 
-6.7 ± 0.1 
 
Butane 2-Butanol -6.71 
 
Pentane 2-Pentanol -6.73 
 
Pentane 3-Pentanol -6.68 
 
Hexane 3-Hexanol -6.41 
 
Heptane 4-Heptanol -6.65 
      
Tertiary Carbon 2-methylpropane 2-methylpropane-2-ol -6.80 
-6.7 ± 0.2 
 
2-methylbutane 2-methylbutane-2-ol -6.81 
 
2-methylpentane 2-methylpentane-2-ol -6.46 
      
Cyclic Carbon cyclopentane cyclopentanol -6.69 
-6.5 ± 0.2 
 
cyclohexane cyclohexanol -6.51 
 
cycloheptane cycloheptanol -6.28 
      
Aromatic Ring Benzene Phenol -5.72 
-5.2 ± 0.4 
 
Toluene 2-methylphenol -5.04 
 
Toluene 3-methylphenol -4.66 
 
Toluene 4-methylphenol -5.30 
 
o-xylene 2,3-dimethylphenol -5.26 
 
o-xylene 3,4-dimethylphenol -5.60 
 
m-xylene 2,6-dimethylphenol -4.44 
 
m-xylene 2,4-dimethylphenol -5.19 
 
m-xylene 3,5-dimethylphenol -5.45 
 
p-xylene 2,5-dimethylphenol -5.10 
 
naphtalene 1-hydroxynapthalene -5.27 
 
naphtalene 2-hydroxynapthalene -5.70 
      
 furan Furan-2-ol -5.23 -5.23  
      
Mean 
   
-6.1 ± 0.8 
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3.4.3.2. CH3 ADDITION  
For the addition of a methyl group we considered 19 cases representing 6 different 
types of addition (primary, secondary, tertiary and cyclic carbons, aromatic rings and 
heterocyclis), present in Table 6. The contribution to the free energy of solvation of 
adding a methyl group to a primary carbon is of 0.1 kcal/mol. The 7 cases analyzed 
present values between 0.13 to 0.25 kcal/mol. When the addition is to a secondary 
carbon, the contribution is a little more larger, 0.3 kcal/mol, with a range of values of 
0.18 to 0.43 kcal/mol for the 7 cases considered. The contribution to the addition of the 
methyl group to a tertiary carbon is quite similar (0.2 kcal/mol). For this group 4 
transformations where analyzed. The values available to the addition to a cyclic carbon 
where just two, not very different, leading to the definition of a typical contribution of 0.4 
kcal/mol. The addition of a methyl group to an aromatic ring has a different impact in 
the free energy of solvation, with a contribution of -0.1 kcal/mol. The 13 cases 
evaluated present values between 0.04 and -0.41 kcal/mol. For the addition to an 
heterocyclic compound, the contribution is very similar (-0.2 kcal/mol) with a also 
similar range of values (0.07 to -0.45 kcal/mol) found in the 12 considered 
transformations. 
With a range of values of 1 kcal/mol, that goes from a minimum of -0.45 to a maximum 
of 0.48 kcal/mol, the mean contribution of the CH3 addition is 0.0 kcal/mol. This mean 
happens because the values are positive for 4 of the considered classes but negative 
for the other two. 
The cases that presented the lowest values of ΔΔGsolv were naphthalene -> 1,4-
Dimethylnapthalene (-0.41 kcal/mol) and pyridine -> 3,4-dimethylpyridine (-0.45 
kcal/mol). The highest values occur in the transformations Cyclohexane -> 
Methylcyclohexane (0.48 kcal/mol) and Hexane -> 2-Metilhexane (0.43 kcal/mol). 
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TABLE 6. Average Contribution to ΔΔGsolv free energies in the addition of CH3 group to different compound classes. 
Values expressed in kcal/mol. 
CH3 addition to: Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Methane Ethane -0.14 
0.1 ± 0.1 
 
Ethane Propane 0.14 
 
Propane Butane 0.13 
 
Butane Pentane 0.24 
 
Pentane Hexane 0.17 
 
Hexane Heptane 0.14 
 
Heptane Octane 0.25 
 
Octane Nonane 0.24 
      
Secondary Carbon Propane 2-methylpropane 0.35 
0.3 ± 0.1 
 
Butane 2-methylbutane 0.29 
 
Pentane 2-methylpentane 0.19 
 
Pentane 3-methylpentane 0.18 
 
Hexane 2-methylhexane 0.43 
 
Hexane 3-methylhexane 0.21 
 
Heptane 3-methylheptane 0.33 
      
Tertiary Carbon 2-methylpropane 2,2-dimethylpropane 0.22 
0.2 ± 0.1  
2-methylbutane 2,2-dimethylbutane 0.19 
 
2-methylpentane 2,2-dimethylpentane 0.36 
 
3-methylpentane 3,3-dimethylpentane 0.05 
      
Cyclic Carbon cylopentane Methylcyclopentane 0.40 
0.4 ± 0.0 
 
cyclohexane Methylcyclohexane 0.48 
      
Aromatic Ring Benzene Toluene 0.04 
-0.1 ± 0.2 
 
Toluene 1,2-dimethylbenzene -0.07 
 
Toluene 1,3-dimethylbenzene 0.01 
 
Toluene 1,4-dimethylbenzene 0.03 
 
o-xylene 1,2,3-trimethylbenzene -0.31 
 
o-xylene 1,2,4-trimethylbenzene 0.04 
 
m-xylene 1,3,5-trimethylbenzene -0.08 
 
naphtalene 1-Methylnapthalene 0.00 
 
naphtalene 1,3-Methylnapthalene -0.07 
 
naphtalene 1,4-Methylnapthalene -0.41 
 
naphtalene 2,3-Methylnapthalene -0.37 
 
naphtalene 2,6-Methylnapthalene -0.22 
 
naphtalene 2,7-Methylnapthalene -0.22 
      
Heterocyclic Ring Pyridine 2-methylpyridine 0.07 
-0.2 ± 0.2 
 
Pyridine 3-methylpyridine -0.08 
 
Pyridine 4-methylpyridine -0.22 
 
2-methylpyridine 2,3-dimethylpyridine -0.19 
 
2-methylpyridine 2,4-dimethylpyridine -0.23 
 
2-methylpyridine 2,5-dimethylpyridine -0.08 
 
2-methylpyridine 2,6-dimethylpyridine 0.03 
 
3-methylpyridine 3,4-dimethylpyridine -0.45 
 
3-methylpyridine 3,5-dimethylpyridine -0.07 
 
3-methylpyridine 2,3-dimethylpyridine -0.04 
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4-methylpyridine 2,4-dimethylpyridine 0.06 
 
4-methylpyridine 3,4-dimethylpyridine -0.30 
 
thiophene 2-Methylthiophene 0.04 
 
Imidazole 2-Methylimidazole -0.62 
 
Imidazole 4-Methylimidazole -0.64 
      
Mean 
   
0.0 ± 0.3 
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3.4.3.3. HALOGENS ADDITION  
In order to study the effects on ΔΔGsolv of adding an halogen to a compound we 
analyzed 29 transformations. The results are presented in Table 7, Table 8, Table 9 
and Table 10. 
For the fluorine addition we only found information for one case, so the contribution of 
0.1 kcal/mol cannot be taken as general.  
The addition of a chlorine to a primary carbon bears a typical contribution of -2.3 
kcal/mol. The range for the 4 cases considered is very short, -2.46 to -2.24 kcal/mol. If 
the addition is on a secondary carbon the contribution is less negative, -2.2 kcal/mol, 
here also with a small range for the 4 transformations analyzed (-2.03 to -2.27 
kcal/mol). For the addition to a cyclic carbon there is only one case, precluding a 
contribution definition. If we consider the addition of chlorine to an aromatic ring the 
typical contribution value is positive, 0.3 kcal/mol. For that contributes greatly one 
particular case of the 4 analyzed: Toluene -> p-chlorotoluene (2.75 kcal/mol), the only 
one with a positive value in the group. If we intented to define a typical contribution to 
ΔΔGsolv for addition of chlorine it would be -1.4 kcal/mol, representing thus the almost 
all negative values found. 
For second, third and fourth chlorine additions the effects are more blurred. The 
addition of a second chlorine to a linear chloroalkane has a contribution of -1.1 kcal/mol 
and for a third addition the contribution does not reach half a kcal (-0.3 kcal/mol). For 
the forth chlorine addition the contribution increases slightly to -0.7 kcal/mol. For 
second and third addition of chlorines do aromatic chloroalkanes, the contribution to 
ΔΔGsolv energies is smaller, 0.0 and 0.3 respectively. 
The addition of a bromine to a primary carbon was evaluated in 4 transformations 
leading to a contribution of -2.5 kcal/mol. The range of values differ less than 0.10 
kcal/mol. The addition to a secondary or terciary carbon could not be accurately 
defined because there is only one case for both these categories. A bromine addition to 
an aromatic ring has a typical contribution of -0.9 kcal/mol, with the values of the 3 
considered transformations ranging between -1.54 and -0.56 kcal/mol. The typical 
contribution of bromine addition can be defined as of -1.8 kcal/mol. 
For second bromine additions, the effects in the linear bromoalkanes are similar to the 
tertiary carbon (-1.5 kcal/mol) like the additions to aromatic bromoalkanes are similar to 
the aromatic ring additions (-0.8 kcal/mol). 
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The addition of an Iodine to a primary carbon has a typical contribution of -2.5 kcal/mol. 
The range of values for the 4 cases considered are of -2.56 to -2.35 kcal/mol. For 
secondary carbon and aromatic ring addition, the contribution could not be defined 
because for both there is just one transformation available. The transformation 
Benzene -> Iodobenzene presents a difference of about 1.5 kcal/mol relatively to the 
others, but more data would be necessary to confirm a trend. 
A global average for a typical contribution of halogen addition to the ΔΔGsolv free 
energy is of -1.7 kcal/mol. Since more than 60% of the transformations present values 
above -2 kcal/mol, this average appears not sufficient representative. 
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TABLE 7. Average Contribution to ΔΔGsolv free energies in the addition of a Fluorine to different compound classes. 
Values expressed in kcal/mol. 
Fluorine addition to: Transformation ΔΔGsolv (kcal/mol) Contribution (kcal/mol) 
      
Aromatic Ring Benzene Fluorobenzene 0.08 0.1 
 
      
 
TABLE 8. Average Contribution to ΔΔGsolv free energies in the addition of a Chlorine to different compound classes. 
Values expressed in kcal/mol. 
Chlorine addition 
to: 
Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Ethane Chloroethane -2.46 
-2.3 ± 0.1  
Propane 1-Chloropropane -2.29 
 
Butane 1-Chlorobutane -2.24 
 
Pentane 1-Chloropentane -2.40 
Secondary Carbon Propane 2-chloropropane -2.21 
-2.2 ± 0.1  
Butane 2-Chlorobutane -2.03 
 
Pentane 2-Chloropentane -2.26 
 
Pentane 3-Chloropentane -2.27 
Tertiary Carbon 2-methylpropane 
2-chloro-2-
methylpropane 
-1.22 -1.2 
 
Aromatic Ring Benzene Chlorobenzene -0.21 
0.3 ± 1.5  
Toluene 2-Chlorotoluene -0.31 
 
Toluene m-chlorotoluene -1.09 
 
Toluene p-chlorotoluene 2.75 
      
Mean 
   
-1.4 ± 1.4 
      
Linear 
Chloroalkanes 
Chloroethane 1,1 dichloroethane -0.22 
-1.1 ± 0.6 
 
Chloroethane 1,2 dichloroethane -1.16 
 
1-Chloropropane 1,2 dichloropropane -0.94 
 
1-Chloropropane 1,3 dichloropropane -1.58 
 
1-Chlorobutane 1,1-dichlorobutane -0.55 
 
1-Chlorobutane 1,4-dichlorobutane -2.17 
      
 
1,1-
dichloroethane 
1,1,1 trichloroethane 0.62 
-0.3 ± 0.9 
 
1,1-
dichloroethane 
1,1,2 trichloroethane -1.12 
      
 
1,1,1 
trichloroethane 
1,1,1,2 
tretrachloroethane 
-0.98 
-0.7 ± 0.3 
 
1,1,2 
trichloroethane 
1,1,2,2 
tretrachloroethane 
-0.45 
      
Aromatic 
ChloroAlkanes 
Chlorobenzene 1,2-dichlorobenzene -0.27 
0.0 ± 0.2 
 
Chlorobenzene 1,3-dichlorobenzene 0.11 
 
Chlorobenzene 1,4-dichlorobenzene 0.08 
 
1,2-
dichlorobenzene 
1,2,3-
trichlorobenzene 
0.12 
0.2 ± 0.0 
 
1,2-
dichlorobenzene 
1,2,4-
trichlorobenzene 
0.24 
 
1,3- 1,3,5- 0.20 
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dichlorobenzene trichlorobenzene 
 
1,2,3-
trichlorobenzene 
1,2,3,4-
tetrachlorobenzene 
-0.10 
-0.2 ± 0.1 
 
1,2,3-
trichlorobenzene 
1,2,3,5-
tetrachlorobenzene 
-0.38 
 
1,2,4-
trichlorobenzene 
1,2,4,5-
tetrachlorobenzene 
-0.22 
      
Mean 
   
-0.5 ± 0.7 
 
TABLE 9.  Average Contribution to ΔΔGsolv free energies in the addition of a Bromine to different compound classes. 
Values expressed in kcal/mol. 
Bromine addition 
to: 
Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Ethane Bromoethane -2.54 
-2.5 ± 0.0  
Propane Bromopropane -2.53 
 
Butane 1-Bromobutane -2.50 
 
Pentane 1-Bromopentane -2.42 
Secondary 
Carbon 
Propane 2-Bromopropane -2.45 -2.4 
 
Tertiary Carbon 
2-
methylpropane 
2-Bromo-2-
methylpropane 
-1.47 -1.5 
 
Aromatic Ring Benzene Bromobenzene -0.58 
-0.9 ± 0.5 
 
Toluene 2-Bromotoluene -1.54 
 
Toluene p-bromotoluene -0.56 
      
Mean 
   
-1.8 ± 0.8 
      
Linear 
Bromoalkanes 
Bromoethane 
1,2-
dibromoethane 
-1.50 
-1.4 ± 0.1 
 
Bromopropane 
1,2-
dibromopropane 
-1.38 
 
Bromopropane 
1,3-
dibromopropane 
-1.41 
Aromatic 
Bromoalkanes 
Bromobenzene 
1,4-
dibromobenzene 
-0.84 -0.8 
 
      
Mean 
   
-1.3 ± 0.3 
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TABLE 10. Average Contribution to ΔΔGsolv free energies in the addition of a Iodine to different compound classes. 
Values expressed in kcal/mol. 
Iodine addition 
to: 
Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Ethane Iodoethane -2.56 
-2.5 ± 0.1 
 
Propane 
1-
Iodopropane 
-2.53 
 
Butane 1-Iodobutane -2.35 
 
Pentane 
1-
Iodopentane 
-2.46 
Secondary 
Carbon 
Propane 
2-
Iodopropane 
-2.43 -2.4 
 
Aromatic Ring Benzene Iodobenzene -0.86 -0.9 
 
      
Mean 
   
-2.2 ± 0.6 
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3.4.3.4. NH2 ADDITION  
10 transformations were considered for the addition of an amine group, 8 of them to a 
primary carbon, and are presented in Table 11. The contribution in the addition of NH2 
to a primary carbon is of -7.7 kcal/mol. The values of this group range between -8.38 to 
-6.54 kcal/mol. The only value to the addition to a cyclic carbon and to an aromatic ring 
are not sufficient to define a trend. If we considered the 10 cases, the average 
contribution is of -7.2 kcal/mol. The difference between primary carbon and aromatic 
ring addition can be explained by protonation. Since the literature always refers to 
amines, we interpreted it as NH2 addition. Our theorectical results, present in section 
3.4.4, are consistent with that. It is our purpose to do further tests using ammonium 
(𝑁𝐻3
+). 
TABLE 11.  Average Contribution to ΔΔGsolv free energies in the addition of NH2 to different compound classes. Values 
expressed in kcal/mol. 
NH2 addition to: Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Methane Methyl amine -8.35 
-7.7 ± 0.7 
 
Ethane Ethyl amine -7.91 
 
Propane n-propyl amine -7.96 
 
Butane n-butyl amine -7.93 
 
Pentane n-pentyl amine -8.06 
 
Hexane n-hexyl amine -8.12 
 
Heptane n-heptylamine -6.43 
 
Octane n-octylamine -6.54 
Cyclic carbon cyclohexane cyclohexylamine -5.82 -5.8 
 
Aromatic Ring Benzene Aniline -4.52 -4.5 
 
      
Mean 
   
-7.2 ± 1.2 
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3.4.3.5. CONH2 ADDITION  
In Table 12 are the 4 transformations involving the addition of amide groups that 
present a contribution to the free energy of solvation of -11.2 kcal/mol. Even with just 
only one case in the aromatic ring, the trend remains close to the average. This 
happens because since the contributions to ΔΔGsolv are big, the difference between 
aliphatic and aromatic fades in the final average. 
 
TABLE 12. Average Contribution to ΔΔGsolv free energies in the addition of CONH2 to different compound classes. 
Values expressed in kcal/mol. 
CONH2 addition to: Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Methane N-Methyl formamide -11.97 
-11.6 ± 0.2 
 
Ethane Acetamide -11.53 
 
Propane Propionamide -11.38 
Aromatic Ring Benzene benzamide -10.10 -10.1 
 
      
Mean 
   
-11.2 ± 0.7 
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3.4.3.6. NO2 ADDITION  
The addition of a NO2 group to a primary carbon entails a contribution of -5.4 kcal/mol 
to the free energy of solvation. The range of values of the 5 transformations are 
between -5.15 and -5.97 kcal/mol, with a noticeable decrease in the absolute value as 
the linear compound grows. For addition in the secondary carbon is available only one 
value that keeps the decreasing trend (-5.11 kcal/mol). The NO2 addition to an aromatic 
ring brings a contribution of -2.29 kcal/mol, considering the 6 transformations data. The 
values range is -4.06 to 2.01 kcal/mol. The ΔΔGsolv value for the addition Phenol -> 2-
nitrophenol is the only positive one in this set of 12 transformations.  
 
TABLE 13.  Average Contribution to ΔΔGsolv free energies in the addition of NO2 to different compound classes. Values 
expressed in kcal/mol 
NO2 addition to: Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution  
(kcal/mol) 
      
Primary Carbon Methane nitrometane -5.97 
-5.4 ± 0.3 
 
Ethane nitroethane -5.54 
 
Propane 1-nitropropane -5.31 
 
Butane 1-nitrobutane -5.18 
 
Pentane 1-nitropentane -5.15 
 
Propane 2-nitropropane -5.11 
Aromatic Ring Benzene nitrobenzene -3.25 
-2.5 ± 1.9 
 
Phenol 2-nitrophenol 2.01 
 
Phenol 3-nitrophenol -3.03 
 
Phenol p-nitrophenol -4.06 
 
Toluene 2-nitrotoluene -2.76 
 
Toluene 3-nitrotoluene -2.63 
 
Aniline m-nitroaniline -3.47 
      
Mean 
   
-3.8 ± 2.0 
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3.4.3.7. COH ADDITION 
For the addition of COH group, 12 cases were considered. When this occurs in a 
primary carbon, the contribution to ΔΔGsolv is of -5.2 kcal/mol. Although there is only 
one case for the secondary carbon, the value falls within this one too. For the aromatic 
ring cases, the addition has a contribution of -3.3 Kcal/mol. The values range is -5.43 to 
-2.92 kcal/mol, so an average of -4.7 is very realistic. 
TABLE 14. Average Contribution to ΔΔGsolv free energies in the addition of COH to different compound classes. Values 
expressed in kcal/mol 
COH addition to: Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Methane acetaldehyde -5.47 
-5.2 ± 0.2 
 
Ethane propionaldehyde -5.26 
 
Propane butyraldehyde -5.15 
 
Butane Pentanal -5.13 
 
Pentane Hexanal -5.14 
 
Hexane Heptanal -5.17 
 
Heptane Octanal -4.93 
 
Octane Nonanal -4.96 
Secondary Carbon Propane isobutaldehyde -4.83 -4.8 
 
Aromatic Ring Benzene Benzaldehyde -3.15 
-3.3 ± 0.4 
 
Phenol m-Hydroxybenzaldehyde -2.92 
 
Phenol p-Hydroxybenzaldehyde -3.89 
      
Mean 
   
-4.7 ± 0.8 
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3.4.3.8. COOH ADDITION  
Only five transformations were evaluated for COOH addition and all in primary carbons. 
The contribution to ΔΔGsolv energies is -8.7 kcal/mol, one of the highest found in this 
study. On this case, the COO- appears to be the form considered. The theoretical 
results, present in section 3.4.4, are consistent with that. 
 
TABLE 15. Average Contribution to ΔΔGsolv free energies in the addition of COOH to different compound classes. 
Values expressed in kcal/mol 
COOH addition to: Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Methane Ethanoic acid -8.66 
-8.4 ± 0.2 
 
Ethane Propanoic acid -8.29 
 
Propane Butanoic acid -8.32 
 
Butane Pentanoic acid -8.26 
 
Pentane Hexanoic acid -8.54 
      
Mean 
   
-8.4 ± 0.2 
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3.4.3.9. OCH3 ADDITION  
For OCH3 group additions, 12 cases were considered and a different category was 
defined (other cases). When adding an OCH3 group to a primary carbon, the 
contribution is of -3.9 kcal/mol. There was the need to defined other cases when the 
OCH3 addition occurs in molecules that already presented other groups like HO and 
NH2. For these, the contribution is inferior (-1.0 kcal/mol) although with higher error 
associated. The values range -4.31 to 1.02 kcal/mol, with a global average of -2.2 
kcal/mol. 
 
TABLE 16.  Average Contribution to ΔΔGsolv free energies in the addition of OCH3 to different compound classes. 
Values expressed in kcal/mol 
OCH3 addition to: Transformation 
ΔΔGsolv  
(kcal/mol) 
Contribution  
(kcal/mol) 
      
Primary Carbon Methane methoxymethane -3.88 
-3.9 ± 0.2 
 
Ethane methyl_ethyl_ether -3.93 
 
Propane Methyl propyl ether -3.63 
 
Propane Methyl isopropyl ether -3.98 
 
Butane t-Butyl methyl ether -4.31 
      
Other cases Ethanol 2-Methoxyethanol -1.80 
-1.0 ± 1.0 
 
Ethyl amine 2_methoxyethanamine -0.46 
 
Phenol 2_methoxyphenol 1.02 
 
Phenol 3_methoxyphenol -1.07 
 
Aniline 2_methoxyaniline -0.73 
 
Aniline 3_methoxyaniline -1.90 
 
Aniline 4_methoxyaniline -2.09 
      
Mean 
   
-2.2 1.6 
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3.4.3.10. SH ADDITION  
In table Table 17, the SH addition are presented. When it occours in a primary carbon, 
a average contribution of -3.1 kcal/mol is expected. Only one case for the aromatic ring 
prevents for defining trends. A minimum of -3.21 to a maximum of -1.68 kcal/mol, the 
mean contribution of this addition is -2.8 kcal/mol. 
TABLE 17. Average Contribution to ΔΔGsolv free energies in the addition of SH to different compound classes. Values 
expressed in kcal/mol 
SH addition to: Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Methane Methanethiol -3.21 
-3.1 ± 0.1  
Ethane Ethanethiol -3.02 
 
Propane 1-Propanethiol -3.03 
 
Butane n_butanethiol -3.09 
      
Aromatic Ring Benzene Thiophenol -1.68 -1.7 
 
      
Mean 
   
-2.8 ± 0.6 
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3.4.3.11. CN ADDITION  
CN group addition was evaluated for 9 cases. The addition to a primary carbon bears a 
contribution to the ΔΔGsolv energy of -5.7 kcal/mol. If the addition is to an aromatic ring, 
the contribution decreases to -3.3 kcal/mol and for an heterocyclic it decreases more to 
-1.33 kcal/mol. With a minimum of –5.88 to a maximum of -1.33 kcal/mol, gradually 
descending along the table, the mean contribution of this addition is -4.0 kcal/mol. 
TABLE 18. Average Contribution to ΔΔGsolv free energies in the addition of CN to different compound classes. Values 
expressed in kcal/mol 
CN addition to: Transformation 
ΔΔGsolv 
(kcal/mol) 
Contribution 
(kcal/mol) 
      
Primary Carbon Methane Acetonitrile -5.86 
-5.7 ±0.1  
Ethane Propanenitrile -5.68 
 
Propane Butanenitrile -5.62 
 
Butane Pentanenitrile -5.62 
      
Aromatic Ring Benzene benzonitrile -3.28 
-3.3 ±0.2 
 
Phenol 3-cyanophenol -3.06 
 
Phenol 4-cyanophenol -3.58 
      
Heterocyclic Ring Pyridine 3-cyanopyridine -2.06 
-1.7 ±0.4 
 
Pyridine 4-cyanopyridine -1.33 
      
Mean 
   
-4.0 1.6 
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3.4.4. COMPUTATIONAL VALUES OF ΔΔGSOLV FREE ENERGIES RESULTING 
FROM THE ADDITION OF DIFFERENT GROUPS TO DIFFERENT COMPOUND 
CLASSES 
Most of the free energy methods are based on calculation of free energy differences. 
As already mentioned, computational values of ΔΔGsolv free energies resulting from 
the addition of 9 different functional groups to different compound classes were 
calculated using Thermodynamic Integration. Those were compared to experimental 
values, presented in section 3.4.2 e 3.4.3. Some cases where the experimental values 
were not available were also tested and are presented in bold. 
TABLE 19. Computational values of ΔΔGsolv free energies resulting from the addition of different groups (HO, CH3, F, 
Cl, Br, I, NH2, CONH2 and NO2) to different compound classes. In bold are presented the cases which no experimental 
data was available. Values expressed in kcal/mol. 
Molecule A Molecule B group addition position 
ΔΔGsolv 
(kcal/mol) 
      
methane methanol HO Primary Carbon -7.77 ± 0.17 
ethane ethanol HO Primary Carbon -7.25 ± 0.16 
propane 1-propanol HO Primary Carbon -8.56 ± 0.17 
butane 1-butanol HO Primary Carbon -8.20 ± 0.16 
pentane 1-pentanol HO Primary Carbon -8.10 ± 0.17 
hexane 1-hexanol HO Primary Carbon -8.49 ± 0.17 
heptane 1-heptanol HO Primary Carbon -9.98 ± 0.17 
octane 1-octanol HO Primary Carbon -8.12 ± 0.19 
propane 2-propanol HO Secondary Carbon -8.12 ± 0.17 
butane 2-butanol HO Secondary Carbon -7.67 ± 0.16 
pentane 2-pentanol HO Secondary Carbon -7.89 ± 0.16 
pentane 3-pentanol HO Secondary Carbon -7.22 ± 0.15 
hexane 2-hexanol HO Secondary Carbon -8.17 ± 0.17 
hexane 3-hexanol HO Secondary Carbon -7.71 ± 0.15 
heptane 2-heptanol HO Secondary Carbon -8.03 ± 0.17 
heptane 3-heptanol HO Secondary Carbon -7.60 ± 0.16 
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heptane 4-heptanol HO Secondary Carbon -8.92 ± 0.16 
octane 2-octanol HO Secondary Carbon -8.23 ± 0.17 
octane 3-octanol HO Secondary Carbon -7.67 ± 0.16 
octane 4-octanol HO Secondary Carbon -8.04 ± 0.17 
2-methylpropane 2-methylpropane-2-ol HO Tertiary Carbon -7.36 ± 0.16 
2-methylbutane 2-methylbutane-2-ol HO Tertiary Carbon -6.93 ± 0.16 
2-methylpentane 2-methylpentane-2-ol HO Tertiary Carbon -7.19 ± 0.16 
3-methylpentane 3-methylpentane-3-ol HO Tertiary Carbon -6.55 ± 0.15 
2-methylhexane 2-methylhexane-2-ol HO Tertiary Carbon -7.12 ± 0.17 
3-methylhexane 3-methylhexane-3-ol HO Tertiary Carbon -7.06 ± 0.16 
2-methylheptane 2-methylheptane-2-ol HO Tertiary Carbon -7.90 ± 0.17 
3-methylheptane 3-methylheptane-3-ol HO Tertiary Carbon -6.55 ± 0.17 
4-methylheptane 4-methylheptane-4-ol HO Tertiary Carbon -7.07 ± 0.16 
cyclobutane cyclobutanol HO Cyclic Carbon -8.11 ± 0.16 
cyclopentane cyclopentanol HO Cyclic Carbon -8.56 ± 0.16 
cyclohexane cyclohexanol HO Cyclic Carbon -7.71 ± 0.16 
cycloheptane cycloheptanol HO Cyclic Carbon -8.59 ± 0.16 
cyclooctane cyclooctanol HO Cyclic Carbon -7.72 ± 0.16 
benzene phenol HO Aromatic Ring -3.62 ± 0.14 
toluene 2-methylphenol HO Aromatic Ring -4.69 ± 0.17 
toluene 4-methylphenol HO Aromatic Ring -3.84 ± 0.15 
o-xylene 2,3-dimethylphenol HO Aromatic Ring -5.23 ± 0.16 
o-xylene 3,4-dimethylphenol HO Aromatic Ring -5.62 ± 0.17 
m-xylene 2,6-dimethylphenol HO Aromatic Ring -4.49 ± 0.17 
m-xylene 2,4-dimethylphenol HO Aromatic Ring -5.19 ± 0.17 
m-xylene 3,5-dimethylphenol HO Aromatic Ring -4.27 ± 0.16 
p-xylene 2,5-dimethylphenol HO Aromatic Ring -4.89 ± 0.17 
naphtalene 1-hydroxynapthalene HO Aromatic Ring -5.00 ± 0.17 
naphtalene 2-hydroxynapthalene HO Aromatic Ring -5.60 ± 0.17 
anthracene 1-hydroxyantracene HO Aromatic Ring -3.40 ± 0.17 
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anthracene 2-hydroxyantracene HO Aromatic Ring -8.57 ± 0.17 
anthracene 9-hydroxyantracene HO Aromatic Ring -2.45 ± 0.15 
phenanthrene 1-hydroxyphenanthrene HO Aromatic Ring -2.13 ± 0.17 
phenanthrene 2-hydroxyphenanthrene HO Aromatic Ring -5.51 ± 0.17 
phenanthrene 3-hydroxyphenanthrene HO Aromatic Ring -3.59 ± 0.17 
phenanthrene 4-hydroxyphenanthrene HO Aromatic Ring -4.54 ± 0.24 
phenanthrene 9-hydroxyphenanthrene HO Aromatic Ring -4.82 ± 0.17 
furan furan-2-ol HO Heterocyclic Carbon -5.39 ± 0.17 
furan furan-3-ol HO Heterocyclic Carbon -5.89 ± 0.17 
benzofuran benzofuran-2-ol HO Heterocyclic Carbon -4.76 ± 0.17 
benzofuran benzofuran-3-ol HO Heterocyclic Carbon -5.96 ± 0.18 
benzofuran benzofuran-4-ol HO Heterocyclic Carbon -5.06 ± 0.17 
benzofuran benzofuran-6-ol HO Heterocyclic Carbon -5.25 ± 0.17 
benzofuran benzofuran-7-ol HO Heterocyclic Carbon -5.78 ± 0.17 
isobenzofuran isobenzofuran-1-ol HO Heterocyclic Carbon -4.22 ± 0.17 
isobenzofuran isobenzofuran-4-ol HO Heterocyclic Carbon -5.84 ± 0.17 
isobenzofuran isobenzofuran-5-ol HO Heterocyclic Carbon -5.32 ± 0.17 
pyrrole pyrrole-2-ol HO Heterocyclic Carbon -4.35 ± 0.18 
pyrrole pyrrole-3-ol HO Heterocyclic Carbon -5.70 ± 0.18 
indole indole-2-ol HO Heterocyclic Carbon -4.58 ± 0.18 
indole indole-3-ol HO Heterocyclic Carbon -5.93 ± 0.19 
indole indole-4-ol HO Heterocyclic Carbon -4.86 ± 0.17 
indole indole-5-ol HO Heterocyclic Carbon -5.62 ± 0.18 
indole indole-6-ol HO Heterocyclic Carbon -5.44 ± 0.17 
indole indole-7-ol HO Heterocyclic Carbon -5.21 ± 0.18 
isoindole isoindole-1-ol HO Heterocyclic Carbon -10.38 ± 0.18 
isoindole isoindole-4-ol HO Heterocyclic Carbon -5.77 ± 0.17 
isoindole isoindole-5-ol HO Heterocyclic Carbon -4.83 ± 0.17 
thiophene thiophene-2-ol HO Heterocyclic Carbon -4.52 ± 0.16 
thiophene thiophene-3-ol HO Heterocyclic Carbon -5.23 ± 0.16 
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benzothiophene benzothiophene-2-ol HO Heterocyclic Carbon -4.98 ± 0.16 
benzothiophene benzothiophene-4-ol HO Heterocyclic Carbon -5.50 ± 0.17 
benzothiophene benzothiophene-6-ol HO Heterocyclic Carbon -6.13 ± 0.17 
benzo[c]thiophene benzo[c]thiophene-1-ol HO Heterocyclic Carbon -4.58 ± 0.17 
benzo[c]thiophene benzo[c]thiophene-4-ol HO Heterocyclic Carbon -5.32 ± 0.18 
benzo[c]thiophene benzo[c]thiophene-5-ol HO Heterocyclic Carbon -5.29 ± 0.17 
imidazole imidazol-2-ol HO Heterocyclic Carbon -2.63 ± 0.17 
imidazole imidazol-4-ol HO Heterocyclic Carbon -3.06 ± 0.18 
imidazole imidazol-5-ol HO Heterocyclic Carbon -4.41 ± 0.17 
benzimidazole benzimidazol-2-ol HO Heterocyclic Carbon -2.75 ± 0.18 
benzimidazole benzimidazol-4-ol HO Heterocyclic Carbon -2.09 ± 0.17 
benzimidazole benzimidazol-6-ol HO Heterocyclic Carbon -5.35 ± 0.17 
purine purin-2-ol HO Heterocyclic Carbon -3.01 ± 0.17 
purine purin-6-ol HO Heterocyclic Carbon -3.00 ± 0.16 
purine purin-8-ol HO Heterocyclic Carbon -3.33 ± 0.17 
pyrazole pyrazol-3-ol HO Heterocyclic Carbon -3.57 ± 0.16 
pyrazole pyrazol-4-ol HO Heterocyclic Carbon -5.56 ± 0.17 
pyrazole pyrazol-5-ol HO Heterocyclic Carbon -6.71 ± 0.18 
oxazole oxazol-2-ol HO Heterocyclic Carbon -3.22 ± 0.16 
oxazole oxazol-4-ol HO Heterocyclic Carbon -4.60 ± 0.18 
oxazole oxazol-5-ol HO Heterocyclic Carbon -6.24 ± 0.18 
isoxazole isoxazol-3-ol HO Heterocyclic Carbon -4.80 ± 0.16 
isoxazole isoxazol-4-ol HO Heterocyclic Carbon -6.01 ± 0.17 
isoxazole isoxazol-5-ol HO Heterocyclic Carbon -6.37 ± 0.16 
thiozole thiozol-2-ol HO Heterocyclic Carbon 0.08 ± 0.15 
thiozole thiozol-4-ol HO Heterocyclic Carbon -4.79 ± 0.17 
thiozole thiozol-5-ol HO Heterocyclic Carbon -4.52 ± 0.15 
      
methane ethane CH3 Primary Carbon 0.19 ± 0.11 
ethane propane CH3 Primary Carbon 0.22 ± 0.09 
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propane butane CH3 Primary Carbon 0.22 ± 0.10 
butane pentane CH3 Primary Carbon -0.13 ± 0.10 
pentane hexane CH3 Primary Carbon -2.92 ± 0.10 
hexane heptane CH3 Primary Carbon -0.03 ± 0.11 
heptane octane CH3 Primary Carbon 0.57 ± 0.11 
octane nonane CH3 Primary Carbon 0.87 ± 0.11 
propane 2-metilpropane CH3 Secondary Carbon -0.06 ± 0.10 
butane 2-metilbutane CH3 Secondary Carbon 0.18 ± 0.10 
pentane 2-metilpentane CH3 Secondary Carbon -0.14 ± 0.11 
pentane 3-metilpentane CH3 Secondary Carbon 0.09 ± 0.10 
hexane 2-metilhexane CH3 Secondary Carbon 0.23 ± 0.11 
hexane 3-metilhexane CH3 Secondary Carbon 0.30 ± 0.11 
heptane 2-metilheptane CH3 Secondary Carbon 0.11 ± 0.11 
heptane 3-metilheptane CH3 Secondary Carbon -0.49 ± 0.11 
heptane 4-metilheptane CH3 Secondary Carbon 0.89 ± 0.12 
octane 2-metiloctane CH3 Secondary Carbon 0.15 ± 0.11 
octane 3-metiloctane CH3 Secondary Carbon 0.13 ± 0.11 
octane 4-metiloctane CH3 Secondary Carbon 0.33 ± 0.11 
2-methylpropane 2,2-dimethylpropane CH3 Tertiary Carbon 0.05 ± 0.10 
2-methylbutane 2,2-dimethylbutane CH3 Tertiary Carbon -0.03 ± 0.11 
2-methylpentane 2,2-dimethylpentane CH3 Tertiary Carbon -0.03 ± 0.11 
2-methylhexane 2,2-dimethylhexane CH3 Tertiary Carbon -0.23 ± 0.12 
3-methylhexane 3,3-dimethylhexane CH3 Tertiary Carbon 0.12 ± 0.12 
2-methylheptane 2,2-dimethylheptane CH3 Tertiary Carbon -0.04 ± 0.11 
cylobutane methylcyclobutane CH3 Cyclic Carbon 0.75 ± 0.10 
cylopentane methylcyclopentane CH3 Cyclic Carbon 0.21 ± 0.11 
cyclohexane methylcyclohexane CH3 Cyclic Carbon 0.23 ± 0.10 
cycloheptane methylcycloheptane CH3 Cyclic Carbon 0.17 ± 0.11 
cyclooctane methylcyclooctane CH3 Cyclic Carbon 0.14 ± 0.10 
benzene toluene CH3 Aromatic Ring 0.48 ± 0.12 
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toluene o-xylene CH3 Aromatic Ring 0.31 ± 0.13 
toluene m-xylene CH3 Aromatic Ring 0.31 ± 0.12 
toluene p-xylene CH3 Aromatic Ring 0.59 ± 0.12 
o-xylene 1,2,3-trimethylbenzene CH3 Aromatic Ring 0.18 ± 0.14 
o-xylene 1,2,4-trimethylbenzene CH3 Aromatic Ring 0.55 ± 0.12 
m-xylene 1,3,5-trimethylbenzene CH3 Aromatic Ring 0.40 ± 0.12 
naphtalene 1-methylnapthalene CH3 Aromatic Ring -0.07 ± 0.14 
naphtalene 2-methylnapthalene CH3 Aromatic Ring 0.47 ± 0.12 
naphtalene 1,3-dimethylnapthalene CH3 Aromatic Ring 0.62 ± 0.19 
naphtalene 1,4-dimethylnapthalene CH3 Aromatic Ring 0.48 ± 0.20 
naphtalene 2,3-dimethylnapthalene CH3 Aromatic Ring 0.76 ± 0.18 
naphtalene 2,6-dimethylnapthalene CH3 Aromatic Ring 1.50 ± 0.17 
naphtalene 2,7-dimethylnapthalene CH3 Aromatic Ring 1.02 ± 0.17 
anthracene 1-methylantracene CH3 Aromatic Ring 1.17 ± 0.14 
anthracene 2-metylantracene CH3 Aromatic Ring -2.49 ± 0.12 
anthracene 9-methylantracene CH3 Aromatic Ring 0.00 ± 0.17 
phenanthrene 1-methylphenanthrene CH3 Aromatic Ring 1.46 ± 0.14 
phenanthrene 2-methylphenanthrene CH3 Aromatic Ring 0.72 ± 0.12 
phenanthrene 3-methylphenanthrene CH3 Aromatic Ring 1.67 ± 0.12 
phenanthrene 4-methylphenanthrene CH3 Aromatic Ring 0.18 ± 0.28 
phenanthrene 9-methylphenanthrene CH3 Aromatic Ring 0.26 ± 0.14 
pyridine 2-methylpyridine CH3 Heterocyclic Carbon 0.28 ± 0.11 
pyridine 3-methylpyridine CH3 Heterocyclic Carbon 0.43 ± 0.13 
pyridine 4-methylpyridine CH3 Heterocyclic Carbon -0.05 ± 0.11 
2-methylpyridine 2,3-dimethylpyridine CH3 Heterocyclic Carbon 0.48 ± 0.15 
2-methylpyridine 2,4-dimethylpyridine CH3 Heterocyclic Carbon 0.01 ± 0.11 
2-methylpyridine 2,5-dimethylpyridine CH3 Heterocyclic Carbon 0.21 ± 0.14 
2-methylpyridine 2,6-dimethylpyridine CH3 Heterocyclic Carbon 0.13 ± 0.11 
3-methylpyridine 3,4-dimethylpyridine CH3 Heterocyclic Carbon -0.17 ± 0.12 
3-methylpyridine 3,5-dimethylpyridine CH3 Heterocyclic Carbon 0.09 ± 0.13 
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3-methylpyridine 2,3-dimethylpyridine CH3 Heterocyclic Carbon 0.46 ± 0.12 
4-methylpyridine 2,4-dimethylpyridine CH3 Heterocyclic Carbon 0.23 ± 0.10 
4-methylpyridine 3,4-dimethylpyridine CH3 Heterocyclic Carbon 0.15 ± 0.15 
benzimidazole 4-methylbenzimidazole CH3 Heterocyclic Carbon 1.20 ± 0.13 
oxazole 2-methyloxazole CH3 Heterocyclic Carbon -0.02 ± 0.12 
thiozole 4-methylthiozole CH3 Heterocyclic Carbon 0.06 ± 0.12 
      
ethane fluorethane F Primary Carbon -1.80 ± 0.13 
ethane chloroethane Cl Primary Carbon -1.92 ± 0.12 
ethane bromoethane Br Primary Carbon -1.74 ± 0.12 
ethane iodoethane I Primary Carbon -1.33 ± 0.12 
propane 1-fluoropropane F Primary Carbon -2.02 ± 0.13 
propane 1-chloropropane Cl Primary Carbon -2.15 ± 0.12 
propane bromopropane Br Primary Carbon -1.59 ± 0.13 
propane iodopropane I Primary Carbon -1.07 ± 0.13 
butane 1-fluorobutane F Primary Carbon -1.93 ± 0.13 
butane 1-chlorobutane Cl Primary Carbon -2.09 ± 0.12 
butane bromobutane Br Primary Carbon -1.74 ± 0.12 
butane iodobutane I Primary Carbon -1.10 ± 0.13 
pentane 1-fluoropentane F Primary Carbon -1.94 ± 0.13 
pentane 1-chloropentane Cl Primary Carbon -2.20 ± 0.12 
pentane bromopentane Br Primary Carbon -1.78 ± 0.12 
pentane iodopentane I Primary Carbon -1.27 ± 0.13 
propane 2-fluoropropane F Secondary Carbon -1.86 ± 0.13 
propane 2-chloropropane Cl Secondary Carbon -2.01 ± 0.11 
propane 2-bromopropane Br Secondary Carbon -1.68 ± 0.12 
propane 2-iodopropane I Secondary Carbon -1.13 ± 0.12 
butane 2-fluorobutane F Secondary Carbon -1.70 ± 0.12 
butane 2-chlorobutane Cl Secondary Carbon -2.08 ± 0.11 
butane 2-bromobutane Br Secondary Carbon -1.57 ± 0.12 
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butane 2-iodobutane I Secondary Carbon -1.48 ± 0.12 
pentane 2-fluoropentane F Secondary Carbon -1.74 ± 0.12 
pentane 2-chloropentane Cl Secondary Carbon -1.75 ± 0.11 
pentane 2-bromopentane Cl Secondary Carbon -1.64 ± 0.12 
pentane 2-iodopentane I Secondary Carbon -1.55 ± 0.13 
pentane 3-fluoropentane F Secondary Carbon -1.53 ± 0.11 
pentane 3-chloropentane Cl Secondary Carbon -1.95 ± 0.11 
pentane 3-bromopentane Br Secondary Carbon -1.25 ± 0.12 
pentane 3-iodopentane I Secondary Carbon -0.90 ± 0.12 
2-methylpropane 2-fluoro-2-methylpropane F Tertiary Carbon -1.59 ± 0.13 
2-methylpropane 2-chloro-2-methylpropane Cl Tertiary Carbon -1.88 ± 0.12 
2-methylpropane 2-bromo-2-methylpropane Br Tertiary Carbon -1.52 ± 0.12 
2-methylpropane 2-Iodo-2-methylpropane I Tertiary Carbon -1.03 ± 0.12 
2-methylbutane 2-fluoro-2-methylbutane F Tertiary Carbon -1.50 ± 0.12 
2-methylbutane 2-chloro-2-methylbutane Cl Tertiary Carbon -1.84 ± 0.11 
2-methylbutane 2-bromo-2-methylbutane Br Tertiary Carbon -1.44 ± 0.12 
2-methylbutane 2-iodo-2-methylbutane I Tertiary Carbon -1.18 ± 0.12 
2-methylpentane 2-fluoro-2-methylpentane F Tertiary Carbon -1.46 ± 0.13 
2-methylpentane 2-chloro-2-methylpentane Cl Tertiary Carbon -1.72 ± 0.11 
2-methylpentane 2-bromo-2-methylpentane Br Tertiary Carbon -1.12 ± 0.13 
2-methylpentane 2-iodo-2-methylpentane I Tertiary Carbon -0.76 ± 0.13 
3-methylpentane 3-fluoro-3-methylpentane F Tertiary Carbon -1.17 ± 0.12 
3-methylpentane 3-chloro-3-methylpentane Cl Tertiary Carbon -1.73 ± 0.11 
3-methylpentane 3-bromo-3-methylpentane Br Tertiary Carbon -1.62 ± 0.12 
3-methylpentane 3-iodo-3-methylpentane I Tertiary Carbon -1.60 ± 0.12 
cyclopentane fluorocyclopentane F Cyclic Carbon -2.14 ± 0.13 
cyclopentane chlorocyclopentane Cl Cyclic Carbon -2.11 ± 0.11 
cyclopentane bromocyclopentane Br Cyclic Carbon -1.75 ± 0.12 
cyclopentane iodocyclopentane I Cyclic Carbon -1.12 ± 0.12 
cyclohexane fluorohexane F Cyclic Carbon -1.94 ± 0.13 
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cyclohexane chlorohexane Cl Cyclic Carbon -2.07 ± 0.11 
cyclohexane bromohexane Br Cyclic Carbon -1.36 ± 0.12 
cyclohexane iodohexane I Cyclic Carbon -1.07 ± 0.12 
benzene fluorobenzene F Aromatic Ring 0.80 ± 0.13 
benzene chlorobenzene Cl Aromatic Ring 0.53 ± 0.12 
benzene bromobenzene Br Aromatic Ring 0.75 ± 0.12 
benzene iodobenzene I Aromatic Ring 0.73 ± 0.12 
toluene 2-fluorotoluene F Aromatic Ring 0.65 ± 0.13 
toluene 2-chlorotoluene Cl Aromatic Ring 0.36 ± 0.12 
toluene 2-bromotoluene Br Aromatic Ring 0.51 ± 0.14 
toluene 2-iodotoluene I Aromatic Ring 0.35 ± 0.14 
toluene 3-fluorotoluene F Aromatic Ring 0.61 ± 0.13 
toluene 3-chlorotoluene Cl Aromatic Ring 0.53 ± 0.12 
toluene 3-bromotoluene Br Aromatic Ring 0.43 ± 0.12 
toluene 3-iodotoluene I Aromatic Ring 0.56 ± 0.13 
toluene 4-fluorotoluene F Aromatic Ring 0.79 ± 0.14 
toluene p-chlorotoluene Cl Aromatic Ring 0.53 ± 0.12 
toluene p-bromotoluene Br Aromatic Ring 0.58 ± 0.12 
toluene 4-iodotoluene I Aromatic Ring 0.52 ± 0.13 
naphtalene 1-fluoronaphthalene F Aromatic Ring 0.81 ± 0.14 
naphtalene 1-chloronaphthalene Cl Aromatic Ring 0.37 ± 0.12 
naphtalene 1-bromonaphthalene Br Aromatic Ring 0.50 ± 0.13 
naphtalene 1-iodonaphthalene I Aromatic Ring 0.05 ± 0.14 
naphtalene 2-fluoronaphthalene F Aromatic Ring 0.62 ± 0.13 
naphtalene 2-chloronaphthalene Cl Aromatic Ring 0.42 ± 0.12 
naphtalene 2-bromonaphthalene Br Aromatic Ring 0.61 ± 0.12 
naphtalene 2-iodonaphthalene I Aromatic Ring 0.32 ± 0.12 
anthracene 1-fluoroanthracene F Aromatic Ring 1.21 ± 0.13 
anthracene 1-chloroanthracene Cl Aromatic Ring 0.62 ± 0.12 
anthracene 1-bromoanthracene Br Aromatic Ring 0.65 ± 0.14 
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anthracene 1-iodoanthracene I Aromatic Ring 0.50 ± 0.14 
anthracene 2-fluoroanthracene F Aromatic Ring -2.58 ± 0.13 
anthracene 2-chloroanthracene Cl Aromatic Ring -1.76 ± 0.11 
anthracene 2-bromoanthracene Br Aromatic Ring -1.07 ± 0.12 
anthracene 2-iodoanthracene I Aromatic Ring -1.29 ± 0.12 
anthracene 9-fluoroanthracene F Aromatic Ring 0.99 ± 0.14 
anthracene 9-chloroanthracene Cl Aromatic Ring 0.57 ± 0.13 
anthracene 9-bromoanthracene Br Aromatic Ring 0.55 ± 0.15 
anthracene 9-iodoanthracene I Aromatic Ring 1.02 ± 0.16 
      
methane methyl amine NH2 Primary Carbon -7.42 ± 0.18 
ethane ethyl amine NH2 Primary Carbon -8.05 ± 0.17 
propane n-propyl amine NH2 Primary Carbon -7.63 ± 0.17 
butane n-butyl amine NH2 Primary Carbon -7.61 ± 0.17 
pentane n-pentyl amine NH2 Primary Carbon -7.68 ± 0.18 
hexane n-hexyl amine NH2 Primary Carbon -7.85 ± 0.18 
heptane n-heptylamine NH2 Primary Carbon -6.67 ± 0.20 
octane n-octylamine NH2 Primary Carbon -7.65 ± 0.19 
      
methane N-methyl formamide CONH2 Primary Carbon -12.11 ± 0.19 
ethane acetamide CONH2 Primary Carbon -11.01 ± 0.18 
propane propionamide CONH2 Primary Carbon -8.40 ± 0.18 
      
methane nitrometane NO2 Primary Carbon -8.44 ± 0.16 
ethane nitroethane NO2 Primary Carbon -8.04 ± 0.15 
propane 1-nitropropane NO2 Primary Carbon -8.06 ± 0.15 
butane 1-nitrobutane NO2 Primary Carbon -6.30 ± 0.15 
pentane 1-nitropentane NO2 Primary Carbon -8.03 ± 0.15 
propane 2-nitropropane NO2 Secondary Carbon -7.36 ± 0.15 
benzene nitrobenzene NO2 Aromatic Ring -4.77 ± 0.16 
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phenol 2-nitrophenol NO2 Aromatic Ring -2.79 ± 0.20 
phenol 3-nitrophenol NO2 Aromatic Ring -6.99 ± 0.16 
phenol p-nitrophenol NO2 Aromatic Ring -5.52 ± 0.16 
toluene 2-nitrotoluene NO2 Aromatic Ring -5.21 ± 0.19 
toluene 3-nitrotoluene NO2 Aromatic Ring -4.90 ± 0.16 
      
 
These results were studied and evaluated, with the conclusions presented in section 3.2. 
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3.5. ADDITIVITY (UNDER DEVELOPMENT) 
Since the late 90s103 that fragment-based drug discovery (FBDD) is a method used for 
finding lead compounds. It is an alternative approach to traditional lead identification 
via high-throughput screening (HTS). FBDD identifies smaller compounds, “fragments”, 
which bind to different parts of a biological target and then they are expanded or linked 
together to produce a lead with a higher affinity.This approach is responsible for 
several drugs already in trials like for example the potential first-in-class drug for 
Alzheimer's disease known as MK-8931, from Merck.104 
Based on this, it was built a table with average contributions to ΔΔGsolv free energies for 
the addition of different groups (HO, CH3, NH2, CONH2, NO2, COH, COOH, OCH3, SH 
and CN) to different compound classes (Table 20 and Table 21). The purpose was to 
test this fragment addititivity calculating ΔΔGsolv for more complex compounds with 
experimental data known (section 3.5.1). Subsequently, the intent is to allow a 
researcher to search which group should be added to a compound to enhance its 
properties.  
 
TABLE 20. Average Contributions to ΔΔGsolv free energies in the addition of different groups (HO, CH3, NH2, CONH2, 
NO2, COH, COOH, OCH3, SH and CN) to different compound classes. In parenthesis is the number of cases 
considered. Values expressed in kcal/mol 
 
 
Compound classes 
G
ro
u
p
 a
d
d
it
io
n
 
 
Primary Carbon Secondary Carbon Tertiary Carbon Cyclic Carbon Aromatic Ring Heterocyclic Ring Other cases 
HO 
-6.9 ± 0.1 
(8) 
-6.7 ± 0.1 
(6) 
-6.7 ± 0.2 
(3) 
-6.5 ± 0.2 
(3) 
-5.2 ± 0.4 
(12)  
CH3 
0.1 ± 0.1 
(8) 
0.3 ± 0.1 
(7) 
0.2 ± 0.1 
(4) 
0.4 ± 0.0 
(2) 
-0.1 ± 0.2 
(13) 
-0.2 ± 0.2 
(15)  
NH2 
-7.7 ± 0.7 
(8) 
-5.8 
(1) 
-4.5 
(1) 
-3.8 
(1) 
CONH2 
-11.6 ± 0.2 
(3) 
-10.1 
(1)  
NO2 
-5.4 ± 0.3 
(6) 
-2.5 ± 1.9 
(7)  
COH 
-5.2 ± 0.2 
(8) 
-4.8 
(1) 
-3.3 ± 0.4 
(3)  
COOH 
-8.4 ± 0.2 
(5)  
OCH3 
-3.9 ± 0.2 
(5) 
-1.0 ± 1.0 
(7) 
SH 
-3.1 ± 0.1 
(4) 
-1.7 
(1)  
 CN 
-5.7 ± 0.1 
(4) 
-3.3 ± 0.2 
(3) 
-1.7 ± 0.4 
(2) 
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TABLE 21. Average Contributions to ΔΔGsolv free energies in the addition of halogens (F, Cl, Br and I) to different 
compound classes. In parenthesis is the number of cases considered. Values expressed in kcal/mol 
 
 
Compound classes 
H
a
lo
g
e
n
 a
d
d
it
io
n
 
 
Primary Carbon Secondary Carbon Tertiary Carbon Cyclic Carbon Aromatic Ring Heterocyclic Ring Other cases 
F 
0.1 
(1) 
Cl 
-2.3±0.1 
(4) 
-2.2±0.1 
(4) 
-1.2 
(1) 
0.3±1.5 
(4) 
-0.5±0.7 
(19) 
Br 
-2.5±0.0 
(4) 
-2.4 
(1) 
-1.5 
(1) 
-0.9±0.5 
(3) 
-1.3±0.3 
(4) 
I 
-2.5±0.1 
(4) 
-2.4 
(1) 
0.9 
(1) 
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Test cases 
The test cases were chosen based on the molecules that best represented the tabulated values. Within the information available in the 
literature, 25 compounds were selected. The ΔGadd value was constructed with the sum of ΔGsolv from the scaffold molecule, plus the 
contribution of each group added (HO, CH3, Cl, Br, NH2, NO2, COH, COOH, OCH3, SH and CN). The different positon of the addition was also 
considered: primary carbon (PC), secondary carbon (SC), tertiary carbon (TC), cyclic aliphatic carbon (CC), aromatic ring carbon (AR), 
heterocyclic ring carbon (HR). In bold are the results more close to the experimental ones. The uncertainties of the calculated values were 
obtained by error propagation. 
 
 
1-bromo-2-chloroethane 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-1.95 
    
 
+ Br (PC) + Cl (PC) -2.97 ±0.14 -1.02  
+ Br (PC) -3.13 ±0.10 -1.18  
+ Cl (PC) -3.01 ±0.00 -1.06  
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2-methoxy-2-methylpropane  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
-2.21 
   
 
 
 
 
+ CH3 (SC) + OCH3 (PC) -1.63 ±0.22 0.58  
 
 
+ OCH3 (PC) -1.59 ±0.20 0.62  
 
2-methoxy-1,1,1-trimethoxyethane  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-5.73 -2.17 ±4.00 3.56 
Proximity effects  
 
 
 
 
+ 4 OCH3 (Oth) 
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3,3,3-trimethoxypropionitrile 
 
ΔGexp 
(kcal/mol) 
ΔGads 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
 
+ 3 OCH3 (Oth) 
-6.4 
-6.85 ±3.00 -0.45 
 
 
 
+ CN (PC) + 3 OCH3 (Oth) -6.87 ±3.00 -0.47 
 
 
   
 
 
2-chloro-1,1,1-trimethoxyethane  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-4.59 -3.47 ±3.00 1.12 
 
 
 
 
 
+ OCH3 (PC) + 2 OCH3 (Oth) + Cl (PC) 
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mannitol 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
 
+ 2 HO (PC) +4 HO (SC) 
-23.6 
-38.10 ±0.45 -14.5 
Proximity effects 
Intramolecular H bonds  
+ HO (PC) +4 HO (SC) 
-38.22 ±0.41 -14.62 
 
menthol 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
 
+ HO (CC) + 2 CH3 (CC) + 2 CH3 (SC) 
-3.20 
-3.87 ±0.28 -0.67 
 
 
+ 2 CH3 (CC) + 2 CH3 (SC) 
-3.88 ±0.20 -0.68 
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1-bromo-2-ethylbenzene 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-1.19 
   
Proximity effects 
 
 
+ CH3 (AR) + CH3 (SC) 
-1.26 ±0.20 -0.07 
 
+ Br (AR) + CH3 (AR) + CH3 (SC) 
-1.57 ±0.55 -0.38 
  
 
+ Br (AR) + CH3 (SC) 
-1.43 ±0.5 -0.24 
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4-chloro-3-methylphenol  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-6.79 
    
 
 
 
+ CH3 (AR) + Cl (AR) -6.39 ±1.51 0.4 
 
 
+ HO (AR) + CH3 (AR) + Cl (AR) 
-5.87 ±1.57 0.92 
 
 
+ HO (AR) + CH3 (AR) 
-6.39 ±0.60 0.4 
 
  
+HO (AR) + Cl (AR) 
-5.73 ±1.6 1.06 
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trimethoxymethylbenzene  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-4.42 
   
 
 
 
+ CH3 (AR) + 3 OCH3 (Oth) 
-3.97 ±3.01 0.45 
 
 
 
+ 3 OCH3 (Oth) -3.83 ±3.00 0.59 
 
     
 
1-bromo-4-methyl benzene  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-1.41 
    
 
 
 
+ CH3 (AR) + Br (AR) -1.87 ±0.54 -0.46  
 
 
+ Br (AR) -1.73 ±0.50 -0.32  
 
+ CH3 (AR) 
-1.56 ±0.20 -0.15  
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benzyl bromide  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-2.38 
   
 
 
 
 
+ CH3 (AR) + Br (PC) -3.47 ±0.20 -1.09 
 
 
 
+ Br (PC) -3.33 ±0.00 -0.95 
 
 
methyl p-methoxybenzoate 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
 
 
+ OCH3 (AR) + COH (AR) + OCH3 (Oth) 
-5.33 -6.27 ±1.10 -0.84 
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1,2-dimethoxybenzene 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
 
 
+ 2 OCH3 (Oth) 
-5.3 -2.87 ±2.00 2.43 
 
  
 
4-propylguaiacol  ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
 
+ OCH3 (Oth)* + CH3 (AR) + 2 CH3 (SC) 
-5.3 
-4.87 ±0.3 -0.43 
* in this case a more 
similar transformation was 
used (2-methoxyphenol) – 
see Table 16 
 
 
+ HO (AR) + OCH3 (Oth)* + CH3 (PC) + CH3 (SC) -4.63 ±0.4 -0.67 
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3,5-dichlorosyringol 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
 
+ HO (AR) + 2 OCH3 (Oth)* + 2 Cl (AR) 
-6.2 
-3.47 ±3.00 -2.73 
* in this case a 
more similar 
transformation was 
used (2-
methoxyphenol) – 
see Table 16 
 
 
+ HO (AR) + 2 OCH3 (Oth)* + Cl (AR) + 2º Cl (AR) -3.77 ±1.60 -2.43 
 
 
+ 2 OCH3 (Oth)* + 2 Cl (AR) -3.99 ±3.00 -2.21 
 
 
+ Cl (AR) + 2 OCH3 (Oth)* + HO (AR) -3.99 ±1.60 -2.21 
 
2-chlorosyringaldehyde 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs 
 
 
+ 2 OCH3 (Oth)* + HO (AR) + Cl (AR) + COH (AR) 
-7.8 -7.07 ±1.60 -0.73 
* in this case a 
more similar 
transformation was 
used (2-
methoxyphenol) – 
see Table 16 
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  ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
3-hydroxybenzaldhyde  
-9.50 
   
Proximity effects 
 
 
 
 
+ COH (AR) + HO (AR) 
-9.37 ±0.57 0.13 
 
 
+ HO (AR) -9.22 ±0.40 0.28 
 
     
 
4-hydroxybenzaldhyde 
 
-8.83 
   
 
 
 
 
+ COH (AR) + HO (AR) -9.37 ±0.57 -0.54 
 
 
 
 
+ HO (AR) 
-9.22 ±0.40 -0.39 
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4-amino-3,5,6-trichloropyridine-2-
carboxylic acid  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-11.96 
   
Extreme 
proximity 
effects 
 
 
+ Cl (AR) + 2ºCl (AR) + 3ºCl (AR) + NH2 (AR) + COOH (AR) 
-17.09 ±1.51 -5.13 
 
+ Cl (AR) + NH2 (AR) + COOH (AR) 
-16.69 ±1.51 -4.73 
 
3,5-dibromo-4-hydroxybenzonitrile  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs 
  
-9.00 
    
 
 
+ CN (AR) + HO (AR) + Br (AR) + 2º Br (AR) 
-11.05 ±0.81 -2.05 
Proximity effects 
 
 
+ HO (AR) + Br (AR) +2ºBr (AR) 
-11.06 ±0.84 -2.06 
 
 
+ CN (AR) + Br (AR) + 2º Br (AR) -11.57 ±0.73 -2.57 
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2,6-dichlorobenzonitrile  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-5.22 
    
 
 
 
+ CN (AR) + 2 Cl (AR) -3.55 ±2.13 1.67 
 
 
 
+ CN (AR) + Cl (AR) + 2ºCl (AR) -3.85 ±2.13 1.37 
 
 
 
+ Cl (AR) +2º Cl (AR) -3.86 ±2.12 1.36 
 
 
2-methyl-1-nitrobenzene  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
-3.59 
    
 
 
 
+ NO2 (AR) + CH3 (AR) -3.47 ±0.28 0.12 
 
 
 
+ NO2 (AR) -3.33 ±0.20 0.26 
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2,6-dichlorothiobenzamide  
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
  
 
 
-10.81 
 
   
SH (SC) values  
not available 
 
 
 
+ 2 Cl (AR) + CH3 (AR) + SH (PC) + NH2 (PC) -11.17 ±1.67 -0.36 
 
2,6-dimethylaniline 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
 
+ 2 CH3 (AR) + NH2 (AR) 
-5.21 
-4.77 ±0.40 0.44 
 
 
+ 2 CH3 (AR) 
-4.79 ±0.40 0.42 
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2-amino-4,6-dinitrotoluene 
 
ΔGexp 
(kcal/mol) 
ΔGadd 
(kcal/mol) 
Error 
(kcal/mol) 
Obs. 
 
 
+ NH2 (AR) + 2 NO2 (AR) 
-9.24 
-10.33 ±3.80 -1.09 
 
 
+ CH3 (AR) + 2 NO2 (AR) 
-10.49 ±3.82 -1.25 
 
 
The calculated values showed a similar percentage of under and overestimation. Only in 23% of the cases, the error was above 2 kcal/mol. 
These were almost always associated with proximity effects. In more than 50% of the cases, the erros were ≤ 1kcal/mol, indicating a promissor 
future for additivity. It was evident that the proximity effects cannot be ignored, with an even higher influence when more negative groups are 
considered. 
It is our purpose to review the classification of the carbons where the additions are made, to better qualify and so identify them in the addition 
scenario. Also, with more cases it wloud be possible to find trends and define rules to be chosen in the process. 
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4. OTHER WORKS 
 
During the time period of this PhD, some other collaborations were stablished that gave 
raise to published/printed work. Two papers and a book chapter were written together 
with other colleagues. These tasks increased and broadened the knowledge gained 
during these years. It was also important to pratice teamwork and personal 
relationships. 
These other works are attached in the section Appendix. 
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5. CONCLUSIONS 
 
The development of new drugs is a very complex and demanding interdisciplinary 
process, guided by the combined efforts of the pharmaceutical industry, biotech 
companies, regulatory authorities, academic researchers, and other private and public 
sectors. Computer-aided drug design techniques are nowadays effective in reducing 
costs and speeding up drug discovery, as a result of the development of more accurate 
and reliable algorithms, the  use of better strategies to apply them, and of course, the 
greatly increased computer power. 
Free energy is one of the most important thermodynamic quantities addressed by 
these techniques, especially for its impact in protein-protein and protein-ligand 
interactions, as it allows to calculate the respective associations constants, among 
others properties. 
The aqueous environment is pivotal to chemical processes, so theoretical and 
computational forecasts have to account for solvent effects to match experimental 
conditions. Hence, the prediction of the free energy of solvation was a major goal of 
this work. The study of this property for HO addition to small molecules provided 
valuable information when addressing the desolvation of the ligand involved in the 
protein-ligand process. The results obtained indicated a good agreement with the 
experimental values (average error below 1 kcal/mol), supporting the predictability of 
this calculations. 
The changes in the ΔGsolv, namely ΔΔGsolv, resulting of specific chemical substitutions 
in small molecules acts as an important indicator when one intends to optimize drug 
binding. An optimized thermodynamic integration protocol was used to calculate 
solvation free energies for typical additions considered in hit-to-lead optimizations. It 
was analized as well the importance of the scaffold molecule. The results brought 
substantial information that allowed the definition of trends for different functional group 
additions, and also demonstrated the mild effect of the position of the substitution. The 
TI protocol, albeit CPU intensive, leads to accurate results, ensuring it as a valuable 
help for CADD studies. 
With all of the learning obtained in the previous studies, ΔΔGbind was also a goal to 
persecute. For that, two different methodologies were applied in the detection of hot-
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spots residues in four protein−protein complexes. The alanine scanning mutagenesis 
was performed using Molecular Mechanics/Poisson−Boltzmann Surface Area (MM-
PBSA) and Thermodynamic Integration (TI). The results demonstrate that the MM-
PBSA protocol gives results at the same level of accuracy as the TI method but at a 
fraction of the computational time. Nevertheless, TI features a wider range of 
applications in the sense that it can be applied in the study of mutations by other 
residues, beyond alanine. 
A database with mostly experimental but also theorectical values for the free energy of 
solvation of chemical groups was build-up during this PhD. Beyond the intent to collect 
the disperse information on the literature, these values were also the base of the 
previous studies and allowed to test of additivity of the contributions for the free energy 
of solvation. With the calculation of the average contribuition for each group addition 
(ΔGfrag), the free energy of solvation of a number of compounds was calculated, based 
on the tabulated ΔGfrag values. 
In the future, the database of experimental and theorectical ΔGsolv and ΔΔGsolv values 
will continue to be increased, in accordance with the literature and new calculations. 
Also, a set of conditions and corrections will be implemented in order to optimize the 
additivity protocol. The addition of a correction factor to account for the proximity 
effects and the incorporation of SASA are some of the alternatives considered. 
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a b s t r a c t
The standard (p = 0.1 MPa) molar enthalpies of formation, in the crystalline state, of the 1- and 2-cyano-
naphthalene were derived from the standard molar energies of combustion, in oxygen, at T = 298.15 K,
measured by static-bomb combustion calorimetry. Vapor pressure measurements at different tempera-
tures, using the Knudsen mass loss effusion technique, enabled the determination of the enthalpy,
entropy, and Gibbs energy of sublimation, at T = 298.15 K, for both isomers. The standard molar enthal-
pies of sublimation, at T = 298.15 K, for 1- and 2-cyanonaphthalene, were also measured by high-temper-
ature Calvet microcalorimetry.
DcUmðcrÞ=ðkJ mol1Þ DfHmðcrÞ=ðkJ mol1Þ DgcrHmðcrÞ=ðkJ mol1Þ
1-Cyanonaphthalene 5514.4 ± 1.6 188.5 ± 2.2 88.6 ± 0.5
2-Cyanonaphthalene 5510.5 ± 1.7 184.6 ± 2.2 92.1 ± 0.1
Combining these two experimental values, the gas-phase standard molar enthalpies, at T = 298.15 K, were
derived and compared with those estimated by employing two different methodologies: one based on the
Cox scheme and the other one based on G3MP2B3 calculations. The calculated values show a good agree-
ment with the experimental values obtained in this work.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
The study of the thermochemistry of naphthalene derivatives
has been among the interests of the Molecular Energetics Research
Group of the University of Porto, aiming to study the inﬂuence of
the polar and steric effects of the substituents on the thermody-
namic stability of the molecules. Following our studies on hydro-
xy- and dihydroxynaphthalenes [1], bromonaphthalenes [2],
nitronaphthalenes [3], and diaminonaphthalene [4], this work
deals with the thermochemical study of the 1- and 2-cyanonaph-
thalene, whose structural formulae are depicted in ﬁgure 1.
Naphthalene and its derivatives are biologically, pharmaceuti-
cally and industrially useful compounds, with technological appli-
cations in a large number of industrial process and have specially
attracted the attention of organic chemists for many years due to
their occurrence in synthetic and natural products possessing valu-
able biological activities. Naphthalenes are used as topical and sys-
temic anti-inﬂammatory drugs [5–7], anti-psoriatic agents [5], and
to treat cardiovascular diseases [8,9]. Compounds with the nitrile
functional group are also very important in many ﬁelds of chemis-
try and biochemistry. The 1-cyanonaphthalene is used in the syn-
thesis of chiral derivatives of Butenaﬁne and Terbinaﬁne; well
established antimicotic agents used among others in the treatment
of dermatocytes invading skin and nails, with antifungal activity
[10,11]. The 3-cyano-1-naphthalenecarboxylic acid is an interme-
diate required for the manufacture of tachykinin receptor antago-
nists; such as ZD60211, under investigation for treatment of
depression, asthma, urinary incontinence, and other disease condi-
tions [12].
To the best of our knowledge the literature reports only ther-
mochemical data concerning the enthalpies of combustion,
T = 298.15 K, of these two compounds, a work performed by Lemo-
ult and Jungﬂeisch [13], in 1909, by static bomb combustion
calorimetry.
The present study provides results on the standard molar en-
ergy of combustion, standard molar enthalpy of sublimation, and
standard molar enthalpy of formation in both crystalline and gas-
eous states, at T = 298.15 K, for the two title compounds. The stan-
dard (p = 0.1 MPa) molar enthalpies of formation of the two
isomers, in the crystalline state, at T = 298.15 K, were derived from
the standard massic energies of combustion, measured by static
0021-9614/$ - see front matter  2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.jct.2011.03.013
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bomb combustion calorimetry. The Knudsen mass-loss effusion
technique was used to measure the vapor pressures as a function
of temperature of the two crystalline compounds. From the vapor
pressure dependence of the temperature, and by application of the
Clausius–Clapeyron equation, the standard molar enthalpies of
sublimation, at the mean temperature of the experimental temper-
ature range, were derived. Standard molar enthalpies, entropies,
and Gibbs energies of sublimation, at the temperature of
298.15 K, were calculated using estimated values of the heat
capacity differences between the gas and the crystal phases of each
compound. The standard molar enthalpies of sublimation, at
T = 298.15 K, were also measured by high-temperature Calvet
microcalorimetry.
The values of the standard molar enthalpies of formation, in the
crystalline phase, and of the standard molar enthalpies of sublima-
tion obtained by Knudsen effusion, were combined to derive the
standard molar enthalpies of formation, in the gaseous phase, at
T = 298.15 K, of the 1- and 2-cyanonaphthalenes. These experimen-
tal values are compared with estimates based on high-level ab ini-
tio molecular orbital calculations at the G3(MP2)//B3LYP level, and
with the ones estimated by the Cox scheme [14].
2. Experimental
2.1. Materials and purity control
Samples of 1-cyanonaphthalene, [CAS 86-53-3] and 2-cyano-
naphthalene, [CAS 613-46-7] were supplied by Aldrich Chemical
Co. with an assessed mass fraction minimum purity of 0.98 and
0.97, respectively, and puriﬁed in this laboratory. The 1-cyano-
naphthalene was puriﬁed by successive vacuum sublimation at
0.1 Pa background pressure, ﬁrstly at T  306 K, being the temper-
ature of the cold ﬁnger T  261 K, and then at T  312 K. The 2-cya-
nonaphthalene was puriﬁed ﬁrstly by sublimation at 0.1 Pa
background pressure and T  306 K, and then was re-crystallized
three times with hexane. Finally, the re-crystallized samples were
sublimated at T  311 K.
The ﬁnal purity of each isomer was checked by gas liquid chro-
matography, performed on an Agilent 4890D gas chromatograph
equipped with an HP-5 column, cross-linked, 5% diphenyl and
95% dimethylpolysiloxane (15 m  0.530 mm i.d.  1.5 lm ﬁlm
thickness), and with nitrogen as carrier gas. The temperature of
the injector was set at T = 473 K and the oven temperature was
programmed as follows: 323 K (60 s), ramp at 0.167 K  s1, 473 K
(600 s). No impurities greater than 103 in mass fraction were
found in each sample used for the calorimetric and for the Knudsen
effusion experiments.
These purities were also conﬁrmed by the mass of carbon diox-
ide recovered in the combustion experiments to that calculated
from the mass of the sample; the averages, together with the stan-
dard deviation of the mean, were: 1-cyanonaphthalene
(1.0005 ± 0.0002) and 2-cyanonaphthalene (1.0007 ± 0.0001).
The speciﬁc densities for 1- and 2-cyanonaphthalene were ta-
ken as, q = 1.22 g  cm3 and 1.20 g  cm3, respectively, deter-
mined from the ratio mass/volume of a pellet of the compound
(made in vacuum, with an applied pressure of 105 kg  cm2).
The relative atomic masses used in the calculation of all molar
quantities throughout this paper were those recommended by
the IUPAC Commission in 2007 [15]; using those values, the molar
mass for the 1- and 2-cyanonaphthalene is 153.1809 g mol1.
2.2. Combustion calorimetry measurements
The combustion experiments were performed with a static
bomb calorimeter, with a twin valve combustion bomb Type
1105, Parr Instrument Company, made of stainless steel, with an
internal volume of 0.340 dm3; the bomb calorimeter, subsidiary
apparatus, and technique have been previously described [16,17].
The energy equivalent e(calor), of the calorimeter was determined
from the combustion of benzoic acid (NIST Standard Reference
Material 39j), having a massic energy of combustion under bomb
conditions of (26434 ± 3) J  g1 [18]. The calibration results were
corrected to give the e(calor) corresponding to the average mass of
water added to the calorimeter: 3119.6 g. From eight calibration
experiments, the value of the energy equivalent of the calorimeter
was found to be e(calor) = (15906.6 ± 1.9) J  K1, where the quoted
uncertainty refers to the standard deviation of the mean. The cali-
bration procedure was the one suggested by Coops et al. [19].
For all experiments, samples in pellet form were ignited at
T = (298.150 ± 0.001) K, with a volume of 1.00 cm3 of deionised
water introduced into the bomb, which was purged twice to re-
move air, before being charged with 3.04 MPa of oxygen. The elec-
trical energy for ignition was determined from the change in
potential difference across a capacitor (1400 lF) when discharged
through the platinum ignition wire (/ = 0.05 mm, Goodfellow,
mass fraction 0.9999).
For all combustion experiments, the calorimeter temperatures
were measured with a precision of ±(1  104) K, at time intervals
of 10 s, with a quartz crystal thermometer (Hewlett–Packard HP
2804A), interfaced to a PC programmed to collect data and to com-
pute the adiabatic temperature change, by means of the program
LABTERMO [20]. At least 100 temperature readings were taken
for the main period and for both the fore and after periods.
All the necessary weights for the combustion experiments were
made with a precision of ±(1  105) g in a Mettler Toledo AG 245
balance, and corrections from apparent mass to true mass were
introduced.
After the combustions, the CO2 was collected in absorption
tubes, previously weighed in a Mettler AT201 balance, sensitivity
±(1  105) g, and the amount of nitric acid produced in the com-
bustion experiments was quantiﬁed by acid–base volumetric titra-
tions of the bomb aqueous solutions. The corrections for nitric acid
formation were based on 59.7 kJ mol1 [21], for the molar en-
ergy of formation of 0.1 mol  dm3 HNO3(aq) from N2(g), O2(g),
and H2O(l). The amount of substance, m0(cpd), used in each exper-
iment was determined from the total mass of carbon dioxide pro-
duced after allowance for that formed from the cotton thread fuse.
For the cotton thread fuse, empirical formula CH1.686O0.843,
Dcu ¼ 16240 J  g1 [19], a value that has been previously con-
ﬁrmed in our laboratory.
An estimated pressure coefﬁcient of massic energy, (ou/
op)T = 0.2 J  g1 MPa1, at T = 298.15 K, a typical value for most
organic compounds [22], was used for the two studied compounds.
For each compound, Dcu was calculated by the procedure given by
Hubbard et al. [23].
2.3. Calvet drop microcalorimetry measurements
The standard molar enthalpies of sublimation of the two mon-
ocyanonaphthalenes were determined with a high temperature
Calvet microcalorimeter (Setaram, HT 1000) by the ‘‘vacuum subli-
mation drop-microcalorimetric method’’ of Skinner et al. [24]. Both
apparatus and measuring procedures have been described [25], to-
gether with the experimental results obtained during its testing, by
CN
CN
1-Cyanonaphthalene 2-Cyanonaphthalene 
FIGURE 1. Structural formula of cyanonaphthalene isomers.
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measuring reference compounds (benzoic acid, phenanthrene,
anthracene, and ferrocene).
The microcalorimeter was calibrated in situ for these measure-
ments using the reported standard molar enthalpy of sublimation
of naphthalene (Aldrich, mass fraction purity >0.99),
DgcrH

mðT ¼ 298:15 KÞ ¼ ð76:60 0:60Þ kJ mol1 [26]. The calibra-
tion procedure was the same as for the samples of cyanonaphtha-
lene isomers. From ﬁve independent experiments, the calibration
constants of the calorimeter, k, together with the uncertainties
(twice the standard deviation of the mean), at experimental tem-
perature, were found to be k(T = 338.7 K) = (0.9968 ± 0.0014) and
k(T = 346.6 K) = (1.0025 ± 0.0017), respectively, for the sublimation
experiments of 1- and 2-cyanonaphathalene; the quoted uncer-
tainties are the standard deviation of the mean. In a typical exper-
iment, the samples with a mass of (4 to 6) mg of solid compounds
were placed into small glass capillary tubes sealed at one end and
weighed with a precision of ±(1  106) g on a Mettler CH-8608
analytical balance. The sample and the reference capillaries were
simultaneously dropped, at room temperature, into the hot reac-
tion cells, held at a predeﬁned working temperature T. After drop-
ping the capillary tubes, an endothermic peak due to the heating of
the sample from room temperature to the temperature of the cal-
orimeter was ﬁrst observed. When the signal returned to the base-
line the sample and reference cells were simultaneously evacuated
and the measuring curve corresponding to the sublimation of the
compound was acquired. The thermal corrections for the glass cap-
illary tubes were determined in separate experiments [25] and
were evaluated and minimized in each experiment by dropping
glass capillary tubes of near equal mass into both measuring cells.
2.4. Vapor pressures measurements
The mass-loss Knudsen effusion technique was used to measure
the vapor pressures of the crystals at several temperatures. For 1-
cyanonaphatlene, due to its low melting point, an apparatus that
enables work at temperatures below room temperature was used,
that employed the simultaneous operation of three Knudsen cells,
with three different effusion holes. Hereafter, this apparatus will
be referred as Knudsen-1. The apparatus, as well as the measuring
procedure and technique have been previously reported [27].
For 2-cyanonaphthalene, the vapor pressures were also mea-
sured at several temperatures using a Knudsen effusion apparatus
which enables the simultaneous operation of nine aluminum effu-
sion cells, which are contained in cylindrical holes inside three alu-
minum blocks, three cells per block. Each block is maintained at a
constant temperature, different from the other two blocks. A de-
tailed description of the apparatus, procedure, and technique has
been reported before [28]. This apparatus will be referred as Knud-
sen-2.
The vapor pressure, p, of each compound in an effusion experi-
ment, is calculated by means of equation (1), knowing the mass of
sublimed compound, m, (determined by weighing the effusion
cells to ±(1  105) g, before and after each effusion experiment),
during a convenient effusion time period, t, at the temperature T
of the experiment, in a system evacuated to a pressure near
(1  104) Pa. The uncertainty of the temperature measurements
is estimated to be less than ±(1  102) K, and the uncertainty of
the calculated vapor pressures is estimated to be less than 0.01 Pa
p ¼ ðm=AowotÞ  ð2pRT=MÞ1=2; ð1Þ
where M represents the molar mass of the effusing vapor, R is the
gas constant, Ao is the area of the effusion hole and wo is the trans-
mission probability factor (Clausing factor) calculated by means of
the following equation (2),
wo ¼ f1þ ð3l=8rÞg1; ð2Þ
where l is the thickness of the effusion hole and r is its radius. The
lid of the cell for the effusion measurements was a platinum foil of
0.0125 mm thickness, and the areas and Clausing factors of the
effusion oriﬁces, for the 1-cyanonaphthalene, studied with the
Knudsen-1 apparatus, were as follows: oriﬁce 1, Ao = 0.5053 mm2,
wo = 0.989; oriﬁce 2, Ao = 0.7765 mm2, wo = 0.991; oriﬁce 3,
Ao = 1.1370 mm2, wo = 0.992. For the Knudsen-2 apparatus, the
areas and Clausing factors of the effusion oriﬁces are presented in
the Supporting Information, table S1.
3. Computational details
In the present work, the enthalpies of all species considered
were obtained using the G3(MP2)//B3LYP method, which is based
on standard ab initio molecular calculations and empirically based
corrections. Full details and the theoretical basis of the method can
be found in Baboul et al. [29]. This approach uses the B3LYP
method and the 6-31G(d) basis set for geometry optimization
and calculation of the vibrational frequencies to compute thermal
corrections for T = 298.15 K by introduction of the vibrational,
translational, rotational and the pV terms, and the QCISD(T)/6-
31G(d) and MP2/GTMP2Large approaches to obtain corrections to
the energy calculated with the DFT method.
All the computations were performed with the Gaussian 03 ser-
ies of programs [30]. This composite method was used to compute
the enthalpies of the gas-phase reaction described by the following
equation:
+ +
CN
CN
ð3Þ
Using the calculated enthalpies of the above reaction and the
experimental gas-phase standard molar enthalpies of formation,
DfH

mðgÞ, for benzonitrile, (215.7 ± 2.1) kJ mol1 [33], naphthalene,
(150.3 ± 1.4) kJ mol1 [31] and benzene, (82.6 ± 0.7) kJ mol1
[31], the enthalpies of the two titled compounds were calculated.
In a previous work, concerning the thermochemistry of 2-, 3- and
4-cyanobenzoic acids [32] it was found that this composite method
was capable of reproducing gas-phase standard molar enthalpies of
this class of compounds. Therefore, this approach was used again in
the present work.
4. Results
4.1. Experimental enthalpies of formation
Detailed results for each combustion experiment performed for
1- and 2-cyanonaphthalene are given, respectively, in tables 1 and
2, where Dm(H2O) is the deviation of the mass of water added to
the calorimeter and the mass assigned to e(calor): 3119.6 g, DUR
is the energy correction to the standard state and the remaining
terms are as previously described [22,23]. The internal energy for
the isothermal bomb process, DU(IBP), was calculated through
equation (4):
DUðIBPÞ ¼ feðcalorÞ þ cpðH2O; lÞ  DmðH2O; lÞ þ efgDTad
þ DUðignÞ ð4Þ
where DTad is the calorimeter temperature change corrected for the
heat exchange and the work of stirring.
In the last row of tables 1 and 2, the mean values of the standard
massic energies of the two isomers are also registered, where the
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indicated uncertainty represents the standard deviation of the
mean. These mean values of Dcu are referred to the combustion
reaction described by the following equation:
C11H7NðcrÞ þ 12:75O2ðgÞ ! 11CO2ðgÞ þ 0:5N2ðgÞ þ 3:5H2OðlÞ
ð5Þ
The derived standard molar energies and enthalpies of combustion,
and the standard molar enthalpies of formation of the compounds,
in the crystalline state, at T = 298.15 K are given in table 3. The
uncertainties assigned to the standard molar energies and enthal-
pies of combustion, DcU

mðcrÞ and DcHmðcrÞ, are, in each case, twice
the overall standard deviation of the mean and include the uncer-
tainties in calibration and in the values of auxiliary quantities used,
in conformity with normal thermochemical practice [33,34].The
values of the standard molar enthalpies of formation, in the
crystalline phase, DfH

mðcrÞ, were derived from DcHmðcrÞ using the
values of the standard molar enthalpies of formation of H2O(l),
(285.830 ± 0.040) kJ mol1 [35], and CO2(g), (393.51 ± 0.13) kJ 
mol1 [35].
TABLE 1
Standard (p = 0.1 MPa) massic energy of combustion of 1-cyanonaphthalene, at T = 298.15 K.
Experiment 1 2 3 4 5 6
m(CO2, total)/g 1.46219 1.92200 1.72010 1.61522 1.67023
m0(cpd)/g 0.46117 0.60655 0.53015 0.54270 0.50956 0.52664
m00(fuse)/g 0.00292 0.00314 0.00272 0.00307 0.00297 0.00362
Ti/K 298.1508 298.1498 298.1514 298.1516 298.1509 298.1505
Tf/K 299.3127 299.6273 299.4630 299.4908 299.4155 299.4539
DTad/K 1.04818 1.37759 1.20485 1.23323 1.15779 1.19735
ei/(J  K1) 14.94 15.15 15.07 15.03 14.99 15.01
ef /(J  K1) 15.21 15.50 15.32 15.36 15.30 15.32
eðcalorÞcorr:/(J  K1) 15906.6 15906.6 15906.6 15906.6 15906.6 15906.6
Dm(H2O)/g 0.0 0.0 0.0 0.0 0.0 0.0
DU(IBP)a/J 16687.89 21933.01 19182.59 19634.31 18433.04 19062.99
DU(fuse)/J 47.42 50.99 44.14 49.86 48.23 58.79
DU(HNO3)/J 28.36 37.37 37.97 31.76 29.79 32.54
DU(ign)/J 1.03 1.12 0.94 1.13 1.18 1.12
DUR/J 10.83 14.56 12.55 12.93 12.07 12.51
Dcu/(J  g1) 35998.18 35990.59 36004.77 36004.72 35997.63 36000.21
hDcui ¼ ð35999:4 2:2Þ J  g1
m(CO2, total) is the mass of CO2 recovered in each combustion; m0(cpd) and m00(fuse) are the mass of compound and of fuse (cotton) used in each experiment; Ti is the initial
temperature rise; Tf is the ﬁnal temperature rise; DTad is the corrected temperature rise; ei is the energy equivalent of the contents in the initial state; ef is the energy
equivalent of the contents in the ﬁnal state; e(calor)corr. is the corrected energy equivalent of the calorimeter for the amount of water used; Dm(H2O) is the deviation of mass
of water added to the calorimeter from 3119.6 g; DU(IBP) is the energy change for the isothermal combustion reaction under actual bomb conditions; DU(fuse) is the energy
of combustion of the fuse (cotton); DU(HNO3) is the energy correction for the nitric acid formation; DU(ign) is the electrical energy for ignition; DUR is the standard state
correction; Dcu is the standard massic energy of combustion.
a DU(IBP) includes DU(ign).
TABLE 2
Standard (p = 0.1 MPa) massic energy of combustion of 2-cyanonaphthalene, at T = 298.15 K.
Experiment 1 2 3 4 5 6
m(CO2, total)/g 1.65301 1.48339 1.62667 1.57440 1.84646
m0(cpd)/g 0.52130 0.46792 0.51295 0.49644 0.55662 0.58262
m00(fuse)/g 0.00341 0.00283 0.00344 0.00337 0.00337 0.00320
Ti/K 298.1500 298.1512 298.1498 298.1506 298.1509 298.1513
Tf/K 299.4406 299.3254 299.4256 299.3872 299.5179 299.5761
DTad/K 1.18409 1.06255 1.16533 1.12784 1.26413 1.32315
ei/(J  K1) 15.01 14.95 15.00 14.98 15.07 15.07
ef /(J  K1) 15.32 15.20 15.26 15.24 15.42 15.41
eðcalorÞcorr:/(J  K1) 15906.6 15906.6 15906.6 15906.6 15906.6 15906.6
Dm(H2O)/g 0.0 0.0 0.0 0.0 0.0 0.0
DU(IBP)a/J 18851.87 16916.63 18553.21 17956.24 20126.44 21066.21
DU(fuse)/J 55.38 45.96 55.87 54.73 54.73 51.97
DU(HNO3)/J 30.86 30.81 34.57 33.31 31.70 35.28
DU(ign)/J 1.12 1.08 1.01 1.05 1.06 1.00
DUR/J 12.37 10.99 12.13 11.72 13.30 13.95
Dcu/(J  g1) 35974.03 35965.27 35969.67 35969.06 35979.14 35984.02
hDcui ¼ ð35973:5 2:9Þ J  g1
a DU(IBP) includes DU(ign).
TABLE 3
Derived standard (p = 0.1 MPa) molar energies of combustion, DcUm, standard molar enthalpies of combustion, DcH

m, and standard molar enthalpies of formation, DfH

m, in the
crystalline phase, for the 1- and 2-cyanonaphthalene at T = 298.15 K.
Compound DcHmðcrÞ=ðkJ mol1Þ DcHmðcrÞ=ðkJ mol1Þ DfUmðcrÞ=ðkJ mol1Þ
1-Cyanonaphthalene 5514.4 ± 1.6 5517.5 ± 1.6 188.5 ± 2.2
2-Cyanonaphthalene 5510.5 ± 1.7 5513.6 ± 1.7 184.6 ± 2.2
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4.2. Calvet microcalorimetry – experimental enthalpies of sublimation
The observed standard molar enthalpies of sublimation,
Dg;Tcr298:15KH

m, at the working temperature, have been corrected to
T = 298.15 K according to the following equation (6)
DgcrH

mð298:15 KÞ ¼ Dg;Tcr;298:15KHm þ DT298:15KHmðgÞ; ð6Þ
where the corrective term DT298:15KH

mðgÞ ¼
R T
298:15K C

p;mðgÞdT
represents the molar enthalpic correction for the heat capacity of
the gaseous phase, derived from statistical thermodynamics using
the vibrational frequencies from DFT calculations, B3LYP/6-31G(d)
approach [36] (scaled by 0.9613 [37]), yielding the following
corrections: D338:8298:15KH

mðgÞ ¼ 6:9 kJ mol1 and D346:6298:15KHmðgÞ ¼ 8:4
kJ mol1, respectively, for 1- and 2-cyanonaphthalene
Cp;mð1-CNNaphthalene; gÞ=ðJ mol1  K1Þ
¼ 1:665  108ðT=KÞ3  2:514  104ðT=KÞ2 þ 6:255
 101ðTKÞ  2:009; ð7Þ
Cp;mð2-CNNaphthalene; gÞ=ðJ mol1  K1Þ
¼ 2:554  109ðT=KÞ3  2:858  104ðT=KÞ2 þ 6:425
 101ðT=KÞ  3:626: ð8Þ
The results of the measurements of the standard molar enthalpies
of sublimation of the cyanonaphthalene isomers, by microcalorime-
try, as well as the respective uncertainties, are given in table 4. The
uncertainties assigned to the standard molar enthalpies of sublima-
tion, DgcrH

mð298:15 KÞ, are twice the overall standard deviation of
the mean and include the uncertainties in calibration [33,34].
4.3. Knudsen effusion technique – vapor pressure measurements
The standard molar enthalpies of sublimation, at the mean tem-
perature of the experimental range, were derived by ﬁtting data to
the integrated form of the Clausius–Clapeyron equation, ln(p/
Pa) = a  b  (T/K)1, where a is a constant and b ¼ DgcrHmðhTiÞ=R.
The experimental results obtained from each effusion cell, to-
gether with the residuals of the Clausius–Clapeyron equation,
102  Dln(p/Pa), derived from least squares adjustments are sum-
marized in tables 5 and 6 for 1- and 2-cyanonaphthalene,
respectively.
Table 7 lists, for each hole used and for the global treatment all
the (p, T) points obtained for each studied compound, the detailed
parameters of the Clausius–Clapeyron equation, together with the
calculated standard deviations and the standard molar enthalpies
of sublimation at the mean temperature of the experiments
T = hTi. The equilibrium pressure at this temperature, p(hTi), and
the entropies of sublimation, at equilibrium conditions, relatively
to the global treatment are also presented.
In ﬁgure 2 are depicted the plots of ln p = f(1/T) for the global
results obtained for the 1- and 2-cyanonaphthalene, straight lines
with correlation coefﬁcients R2 = 0.9990 and R2 = 0.9994, respec-
tively. The enthalpies of sublimation, at T = 298.15 K, were calcu-
lated from the sublimation enthalpies, at the mean temperature
hTi of the experiment, by equation (9):
DgcrH

mðT ¼ 298:15 KÞ ¼ DgcrHðhTiÞ þ DgcrCp;mð298:15 hTiÞ; ð9Þ
TABLE 4
Standard (p = 0.1 MPa) molar enthalpies of sublimation, DgcrH

m, at T = 298.15 K determined by microcalorimetry for the cyanonaphthalene isomers.
Compound No. of expts T/K Dg;Tcr;298:15KH

m=ðkJ mol1Þ DT298:15KHmðgÞ=ðkJ mol1Þ DgcrHmð298:15 KÞ=ðkJ mol1Þ
1-Cyanonaphthalene 5 338.8 95.0 ± 0.4 6.9 88.1 ± 1.7
2-Cyanonaphthalene 5 346.6 99.1 ± 0.1 8.4 90.7 ± 1.6
TABLE 5
Knudsen effusion results for the 1-cyanonaphthalene.
T/K t/s pa/Pa 102  Dln(p/Pa)b
Hole 1 Hole 2 Hole 3 Hole 1 Hole 2 Hole 3
1-Cyanonaphthalene
289.10 22089 0.120 0.125 0.120 1.8 2.3 1.8
291.12 22803 0.163 0.156 0.157 3.3 1.1 0.5
293.12 19505 0.208 0.200 0.196 2.7 1.2 3.3
295.12 18716 0.265 0.275 0.251 2.3 6.0 3.2
297.13 15081 0.324 0.319 2.0 3.6
299.13 16453 0.426 0.418 0.416 1.3 0.5 1.0
301.12 15157 0.535 0.532 0.527 0.6 0.0 0.9
303.30 11784 0.724 0.690 0.686 5.4 0.6 0.0
305.12 13351 0.843 0.849 0.840 0.3 0.4 0.7
307.00 5415 1.033 1.044 1.034 1.4 0.3 1.3
a The uncertainty associated with each calculated individual vapor pressure mea-
surement is estimated to be less than 0.01 Pa.
b The deviations of the experimental results from those given by the Clausius–
Clapeyron equations are denoted by Dln(p/Pa).
TABLE 6
Knudsen effusion results for the 2-cyanonaphthalene.
T/K t/s Oriﬁces pa/Pa 102  Dln(p/Pa)b
Small Medium Large Small Medium Large
2-Cyanonaphthalene
296.18 22219 A2–B5–C8 0.090 0.092 0.091 2.5 0.4 2.9
298.11 22219 A1–B4–C7 0.115 0.117 0.116 2.4 0.6 3.0
300.19 17812 A3–B6–C9 0.159 0.153 0.154 4.5 0.8 1.1
302.18 17812 A2–B5–C8 0.197 0.196 0.201 2.0 1.2 0.1
304.10 17812 A1–B4–C7 0.245 0.245 0.244 0.5 0.7 3.6
306.18 15527 A3–B6–C9 0.319 0.303 0.304 2.2 2.8 1.4
308.15 15527 A2–B5–C8 0.391 0.388 0.396 0.3 1.1 1.6
310.09 15527 A1–B4–C7 0.487 0.485 0.491 0.8 1.2 1.4
312.19 10255 A3–B6–C9 0.636 0.617 0.618 1.8 1.2 0.1
314.16 10255 A2–B5–C8 0.783 0.762 0.803 0.5 2.2 0.9
316.10 10255 A1–B4–C7 0.948 0.947 0.994 1.8 2.0 2.6
a The uncertainty associated with each calculated individual vapor pressure measurement is estimated to be less than 0.01 Pa.
b The deviations of the experimental results from those given by the Clausius–Clapeyron equations are denoted by Dln(p/Pa).
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where DgcrC

p;m ¼ 37:1 J  K1 mol1, for both isomers of cyano-
naphthalene. The Cp;mðgÞ ¼ 136:4 J  K1 mol1 and Cp;mðcrÞ ¼
173:5 J  K1 mol1 were derived from data of Domalski and
Hearing [38] and using a second-order group additivity approach
developed by Benson and co-workers [39], considering the
following expression:
fð7  ½CB—ðHÞðCBÞ2Þ þ 7  ½CBF—ðCBFÞðCBÞ2 þ 1  ½CB—ðCNÞðCBÞ2g;
ð10Þ
where Cp;m½CB—ðHÞðCBÞ2; g ¼ 13:61 J  K1 mol1; Cp;m½CB—ðHÞ
ðCBÞ2; cr ¼ 20:13 J  K1  mol1; Cp;m½CBF—ðCBFÞðCBÞ2;g¼0:0JK1
mol1; Cp;m½CBF—ðCBFÞðCBÞ2; cr ¼ 2:30 J  K1 mol1; Cp;m½CB—ðCNÞ
ðCBÞ2;g ¼ 41:09 J  K1 mol1 and for Cp;m½CB—ðCNÞðCBÞ2; cr was
estimated the value of 28.02 J  K1 mol1, as the average of the
same parameter for the three nitrobenzonitrile isomers, equation
(11):
Cp;m½CB—ðCNÞðCBÞ2; cr
¼ Cp;mð2-;3- or 4-nitrobenzonitrile; crÞ  4  Cp;m½CB—ðHÞðCBÞ2
 Cp;m½CB—ðNO2ÞðCBÞ2 ð11Þ
where Cp;m½CB—ðNO2ÞðCBÞ2 ¼ 50:96 J  K1 mol1 and Cp;mðcrÞ for 2-
, 3- and 4-nitrobenzonitrile were determined by differential scan-
ning calorimetry DCS [40] as being, respectively,
169.8 J  K1 mol1, 165.6 J  K1 mol1 and 168.0 J  K1 mol1.
The standard molar entropies of sublimation were calculated by
equation (12), where p = 0.1 MPa, and the standard molar Gibbs
energies of sublimation were calculated through equation (13),
where all thermodynamic parameters are referred to the tempera-
ture of 298.15 K
DgcrS

mðT ¼ 298:15 KÞDgcrSmfhTiÞg þ DgcrCp;m lnð298:15 K=hTiÞ  R
 lnfp=pðhTiÞg; ð12Þ
DgcrG

m ¼ DgcrHm  298:15  DgcrSm: ð13Þ
The values of the standard molar enthalpies, entropies and
Gibbs energies of sublimation, at T = 298.15 K, for 1- and 2-cyano-
naphthalene, are presented in table 8.
TABLE 7
Experimental results for 1- and 2-cyanonaphthalene, where a and b are from Clausius–Clapeyron equation, ln(p/Pa) = a  b  (K/T) and b ¼ DgcrHmðhTiÞ=R;
R = 8.314472 J  K1 mol1.
Oriﬁces a b hTi/K pðhTiÞ/Pa DgcrHmðhTiÞ/(kJ mol1) DgcrSmðhTi;pðhTiÞÞ/(J  K1 mol1)
1-Cyanonaphthalene
Oriﬁce 1 34.67 ± 0.41 10625 ± 121 88.3 ± 1.0
Oriﬁce 2 34.57 ± 0.39 10600 ± 117 88.1 ± 1.0
Oriﬁce 3 34.99 ± 0.20 10731 ± 60 89.2 ± 0.5
Global results 34.75 ± 0.22 10653 ± 66 298.13 0.374 88.6 ± 0.5 297.2 ± 1.7
2-Cyanonaphthalene
A1–A2–A3 34.90 ± 0.34 11041 ± 103 91.8 ± 0.9
B4–B5–B6 34.50 ± 0.15 10921 ± 47 90.8 ± 0.4
C7–C8–C9 34.67 ± 0.36 11145 ± 91 92.7 ± 0.8
Global results 34.88 ± 0.17 11036 ± 50 306.14 0.311 91.8 ± 0.4 299.9 ± 1.3
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FIGURE 2. Plots of ln (p/Pa) against 1/T for 1- and 2-cyanonaphtalene: s, small
holes; 4, medium holes; h, large holes.
TABLE 8
Values of the standard (p = 0.1 MPa) molar enthalpies, DgcrH

m, entropies, D
g
crS

m, and Gibbs energies D
g
crG

m, of sublimation, at T = 298.15 K, for the compounds studied.
Compound DgcrH

m=ðkJ mol1Þ DgcrSm=ðJ  K1 mol1Þ DgcrGm=ðkJ mol1Þ
1-Cyanonaphthalene 88.6 ± 0.5 193.3 ± 1.7 31.0 ± 0.7
2-Cyanonaphthalene 92.1 ± 0.1 195.4 ± 1.3 33.8 ± 0.4
TABLE 9
Standard (p = 0.1 MPa) molar enthalpies of formation, DfHm, and of sublimation, D
g
crH

m, at T = 298.15 K.
Compound DfH

mðcrÞ=ðkJ mol1Þ DgcrHm=ðkJ mol1Þ DfHmðgÞ=ðkJ mol1Þ
1-Cyanonaphthalene 188.5 ± 2.2 88.6 ± 0.5 277.1 ± 2.3
2-Cyanonaphthalene 184.6 ± 2.2 92.1 ± 0.1 276.7 ± 2.2
CN
1-Cyanonaphthalene
and
2-Cyanonaphthalene
= + 
CN
− 
Naphthalene Benzonitrile Benzene 
FIGURE 3. Empirical scheme for DfH

mðgÞ estimation.
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The combination of the derived standard molar enthalpies of
formation, in the crystalline phase, with the standard molar
enthalpies of sublimation, measured by Knudsen effusion method,
yields the standard molar enthalpies of formation, in the gaseous
phase, at T = 298.15 K, for 1- and 2-cyanonaphthalene, registered
in table 9.
4.4. Enthalpies of formation estimated with the Cox scheme
For gaseous aromatic compounds there are few well-estab-
lished schemes for the estimation of gas-phase enthalpies of for-
mation due to the fact that those empirical schemes must take in
account the effect of perturbation on the p-electron system. Cox
[14] examined the method of estimating DfH

mðgÞ for substituted
benzenes, based on assuming a constant increment in the
DfH

mðgÞ on substitution of a particular group, independent of the
position of the substituent. So, from the values of DfH

mðgÞ, at
T = 298.15 K, available in the literature [31] for benzene and for
benzonitrile, respectively, (82.6 ± 0.7) kJ mol1 and (215.7 ±
2.1) kJ mol1, the calculated enthalpic increment of the substitu-
tion of a nitrile group in a benzene ring is (133.1 ± 2.2) kJ mol1,
which together with the enthalpy of formation of naphthalene,
(150.3 ± 1.4) kJ mol1 [31], allows the estimation of the standard
molar enthalpies of formation of the 1- and 2-cyanonaphthalene
isomers, taking into account the approach represented in ﬁgure
3, as DfH

mðgÞ is (283.4 ± 2.6) kJ mol1, registered in table 10.
TABLE 10
Experimental and estimated (Cox scheme) and calculated (G3MP2B3) values for the gas-phase enthalpies of formation of 1- and 2-cyanonaphthalenes.
Compound Experimental DfH

mðgÞ=ðkJ mol1Þ D
a/(kJ mol1)
Cox scheme G3MP2B3 Cox scheme G3MP2B3
1-Cyanonaphthalene 277.1 ± 2.3 283.4 ± 2.6 281.0 6.3 ± 3.5 3.9
2-Cyanonaphthalene 276.7 ± 2.2 283.4 ± 2.6 283.1 6.7 ± 3.4 6.4
a Difference between the experimental and the estimated values.
FIGURE 4. Selected geometrical parameters optimized at the B3LYP/6-31G(d), shown in normal text, and experimental values, shown in italic, for naphthalene [41],
benzonitrile [42], and benzene [43]. Selected bond lengths (nm) and bond angles () are included.
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4.5. Computational enthalpies of formation
The most stable conformations obtained for 1- and 2-cyano-
naphthalene, taking into account the geometry optimization per-
formed at the B3LYP/6-31G(d) level of theory (G3MP2//B3LYP
calculations) are those represented in ﬁgure 4. Bond distances
and angles are also included. No structural data for both com-
pounds have been found in the literature for comparison with
our results. Both molecules of cyanonaphthalene isomers are pla-
nar like the parent compound [41], and the –CN group remains
in the plane of the molecule such as in the case of the benzonitrile
[42]. The geometrical parameters obtained for 1- and 2-cyano-
naphthalene are similar and agree with the corresponding ones
calculated and found in the literature for naphthalene [41], benzo-
nitrile and benzene [43], as shown in ﬁgure 4.
The gas-phase enthalpies of formation of the two isomers stud-
ied were estimated using the reactions described by equation (3)
using the experimental enthalpies of formation in the gaseous
phase of the other molecules involved, as stated above. Table 10 re-
ports the calculated enthalpies of formation along with the exper-
imental ones. The table shows that the agreement between the
experimental and the G3MP2B3 calculated values is good, with
the maximum deviation from the experimental result of
6.4 kJ mol1.
At the G3MP2B3 level, the values of the gas-phase enthalpies of
formation of the two isomers are very similar, although this meth-
od point out the 2-cyanopnaphthalene as the least stable isomer,
which lies 2.1 kJ mol1 higher than the 1-cyanonapthalene.
5. Discussion
The experimental values of the standard molar enthalpies of
formation, in gaseous state, for the two compounds studied were
derived from the values of the standard molar enthalpies of com-
bustion obtained by static bomb combustion calorimetry, and from
the standard molar enthalpies of sublimation derived from the val-
ues of vapor pressures at different temperatures measured by the
Knudsen effusion technique.
For the 2-cyanonaphthalene, a slightly higher value of standard
molar enthalpy of sublimation was obtained than that observed for
the 1-cyanonaphthalene, by both Calvet microcalorimetry and the
Knudsen effusion technique, which shows that intermolecular
interactions in the ﬁrst compound are slightly stronger than those
in the 1-cyanonaphthalene. If we focus on the values DgcrS

m for
these two isomers, one can see that the value of this parameter
is very similar for both isomers suggesting an identical degree of
orientational disorder in the crystalline phase for both monocyano
substituted naphthalenes.
The experimental values of gas-phase enthalpies for the 1- and
2-cyanonaphthalene, (277.1 ± 2.3) kJ mol1 and (276.7 ± 2.2) kJ 
mol1, respectively, reveal that these two compounds have similar
enthalpic stabilities. The G3(MP2)//B3LYP approach was used to
estimate the gas-phase enthalpies of formation of the title com-
pounds at T = 298.15 K by considering the working reaction given
by Eq. (3). The computed values 281.0 kJ mol1 and 283.1 kJ 
mol1, for 1- and 2-cyanonaphthalene, respectively, are in good
agreement with the experimental ones, giving the 2-cyanonaph-
thalene as the least stable isomer.
The gas-phase enthalpy of formation, derived from the Cox
scheme, leads to an acceptable agreement between the experimen-
tal and estimated values, since the differences D between the
experimental and the estimated ones are within the usually ac-
cepted limit of ±10 kJ mol1.
Figure 5 presents an analysis of the enthalpic increments due to
the introduction of a nitrile group in benzene and in the position
one and two of the naphthalene ring, respectively, is presented,
making use of the of the literature values of the standard molar
enthalpies of formation, in the gaseous phase, of benzene, naphtha-
lene and benzonitrile [31]. This graphical representation clearly
shows that substitution of the nitrile group in the aromatic ring
of naphthalene introduces a destabilizing enthalpic effect, similar
to the corresponding increment in the benzene ring, and this
scheme also clearly shows that the entrance of the nitrile group
in the 1st and 2nd position of the naphthalene ring is exactly the
same, within the associated uncertainties, showing that the molec-
ular increment in either structural position does not induce differ-
ent enthalpic effects.
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Protein-Ligand Docking in the New Millennium – A Retrospective of 10 
Years in the Field 
S.F. Sousa, A.J.M. Ribeiro, J.T.S. Coimbra, R.P.P. Neves, S.A. Martins, N.S.H.N. Moorthy,  
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Abstract: Protein-ligand docking is currently an important tool in drug discovery efforts and an active area of research 
that has been the subject of important developments over the last decade. These are well portrayed in the rising number of 
available protein-ligand docking software programs, increasing level of sophistication of its most recent applications, and 
growing number of users. While starting by summarizing the key concepts in protein-ligand docking, this article presents 
an analysis of the evolution of this important field of research over the past decade. Particular attention is given to the 
massive range of alternatives, in terms of protein-ligand docking software programs currently available. The emerging 
trends in this field are the subject of special attention, while old established docking alternatives are critically revisited. 
Current challenges in the field of protein-ligand docking such as the treatment of protein flexibility, the presence of struc-
tural water molecules and its effect in docking, and the entropy of binding are dissected and discussed, trying to anticipate 
the next years in the field. 
Keywords: Docking, drug design, entropy, flexibility, scoring, software, virtual Screening. 
INTRODUCTION 
Protein-ligand docking is a widely used computational 
tool that tries to predict the most favourable structure of the 
complex formed between a given protein-target (often an 
enzyme) and a small-molecule ligand. It can be regarded as 
part of the more general field of molecular docking, which 
aims to predict the most favourable structure of the intermo-
lecular complex formed between two or more generic con-
stituent molecules, a definition which also encompasses the 
field of protein-protein docking [1, 2]. 
Molecular recognition events are essential in many bio-
logical processes, including signal transduction, cell regula-
tion and other macromolecular association actions. These 
processes rely on a variety of atomic-level scale events in-
cluding enzyme-substrate, drug-protein, drug-nucleic acid 
and protein-protein recognition [3], that are of great thera-
peutic importance. Docking offers a relatively fast and eco-
nomic alternative to standard experimental techniques, al-
lowing the prediction in silico (i.e. computationally) of the 
binding modes and affinities for molecular recognition 
events such as the ones outlined above [4]. Within the mo-
lecular docking field, protein-ligand docking represents a 
particularly important and well-established methodology, 
and a relevant part of the current drug discovery process [1, 
2, 5, 6]. 
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From a functional point of view, docking involves the 
generation of an ensemble of 3D conformers of a complex 
starting from the known structures of its free components 
[7]. In protein-ligand docking this process involves the 
search through different ligand conformations and orienta-
tions (the pose) within a given target protein, and the meas-
ure of the binding affinity of the different alternatives (the 
scoring).  
Different poses are generated by a search algorithm, 
which ideally should sample the degrees of freedom of the 
protein-ligand complex adequately enough as to include the 
true binding modes. These different poses are evaluated 
through a scoring function. This should be able to rank them, 
and to identify the true binding mode(s) for a given ligand, 
and to estimate their binding affinity. Hence, a scoring func-
tion should be able not only to ensure a distinction between 
different similar alternatives and ranking them accordingly, 
but also to represent the thermodynamics of interaction of 
the protein-ligand system accurately.  
Over time different search algorithms have become 
available, based on quite different approaches. Naturally, the 
two critical elements in a search algorithm are speed and 
effectiveness in covering the relevant conformational space 
[1]. Efficiently dealing with the flexibility is a major chal-
lenge, as the computational time associated scales with the 
number of degrees of freedom included in the conforma-
tional search. Several approaches, at different levels of so-
phistication, have been devised to deal with this issue. These 
have traditionally been grouped in: rigid-body methods, 
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flexible-ligand docking methods, and flexible ligand - flexi-
ble target methods.  
Rigid-body algorithms comprise the most basic approach 
to sample the conformational space resulting from a ligand-
target association. These methods treat both the ligand and 
the target as rigid and explore only the six degrees of transla-
tion and rotational freedom. For flexible-ligand docking 
some quite different approaches exist, including systematic, 
random and stochastic algorithms. Flexible ligand – flexible 
target methods represent the high-end approach and intro-
duce flexibility in the protein target, in addition to the ligand. 
As the potential number of degrees of freedom in such a 
complex is virtually untreatable, several ingenious schemes 
able to include at least partially, flexibility into the descrip-
tion of the target protein have been developed [8-14]. This 
topic will be the subject of particular detail in this review. 
In terms of scoring functions the number of available al-
ternatives is also quite vast, even though the availability of 
some scoring functions is sometimes restricted to specific 
software packages. The most common scoring functions 
normally applied can be divided into three major classes: 
force-field-based, empirical, and knowledge-based scoring 
functions. In addition to good accuracy, an important condi-
tion for scoring functions is that they should be fast enough 
to allow their application to a large number of potential solu-
tions, a feature that implies a number of simplifications that 
tend to reduce the complexity and computational cost of the 
scoring functions at the cost of accuracy. Popular examples 
of scoring functions include ChemScore [15], DrugScore 
[16, 17], D-Score [18], Fresno [19], F-Score [20], G-Score 
[18], GoldScore [21], SMoG score [22], and X-SCORE [23].  
The best logical solution would seem to be that of com-
paring the best searching algorithm with the best scoring 
function. The answer is, however, not so easy, as the per-
formance of most docking tools can be highly dependent on 
the particular characteristics of the binding site and of the 
ligands to be investigated. Given the vast number of possible 
search algorithm/scoring function combinations, establishing 
which method would be more suitable in a specific context is 
almost impossible [24-30]. Even though some strategies 
have been devised to deal with these problems, such as con-
sensus scoring [31], the user’s experience continues to be 
one of the most critical features for the success of a docking 
study.  
The other big factor to take into account is the one thing 
that connects the user knowledge and experience, the scoring 
function, the search algorithm, the target, and the ligand(s), 
and that ideally should be able to get the most out of these 
components: the protein-ligand docking software program. 
Over time several studies have tried to evaluate the accuracy 
of different protein-ligand docking programs. Historically, 
most of these comparisons have been made in terms of their 
ability to reproduce the X-ray pose of selected ligands [8, 18, 
21, 32-50], their capability to predict binding free energies 
from the best-scored pose [16, 21, 24, 27, 28, 35, 51-56], or 
their ability to identify known binders from randomly chosen 
molecules [21, 24, 27, 29, 47, 48, 50, 56-58]. However, gen-
eralizing these partial results in terms of the docking pro-
grams themselves is very difficult and often misleading. It is 
also important to take into consideration that the perform-
ance of most docking tools can significantly vary with the 
particular target under study, and with the particular docking 
protocol and variables chosen by the user [24, 27-30]. Time 
is also an important variable to consider, with different soft-
ware packages working in quite different time-scales. For 
these reasons establishing a rigorous comparison of protein-
ligand docking programs is a daunting task, as it is difficult 
to draw conclusions of general applicability [59]. 
CHALLENGES FOR PROTEIN-LIGAND DOCKING 
Despite the significant progress that has characterized the 
past 10 years in the field of protein-ligand docking, several 
aspects have remained important challenges, with significant 
margin for improvement. In this section, we review three 
critical issues for protein-ligand docking: the treatment of 
protein flexibility, the presence of structural water molecules 
and its effect in docking, and the entropy of binding. 
Treatment of Protein Flexibility 
Protein flexibility, including side-chain reorientations 
and backbone motions, can significantly modulate the ge-
ometry and characteristics of the ligand binding site. How-
ever, even though most currently available docking methods 
already treat ligands as flexible, the inclusion of protein 
flexibility is still a challenging task, remaining one of the 
most important topics in development within the field of 
protein ligand docking [60-69]. In fact, although some 
analogies exist, most of the methods used in the context of 
ligand flexibility cannot be directly transferred to the protein 
due to the huge number of degrees of freedom associated 
[66]. Several strategies to circumvent this problem and to 
account for protein flexibility, at least at a partial level, have 
been described in the literature and have gained considerable 
momentum over the past few years. Most of the strategies 
already implemented in protein-ligand docking programs 
account for side chain flexibility only, with the inclusion of 
backbone flexibility being still in its infancy [62]. Soft dock-
ing applications, rotamer exploration approaches, multiple 
protein structure protocols and molecular dynamics simula-
tion methods represent the main strategies to include some 
level of protein flexibility into protein-ligand docking.  
Soft Docking 
Soft docking is a simplistic way to partially introduce re-
ceptor flexibility and ligand-induced fit effects. Soft docking 
methods typically work by allowing a certain overlap be-
tween receptor and ligand, normally by tolerant scoring func-
tions, called “soft core potentials”. Soft docking methods can 
efficiently detect subtle conformational changes on the re-
ceptor, often not easily perceived through other more sophis-
ticated approaches and do not normally involve an increase 
in the computational time associated. However, their scope is 
rather limited to small scale rearrangements associated to 
side-chain plasticity, without the corresponding backbone 
adjustment [62, 68]. 
Rotamer Exploration 
Methods based on a systematic exploration of rotamers 
ensure an effective consideration of side-chain flexibility 
[62]. Such approaches are typically based on rotamer librar-
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ies that try to represent the protein conformational space as a 
set of experimentally observed and preferred rotameric states 
for each side chain [10, 70]. Naturally, the application of 
these methods is in general limited to only a few active site 
amino acid residues, normally selected by the user. The 
computational cost associated depends not only on the num-
ber of residues subject to rotamer exploration, but also on the 
size and completeness of the corresponding rotamer libraries. 
Such approaches present a very useful alternative when tack-
ling receptors for which there is a good structural knowledge 
on both unbound and bound receptor forms for similar 
ligands, with such structures suggesting limited structural 
changes involving only active-site residues. However, focus-
ing on the side chains neglects any real change in the back-
bone of the receptor, and therefore to give a reasonable ac-
count of protein flexibility going beyond simple-side chain 
reorientation is often required. 
Multiple Protein Structures 
An alternative way to implicitly introduce flexibility into 
protein-ligand docking involves the use of an ensemble of 
protein conformations as a target for docking instead of a 
single structure. Some different approaches have explored 
this basic idea [12, 60, 71-76], with alternatives differing on 
the sources employed to generate multiple protein structures 
(X-ray crystallographic structures, NMR, molecular dynam-
ics, monte carlo simulations, or elastic network normal mode 
analysis techniques) and on how information obtained from 
the several conformations is combined [60, 62, 74-76]. Such 
approaches typically have a high computational cost, which 
depends on the number of multiple target structures consid-
ered. In addition, they do not enable the generation of novel 
protein conformations as a result of ligand binding and its 
exploration of the target conformational space is highly bi-
ased and dependent on the set of structures considered as 
input. Nevertheless such approaches are currently regarded 
as the most promising routes of future progress [62]. 
Molecular Dynamics Simulations 
The application of molecular dynamics simulations en-
ables an evaluation of side-chain and backbone movement 
within protein-ligand docking, allowing in principle the gen-
eration of novel protein-ligand conformations. However, the 
practical success of such approaches is still quite small, 
mainly due to the limited extent of the corresponding MD 
simulations. In fact, the computational cost required to guar-
antee a reasonable exploration of the conformational sam-
pling through molecular dynamics simulations is extremely 
high.  
Several studies have applied enhanced sampling tech-
niques to render the application of MD simulations in pro-
tein-ligand docking more efficient, involving for example the 
application of implicit solvent models or the use of geomet-
ric constrains on the residues outside the ligand binding re-
gion [77-79]. Despite some promising strategies, most appli-
cations of molecular dynamics simulations in the field of 
docking are still done at a post-docking stage, to assess the 
stability of different docked conformations, to obtain addi-
tional conformational and energetic insight into ligand bind-
ing, or simply to improve the ligand pose as a refinement 
tool [80-87]. 
Presence of Structural Water Molecules 
Solvation effects are well-known to influence the binding 
ability of a drug [69, 88]. As such they have become an inte-
gral part of many scoring functions used in protein-ligand 
docking [2, 3]. Force field-based scoring methods, for exam-
ple, have long used a distance-dependent dielectric constant 
to reflect the screening effect of water molecules in electro-
static interactions. In empirical-based scoring methods the 
inclusion of specific terms related to solvation (e.g. a desol-
vation energy term) is also quite common, with the corre-
sponding coefficient in the overall energy expression being 
adjusted to fit binding affinity data from an experimentally 
determined training set. However, more than solvation, it is 
the presence of structural water molecules that remains a 
hard challenge in present day protein-ligand docking. 
Water molecules often appear around ligands in protein 
crystallographic structures, and their presence and precise 
positioning can lead to significant alterations on both the 
ligand binding affinity and range of most favored conforma-
tions, important issues for protein-ligand docking and virtual 
screening applications [89-93]. An analysis of a representa-
tive set of 392 high-resolution protein-ligand complexes 
from the Protein Data Bank revealed an average of 4.6 
ligand-bound water molecules, 76% of which interacting 
simultaneously with both the ligand and the protein [94]. For 
these specific cases, an implicit representation of the solvent 
is clearly not enough. Hence in general, while part of the 
function of water in ligand binding can be accounted through 
a better description of solvation effects, there are a number 
of important issues that require an explicit atomic level de-
scription of water. 
In principle, an explicit description of structural water 
molecules can be done in a number of ways [95]. Typical 
molecular mechanical force fields contain reasonable water 
models [96] that can be adopted in protein ligand docking. 3-
Point water models, such as TIP3P [97], SPC [98], SPC/E 
[99], which have a van der Waals center at the water oxygen 
atom and partial charges at the oxygen and hydrogen atoms 
are a popular choice. An improved description can be ob-
tained with more sophisticated models, like the TIP4P [100] 
and TIP5P [101] water models. 
In the particular case of protein-ligand docking, through 
the application of such models, the presence of structural 
water molecules can be reasonably accounted for in several 
very precise situations. Imagine, for example, that one is 
starting a protein-ligand docking (or even a virtual screening 
campaign) for a protein target on which there is precise in-
formation for the presence of a strongly-bound or conserved 
water molecule (present in a variety of similar X-ray struc-
tures for the same target). In such cases, the water molecule 
can be treated as being an integral part of the protein target 
for docking. A similar decision can be made regarding dock-
ing with ligands containing a common scaffold, when there 
is an X-ray structure available for one of the ligands in the 
series showing the presence of a water molecule.  
For most situations of interest, however, when no a priori 
information is available or can be easily obtained, water 
molecules emerge as an additional participant in docking, 
often the most elusive one, and an additional variable in the 
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docking process. While ideally the conformational space 
associated to the interaction of a variable number of water 
molecules with a given ligand should be explored together, 
against a given protein target, and evaluated accordingly, the 
immense range of possibilities associated greatly limits the 
practical application of such principles. 
An ingenious approach to partially circumvent this issue 
is the “Just Add Water Molecules” (JAWS) procedure de-
veloped by Michel & co-workers [102]. This method uses a 
double-decoupling scheme to compare the energetic cost 
associated to water molecule appearance and disappearance 
on a binding-site grid. Its accuracy in locating hydration sites 
has been demonstrated for five different biomolecular sys-
tems, namely neuraminidase, scytalone dehydratase, major 
urinary protein 1, -lactoglobulin, and COX-2. The JAWS 
methodology has been shown to work particularly well for 
water molecules well-buried in cavities, in which the grid is 
isolated from the bulk water. More challenging has been its 
application to more exposed binding sites, where neverthe-
less quite reasonable results have been obtained [102]. Other 
less recent approaches such as AQUARIUS [103], CS-Map 
[104], MCSS [105], SuperStar [106] and most notably 
GRID[107] have also been described in the literature to iden-
tify potential water binding sites. 
Assuming that a good knowledge on the preferred hydra-
tion sites is known, either from X-ray or NMR approaches or 
from computational alternatives such as JAWS, it is neces-
sary for protein-ligand docking to anticipate which water 
molecules are more likely to be displaced to allow ligand 
binding. Fast methods like WaterScore [108], HINT [109], 
or Consolv [110] can be used to differentiate between water 
molecules that should be included in the docking process and 
those that should be replaced to make room for the ligand, 
helping to prepare initial structures for docking. Several 
docking programs have also implemented strategies to alter 
water positioning (including its addition or removal) during 
docking or even after docking, typically through an energy 
penalty associated [90]. 
Entropy 
It is well known that entropic effects have an important 
contribution to the protein-ligand binding energy [111-116]. 
Entropy contributions arise from a variety of aspects. These 
include the reduction of the translational and rotational de-
grees of freedom in the ligand, changes in the normal modes 
of the protein and the ligand during binding, from the ar-
rangement of water layers around the two solutes and even 
from protonation and deprotonation events [112, 113, 117-
122] However, in most commonly used computational appli-
cations that deal with protein complexes, including free en-
ergy calculations [123, 124], entropy is neglected altogether, 
or at least the subject of quite dramatic simplifications [114, 
125]. In fact, the calculation of the entropic contribution is 
computationally very expensive as it requires extremely well 
minimized structures for a Normal Mode analysis, or large 
numbers of conformations for a Quasi-harmonic analysis 
[126-128]. This problem is even more striking in the case of 
protein-ligand docking, for which computational efficiency 
is an important requirement, with issues like protein flexibil-
ity often posing already quite a heavy requirement for a rea-
sonably accurate protocol. 
Designing efficient scoring functions able to incorporate 
entropy is hence a challenge for the next years, although 
several attempts to include the binding entropy in protein-
ligand docking have been reported in the literature, particu-
larly involving re-scoring schemes [117, 129, 130].  
Ruvinsky et al. [117] have introduced a novel method to 
estimate the contributions of translational, rotational, and 
torsional entropy into the protein-ligand binding affinity. The 
method works by performing multiple docking experiments, 
clustering the resulting conformations by similarity, and then 
using a measure of the cluster size to estimate the entropic 
contribution. Hence, the method assumes that large clusters 
of conformations are indicative of favorable entropic contri-
butions of the local energy landscapes, and that the docking 
algorithm provides a reasonable exploration of the associated 
conformational space. Despite this assumption, this treat-
ment of entropy was shown to improve docking accuracy by 
10 –21% when used with the AutoDock scoring function 
[117]. The authors subsequently showed important im-
provements when applied in conjunction with other well-
known scoring functions [129], namely by 2–25% when used 
with G-Score, 7–41% with D-Score, 0–8% with LigScore, 1–
6% with PLP, 0–12% with LUDI, 2–8% with F-Score, 7–
29% with ChemScore, 0–9% with X-Score, 2–19% with 
PMF, and 1–7% with DrugScore. Tests were performed 
against a dataset of 100 PDB protein-ligand complexes and 
ensembles of 101 docked positions generated by Wang et al. 
[131]. 
Lee et al. [130] proposed a similar statistical rescoring 
method to introduce entropy into the protein-ligand docking 
problem. According to the method developed by Lee et al. a 
probability function is introduced to analyze the populations 
of different binding modes in the context of statistical me-
chanics. This is then used to allow an estimate of the contri-
bution of the state represented by a sampled conformation to 
the configurational integral, applying the notion of colony 
energy, proposed by Xiang et al. [132]. Improved accuracy 
in pose prediction has been demonstrated for several com-
mon scoring functions, but this method can be easily com-
bined with other preexisting scoring functions, and requires 
very little extra computational costs because no energy 
minimizations, dynamics simulations, or clustering is needed 
[130]. 
Other attempts to accurately account for entropy involve 
the inclusion of entropic terms in Knowledge-Based Scoring 
Functions used in docking [111]. Globally however, the 
challenge still remains.  
PROTEIN-LIGAND DOCKING PROGRAMS 
The number of docking programs currently available is 
high and has been steadily increasing over the last decades. 
(Table 1) presents an overview of the most common protein-
ligand docking programs, listed alphabetically, with indica-
tion of its main citations (original paper), and of the corre-
sponding year of publication and country of origin. This list 
is comprehensive but not complete. Software programs re-
leased in the period 2006-2011 are highlighted and will be
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Table 1. Comprehensive List of the Most Common Protein-Ligand Docking Programs 
Program Country
a
 Year
b
 Reference
c
 
AADS India 2011 [133] 
ADAM Japan 1994 [134] 
AutoDock USA 1990 [8, 135, 136] 
AutoDock Vina USA 2010 [137] 
BetaDock South Korea 2011 [138] 
DARWIN USA 2000 [139] 
DIVALI USA 1995 [140] 
DOCK USA 1988 [39, 141-146] 
DockVision Canada 1992 [9] 
EADock Switzerland 2007 [147] 
eHiTS Canada | UK 2006 [148] 
EUDOC USA 2001 [44] 
FDS UK 2003 [38] 
FlexE Germany 2001 [149] 
FlexX Germany 1996 [18, 20] 
FLIPDock USA 2007 [150] 
FLOG USA 1994 [151] 
FRED USA | UK 2003 [49] 
FTDOCK UK 1997 [152] 
GEMDOCK Taiwan 2004 [153] 
Glide USA 2004 [154, 155] 
GOLD UK 1995 [33, 156] 
Hammerhead USA 1996 [157] 
ICM-Dock USA 1997 [41] 
Lead finder Russia | Canada 2008 [158] 
LigandFit USA 2003 [50] 
LigDockCSA South Korea 2011 [159] 
LIGIN Israel | Germany 1996 [34] 
LUDI Germany 1992 [160] 
MADAMM Portugal 2009 [161] 
MCDOCK USA 1999 [162] 
MDock USA 2007 [163] 
MolDock Denmark 2006 [164] 
MS-DOCK France 2008 [165] 
ParDOCK India 2007 [166] 
PhDOCK USA 2003 [167] 
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(Table 1) contd…. 
Program Country
a
 Year
b
 Reference
c
 
PLANTS Belgium | Germany 2006 [168] 
PRO_LEADS UK 1998 [35] 
PRODOCK USA 1999 [169] 
ProPose Germany 2004 [170] 
PSI-DOCK China 2006 [171] 
PSO@AUTODOCK Germany 2007 [172] 
PythDock South Korea 2011 [173] 
Q-Dock USA 2008 [174] 
QXP USA 1997 [175] 
SANDOCK UK 1998 [176] 
SFDOCK China 1999 [177] 
SODOCK Taiwan 2007 [178] 
SOFTDocking USA 1991 [179] 
Surflex USA 2003 [48] 
SYSDOC USA 1994 [71] 
VoteDock Poland 2011 [180] 
YUCCA USA 2005 [181] 
[a] Country of origin, as indicated in the author address in the corresponding paper; [b] Programs released in the period 2006-2011 marked in bold; [c] Original main reference 
considered in the citation analysis. 
the subject of particular care, particularly in light of the chal-
lenges outlined previously. Special attention will also be 
dedicated to the docking programs that have been available 
for longer and that continue to be regarded by users world-
wide as a solid and competitive alternative. Finally, a par-
ticular look will be dedicated towards protein-ligand docking 
programs that are emerging as particular promising alterna-
tives and gaining a considerable number of users. 
Most Common Docking Alternatives 
(Fig. 1) illustrates the number of citations of the most 
common protein-ligand docking programs in the period 
2001-2011. AutoDock, GOLD, DOCK, FlexX, Glide, FTD 
OCK and QXP are the most cited docking programs, with 
over 300 citations each in this period. With the exception of 
Glide, all the other top cited docking programs have been 
available since the 1990s. Hence, they may be regarded as 
well-established mature docking alternatives, with a large 
and rather stable number of users. LigandFit, Surflex and 
FlexE are other more recent highly cited docking alterna-
tives. 
AutoDock is a versatile protein-ligand docking program 
developed by Morris & co-workers at the Scripps Research 
Institute [8, 135, 136]. Its free availability to academic users, 
together with the good accuracy and high versatility shown, 
have made it a very popular first choice for new users. These 
reasons have contributed to its widespread use, well por-
trayed in the impressively high number of citations in the 
past 10 years (3980 according to ISI Web of Science). The 
most recent version - AutoDock 4 (AutoDock Vina is de-
scribed separately in this review) - includes already side-
chain flexibility on selected amino acid residues. AutoDock 
offers a variety of search algorithms including a Monte Carlo 
Simulated Annealing algorithm, a Genetic Algorithm (GA), 
and a hybrid local search GA, also known as the Lamarckian 
Genetic Algorithm (LGA). The program can be used with a 
visual interface called AutoDock Tools (ADT) which en-
sures an efficient analysis of the docking results.  
GOLD is another highly regarded protein-ligand docking 
program. This program is the result of collaboration between 
the University of Sheffield, GlaxoSmithKline and the Cam-
bridge Crystallographic Data Centre (CCDC), and is com-
mercially available, following the initial development by 
Jones and co-workers [33, 156]. The program contains a 
genetic algorithm (GA) based search method for generating 
ligand poses, a user interface with interactive docking set-up 
via Hermes, and a comprehensive docking set-up wizard. 
GOLD allows full ligand flexibility, while ensuring partial 
protein flexibility, through protein side-chain and backbone 
flexibility for up to a maximum of ten user-defined residues. 
The program contains a useful variety of constraint options 
and allows the automatic consideration of cavity bound wa-
ter molecules. Several different scoring functions can be 
considered including GoldScore, ChemScore, Astex Statisti-
cal Potential (ASP), and Piecewise Linear Potential (PLP). 
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Extensive options for customizing or implementing new 
scoring functions through a Scoring Function Application 
Programming Interface are also present, allowing the user to 
improve the scoring function to be used in specific receptors. 
DOCK [39, 141-146] is a successful docking software 
initially developed by Irwin Kuntz that has been in the mar-
ket since 1988 and that is available free of charge for aca-
demic institutions. The present version - DOCK 6 - contains 
a series of improved scoring options including explicit terms 
for ligand conformational entropy corrections, ligand desol-
vation, and receptor desolvation. An AMBER molecular 
mechanics scoring function with implicit solvent, conjugate 
gradient minimization, and molecular dynamics simulation 
capabilities are also present. 
FlexX [18, 20] (now part of LeadIT) is a very interesting 
docking program developed by Rarey and co-workers that is 
presently commercialized by BioSolveIT. FlexX is based on 
a robust incremental construction algorithm through which 
the ligand is decomposed into pieces and then flexibly built 
up in the active site, using diverse placement strategies. The 
program contains improved capabilities to deal with flexible 
water molecules and with metal coordination.  
Originally developed by Friesner et al. [154, 155] in 
2004, Glide is a complete solution for protein-ligand docking 
that is now available as a module in the Schrodinger soft-
ware suite, commercialized by the Schrodinger LLC. Glide 
has gained a considerable number of users in just a few years 
and is emerging as an exciting alternative for protein-ligand 
docking. Glide generates a set of grids with different types of 
fields representing geometries and properties of the binding 
site region of the receptor. The torsional space of the ligand 
is then exhaustively sampled, generating a large number of 
binding poses. Following this initial rough positioning, a 
hierarchical strategy is employed in scoring. This starts with 
the application of a series of filters that narrows down the 
range of alternatives to be evaluated, and is followed by a 
GlideScore scoring, evolving to an in situ minimization with 
the OPLS-AA force field [182, 183] for the best alternatives. 
A final energy evaluation with a composite scoring function, 
which combines empirical and force-field-based terms, is 
then performed in a selected number of ligand-receptor 
poses, ensuring a very accurate scoring.  
FTDOCK (Fourier Transform rigid-body DOCKing) is a 
rigid docking program developed by Sternberg & co-workers 
[152] in 1997 that uses a docking algorithm based on that of 
Katchalski-Katzir [152]. The program divides the ligand and 
the receptor into orthogonal grids and scans the translational 
and rotational space of the two. The scoring method is based 
in a surface complementary score between the two grids, 
calculated with the help of Fourier transforms. Although 
surface complementarity was the only score used in the 
original method [152], recent versions apply also an electro-
static-based filter [152]. The program is free to both aca-
demic and commercial users, but it is no longer supported 
and no development has taken place in the last decade. 
QXP (Quick eXPlore) is a protein-ligand docking appli-
cation developed by McMarting & Bohacek and originally 
published in 1997 [32], with a search algorithm derived from 
the method of Monte Carlo perturbation with energy mini-
mization in the Cartesian space. QXP uses a modified ver-
sion of the AMBER force field [184, 185], with partial 
charges calculated from bond-dipole moments [186] and 
applies a superposition force field that automatically assigns 
short-range attractive forces to similar atoms within different 
molecules [187]. After an initial Monte Carlo perturbation, a 
fast search step is introduced, yielding an approximate low-
energy structure prior to energy minimization. 
We would like to state very clearly that the number of cita-
tions of a given paper is no measure of quality of the corre-
sponding protein-ligand docking software program. It can be 
taken as much as a rough indicator of the popularity of a spe-
cific docking software. Naturally, this popularity reflects mostly 
 
 
Fig. (1). Number of citations for the most common protein-ligand docking programs in the period 2001-2011. Programs published in 2011 
not included. 
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the views of the academic milieu, and only a scarce fraction of 
the protein-ligand docking applications in the pharmaceutical 
industry, as most of the research work conducted at the latter is 
not publicly available and does not get published.  
Several features can be associated to this popularity. The 
price of the program is naturally an important issue. Open 
source alternatives and programs that are made publicly 
available to academic institutions tend to get a higher num-
ber of citations than the ones that require a paid license. 
Even within the latter, there can be large differences in price 
for different software alternatives, which reflect in the num-
ber of users, but this can also be affected by the marketing 
efforts. Another set of issues that are important to the num-
ber of citations associated to a given program involves its 
ease of installation and use, the existence of support and the 
availability of adequate learning tutorials that could help a 
user to make the most of the program. Then, on top of all 
these issues we have, of course, the quality of the program, 
its range of application, the variety and quality of the avail-
able scoring functions and search algorithms, the computa-
tional times associated, etc. 
Despite these potential limitations, the number of cita-
tion, when used with care, presents a useful way to identify 
and track emerging trends within this rapidly evolving field 
that is program-ligand docking.  
Evolution in the Last 10 Years 
(Fig. 2) shows the evolution of the number of citations 
per year of the 7 most cited protein-ligand docking programs 
over the last 10 years, together with its relative percentage in 
terms of citations per year. 
The results show that AutoDock was the top cited pro-
tein-ligand docking software throughout the last decade, 
reaching a level around 500 citations per year. In addition, 
the results show that while in 2001 its difference towards the 
second most cited alternative - DOCK - was of only a few 
citations, in 2010 the difference towards the second most 
cited docking program – GOLD - grew to close to 200 cita-
tions per year. In the past five years, its relative number of 
citations among the top cited alternatives was maintained 
among 36-37%, indicating a stable and very significant 
“market share”.  
Between 2001 and 2011, DOCK went from being the sec-
ond most cited program to the fourth place, behind GOLD and 
Glide, while keeping close to an average number of 150 cita-
tions per year. GOLD has been through this period the most 
cited commercially available docking program. While be-
tween 2001 and 2007 GOLD’s main competitor among paid 
alternatives was FlexX, Schrodinger’s Glide has emerged as 
its most cited competitor. Nevertheless, Gold has been able to 
secure through the past five years a “market-share” of 20-23% 
among all the most cited alternatives, while Glide is currently 
at 17% and FlexX at 9%. FTDOCK and QXP only represent 3 
and 1% respectively of the total number of citations per year 
of the seven most cited docking alternatives. 
Globally, these results show that AutoDock has been 
dominating the competition, in terms of number of citations, 
 
 
Fig. (2). Evolution of the number of citations per year for the 7 most cited protein-ligand docking programs over the period 2001-2011 and 
its relative percentage. 
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and that its number of citations per year and “market share” 
continues very high. GOLD is a stable second, while DOCK, 
FlexX, and QXP have been losing “market share”. Glide is 
the fastest growing protein-ligand docking program, in terms 
of number of citations, among the top 7 alternatives. 
Emerging Protein-Ligand Docking Alternatives 
In addition to these top cited alternatives other 46 dock-
ing programs are mentioned in (Table 1 and Fig. 1). (Fig. 3) 
shows the different proveniences of such alternatives, high-
lighting the richness of this field of research. In fact, among 
the docking programs listed in (Table 1) are creations from 
17 different countries from all around the globe. USA, UK 
and Germany are the countries with the highest number of 
programs in this field, but in recent years several very ap-
pealing alternatives have emerged, particularly in Asia.  
AADS (Automated Active site identification, Docking, 
and Scoring protocol) is an integrated protein-ligand docking 
tool recently developed by Jayaram and co-workers at the 
Indian Institute of Technology, New Delhi, India [133]. The 
program incorporates active site detection, docking, and 
scoring within a single tool. The AADS methodology is im-
plemented on an 80 processor cluster and presented as a 
freely accessible web-available tool [133]. The program de-
tects a total of 10 possible binding sites within a target-
protein, taking into consideration the physicochemical prop-
erties of the amino acid side chains around the possible pro-
tein cavities. The program then performs rigid docking of an 
input ligand/candidate molecule at the 10 predicted binding 
sites, using an all-atom energy based Monte Carlo method. 
Scoring is performed through a previously developed in-
house scoring function called Bappl (Binding Affinity Pre-
diction of Protein-Ligand) [188] which embeds an effective 
free energy function, including specific energy terms for 
electrostatics, van der Waals, hydrophobicity, and loss of 
conformational entropy of protein side-chains upon ligand 
binding. Results, including the best four ligand-protein poses 
and the expected association energy (in kcal/mol) can be 
emailed back to the user.  
BetaDock is a new freely available protein-ligand dock-
ing software developed by Kim & co-workers at Hanyang 
University, Seoul, South Korea [138] and based on the use of 
Voronoi diagrams. BetaDock differs from other alternatives 
in the field as it applies a new approach to the protein-ligand 
docking problem based on the recently developed theory of 
-complex and -shape of molecules, giving higher priority 
to shape complementarity between a receptor and a ligand 
[189, 190]. Although the present version is working with 
rigid ligands only, very promising results have been ob-
tained. In particular, BetaDock was tested against AutoDock 
4 (with ligand flexibility turned off) for 85 protein-ligand 
complexes from the Astex Diverse set database [191], giving 
superior results, both in terms of the structural quality of the 
solutions obtained and in terms of speed.  
LigDockCSA is a docking program developed by Shin & 
co-workers [159] at the Seoul National University, in South 
Korea, that combines a highly efficient search method - Con-
formational Space Annealing (CSA) - with a scoring func-
tion based on the AutoDock energy function with a piece-
wise linear potential (PLP) torsional energy. Conformational 
space annealing is designed to search over broad ranges of 
conformational space, generating numerous local minima 
before arriving at the global minimum free energy conforma-
tion. LigDockCSA applies this principle iteratively, gradu-
ally narrowing the conformational space associated to the 
lower energy conformations. For this reason it is particularly 
efficient. The performance of LigDockCSA was tested on 
the Astex diverse set [191] against AutoDock and GOLD, 
with improved success rates.  
ParDOCK (Paralel DOCK) is a web-enabled freely avail-
able all-atom energy based Monte Carlo docking program 
that is implemented as a fully automated, parallel processing 
mode. The program was developed also by Jayaram and co-
workers at the Indian Institute of Technology, New Delhi, 
India, and takes as initial input a reference complex (includ-
ing the target protein bound to a reference ligand) and a can-
didate molecule [166]. The reference complex is automati-
cally taken into consideration in optimizing the conditions 
for docking the candidate molecule. In this program the ge-
ometry of the ligand is optimized with the semi-empirical 
method AM1 [192], in a process that is followed by a partial 
charge determination through the AM1-BCC procedure [193, 
194]. The General AMBER force field [195], is used to as-
sign atom types, bond angle, dihedral and van der Waals 
parameters for the ligand. The program was tested on a 
dataset of 226 protein-ligand complexes through both self-
docking and cross-docking, with the authors obtaining the 
crystal conformation to an average RMSD of 0.53 in 98% of 
all the cases. Binding site prediction, torsional flexibility of 
the ligands and protein are some improvements proposed by 
the authors. 
PSI-DOCK (Pose Sensitive Inclined Docking) is a flexi-
ble docking method developed by Lai and co-workers [171] 
at Beijing University, China. The program uses a tabu-
enhanced genetic algorithm (TEGA) with a shape comple-
mentary scoring function to explore in a first step the poten-
tial binding poses of the ligand. The predicted binding poses 
are then optimized through a competition genetic algorithm 
and evaluated through a specifically developed improved 
scoring function (SCORE) to determine the binding pose 
with the lowest docking energy. For a test dataset of 194 
complexes, PSI-DOCK was shown to achieve a 67% success 
rate (RMSD <2.0 Å) with just a docking run, which was im-
proved to a 74% success rate for 10 runs. The program was 
also shown to be able to reproduce the binding energy of a 
training set of 200 protein–ligand complexes with a correla-
tion coefficient of 0.788 and a standard error of 8.13 kJ/mol, 
while in a test set of 64 complexes a correlation coefficient 
of 0.777 and standard error of 7.96 kJ/mol were obtained. All 
protein hydrogen atoms and the flexibility of the terminal 
protein atoms are intrinsically taken into account in PSI-
DOCK. Additionally, there is no need to calculate partial 
atomic charges, as PSI-DOCK energy function does not con-
tain an electrostatic energy term. These features cancel the 
need for the user to add hydrogen atoms and restrain the ini-
tial docking preparations to a minimum, helping to make this 
program a particularly easy one to use.  
PythDock is a python-based protein-ligand docking pro-
gram developed by Chung and co-workers [173] at Hanyang 
University, Ansan, South Korea, that uses a simple scoring
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Fig. (3). The World of Protein-Ligand Docking. Distribution of the most common Protein-Ligand Docking programs by country of origin 
taking into consideration the affiliation of the authors at the time of the publication of the original paper. 
function including electrostatic and dispersion/repulsion 
terms only, together with a search algorithm based on the 
particle swarm optimization method. The program is a rigid 
protein-ligand docking program, in the sense that treats 
ligands and proteins with fixed conformations. A representa-
tive number of conformers must be generated using other 
conformation generating programs prior to docking [173]. 
Nevertheless, despite its simplicity, the performance of 
PythDock was evaluated against both AutoDock 4.2 and 
DOCK 6.2, in a dataset of 14 protein-ligand experimentally 
determined complexes, giving quite reasonable results [173]. 
SODOCK (Swarm Optimization for Highly Flexible Pro-
tein–Ligand Docking) is a sophisticated protein-ligand dock-
ing program developed by Ho and co-workers [178] in Tai-
wan, specialized in highly flexible ligands. SODOCK con-
tains a novel hybrid search algorithm that couples a Particle 
Swarm Optimization (PSO)[178] method for solving flexible 
protein–ligand docking problems with a local search ap-
proach. The PSO method used is a population-based search 
algorithm inspired by the social behaviors of organisms, such 
as the flocking of birds, simpler and quicker to converge than 
standard genetic algorithms. The success of PSO is improved 
with the joint use of the local search algorithm, which is 
based on the Solis and Wets local search technique [196]. 
For scoring, SODOCK applies the empirical energy function 
of AutoDock 3.05. SODOCK has been shown to outperform 
GOLD 1.2, DOCK 4.0, FlexX 1.8, and AutoDock 3.05 (with 
a Lamarckian genetic algorithm) in 19 out of a total of 37 
ligand-receptor test cases, in terms of RMSD, as reported by 
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Ho and co-workers [178]. Improvements in the scoring func-
tion have been proposed by the authors, as to make this an 
even more competitive alternative to the treatment of the 
docking problem. 
European protein-ligand docking programs such as Vote-
dock, PSO@AUTODOCK, MolDock, MS-DOCK, MAD 
AMM, and PLANTS have also been made available in re-
cent years. 
VoteDock is a protein-ligand docking program based on 
a consensus docking approach developed by Plewczynski 
and coworkers at the University of Warsaw, Poland [180]. 
The program enables massive ligand-docking to the corre-
sponding targets by applying a combination of several inde-
pendent docking algorithms and scoring functions, which run 
in parallel. The method then combines the results from the 
various programs into a single consensus prediction of the 
tridimensional structure of the protein-ligand complex. The 
Seven docking software programs that VoteDock uses, in its 
consensus approach, are AutoDock 4.2.1, Glide 4.5, GOLD 
3.2, Surflex 2.2, FlexX 2.2.1, eHiTS 9.0, and LigandFit 2.3, 
covering a variety of types of docking algorithms. The per-
formance of this approach was evaluated against an exten-
sive benchmark dataset of 1300 protein–ligands pairs in the 
PDBbind database for which structural and affinity data was 
available, with the authors showing that VoteDock is able to 
dock properly approximately 20% more pairs on average 
than typical docking methods alone, and 10% more pairs 
than the single best program tested alone. Despite the fact 
that most of the individual docking programs required to run 
VoteDock cannot be distributed under academic license 
agreement, greatly limiting its availability to standard users, 
a modified version of VoteDock is in preparation and will be 
made available through an internet server [180].  
PSO@AUTODOCK is a very fast and efficient protein-
ligand docking program specifically designed for the treat-
ment of highly flexible ligands and like SODOCK is based 
on swarm intelligence [172]. PSO@AUTODOCK was de-
veloped at the University of Leipzig, Germany, by Nama-
sivayam & Gunther and includes two Particle Swarm Opti-
mization algorithms (varCPSO and varCPSO-Is) designed 
for the rapid docking of highly flexible ligands. These 
searching algorithms were embedded in the source code of 
AutoDock 3 [14]. Hence, PSO@AUTODOCK uses the same 
energy function that is available in AutoDock 3 (and in 
SODOCK) for scoring. The main difference resides in the 
efficiency of the search algorithms developed, with the 
authors reporting for a selected number of examples, a 10-
fold decrease in the number of steps required for identifica-
tion of the local minimum in comparison with SODOCK, 
and a 60-fold decrease when comparing with AutoDock 3. 
These results make PSO@AUTODOCK a very promising 
alternative for flexible ligand docking, and enable the inclu-
sion of ligand flexibility in virtual screening campaigns of 
reasonably-sized libraries comprising several thousands of 
compounds.  
MolDock is a docking program developed by Thomsen 
& Christensen, in Denmark, that is included in the Molegro 
Virtual Docker package, commercialized by Molegro Aps 
[164]. MolDock is based on a heuristic search algorithm that 
combines differential evolution with a cavity prediction algo-
rithm. MolDock automatically identifies potential binding 
sites, which are then evaluated with the differential evolution 
search algorithm. The program also applies a scoring func-
tion that is an extension of the piecewise linear potential 
(PLP) introduced by Gehlhaar et al. [197]. This new version 
includes a new hydrogen bonding term that takes directional-
ity into account and an improved electrostatic term with a 
new charge scheme. The performance of MolDock has been 
evaluated against 77 protein-ligand complexes from the 
GOLD dataset [198], resulting, in general, in higher average 
accuracies than Glide, Surflex, FlexX and GOLD.  
MS-DOCK is Multi-Staged docking/scoring protocol 
[165] developed by Miteva & coworkers at University Paris 
Descartes, France, based on the program DOCK. The pro-
gram starts by employing an algorithm called Multiconf-
DOCK to generate several conformers per input ligand and 
then performs a rigid docking of those conformers against 
the protein target, using DOCK 6.0. In particular, MS-
DOCK was specifically designed to allow the rapid screen-
ing of a large molecular database, enriching the set of ligands 
to be effectively evaluated with more sophisticated and ex-
pensive methods with molecules having a good shape com-
plementarity for a given target protein binding site. Depend-
ing on the target-binding site, MS-DOCK allows the use of 
only a fraction of the initial database (typically 30-50%) 
without compromising the performance of a virtual screening 
protocol in retrieving actives compounds, effectively im-
proving the speed and rate in the search of hit compounds 
with new scaffolds.  
MADAMM (MultistAged Docking with an Automated 
Molecular Modeling protocol) [161] is a protein-ligand 
docking application designed by Ramos & co-workers at the 
University of Porto, Portugal, that allows the flexibilization 
of both the receptor and the ligand during a multistaged 
automated hierarchical docking process. MADAMM in-
volves an initial stage in which protein-flexibility is taken 
into account by using rotamer libraries to generate different 
combinations of conformers involving the most important 
amino acid residues at the active-site. From this stage a given 
target structure can be transformed into as much as 1000 
target structures, implicitly accounting for protein flexibility. 
The program then automatically docks the ligand against 
each of these target structures using a standard docking pro-
gram that treats the ligand as flexible, with the current ver-
sion using GOLD. In the subsequent steps – the automated 
minimization protocol - a series of energy minimization 
stages (typically 4) with a molecular mechanics force field 
(CHARMM) are automatically applied to a selected percent-
age of the top ranked solutions, with the radius of amino acid 
residues around the active-site effectively considered in the 
minimization increasing in each of these steps, as the number 
of solutions evolving to the next stages is decreasing. Glob-
ally, this approach proved to be particularly effective in 
docking ligands when starting from an unbound structure of 
the protein. MADAMM is available free of charge.  
PLANTS (Protein-Ligand ANT System) [168] is an in-
teresting docking program developed by Korb, Stutzle & 
Exner at the Universitat Kontanz (Germany) and Universite 
Libre de Bruxelles (Belgium). This program is based in Ant 
Colony Optimization (ACO), a methodological approach that 
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is based on the behavior of real ants on finding the shortest 
path between their nest and a food source. In the case of pro-
tein-ligand docking, an artificial ant colony is employed to 
find a minimum energy conformation of the ligand in the 
binding site. These ants are used to mimic the behavior of 
real ants and mark low energy ligand conformations with 
pheromone trails. The artificial pheromone trail information 
is then modified in subsequent iterations to generate low 
energy conformations with a higher probability [168]. While 
the ligand is treated as flexible, the flexibility of the protein 
is only marginally taken into account through the optimiza-
tion of the atomic position of the hydrogen atoms that are 
involved in hydrogen bonding. Two specifically designed 
scoring functions (PLANTSCHEMPLP and PLANTSPLP) have 
also been made available [199]. The program has been 
shown to reproduce 87% of the complexes present in the 
Astex diverse set, and 77% of the ones available at 
CCDC/Astex (non-covalently bound), with root-mean-square 
deviations of less than 2 angstrom with respect to the ex-
perimentally determined structures. PLANTS is available 
free of charge for academic users. 
In addition to these protein-ligand programs, developed 
in Asia and Europe, several very interesting alternatives have 
also been developed in the USA. Notable examples include 
AutoDock Vina, MDOCK, FLIPDock, and Q-Dock.  
AutoDock Vina [137] is a new generation docking pro-
gram developed by Trott & Olson at the Scripps Research 
Institute, La Jolla, California, following the success of previ-
ous AutoDock versions. Like its predecessors AutoDock 
Vina is freely accessible to a large number of users, as it is 
open-source. AutoDock Vina inherits some of the ideas and 
approaches of AutoDock 4, but it is designed in a conceptu-
ally different way. It offers significant improvements in the 
average accuracy of the binding mode predictions, while also 
being up to two orders of magnitude faster than AutoDock 4. 
It features also new search and scoring algorithms [137]. Its 
multi-core capability, high performance and enhanced accu-
racy, ease of use and free-availability have contributed to an 
extremely fast dissemination through the docking commu-
nity, well portrayed in the high number of citations in the 
first two years after the publication of the original paper. 
Vina is more than likely to become the most cited docking 
software in a nearby future. Its high computational efficiency 
and ability to use multiple CPUs or CPU cores make this 
program also a very competitive alternative for virtual 
screening. 
MDOCK [163] is a protein-ligand docking software de-
veloped by Huang & Zhou at the University of Missouri, 
USA, that allows the simultaneous docking of ligands 
against multiple protein structures/conformations, thereby 
accounting for protein flexibility. The program employs a 
fast ensemble docking algorithm to account for protein struc-
tural variations, which can be applied to different structures 
for a given target protein taken from the Protein Data Bank 
(PDB), or to different protein conformations generated from 
computational methods like molecular dynamics or Monte 
Carlo simulations, when starting from a single PDB struc-
ture. Each protein conformation is treated as an independent 
target for docking, with the algorithm then automatically 
selecting the optimal protein conformation. The program 
uses an iterative knowledge-based scoring function [200, 
201] called ITScore that includes only intermolecular inter-
actions. MDOCK was validated on 10 protein ensembles 
containing 104 crystal structures and 87 ligands, both in 
terms of binding mode and energy score predictions. An 
overall success rate of 93% was obtained, when considering 
as criterion a root-mean-square deviation below 2.5 Å when 
comparing with the experimentally determined structure. 
MDOCK package is available free of charge for academic 
users. 
FLIPDock (Flexible LIgand-Protein Docking) [150] is a 
docking software developed by Zhao & Sanner at the Scripps 
Research Institute, La Jolla, California that allows the auto-
mated docking of flexible ligand molecules into the active 
site of flexible protein targets. A data structure called Flexi-
bility Tree (FT) [202] is used to represent the conformational 
space of the receptor and ligand molecules, allowing a hier-
archical and multi-resolution representation of conforma-
tional changes in macromolecules. In particular, FT breaks 
down the molecular systems into a set of molecular frag-
ments moving relative to each other, using inter-domain mo-
tion descriptors such as hinge, shear, twist, and screw and 
intra-domain motion descriptors like rotameric side chains, 
normal modes, and essential dynamics. These descriptions 
are used to generate a complex subspace involving the most 
relevant portion of the conformational space of the bio-
molecular system. A genetic algorithm is employed to search 
through the solution space in a process that can also involve 
a two-step divide and conquer algorithm. The current FLIP-
Dock version uses an empirical scoring function based on 
AutoDock 3.05, but its modular nature and overall architec-
ture of the program offer the ability to incorporate different 
search algorithms and scoring functions in the future [150]. 
FLIPDock is particularly strong in handling conformational 
changes that involve the receptor backbone, when most pro-
tein-ligand docking programs fail. The program is free for 
academic users and will surely become a major docking al-
ternative in the following years. 
Q-Dock [174] is a low-resolution flexible ligand docking 
program with pocket-specific threading restraints developed 
by Brylinski & Skolnick at Georgia Institute of Technology, 
Atlanta, USA, designed to deal with the structural inaccura-
cies in predicted receptor models. Q-Dock describes both the 
ligand and the protein in a reduced representation mode, i.e. 
through a coarse-grained knowledge-based potential. Such 
approach enables the use of low-quality receptor structures, 
such as the ones routinely produced by proteome-scale pro-
tein structure modeling projects, ensuring a wider-range of 
applicability than typical all-atom approaches. The program 
uses pocket-specific statistical potentials and harmonic re-
straints imposed on the binding poses of the common mole-
cule substructures extracted from evolutionarily related pro-
teins. Ligand flexibility is accounted for through an ensem-
ble docking of pre-calculated discrete ligand conformations 
with Replica Exchange Monte Carlo (REMC). Globally, the 
authors show that Q-Dock is able to recover on average 25-
35% more binding residues and 15-20% more specific native 
contacts than a variety of commonly used standard all-atom 
protein-ligand docking approaches in self-docking experi-
ments for a database of 206 X-ray structures. 
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Performance of Protein-Ligand Docking Programs 
As highlighted in the introductory section, comparing 
docking programs can be difficult. Many studies comparing 
different docking programs have been made available in the 
literature. However, the performance of different alternatives 
can vary significantly with the target, the docking protocol, 
the specific set of variables, or the user. For these reasons 
comparisons are not always fair and should be regarded with 
care. The evaluation of Protein-ligand docking programs 
against reference validation sets is, in principle, a more 
trustworthy strategy to assess the quality of different alterna-
tives. Other interesting alternative is the evaluation of the 
performance of specific docking tools in well-defined struc-
ture-prediction challenges, such as the GPCR Dock assess-
ment [203-205]. Here, we review the performance of some 
of the most common docking alternatives in two specific 
settings: (1) against the ASTEX diverse set of protein-ligand 
compounds; (2) against the directory of useful decoys data-
base;  
The ASTEX Diverse Set 
The ASTEX Diverse Set [191] is a docking validation 
set, derived from the Protein Data Bank, that contains 85 
diverse, relevant protein-ligand complexes. It has become a 
standard test of reference in terms of pose prediction for 
docking programs in the last years. 
Liebeschuetz et al. [206] have evaluated the several scor-
ing functions available in GOLD against this test set. They 
found that GOLD's ChemPLP was the most effective scoring 
function for pose prediction in cognate protein–ligand com-
plexes among those available in GOLD, achieving a success 
rate of 87% over the ASTEX 85 sites below a 2.0 Å RMSD 
and 68 % below 1.0 Å RMSD. ChemScore, ASP and Gold-
Score gave sucess rates of 82%, 79% and 78% , respectively, 
for a 2.0 Å RMSD cut-off, values that decreased to a 53-58% 
range when a 1.0 Å RMSD criterion was considered.  
The performance of DOCK 6.0 against the ASTEX di-
verse set was analyzed by Brozell and co-workers [207]. 
Considering as a success criterion a RMSD below 2.0 Å, the 
authors were able to obtain success rates between 61.4% and 
72.4%, depending on the initial starting coordinates used, or 
the lab where docking was conducted.  
GLIDE was also evaluated against the ASTEX set. Re-
pasky et al. [208] obtained a success rate of 71% (for a 
RMSD below 2.0 Å) when using the initial structures taken 
from the ASTEX set. This success rate was increased to 82% 
when some improvements were added to the protocol, 
through the application of the "Schrödinger best-practices" 
procedure [208], which involved among other issues, the 
manual inspection and correction of all the bond-orders and 
charges of the ligands.  
Neves & co-workers [209] have analyzed also the per-
formance of ICM against the 85 co-crystal structures of 
ASTEX. That were able to predict with ICM the top 1 scor-
ing poses below a 2.0 Å RMSD in 91% of the sites with an 
average RMSD of 0.91 Å (median= 0.54 Å). Predictions 
below 1 Å and below 0.5 Å were found in 78% and 43% of 
the cases, respectively. 
The Directory of Useful Decoys 
The Directory of Useful Decoys (DUD) is a collection of 
useful decoys for benchmarking virtual screening containing 
2950 active ligands for 40 different targets, set by Huang, 
Shoichet, and Irwin [210]. For each of the active compounds, 
this database contains a set of 36 "decoys" with similar 
physical properties, but dissimilar topology, making it a 
challenging dataset to test protein-ligand docking algorithms.  
Using this dataset, the performance of a docking program 
in this virtual screening procedure is expressed through a 
graphical representation of the true positive rate versus the 
false positive rate in terms of receiver operating characteris-
tic (ROC) plots. In ROC plots the True Positive Rate (TPR = 
TP/P) is plotted versus the False Positive Rate (FPR = 
FP/N), where TP is the number of True Positives, P is the 
total number of Positives (actives), FP is the number of False 
Positives, and N is the total number of Negatives (decoys). 
An useful measure is the area under the curve (AUC). The 
higher the AUC value in a ROC curve, the better the dis-
crimination between the true positive and the false positive 
poses. As a successful docking program in virtual screening 
should rank active compounds early on a large score list, the 
fraction of actives recovered at 0.1%, 1% and 2% decoys 
recovered (abbreviated to ROC(0.1%), ROC(1%) and ROC(2%)) 
are normally used also as early recognition metrics. 
Liebeschuetz et al. [206] have evaluated the four scoring 
functions available in GOLD against the DUD dataset. 
ChemPLP and ChemScore resulted in average AUC values 
of 0.70, while ASP gave an AUC of 0.66 and GoldScore of 
0.61. ChemPLP showed the best overall performance in the 
test with ROC(0.1%), ROC(1%) and ROC(2%) at 8, 14, and 17% 
respectively. The worst performance was shown by Chem-
Score with ROC(0.1%), ROC(1%) and ROC(2%) at 3, 8 and 12%, 
while ASP and GoldScore exhibited intermediate enrichment 
factor rates.  
Brozell and co-workers [207] have analyzed the perform-
ance of DOCK 6.0 against the DUD set and have obtained an 
average AUC of 0.60 (maximum 0.96; minimum 0.29) with 
native pairing. True positive rates ROC(0.1%), ROC(1%) and 
ROC(2%) at 2.3%, 13.0% and 17.3% were obtained with the 
default DUD structures, values that increased to 2.6, 15.1 
and 20.4% respectively when starting from raw pdb coordi-
nates.  
GLIDE was also evaluated against the DUD set by Re-
pasky et al. [208], yielding an average AUC of 0.74, a value 
that increased to 0.80 when using the "Schrödinger best-
practices" procedure [208]. Virtual screening experiments 
with best-practices inputs give true positive rates ROC(0.1%), 
ROC(1%) and ROC(2%) at 12%, 25%, and 34 % of known ac-
tives, whereas with the default set these recovery rates de-
crease to 7, 21, and 29 %. 
Using ICM against the DUD set, Neves et al. [209] were 
able to obtain an average AUC of 0.72, although the varia-
tion between the calculated AUC for the individual templates 
was quite significant, varying from 0.96 for Neuraminidase 
to 0.27 for the platelet derived growth factor receptor kinase. 
True positive rates ROC(0.1%), ROC(1%) and ROC(2%) at 7.3%, 
21.0% and 26.6% of true positives, respectively, were ob-
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tained using the original pocket coordinates and the default 
scoring method. 
Cross et al. [211] have also evaluated the performance of 
DOCK, FlexX, GLIDE, ICM, PhDOCK, and Surflex against 
the DUD database. In particular, the authors found that 
GLIDE (average AUC of 0.72) and Surflex (average AUC of 
0.66) outperformed the other docking programs when used 
for virtual screening (with average AUC values in the range 
0.55 - 0.63).  
CONCLUSIONS AND OUTLOOK 
Over the past decade, protein-ligand docking has 
emerged as a particular important tool in drug design and 
development programs. This gain in standing is well por-
trayed in the rising number of available protein-ligand dock-
ing software programs, increasing level of sophistication of 
its most recent applications, and growing number of users. In 
spite of the large number of alternatives, we are still far from 
a perfect docking program. In terms of the searching algo-
rithms, efficiently accounting for protein flexibility remains 
a challenging task. In terms of the scoring functions features 
like the presence of structural water molecules and the treat-
ment of entropy, among others, still pose considerable prob-
lems for protein-ligand docking. However, the high number 
of programs, their geographically diverse origin, and the 
different way in how they deal with the diverse challenges 
posed by protein-ligand docking are all reasons that demon-
strate the vividness of the field.  
Many protein-ligand docking programs are currently 
available and new alternatives are continuing to appear every 
year. Some of these alternatives will fade among the plethora 
of protein-ligand docking applications, while others will rise 
to become top choices among the users of the field. Given 
the technical development pace in the field all alternatives 
will eventually become obsolete, at least without a major 
effort by the development teams in keeping their software 
programs updated and competitive. Early adopters have the 
major gain here, even though mastering a new software can 
be difficult. The richness of this field is sure to make it worth 
their effort. 
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Introdução 
O processo actual de descoberta e desenvolvimento de um novo medicamento até à sua 
comercialização é complexo, longo e extremamente dispendioso. Apesar de todo o 
desenvolvimento tecnológico que caracterizou a nossa sociedade nas últimas décadas, um 
novo medicamento demora ainda em média 12 a 14 anos até ser aprovado para 
comercialização e o custo médio em investigação por cada novo medicamento no mercado é 
superior a mil milhões de euros (1; 2). Apesar do enorme esforço em investigação, o número 
de novos medicamentos no mercado tem vindo a diminuir nos últimos anos (3). O elevado 
custo associado ao processo faz com que a investigação científica para a descoberta de novos 
fármacos se tenda a centrar nas chamadas doenças dos países ricos, deixando à margem males 
que afectam largos milhões de pessoas, mas que encontram uma maior prevalência em países 
com menos recursos económicos como a malária, a doença do sono (tripanossomíase 
africana), a doença de Chagas (tripanossomíase americana), a leishmaniose e mesmo a 
tuberculose. Com efeito, o investimento em investigação nestas doenças por parte de 
empresas farmacêuticas representa menos de 10% do valor total que despendem em 
investigação (2-4). Por estes motivos, a procura de novas metodologias mais económicas, mais 
eficientes e mais racionais no processo de desenvolvimento de novos fármacos tem vindo a 
assumir uma maior relevância. 
A química computacional é uma área da química ainda relativamente jovem que tem sofrido 
uma evolução galopante com o crescente desenvolvimento computacional que tem marcado 
os últimos anos. A sofisticação e nível de detalhe que a química computacional tem vindo a 
atingir permitem uma análise, à escala atómica e com rigor químico, de várias das etapas 
chave no processo de descoberta e desenvolvimento de novos medicamentos, assegurando 
uma exploração virtual e uma compreensão atomística de todo um mundo de possibilidades e 
alternativas químicas. Apenas as alternativas mais promissoras são depois alvo de análise e 
estudo experimental em laboratório e avançam para as etapas seguintes do processo de 
desenvolvimento de novos medicamentos, minimizando também em larga escala as 
experiências em animais. A aplicação da química computacional no mundo do medicamento 
assegura assim uma maior racionalidade, sustentabilidade e eficácia em todo o seu processo 
de descoberta e desenvolvimento.  
 Este capítulo começa por apresentar a evolução do medicamento ao longo da história, desde 
as primeiras civilizações até aos nossos dias, ilustrando a mudança de paradigma que 
caracterizou este processo, na passagem do empirismo primordial para o surgimento de uma 
indústria multimilionária, altamente competitiva e fortemente interdisciplinar, alicerçada em 
domínios científicos sólidos e numa constante busca por inovação: a indústria farmacêutica. O 
papel crescente da química computacional em todo o processo é alvo de particular atenção, 
em especial à luz do seu imenso potencial, do crescente desenvolvimento computacional que 
tem caracterizado a nossa sociedade e da necessidade premente por novas técnicas e 
metodologias que tornem o processo de desenvolvimento de novos medicamentos mais 
rápido, económico e eficaz. 
 
O Medicamento na Antiguidade 
O Infarmed define medicamentos como “substâncias ou composições de substâncias que 
possuam propriedades curativas ou preventivas das doenças e dos seus sintomas, do homem 
ou do animal, com vista a estabelecer um diagnóstico médico ou a restaurar, corrigir ou 
modificar as suas funções.” No entanto, a história do medicamento é quase tão antiga como a 
história da própria civilização humana e a percepção do que é um medicamento variou 
significativamente ao longo dos séculos. Nas primeiras sociedades, os medicamentos 
funcionavam não só como produtos capazes de restaurar as capacidades físicas de um 
indivíduo, mas estavam também associados a curas religiosas e espirituais. Eram tipicamente 
administrados por curandeiros ou líderes espirituais que os preparavam a partir de plantas, em 
formulações que continham por vezes também materiais de origem animal e mineral. A 
descoberta e desenvolvimento destes primeiros medicamentos parece estar associada à 
combinação de um processo de tentativa e erro e à observação dos efeitos resultantes da 
ingestão desses produtos por parte de seres humanos e mesmo animais. Não existia, por isso, 
um conhecimento das bases fisiológicas associadas à própria doença.  
Uma lenda chinesa atribui a Sheng Nong (por vezes referido como Shennong), mítico 
imperador chinês que terá vivido por volta do ano 3500 a.c., a origem da medicina tradicional 
chinesa. De acordo com a lenda, Sheng Nong tentou certo dia matar uma cobra que encontrou 
no seu jardim, atingindo-a com violência e deixando-a supostamente morta. Alguns dias mais 
tarde a cobra surgiu novamente, totalmente recuperada. Sheng Nong bateu novamente na 
cobra, desta vez ainda com mais força ainda e deixou-a depois, crendo-a morta. No entanto, 
alguns dias mais tarde a cobra voltou. Desta vez, após bater na cobra, Sheng Nong observou 
cuidadosamente o seu comportamento e verificou que esta se escondeu num arbusto e comeu 
uma certa planta. Essa planta é hoje conhecida como San Qi (Panax notoginseng) e é um dos 
principais ingredientes do famoso preparado de origem vegetal conhecido como Yunnan 
Baiyao, famoso pelas suas propriedades hemostáticas e usado em medicina tradicional chinesa 
(2).  
Este empirismo esteve na base da origem e desenvolvimento do medicamento em todo o 
mundo antigo. Para além da China, importantes desenvolvimentos neste domínio encontram-
se já reportados nas antigas civilizações do vale do Indostão, Grécia antiga, Império Romano e 
mais tarde na civilização Árabe. No antigo Egipto, por exemplo, o papiro Ebers (datado de 1500 
 a.c.) inclui já um total de 877 receitas para preparação de formulações de importância 
farmacológica, com aplicação no tratamento de problemas de medicina interna, oculares, de 
pele e mesmo problemas ginecológicos (2). Mas foi na Grécia antiga no século IV a.c. que viveu 
Hipócrates, considerado por muitos como o pai da medicina moderna e como o homem que 
estabeleceu que cada doença tem uma origem natural, descartando a sua origem sobrenatural 
e transformando o seu estudo numa ciência.  
O declínio das civilizações grega e romana e a entrada da Europa no período conhecido como 
Idade Média travou este desenvolvimento. Posteriormente, com o Renascimento, o papel 
espiritual e divino na maioria das doenças foi progressivamente desmistificado. Com ele 
também o efeito sobrenatural dos medicamentos empregues foi abandonando, criando 
condições para uma abordagem mais científica e racional do papel do medicamento na 
sociedade moderna.  
Ao longo dos séculos seguintes, esta visão científica da relação doenças/medicamentos foi 
evoluindo, mas foi só na segunda metade do século XIX que a indústria farmacêutica começou 
a dar os seus primeiros passos, em grande parte através da produção de versões sintéticas de 
produtos naturais que se sabiam ter aplicações terapêuticas relevantes, de forma a aumentar 
a sua disponibilidade e eficácia.  
Assim, apesar de a civilização humana ter vindo a desenvolver e consumir medicamentos ao 
longo de vários milénios, as bases para um processo sistemático de descoberta e 
desenvolvimento de medicamentos apenas foram estabelecidas nos últimos 100 anos. 
 
O Medicamento no Mundo Actual 
Apesar de todo o desenvolvimento tecnológico verificado ao longo do século XX, o processo de 
descoberta e desenvolvimento de um novo medicamento é ainda extremamente complexo e 
demorado. Conforme apresentado na Figura 1, este processo pode ser dividido em 6 etapas 
fundamentais: (1) Descoberta e Validação do Alvo Terapêutico; (2) Procura e Identificação de 
Moléculas Promissoras; (3) Optimização do Medicamento; (4) Ensaios Pré-clínicos; (5) Ensaios 
Clínicos; (6) Aprovação e Comercialização. 
 
1. Descoberta e Validação do Alvo Terapêutico 
Esta etapa envolve, entre outros aspectos, a descoberta e validação do alvo terapêutico 
associado a determinada doença que se pretende tratar. Entre os alvos terapêuticos mais 
comuns encontram-se os receptores e as enzimas (5).  
Os receptores são proteínas que se encontram na superfície de membranas celulares e que 
permitem a comunicação entre diferentes células do organismo e também entre os meios 
intra e extracelulares, através da interacção com diferentes moléculas de sinalização que se 
ligam a eles. Entre a informação transmitida desta forma encontram-se indicações para que a 
célula se divida ou morra, ou para que permita a entrada ou saída de certas moléculas.  
 As enzimas são geralmente proteínas, constituídas fundamentalmente por sequências de 
aminoácidos, e que têm funções catalisadoras, permitindo a ocorrência no nosso organismo de 
forma rápida e altamente controlada de reacções químicas que, sem a sua presença, 
dificilmente aconteceriam em tempo útil. As enzimas convertem uma substância (substrato) 
noutra (produto), e são extremamente específicas para a reacção que catalisam. Isso significa 
que na maioria dos casos uma enzima catalisa um e só um tipo de reacção química. No nosso 
organismo e nos seres vivos em geral, a grande maioria das transformações químicas de 
biossíntese de moléculas essenciais e de metabolismo ocorre através de sequências de 
reacções em que o produto de uma reacção é utilizado como reagente na reacção seguinte. 
Diferentes enzimas catalisam diferentes passos nestes processos em cadeia.  
Muitas das doenças que afligem o ser humano são caracterizadas por um mau funcionamento 
destes processos em cadeia ou de sinalização, quer pela existência de mutações na estrutura 
de alguma das enzimas ou receptores que o constituem, quer pela não produção pelo 
organismo humano de certas enzimas, receptores ou moléculas sinalizadoras. Assim, muitos 
medicamentos actuam de forma estratégica inibindo ou bloqueando a actividade de certas 
enzimas ou de determinados receptores.  
Estes alvos terapêuticos são alvos moleculares. Um conhecimento químico detalhado da sua 
estrutura molecular e funcionamento a nível atómico é por isso fundamental. Após a 
identificação e validação do alvo terapêutico desejado, a primeira etapa no processo de 
descoberta e desenvolvimento de novos medicamentos passa assim pelo seu estudo e 
caracterização a nível molecular. 
 
2. Procura e Identificação de Moléculas Promissoras 
Uma vez bem conhecido o alvo segue-se uma fase de rastreio biológico em que é avaliada a 
capacidade de um vasto número de moléculas diferentes se associarem a esse alvo 
terapêutico inibindo a sua actividade. Este rastreio pode ser de natureza experimental ou 
computacional e pode envolver largos milhares de moléculas com propriedades físico-químicas 
bastante distintas entre si.  
Este processo de rastreio permite identificar o tipo de moléculas que se liga preferencialmente 
ao alvo terapêutico, lançando as bases para um conhecimento à escala atómica da molécula 
que no futuro irá constituir o princípio activo do medicamento que irá actuar sobre esse alvo 
terapêutico. Do elevado número de candidatos avaliados são seleccionadas algumas centenas 
de moléculas que são alvo de estudos posteriores, mais rigorosos. Só as moléculas mais 
promissoras passam à etapa seguinte. 
 
3. Optimização do Medicamento 
Nesta etapa, as moléculas mais promissoras que emergiram da fase anterior são 
cuidadosamente avaliadas em laboratório, através de testes in vitro (isto é, em tubos de 
ensaio). Estes testes permitem avaliar com rigor a capacidade das diferentes moléculas 
 inibirem o alvo terapêutico. Pequenas modificações químicas nas moléculas mais promissoras 
são testadas de forma a melhorar as suas interacções com o alvo terapêutico.  
No final desta etapa, obtém-se uma versão optimizada do conjunto de moléculas testadas: 
uma espécie de super-molécula, especialmente aperfeiçoada para ter o máximo de eficácia em 
relação ao alvo terapêutico. A etapa seguinte destina-se a confirmar estas características em 
seres vivos. Com efeito não basta a um medicamento conseguir associar-se com grande 
afinidade a um alvo terapêutico. Tem que conseguir atingir essa enzima ou receptor dentro do 
organismo, causando o mínimo de efeito secundário. 
 
4. Ensaios Pré-Clínicos 
Nos ensaios pré-clínicos é avaliado o comportamento das moléculas mais promissoras em 
sistemas biológicos. Modelos celulares e espécies animais são considerados como sistemas de 
referência nesta etapa. Em especial são avaliadas com o máximo de rigor as propriedades 
toxicológicas, farmacocinéticas e farmacodinâmicas destes compostos, apesar de muitas vezes 
alguns destes aspectos serem já tidos em conta, pelo menos parcialmente, na etapa anterior.  
Por farmacocinética compreende-se a análise dos mecanismos de absorção e distribuição dos 
medicamentos no organismo, o seu tempo de acção, as alterações químicas que sofrem no 
organismo e os mecanismos de excreção das substâncias resultantes. A farmacodinâmica 
estuda os efeitos fisiológicos dos medicamentos no organismo, incluindo os seus mecanismos 
de acção e a relação entre a concentração do medicamento e o seu efeito. Assim, a 
farmacocinética engloba o estudo dos efeitos que o organismo provoca no medicamento, 
enquanto a farmacodinâmica aborda a análise dos diversos efeitos do medicamento no 
organismo. 
Por cada 250 moléculas testadas nesta fase apenas 5 passam para a etapa seguinte (Figura 1). 
A etapa seguinte destina-se a confirmar a eficácia e segurança do medicamento em seres 
humanos, com vista à aprovação do medicamento. 
 
5. Ensaios Clínicos 
Os ensaios clínicos são presentemente uma das etapas mais importantes e também mais 
demoradas do processo de desenvolvimento de um novo medicamento. É nesta etapa que a 
eficiência do medicamento em humanos é testada de forma rigorosa, bem como possíveis 
efeitos adversos. Regra geral, os ensaios clínicos demoram em média entre 5 e 7 anos e são 
divididos em 3 fases fundamentais:  
Fase 1 – Nesta fase, o medicamento é tipicamente testado num pequeno grupo de voluntários 
saudáveis (10-100 participantes). Aspectos como a tolerabilidade e a farmacocinética 
(absorção, distribuição, metabolismo e excreção) do medicamento em humanos são avaliados, 
bem como a sua interacção com alimentos e toxicidade aguda. Dependendo do tipo de 
medicamento em avaliação estes testes demoram desde vários meses até a um ano, com um 
custo médio de cerca de 8 milhões de euros por ensaio clínico (1; 2). 
 Fase 2 – Na fase 2 os testes são efectuados em grupos significativamente maiores (50 a 500 
participantes) e têm como principal objectivo avaliar a eficácia terapêutica e a toxicidade do 
medicamento. Os pacientes são divididos em dois grupos principais, sendo parte deles 
tratados com o medicamento e a outra parte com um placebo (uma substância inerte sem 
efeito terapêutico). Normalmente os pacientes desconhecem em qual dos dois grupos estão 
inseridos. É nesta etapa que a maioria dos medicamentos que chegam à fase de ensaios 
clínicos acaba por falhar (cerca de 70%). É também nesta fase que a dosagem adequada para 
administração do medicamento é determinada. Esta fase dura geralmente pelo menos 1 a 2 
anos e o custo por teste clínico pode ser superior a 20 milhões de euros (1; 2).  
Fase 3 - Nesta fase, aspectos como a eficácia e a toxicidade dos medicamentos são avaliados 
em grupos significativamente maiores de pacientes (1000 a 5000 participantes). O número 
elevado de envolvidos permite uma maior significância estatística na análise da eficiência do 
medicamento e de eventuais efeitos secundários associados, tornando-a também a fase de 
testes clínicos mais dispendiosa e demorada, com um custo da ordem dos 50 a 100 milhões de 
euros por teste e uma duração média da ordem dos 3 a 5 anos (1; 2). 
 
6. Aprovação e Comercialização 
O resultado dos ensaios clínicos determina a sua aprovação pelas entidades que regulam a 
política do medicamento: FDA (Federal Drug Adminstration) nos Estados Unidos, EMEA 
(European Agency for the Evaluation of Medicinal Products) na União Europeia, MHLW 
(Ministry of Health, Labor and Welfare) no Japão, etc. Em Portugal, este papel é 
desempenhado pelo Infarmed (Instituto Nacional da Farmácia e do Medicamento), no âmbito 
da Autoridade Nacional do Medicamento e Produtos de Saúde. Estas entidades analisam de 
forma detalhada toda a informação referente à produção dos medicamentos e aos ensaios 
clínicos, prestando especial atenção a possíveis efeitos secundários indesejáveis. As empresas 
farmacêuticas que pretendem comercializar estes medicamentos são assim obrigadas a 
garantir a sua segurança, eficácia e pureza. Só após a aprovação por parte das agências de 
regulação é que os medicamentos passam a estar disponíveis para comercialização. Esta etapa 
demora tipicamente entre 6 meses e 2 anos (1). 
 
7. Implicações: Necessidade de Inovar o Processo 
Na sua globalidade, o processo de descoberta e desenvolvimento de um medicamento é 
extremamente dispendioso e demorado, conforme ilustrado na secção anterior. Um outro 
problema inerente a todo este processo é a sua baixíssima taxa de sucesso. De facto, por cada 
10000 compostos que são descobertos e explorados nas etapas iniciais de desenvolvimento de 
um medicamento, apenas 250 chegam a atingir a fase de ensaios pré-clínicos (2,5%) e apenas 
5 avançam para ensaios clínicos (0,5%). Para além disso, dos medicamentos avaliados em 
ensaios clínicos apenas uma percentagem inferior a 20% é aprovada e segue para 
comercialização. Assim, estes dados implicam que por cada 10000 compostos que iniciam o 
processo apenas 1 medicamento chega a ser aprovado. Em termos financeiros, estes valores 
implicam que o custo médio associado ao desenvolvimento de um medicamento aprovado 
para comercialização é de cerca de 1,3 mil milhões de euros (2), o que em termos relativos 
 equivale, por exemplo, a quase metade do orçamento de estado atribuído pelo governo 
português ao Ministério da Ciência e do Ensino Superior para o ano de 2010 (2,6 mil milhões 
de euros).  
 
 
Figura 1 – As várias etapas no processo de descoberta e desenvolvimento de um 
medicamento. 
 
As empresas farmacêuticas têm necessariamente de patentear os medicamentos que 
descobrem para se defenderem dos elevados custos associados ao processo de descoberta e 
desenvolvimento de um novo fármaco, assegurando um retorno do investimento ao longo dos 
vários anos subsequentes. Uma patente é uma concessão pública conferida por um estado, 
que garante ao seu titular a exclusividade de explorar comercialmente a sua criação, durante 
um período de 20 anos. Esta pode envolver um aparelho, um produto ou um processo. Em 
contrapartida, é disponibilizado ao público o conhecimento dos pontos essenciais e as 
reivindicações que caracterizam a novidade do invento. Os direitos exclusivos garantidos pela 
patente referem-se ao direito de prevenção de outros de fabricarem, usarem e venderem a 
dita invenção. Passado este período de tempo, a patente entra no chamado domínio público e 
qualquer pessoa ou empresa é livre para a explorar comercialmente.  
De forma a defender a sua invenção da concorrência as empresas farmacêuticas são assim 
forçadas a proteger por patente os seus medicamentos logo após a etapa de descoberta do 
medicamento. No entanto só podem comercializar o medicamento após a sua aprovação o 
que conforme referido anteriormente tipicamente demora entre 12 e 14 anos. Isto implica que 
apenas dispõem de um número reduzido de anos em que têm o monopólio do seu 
medicamento para tentarem compensar o elevado investimento despendido. Este factor 
contribui para o elevado preço de muitos medicamentos. 
 Após o término da patente, empresas concorrentes podem começar a produzir o mesmo 
medicamento em regime de concorrência. Esta é a ideia que está subjacente à comercialização 
dos medicamentos genéricos. Como as empresas concorrentes não têm que compensar o 
enorme investimento inicial necessário para a descoberta e desenvolvimento do 
medicamento, podem apresentar preços mais competitivos para esses medicamentos. 
A complexidade associada a todo este processo e as implicações económicas, financeiras, 
legais e sociais associadas vieram diversificar as equipas de especialistas envolvidas no 
processo de desenvolvimento de medicamentos. Com efeito, hoje em dia estas equipas são 
constituídas não só por cientistas e por médicos, mas também por advogados, economistas, 
especialistas em marketing, etc. Para as empresas que suportam os custos de todo este 
processo, a aposta para assegurar um retorno financeiro do enorme investimento feito passa 
por tentarem maximizar o período de tempo entre a aprovação do medicamento e o final da 
validade da patente. Na realidade, este objectivo pressupõe uma redução no número de anos 
necessários para a comercialização do medicamento, o que na prática exige um aumento da 
eficiência nas três primeiras etapas do processo: descoberta e validação do alvo terapêutico, 
procura e identificação de moléculas promissoras e optimização do medicamento. Com efeito, 
na quarta e quinta etapas do processo – os ensaios pré-clínicos e clínicos – as tendências 
actuais da nossa sociedade têm vindo a passar por um aumento do período de tempo 
necessário e por um aumento do seu rigor, uma vez que os requisitos em termos de segurança 
e qualidade por parte das autoridades reguladoras têm também vindo a aumentar. Assim 
alguns estudos mostram que nas últimas décadas a razão entre o número de ensaios clínicos 
realizados e o número de novos medicamentos aprovados aumentou de cerca de 30:1 para 
mais de 70:1 (2).  
Neste contexto, existe uma necessidade premente por novas técnicas capazes de aumentar a 
eficiência do processo de descoberta e o desenvolvimento de novos medicamentos nas etapas 
que antecedem os ensaios clínicos, tirando partido dos desenvolvimentos mais recentes da 
ciência nas suas várias vertentes. Em termos do pessoal envolvido na parte científica do 
processo de investigação e desenvolvimento do medicamento, as últimas décadas foram 
também caracterizadas por uma mudança significativa de paradigma.  
Nos anos 60 e 70 estas equipas eram constituídas em grande parte por químicos de síntese, 
que desenvolviam e melhoravam medicamentos existentes, tentando maximizar a actividade 
de compostos de actividade farmacológica promissora, e tentavam optimizar processos de 
produção de medicamentos. Nos dias de hoje, em que se tenta entender cada vez melhor a 
base molecular por trás das diversas doenças e com os progressos na área da genómica e da 
biotecnologia, este processo tornou-se muito mais global e mais interdisciplinar, envolvendo 
especialistas em domínios científicos tão variados como a biologia molecular, a bioquímica, a 
microbiologia, etc.   
Um papel também consideravelmente importante e de relevância crescente é hoje em dia 
ocupado por um novo tipo de cientistas: os Químicos Computacionais.  
 
 A História da Química Computacional 
A invenção do computador e o desenvolvimento tecnológico dele decorrente marcaram uma 
das etapas de mais rápida evolução na história da humanidade. Com efeito, o crescente 
desenvolvimento computacional que caracterizou as últimas décadas, juntamente com a 
evolução da internet, vieram alterar completamente o paradigma dominante do mundo em 
que vivemos.  
Aliado ao desenvolvimento dos meios de transporte e ao aumento da segurança nas 
deslocações e no transporte de mercadorias, o desenvolvimento computacional veio contribuir 
para mundo cada vez mais global. Um mundo mais pequeno nas distâncias, mas maior nas 
oportunidades e no acesso ao conhecimento. Se nesta nova construção em que assenta a 
sociedade contemporânea, a indústria pesada, o petróleo e a globalização dos mercados 
constituem as pedras basilares, os computadores e a internet assumem-se como a supercola 
que as une e lhes confere viabilidade e consistência. 
Facilitando as grandes tendências, potenciando as novas ideias, aproximando os mundos e as 
mentes, os desenvolvimentos computacionais das últimas décadas do século XX e do princípio 
do século XXI mudaram a forma como vivemos, como nos relacionamos uns com os outros, 
como acedemos à informação e a transmitimos. Alteraram a própria forma como pensamos.  
Estas mudanças foram de tal magnitude que, da mesma forma que o desenvolvimento da 
escrita define a fronteira entre a pré-história e a história, a invenção do computador poderá vir 
a ser encarada por historiadores futuros como o acontecimento precursor de uma nova idade 
na história da humanidade.  
Assim como estes acontecimentos tiveram um profundo efeito na nossa sociedade nas suas 
mais variadas vertentes, o desenvolvimento computacional mudou a forma como se faz 
ciência. Novas técnicas, novas metodologias, novas formas de estudar e de compreender os 
problemas científicos, de ver o mundo e a natureza, passaram a estar disponíveis com o 
desenvolvimento computacional. A internet potenciou ainda o acesso a uma massa 
impressionante de informação científica, ao mesmo tempo que permitiu a livre troca de ideias 
e informações, entre lugares distantes, em tempo real. 
Do casamento entre a Química e esta nova sociedade da informação, que tem no computador 
e na internet o pergaminho e a pena da antiguidade, nasceu a química computacional. 
A química computacional é um ramo da química que utiliza computadores para tratar 
problemas químicos. Em particular, a química computacional utiliza programas de computador 
que aplicam princípios da química teórica, baseados em leis da física, para determinar 
estruturas e propriedades de moléculas, confirmando e complementando a informação obtida 
a partir de técnicas experimentais. A química computacional permite ainda prever, muitas 
vezes, fenómenos químicos e propriedades físico-químicas ainda não observados 
experimentalmente, ou cuja determinação experimental é particularmente dispendiosa, 
demorada, tecnicamente exigente, poluente ou até mesmo perigosa. Ajuda ainda a explicar e 
interpretar, à escala atómica, os resultados provenientes de diferentes técnicas experimentais.  
 A química computacional tem vindo a ganhar uma importância crescente, sobretudo ao longo 
das últimas duas décadas, em áreas tão variadas como o estudo da reactividade química, o 
desenvolvimento de novos materiais e a descoberta e desenvolvimento de novos 
medicamentos, beneficiando dos grandes avanços em termos de computadores que tem 
caracterizado este período. Com efeito, a cada ano que passa, mais rápidos e mais potentes se 
tornam os computadores disponíveis no mercado e mais baixo se torna o seu custo. Assim, o 
conjunto de problemas a que a química computacional pode ser aplicada com sucesso tem 
vindo também a crescer. Os termos in vitro e in vivo, associados aos estudos realizados 
respectivamente em tubos de vidro e em organismos vivos, têm vindo a dar lugar a um 
número crescente de testes in silico, isto é, no computador.  
Com efeito, uma das grandes vantagens da química computacional é que permite o estudo de 
um grande número de problemas químicos sem consumir os sempre dispendiosos reagentes 
químicos e sem produzir resíduos tóxicos ou perigosos. Permite também simular condições 
difíceis, perigosas, dispendiosas ou mesmo impossíveis de testar experimentalmente, como 
processos químicos a valores de temperatura ou pressão extremas, e processos envolvendo a 
utilização ou formação de substâncias tóxicas, explosivas ou radioactivas. Para além disso, 
permite observar fenómenos em moléculas individuais e em escalas temporais demasiado 
curtas para a experimentação. 
Assim, ao longo dos últimos anos a química computacional tornou-se uma parte integrante do 
processo de descoberta e desenvolvimento de novos medicamentos e uma área emergente no 
competitivo mundo da indústria farmacêutica.  
 
Métodos de Química Computacional 
A designação de química computacional é bastante genérica e envolve a aplicação de um vasto 
conjunto de metodologias bastante diversas entre si, baseadas em princípios fundamentais 
diferentes, simplificações e aproximações distintas e mesmo formas de pensar próprias. 
Também diferente é o nível de exactidão que pode ser obtido com diferentes métodos 
computacionais e o tempo de computação associado. Naturalmente, a escolha do melhor 
método computacional a aplicar em determinada situação dependerá do problema específico 
em estudo. 
Os métodos usados em química computacional podem ser divididos em duas famílias 
principais: os métodos baseados na mecânica quântica e os baseados na mecânica clássica. 
 
Métodos baseados na Mecânica Quântica  
Estes métodos são baseados nos princípios da mecânica quântica, que permitem uma 
descrição física correcta do comportamento fundamental da matéria e energia em processos 
envolvendo partículas de dimensões próximas ou inferiores à escala atómica, com particular 
realce para os electrões, os protões, os núcleos atómicos e outras partículas e agregados de 
partículas subatómicas. 
 Com efeito, a química quântica baseia-se no facto de que os sistemas podem ser descritos 
através da chamada equação de Schrödinger, que descreve estas partículas como contendo 
propriedades de onda e de partícula e abarca a noção de quantização da energia.  
Na prática, a complexidade matemática associada à resolução da equação de Schrödinger para 
estes sistemas implica que apenas os mais simples podem ser tratados exactamente pela 
mecânica quântica. Para a maioria dos sistemas de interesse químico torna-se necessária a 
aplicação de algumas aproximações. É a natureza e a extensão das aproximações aplicadas que 
diferencia as diferentes abordagens computacionais dentro da química quântica, como os 
Métodos Hartree-Fock, Pós-Hartree-Fock, Semi-empíricos e a Teoria do Funcional da 
Densidade.  
Este tipo de métodos permite um tratamento adequado de processos que envolvem a 
formação e quebra de ligações químicas, como reacções de catálise enzimática e de inibição 
covalente. Têm a desvantagem de que a sua aplicação directa está, regra geral, limitada a 
sistemas contendo um número relativamente reduzido de átomos (tipicamente inferior a 200 
átomos).  
 
Métodos baseados na Mecânica Clássica 
Em muitos casos, os sistemas moleculares podem ser modelados de forma realista sem 
necessidade de recorrer aos princípios da mecânica quântica. Com efeito, a mecânica clássica, 
que aplica os princípios da chamada mecânica newtoniana, permite uma descrição atomística 
adequada de muitos problemas químicos e biológicos, com vantagens em termos de 
simplicidade de tratamento matemático e de custo em termos de tempo computacional 
necessário.  
Este tipo de métodos descreve, regra geral, as moléculas como um conjunto de átomos 
indivisos, com determinada massa e carga, mas sem considerar de forma explícita o conceito 
de electrão e de núcleo. Também comum nestas metodologias é a descrição das ligações entre 
os diferentes átomos que constituem estas moléculas como molas, de comprimento e rigidez 
diferentes dependendo das características específicas dos átomos envolvidos (massa) e da 
ligação química particular entre eles (simples, dupla, tripla), entre outros factores. 
A inclusão implícita dos electrões e núcleos e outros aspectos quânticos é tratada pela 
atribuição de parâmetros de ajuste às expressões matemáticas usadas para descrever os 
átomos do sistema. Estes podem ser obtidos a partir de dados experimentais e/ou de cálculos 
computacionais usando métodos quânticos.  
A maior simplicidade conceptual associada a este tipo de métodos permite a simulação 
computacional de sistemas de dimensões consideravelmente maiores, como por exemplo 
proteínas e enzimas em solução, receptores associados a modelos de membranas celulares 
contendo milhares de átomos. Permitem também a simulação computacional da evolução de 
sistemas moleculares no tempo e no espaço, aspectos fundamentais para uma boa 
compreensão do funcionamento de sistemas biológicos no nosso organismo, uma vez que 
estes sistemas não são estáticos. Com efeito, os sistemas biológicos têm uma natureza 
 dinâmica que se traduz numa alternância de estados e conformações em resposta ao 
ambiente envolvente e à presença de outras moléculas. Estes aspectos são fundamentais para 
o normal desenrolar da sua actividade.  
 
Aplicações na descoberta e desenvolvimento de medicamentos 
As duas famílias gerais de métodos computacionais apresentadas na secção anterior 
constituem apenas as ferramentas base de que os químicos e os bioquímicos computacionais 
se servem no seu dia-a-dia no estudo de sistemas moleculares, em áreas tão variadas como a 
química-física, a química orgânica, a química bioinorgânica, a química medicinal, as ciências 
farmacêuticas, etc. Dependendo da natureza específica do problema em foco em cada uma 
destas áreas, estas metodologias podem ser moldadas, aperfeiçoadas e mesmo combinadas de 
forma a maximizarem a sua utilidade e impacto. 
No longo e demorado processo de desenvolvimento de novos medicamentos, os métodos de 
química computacional têm vindo a assumir uma importância decisiva em 3 pontos 
estratégicos: (1) a catálise enzimática computacional; (2) o encaixe molecular; (3) o rastreio de 
novos medicamentos.  
 
1. Catálise enzimática computacional 
Conforme apresentado anteriormente, um número muito significativo de alvos terapêuticos 
apresenta actividade enzimática, catalisando processos químicos relevantes no nosso 
organismo, muitas vezes integrados em longas cadeias de diferentes reacções concertadas 
envolvendo várias enzimas e processos.  
Inibir um determinado alvo terapêutico implica bloquear ou limitar a sua actividade biológica; 
implica desenvolver uma molécula que consiga, de alguma forma, actuar sob esse alvo e 
impedir o seu mecanismo normal de actuação no organismo. É esta molécula que irá depois 
estar na base do desenvolvimento do medicamento.  
Para que esta molécula seja o mais eficaz possível deve actuar, de forma estratégica, na etapa 
mais crítica do mecanismo de actuação normal desse alvo terapêutico. Para isso, torna-se 
necessário conhecer à escala atómica e com o máximo rigor esse mecanismo. Conhecendo os 
vários passos individuais que constituem o processo, os átomos directamente envolvidos e a 
energética e cinética (isto é a tendência energética e a velocidade de cada passo) associada, 
torna-se possível identificar o passo-chave para bloquear todo o processo e o ponto crítico 
para actuação.  
Apesar de existirem diversos métodos experimentais que permitem obter informação 
detalhada sobre muitos destes mecanismos enzimáticos, muitas vezes essa informação é 
apenas indirecta e fornece somente uma visão incompleta do processo, deixando em aberto 
várias hipóteses. Em química computacional diferentes alternativas mecanísticas podem ser 
simuladas atomisticamente, com considerável rigor, permitindo o cálculo da energia e 
velocidade de cada reacção e a previsão da estrutura molecular dos reagentes, produtos e 
 estados de transição associados (Figura 2), distinguindo na prática o mecanismo enzimático 
real das outras hipóteses (6).  
Uma vez conhecida a química por trás do mecanismo de actuação de uma determinada 
enzima, estão lançadas as bases para o desenvolvimento de novos medicamentos 
especificamente desenhados para actuarem de forma cirúrgica sob esse alvo terapêutico.  
 
 
Figura 2 – Representação computacional da enzima Farnesiltransferase ilustrando a interacção 
entre duas moléculas substrato (representadas a amarelo e verde), forma de coordenação à 
enzima na cavidade do centro activo e grau de conservação dos diferentes aminoácidos que 
definem a superfície da enzima, imediatamente antes da reacção enzimática que vai juntar os 
dois substratos numa só molécula de produto. 
 
2. Encaixe Molecular 
O encaixe molecular é uma técnica que analisa, do ponto de vista computacional, um outro 
aspecto fundamental no processo de descoberta e desenvolvimento de novos medicamentos 
(7). Imagine uma determinada molécula. Conseguirá essa molécula associar-se a uma 
determinada enzima ou receptor? Se sim, de que forma? Em que região do alvo se vai 
associar? Com que afinidade? Que orientação e conformação adoptam? Como podemos 
melhorar essa molécula para aumentar a sua capacidade de associação a esse alvo?  
Todas estas questões, tão comuns quanto pertinentes, podem ser estudadas adequadamente 
com a ajuda da química computacional, a uma fracção do custo económico que uma 
abordagem puramente experimental implicaria. Com efeito, um estudo destas questões por 
 recurso apenas a técnicas experimentais envolveria tipicamente pelo menos a síntese ou 
aquisição da uma certa quantidade da molécula inicial em causa, o isolamento e purificação ou 
aquisição de uma determinada quantidade do alvo terapêutico, a realização de ensaios in vitro 
de associação molécula-alvo, a obtenção de cristais do complexo resultante da associação 
enzima-alvo para a determinação de uma estrutura por cristalografia de raio-X e a sua análise 
detalhada. Finalmente, por cada proposta de alteração na estrutura dessa molécula, no 
sentido de aumentar a afinidade para o alvo terapêutico, várias destas etapas teriam de ser 
repetidas.  
A química computacional consegue responder a estas questões por recurso ao encaixe 
molecular, uma poderosa técnica computacional baseada fundamentalmente nos princípios da 
mecânica clássica.  
 
 
Figura 3 – Representação computacional da estrutura de associação de uma molécula na 
cavidade de um alvo terapêutico, ilustrando as interacções moleculares mais relevantes (a 
amarelo) e as características dos aminoácidos que definem a superfície molecular dessa 
cavidade.  
 
O encaixe molecular parte de um modelo computacional da estrutura do alvo terapêutico que, 
regra geral, pode ser facilmente construído a partir de uma estrutura experimental do alvo 
terapêutico sozinho ou associado a outra qualquer molécula. A base de dados Protein Data 
Bank (8) contém cerca de 60000 estruturas experimentais de enzimas, proteínas e receptores, 
determinadas por cristalografia de raio-X ou por ressonância magnética nuclear, sendo este o 
ponto de partida natural para estes estudos.  
Partindo de um modelo computacional da estrutura do alvo terapêutico e de uma simples 
estrutura tridimensional da molécula, os programas computacionais de encaixe molecular 
tentam posicionar a molécula inicial em diversas posições na superfície do alvo terapêutico e 
em diferentes orientações e conformações, avaliando a sua energia de interacção e 
 procurando as regiões do alvo para as quais a afinidade é maior. Esta análise tem em atenção 
as características físico-químicas locais, tanto do alvo terapêutico como da molécula em 
análise, e em especial a complementaridade de forma e carga entre ambos (ver Figura 3). 
Especial atenção é prestada às cavidades na superfície do alvo terapêutico e à região do centro 
activo. No final deste processo de encaixe molecular, o programa sugere a localização mais 
provável para a molécula avaliada, bem como a sua conformação mais estável.  
Analisando computacionalmente a estrutura resultante e o conjunto de interacções entre o 
alvo terapêutico e as moléculas, os químicos computacionais conseguem então sugerir novas 
moléculas, nomeadamente através da introdução de pequenas alterações na estrutura da 
molécula inicial no sentido de aumentar a sua afinidade para o alvo. Estas novas moléculas 
podem então ser novamente testadas por encaixe molecular ou por metodologias 
computacionais mais rigorosas, permitindo a determinação das suas energias de associação ao 
alvo terapêutico com grande rigor.  
O princípio subjacente a todo este processo computacional é o de que quanto mais forte for a 
complementaridade de forma e de carga de uma determinada molécula relativamente a um 
determinado alvo terapêutico e a sua energia de associação resultante, então mais específica 
será essa molécula para esse alvo terapêutico. Com efeito, tendo em conta que no nosso 
organismo milhares de enzimas diferentes catalisam inúmeras reacções em simultâneo, é 
indispensável assegurar que a molécula que tentamos desenvolver irá actuar de forma o mais 
exclusiva possível sob o alvo terapêutico que queremos inibir, em detrimento de outras 
enzimas e receptores no organismo. Quanto menos específica for a sua actividade, maior o 
número de enzimas, receptores e processos biológicos em que tenderá a interferir e maior 
número de efeitos secundários irá ter. Adequar ao máximo a molécula ao alvo terapêutico é 
por isso fundamental para a segurança do medicamento que daí irá resultar.  
No final, apenas as moléculas computacionalmente mais promissoras são sintetizadas e 
testadas experimentalmente in vitro e in vivo, reduzindo grandemente o custo associado a 
todo o processo de desenvolvimento de novos medicamentos e aumentando a sua 
racionalidade.  
 
3. Rastreio Virtual de Novos Medicamentos   
Enquanto para alguns alvos terapêuticos existe um conhecimento prévio do tipo de moléculas 
que poderão em princípio funcionar como inibidores, tendo por base, por exemplo, o 
conhecimento já existente relativo às estruturas de substratos naturais, produtos, ou mesmo 
estados de transição das reacções que catalisam, para muitas enzimas e receptores o ponto de 
partida para o desenvolvimento de novos medicamentos é uma grande incógnita.  
O rastreio virtual de novos medicamentos é uma técnica computacional especialmente 
desenhada para tratar este tipo de situações (9; 10). Na sua essência, o rastreio virtual de 
novos medicamentos usa um grande número de moléculas conhecidas contidas em extensas 
bibliotecas computacionais e avalia computacionalmente a capacidade de cada uma dessas 
moléculas se associar ao alvo terapêutico que se pretende inibir (Figura 4). Na prática, este 
processo permite identificar as principais características que uma molécula deverá ter para 
 funcionar como um inibidor promissor para esse alvo específico. Ajuda também a identificar 
moléculas de partida mais promissoras para o processo de desenvolvimento de novos 
medicamentos.  
De forma a permitir uma exploração minuciosa do universo de moléculas possíveis, alguns 
destes métodos baseiam-se numa filosofia que passa pela associação inicial de pequenos 
fragmentos moleculares ao alvo, tentando depois fazer crescer as moléculas progressivamente 
pela introdução de outros fragmentos moleculares de forma a ir aumentando a afinidade 
molécula-alvo terapêutico.  
No final deste processo, são seleccionadas algumas centenas de moléculas que são 
posteriormente avaliadas por métodos computacionais mais rigorosos. Factores como a 
possível toxicidade, o custo de produção associado e a sua disponibilidade são também tidos 
em consideração para a selecção deste conjunto de candidatos. 
 
 
Figura 4 – Representação da ideia base do rastreio computacional de novos medicamentos, 
em que é avaliada computacionalmente a capacidade de um grande número de moléculas 
diferentes se associarem a um determinado alvo terapêutico. A imagem à esquerda ilustra a 
estrutura de um alvo terapêutico típico, dando particular realce à região da cavidade do centro 
activo. À direita podem ser observadas as estruturas de diferentes moléculas da base de dados 
e o seu mapa de potencial electrostático, ilustrando as regiões à superfície destas moléculas 
com maior carga negativa (a vermelho) e positiva (a azul). 
 
 Conclusão 
Actualmente a química computacional assume já um papel importante nas etapas de 
descoberta e validação de alvos terapêuticos, procura e identificação de moléculas 
promissoras e optimização de medicamentos. No entanto, a era dos computadores está ainda 
só no seu início e como tal a química computacional tem ainda um larga margem de evolução. 
Ao longo das próximas décadas, o número de processos químicos e farmacológicos que 
conseguem ser efectivamente descritos pela química computacional, com rigor químico e nível 
de detalhe atomístico, tenderá certamente a aumentar. 
Estes desenvolvimentos irão contribuir decisivamente para uma ampliação do já importante 
papel da química computacional na indústria farmacêutica, contribuindo para uma maior 
racionalidade, sustentabilidade e eficiência de todo o processo.  
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